---
document_datetime: 2024-02-06 13:28:31
document_pages: 179
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/ayvakyt-h-c-005208-ii-0023-epar-assessment-report-variation_en.pdf
document_name: ayvakyt-h-c-005208-ii-0023-epar-assessment-report-variation_en.pdf
version: success
processing_time: 247.1007647
conversion_datetime: 2025-12-23 05:05:47.180617
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

EMA/548651/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## AYVAKYT

International non-proprietary name: avapritinib

Procedure No. EMEA/H/C/005208/II/0023

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 8                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation................................................................................................    | 8                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................                 | 9                                                                                                      |
| 2. Scientific discussion..............................................................................                    | 10                                                                                                     |
| 2.1. Introduction.....................................................................................................10  |                                                                                                        |
| 2.1.1. Problem statement.........................................................................................10       |                                                                                                        |
| 2.1.2. About the product                                                                                                  | ..........................................................................................14           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                 | advice......15                                                                                         |
| 2.1.4. General comments on compliance with                                                                                | GCP.......................................................15                                           |
| 2.2. Non-clinical aspects...........................................................................................15    |                                                                                                        |
| 2.2.1. Introduction                                                                                                       | ..................................................................................................15   |
| 2.2.2. Pharmacology................................................................................................15     |                                                                                                        |
| 2.2.3. Toxicology                                                                                                         | ....................................................................................................16 |
| 2.2.4. Ecotoxicity/environmental risk assessment                                                                          | ........................................................18                                             |
| 2.2.5. Discussion on non-clinical aspects                                                                                 | ....................................................................18                                 |
| 2.2.6. Conclusion on the non-clinical aspects...............................................................19            |                                                                                                        |
| 2.3. Clinical aspects.................................................................................................20  |                                                                                                        |
| 2.3.1. Introduction                                                                                                       | ..................................................................................................20   |
| 2.3.2. Pharmacokinetics                                                                                                   | ...........................................................................................21          |
| 2.3.3. Pharmacodynamics.........................................................................................52        |                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                    | ............................................................................................52         |
| 2.3.5. Discussion on clinical pharmacology..................................................................61            |                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology................................................................63             |                                                                                                        |
| 2.4. Clinical efficacy.................................................................................................63 |                                                                                                        |
| 2.4.1. Dose response studies                                                                                              | ....................................................................................64                 |
| 2.4.2. Main study                                                                                                         | ....................................................................................................64 |
| 2.4.3. Discussion on clinical efficacy.........................................................................121        |                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy..................................................................127          |                                                                                                        |
| 2.5. Clinical safety.................................................................................................127  |                                                                                                        |
| 2.5.1. Discussion on clinical safety...........................................................................166        |                                                                                                        |
| 2.5.2. Conclusions on clinical safety                                                                                     | .........................................................................168                           |
| 2.5.3. PSUR cycle..................................................................................................168    |                                                                                                        |
| 2.6. Risk management plan                                                                                                 | ....................................................................................168                |
| 2.7. Update of the Product information.....................................................................172            |                                                                                                        |
| 2.7.1. User consultation                                                                                                  | .........................................................................................172           |
| 3. Benefit-Risk Balance ...........................................................................                       | 172                                                                                                    |
| 3.1. Therapeutic Context........................................................................................172       |                                                                                                        |
| 3.1.1. Disease or condition                                                                                               | .....................................................................................172               |
| 3.1.2. Available therapies and unmet medical                                                                              | need....................................................173                                            |
| 3.1.3. Main clinical studies......................................................................................173     |                                                                                                        |
| 3.2. Favourable effects...........................................................................................173     |                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ..........................................174                                                          |
| 3.4. Unfavourable effects                                                                                                 | .......................................................................................174             |

<div style=\"page-break-after: always\"></div>

3.5. Uncertainties and limitations about unfavourable effects  .......................................  175

3.6. Effects Table ..................................................................................................  175

3.7. Benefit-risk assessment and discussion  ..............................................................  177

3.7.1. Importance of favourable and unfavourable effects ...........................................  177

3.7.2. Balance of benefits and risks  ..........................................................................  178

3.7.3. Additional considerations on the benefit-risk balance  .........................................  178

3.8. Conclusions  ....................................................................................................  178

4. Recommendations  ............................................................................... 179

5. EPAR changes ..................................................................................... 179

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AdvSM

Advanced systemic mastocytosis

AE

Adverse event

AESI

Adverse events of special interest

AIM

American Initiative in Mast Cell Diseases

ALP

Alkaline phosphatase

ANCOVA

Analysis of covariance

APTT

Activated partial thromboplastin time

ASM

Aggressive systemic mastocytosis

ATC

Anatomical Therapeutic Chemical

BCRP

Breast cancer resistance protein

BM

Bone marrow

BSC

Best supportive care

CDF

Cumulative density function

CFB

Change from baseline

CI

Confidence interval

CID

Clinically important difference

CIR

Clinically important response

CMQ

Customised MedDRA queries

COA

Clinical Outcome Assessment

COVID-19

Coronavirus disease 2019

CRF

Case report form

CS-AP

Cross sectional analysis population

CSR

Clinical study report

CT

Computerized tomography

CTCAE

Common Terminology Criteria for Adverse Events

CXDX

Cycle X Day X

CYP

Cytochrome P450

DNA

Deoxyribonucleic acid

DXA

Dual x-ray energy assessment

ECG

Electrocardiogram

ECNM

European Competence Network on Mastocytosis

ECOG PS

Eastern Cooperative Oncology Group Performance Status

<div style=\"page-break-after: always\"></div>

| eCRF         | Electronic case report form                                                                                                  |
|--------------|------------------------------------------------------------------------------------------------------------------------------|
| EMA          | European Medicines Agency                                                                                                    |
| EOT          | End-of-Treatment                                                                                                             |
| EQ           | EuroQuol                                                                                                                     |
| EQ-5D-5L     | EuroQol-5 Dimensions-5 Levels                                                                                                |
| FDA          | US Food and Drug Administration                                                                                              |
| GCP          | Good Clinical Practice                                                                                                       |
| GERD         | Gastrooesophageal reflux disease                                                                                             |
| GI           | Gastrointestinal                                                                                                             |
| GIST         | Gastrointestinal stromal tumor                                                                                               |
| HLT          | High-level Term                                                                                                              |
| ICB          | Intracranial bleeding                                                                                                        |
| ICH          | International Conference on Harmonization                                                                                    |
| IDMC         | Independent Data Monitoring Committee                                                                                        |
| IEC          | Independent Ethics Committee                                                                                                 |
| IgE          | Immunoglobulin E                                                                                                             |
| INR          | International normalized ratio                                                                                               |
| IRB          | Institutional Review Board                                                                                                   |
| IRT          | Interactive Response Technology                                                                                              |
| ISM          | Indolent systemic mastocytosis                                                                                               |
| ISM-SAF      | Indolent Systemic Mastocytosis-Symptom Assessment Form                                                                       |
| ITT          | Intent-to-treat                                                                                                              |
| IWG-MRT-ECNM | International Working Group-Myeloproliferative Neoplasms Research and Treatment- European Competence Network on Mastocytosis |
| KM           | Kaplan-Meier                                                                                                                 |
| LOCF         | last observation carried forward                                                                                             |
| LPLV         | last patient last visit                                                                                                      |
| LS           | Least Squares                                                                                                                |
| MAF          | Mutant allele fraction                                                                                                       |
| MATE         | Mammalian multidrug and toxin extrusion                                                                                      |
| Max          | maximum                                                                                                                      |
| MC           | mast cell                                                                                                                    |
| MCS          | Mental Component Score                                                                                                       |
| MCL          | mast cell leukemia                                                                                                           |

<div style=\"page-break-after: always\"></div>

| MCMC   | Markov chain Monte Carlo                         |
|--------|--------------------------------------------------|
| MC-QoL | Mastocytosis Quality of Life Questionnaire       |
| MedDRA | Medical Dictionary for Regulatory Activities     |
| Min    | minimum                                          |
| MRI    | Magnetic resonance imaging                       |
| MSAF   | Mastocytosis Symptom Assessment Form             |
| NCI    | National Cancer Institute                        |
| NCS    | Nerve Conduction Study                           |
| NE     | Not evaluable                                    |
| NEC    | Not elsewhere classified                         |
| PCS    | Physical Component Score                         |
| PDGFRA | Platelet-derived growth factor alpha             |
| PGIC   | Patients' Global Impression of Change            |
| PGIS   | Patient's Global Impression of Symptom Severity  |
| PK     | Pharmacokinetic(s)                               |
| PP     | Per-Protocol                                     |
| PPI    | Proton pump inhibitor                            |
| PRO    | Patient-Reported Outcome                         |
| PsAP   | Psychometric Analysis Population                 |
| PT     | Preferred term                                   |
| PUVA   | Psoralen and ultraviolet A                       |
| QD     | Once daily                                       |
| QOD    | Every Other Day                                  |
| QoL    | Quality of Life                                  |
| QTc    | Corrected QT interval                            |
| QTcF   | QT interval corrected using Fridericia's formula |
| RNA    | Ribonucleic acid                                 |
| ROC    | Receiver operating characteristic                |
| RP2D   | Recommended Phase 2 dose                         |
| SAE    | Serious adverse event                            |
| SAP    | Statistical Analysis Plan                        |
| SD     | Standard deviation                               |
| SE     | Standard error                                   |

<div style=\"page-break-after: always\"></div>

| SF-12   | Twelve-item Short Form Health Survey                                            |
|---------|---------------------------------------------------------------------------------|
| SM      | Systemic mastocytosis                                                           |
| SM-AHN  | Systemic mastocytosis with an associated hematologic neoplasm of non-MC lineage |
| SMQ     | Standardised MedDRA Queries                                                     |
| SOC     | System Organ Class                                                              |
| SSM     | Smouldering systemic mastocytosis                                               |
| TEAE(s) | Treatment emergent adverse event(s)                                             |
| TKI     | Tyrosine kinase inhibitor                                                       |
| TRT-AP  | Test-retest Analysis Population                                                 |
| TSS     | Total symptom score                                                             |
| UK      | United Kingdom                                                                  |
| US      | United States                                                                   |
| VAS     | Visual analogue scale                                                           |
| WHO     | World Health Organization                                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Blueprint Medicines (Netherlands) B.V. submitted to the European Medicines Agency on 15 December 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

AYVAKYT, was designated as an orphan medicinal product EU/3/18/2074 on 26 October 2018. AYVAKYT was designated as an orphan medicinal product in the following indication: Treatment of mastocytosis.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Ayvakyt as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: http://www.ema.europa.eu/en/medicines/human/EPAR/Ayvakyt

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0083/2020 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The MAH received scientific advice from the CHMP on 31 May 2018 (EMEA/H/SA/3738/2/2018/SME/III) regarding non-clinical and clinical aspects of their proposal. After orphan drug designation, follow-up protocol assistance was provided by CHMP on 15 October 2020

(EMEA/H/SA/3738/2/FU/1/2020/PA/SME/II). The advice sought at that time pertained to the following clinical aspects of the dossier.

- Agreement with the dose selection for Part 2 of Study BLU-285-2203.
- Agreement with the proposal to include only patients with moderate-to-severe ISM in Part 2 of Study BLU-285-2203.
- Acceptability of the primary endpoint (proportion of responders, defined as patients experiencing at least a 30% decrease in ISM-SAF Total Symptom Score, from baseline to Cycle 7 Day 1), the statistical hypothesis to analyse the primary endpoint and the selection of and statistical hypotheses for key secondary endpoints.
- Adequacy of the safety database to support an extension of the indication for avapritinib to include the treatment of patients with moderate-to-severe ISM.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                                                          | Carolina Prieto Fernandez                                                            | Co-Rapporteur: N/A   |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------|
| Timetable                                                                            | Timetable                                                                            | Actual dates         |
| Submission date                                                                      | Submission date                                                                      | 15 December 2022     |
| Start of procedure                                                                   | Start of procedure                                                                   | 27 January 2023      |
| CHMP Rapporteur's preliminary assessment report circulated on                        | CHMP Rapporteur's preliminary assessment report circulated on                        | 11 April 2023        |
| PRAC Rapporteur's preliminary assessment report circulated on                        | PRAC Rapporteur's preliminary assessment report circulated on                        | 5 April 2023         |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | PRAC RMP advice and assessment overview adopted by PRAC on                           | 14 April 2023        |
| CHMP Rapporteur's updated assessment report circulated on                            | CHMP Rapporteur's updated assessment report circulated on                            | 22 April 2023        |
| Request for supplementary information adopted by the CHMP on                         | Request for supplementary information adopted by the CHMP on                         | 26 April 2023        |
| MAH's responses submitted to the CHMP on:                                            | MAH's responses submitted to the CHMP on:                                            | 12 July 2023         |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 18 August 2023       |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 18 August 2023       |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | PRAC RMP advice and assessment overview adopted by PRAC on                           | 31 August 2023       |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | 10 September 2023    |
| Request for supplementary information adopted by the CHMP on                         | Request for supplementary information adopted by the CHMP on                         | 14 September 2023    |
| MAH's responses submitted to the CHMP on:                                            | MAH's responses submitted to the CHMP on:                                            | 6 October 2023       |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 17 October 2023      |

<div style=\"page-break-after: always\"></div>

| Timetable                                                                            | Actual dates     |
|--------------------------------------------------------------------------------------|------------------|
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 30 October 2023  |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 26 October 2023  |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | 03 November 2023 |
| CHMP opinion adopted on                                                              | 9 November 2023  |
| The CHMP adopted a report on similarity of Ayvakyt with Rydapt on                    | 9 November 2023  |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment

## Epidemiology and risk factors, screening tools/prevention

Systemic mastocytosis (SM) is a rare, clonal mast cells (MC) neoplasm driven by the KIT D816V mutation in ~95% of cases, which results in the abnormal activation of mast cells (Garcia-Montero et al, 2006; JaraAcevedo et al, 2015; Ungerstedt et al, 2022).

The SM sub-classification based on WHO criteria is provided in the table below:

Table 1. Systemic Mastocytosis Subclassification Based on WHO Criteria

| Variant             | Variant                                               | Diagnostic criteria                          |
|---------------------|-------------------------------------------------------|----------------------------------------------|
| Nonadvanced SM      | Indolent SM (ISM)                                     | No C-findings; < 2 B-findings                |
| Nonadvanced SM      | Smoldering SM (SSM)                                   | No C-findings;≥ 2 B-findings                 |
| Advanced SM (AdvSM) | SM with an associated hematological neoplasm (SM-AHN) | Meets diagnostic criteria for AHN            |
| Advanced SM (AdvSM) | Aggressive SM (ASM)                                   | ≥ 1 C-finding Does not meet criteria for MCL |
| Advanced SM (AdvSM) | Mast cell leukemia (MCL)                              | ≥ 20% mast cells in BM smear                 |

Abbreviations: AHN = associated hematologic neoplasm; MCL = mast cell leukemia; SM = systemic mastocytosis; WHO =World Health Organization.

Source: Swerdlow et al, 2017: Carter et al, 2014: Metcalfe and Mekori,2017: Valent 2013.

<div style=\"page-break-after: always\"></div>

The prevalence of all types of SM is estimated at ~1 per 10,000, with the prevalence of indolent SM (ISM) accounting for ~0.8 per 10,000 (Cohen et al, 2014). In the Groningen region of the Netherlands, a major referral area for SM patients, the prevalence is estimated at 13 per 100,000.

Systemic mastocytosis preferentially affects Caucasians and there is no sex predominance. Most cases of SM are sporadic and not inherited, occurring in people with no family history of the condition.

Patients with non-advanced SM (90% to 95% of SM patients) primarily have ISM, but a small number of patients have the smouldering SM (SSM) variant, which is associated with increased organ infiltration and MC burden (Swerdlow et al, 2017).

Although organ infiltration by MCs is less extensive in patients with ISM, MC activation leads to severe, even life-threatening, MC mediator-related symptoms and a poor quality of life (Pardanani, 2019; Gilreath et al, 2019). Patients with ISM progress to advanced SM (AdvSM) in approximately 2% of cases. Patients with SSM progress to AdvSM or transform to leukemia in approximately 9% of cases and have a worse survival compared with ISM patients (Trizuljak et al, 2020; Sperr et al, 2019).

An overview of prevalence and incidence of SM in the EU is provided in table 2.

<div style=\"page-break-after: always\"></div>

Table 2. Overview of Prevalence and Incidence of Systemic Mastocytosis in the European Union

| Disease        | Disease      | Annual Incidence per 10,000   | Prevalence per 10,000   | References                                                                  |
|----------------|--------------|-------------------------------|-------------------------|-----------------------------------------------------------------------------|
| SM             | SM           | 0.021 to 0.89                 | 0.959 to 5              | Cohen et al, 2014: Marton et al, 2016; Orphanet, 2020                       |
| Nonadvanced SM | ISM          | 0.04 to 0.073                 | 0.824 to 1.8            | Cohen et al, 2014; Kibsgaard et al, 2020; Marton et al, 2016: Orphanet,2020 |
| Nonadvanced SM | SSM          |                               | 0.13 (ISM+SSM)          | Van Doormaal et al, 2013                                                    |
| AdvSM          | All subtypes | 0.008                         | 0.052                   | Schwaab et al, 2020                                                         |
| AdvSM          | SM- AHN      | 0.004                         | 0.031                   | Cohen et al, 2014                                                           |
| AdvSM          | ASM          | 0.001                         | 0.009 to 0.09           | Cohen et al, 2014; Orphanet, 2020                                           |
| AdvSM          | MCL          | 0.001                         | 0.000                   | Cohen et al, 2014                                                           |

Abbreviations: AdvSM = advanced systemic mastocytosis; ASM = aggressive systemic mastocytosis;

ISM = indolent systemic mastocytosis; MCL = mast cell leukemia; SM = systemic mastocytosis;

SM-AHN = systemic mastocytosis with an associated hematologic neoplasm; SSM = smoldering systemic mastocytosis.

## Biologic features, aetiology and pathogenesis

Systemic mastocytosis is a clonal mast cell neoplasm, driven by the KIT D816V mutation, where abnormal activation of MC leads to debilitating life-threatening symptoms. Although heterogeneity characterizes the clinical presentation and prognosis of SM, the pathogenesis is largely shared, with gain of function D816 KIT mutations occurring in 93% of SM cases, regardless of subtype (Garcia-Montero et al, 2006). This shared molecular pathogenesis suggests that a potent, selective, targeted agent against the KIT D816V mutation could be effective across SM subtypes, regardless of the clinicopathological presentation.

Serum tryptase is an important biomarker for mast cell burden and activity and is part of the WHO diagnostic criteria for SM. Although specific criteria of response in objective measures of mast cell burden do not exist for ISM, reduction of 50% or greater from baseline serum tryptase is a criterion for partial remission in the IWG-MRT-ECNM criteria used in AdvSM (Gotlib et al, 2013), and potentially a marker of disease modification in ISM.

## Clinical presentation, diagnosis and stage/prognosis

The formal diagnosis of SM is based on pathologic and laboratory criteria established by the WHO (Swerdlow et al, 2017). A diagnosis of SM can be made with the documentation of multifocal dense

<div style=\"page-break-after: always\"></div>

infiltrates of neoplastic MCs in bone marrow (BM) and/or other extra cutaneous organs (major criterion) and at least 1 of the following minor criteria:

- Atypical MC morphology in BM and/or extra cutaneous tissue
- Presence of the KIT D816V mutation in BM, blood, or other extracutaneous organ
- Abnormal expression of CD25 with or without CD2 on MCs in BM, blood, or other extracutaneous organ
- Elevated serum tryptase levels

If the major criterion is not present, a diagnosis of SM can still be made if 3 of the 4 minor criteria are fulfilled.

SM is broadly divided into advanced SM and non-advanced SM, - based on the degree of organ infiltration (B-findings) and organ damage (C-findings) present, as well as the presence of adverse pathologic features - both of which are characterized by the uncontrolled proliferation and activation of mast cells, often present as aggregates in bone marrow, skin, spleen, liver, GI tract, and other organs (Metcalfe, 2008).  (Table 3).

Table 3. B- and C-Findings in Systemic Mastocytosis

| B-Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | C-Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| High MC burden (shown on BM biopsy): > 30% infiltration of cellularity by MCs (focal, dense aggregate) and serum total tryptase > 200 ng/mL. Signs of dysplasia or myeloproliferation in non-MC lineages(s), but criteria are not met for a definitive diagnosis of an associated hematological neoplasm,with normal or only slightly abnormal blood counts. Hepatomegaly with impairment of liver function, palpable splenomegaly with hypersplenism, and/or lymphadenopathy on palpation or imaging | BM dysfunction caused by neoplastic MC infiltration, manifested by ≥ 1 cytopenia: ANC < 1.0 x 10°/L, Hgb < 10 g/dL, and/or platelet count < 100 x 109/L. Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension. Skeletal involvement, with large osteolytic lesions with or without pathologic fractures (pathologic fractures caused by osteoporosis do not qualify as a C-finding). Palpable splenomegaly with hypersplenism. Malabsorption with weight loss due to gastrointestinal MC infiltrates. |

Abbreviations: ANC = absolute neutrophil count; BM = bone marrow; Hgb = hemoglobin: MC = mast cell. Source: Swerdlow ct al, 2017.

Approximately 10% to 20% of patients meet the WHO diagnostic criteria for advanced SM; the remainder have non-advanced ISM with the exception of a small subset who have non-advanced SSM (Sperr et al, 2019).

Patients with ISM suffer from a broad spectrum of persistent and debilitating symptoms (Jennings et al, 2018; Mesa et al, 2022; Pulfer et al, 2021; van Anrooij et al, 2016). Mutant KIT drives the accumulation and hyperactivity of aberrant mast cells, leading to excessive signaling of vasoactive and inflammatory cytokines, including leukotrienes, prostaglandins, and interleukins (Jackson et al, 2021). Aggregates of activated proliferating mast cells, driven by mutant KIT, result in a constellation of symptoms leading to a significant reduction in quality of life (QoL) caused by recurrent diarrhoea, pruritus, abdominal pain, nausea, headache, flushing, cognitive impairment, fatigue, bone pain, and disfiguring skin lesions that are observed across the spectrum of the disease (Magliacane et al, 2014; Theoharides et al, 2015).

<div style=\"page-break-after: always\"></div>

Among patients with SM, 46% (ISM) to 56% (SM) experience anaphylaxis (Brockow et al, 2008; Gülen et al, 2014).

## Management

Therapies currently recommended for ISM are considered palliative, administered with the intent of only improving symptoms. Commonly used therapies for treatment of ISM symptoms are presented in the table below.

Table 4. Commonly Used Therapies Directed for Treatment of ISM Symptoms

| Symptom                                                         | Drug class                                        |
|-----------------------------------------------------------------|---------------------------------------------------|
| Pruritis, flushing                                              | H1 antihistamines, leukotriene inhibitors, NSAIDs |
| Abdominal pain, cramping, diarrhea, heartburn, nausea, vomiting | H2 antihistamines, PPI, cromolyn, corticosteroids |
| Headache, cognitive impairment, depression                      | H1 antihistamines, cromolyn                       |
| Hypotension                                                     | H1 antihistamines, corticosteroids                |
| Osteoporosis                                                    | Bisphosphonate                                    |
| Anaphylaxis                                                     | Corticosteroids, anti-IgE antibody, epinephrine   |

Abbreviations: IgE = Immunoglobulin E; ISM = indolent systemic mastocytosis; NSAID = nonsteroidal anti-inflammatory drug; PPI = proton pump inhibitor. Source: Pardanani 2013.

Globally, there are currently no approved treatments for patients with ISM aiming to reduce their disease burden, treat the underlying driver of ISM, or which impact the ISM disease course.

## 2.1.2. About the product

Avapritinib (BLU-285) is a small molecule protein tyrosine kinase inhibitor (ATC classification code L01EX18) that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17 and 17 mutants. Certain mutations in PDGFRA and KIT can result in the autophosphorylation and constitutive activation of these receptors which can contribute to tumour cell proliferation. Other potential targets for avapritinib include wild type KIT, PDGFRB, and CSFR1.

Avapritinib is currently approved for treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST) - with a recommended starting dose of 300 mg once daily-, and for the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL), after at least one systemic therapy - with a recommended starting dose of 200 mg once daily.

The new (initially) claimed indication is:

'AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).' For ISM, the recommended dose of avapritinib is 25 mg orally once daily.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The avapritinib SM clinical development program was initiated in June 2015 and to date consists of the following studies.

## Systemic mastocytosis - AdvSM

- 2 clinical studies in patients with AdvSM (BLU-285-2101 and BLU-285-2202, both ongoing)
- An open-label expanded-access program in patients with AdvSM (BLU-285-EAP-02, completed)
- An external control, observational, retrospective study of avapritinib in patients with AdvSM that collected retrospective data on patients treated with BSC in the real-world setting to enable comparative analyses on the efficacy and safety of avapritinib vs BSC (BLU-285-2405, completed)

## Systemic mastocytosis - ISM

- A clinical study in patients with ISM (BLU-285-2203, ongoing)
- An open-label expanded-access program in patients with ISM (BLU-EAP-ISM, ongoing)

## Systemic mastocytosis - General

- A registry for patients with mastocytosis (Mast Cell Connect Mastocytosis Registry, completed)
- A screening study evaluating the prevalence of KIT D816V mutation in patients with systemic mast cell activation (BLU-SM-1101, ongoing)

As outlined above, scientific advice/protocol assistance was requested in two occasions. The recommendations regarding clinical aspects have overall been followed. However, the same does not apply to suggestions made regarding the non-clinical development; see section 2.2.

## 2.1.4. General comments on compliance with GCP

The MAH has provided a statement confirming that the clinical studies have been conducted in agreement with GCP compliance.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

New non-clinical information related to the potential genotoxic and carcinogenic effect of avapritinib has been produced from the last line extension of Ayvakit. The new studies submitted in this variation included a new in vivo mammalian alkaline Comet assay in rat and the 6-month transgenic mouse carcinogenic assessment study. Also, an exploratory brain analysis from samples of the 3-month repeatdose toxicology study conducted in dogs was reported.

## 2.2.2. Pharmacology

No additional pharmacology studies have been conducted with avapritinib for this new indication, which was considered acceptable by CHMP. These studies were provided in the initial MAA.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Toxicology

## Repeat dose toxicity

Repeated dose toxicity studies indicated that cases of haemorrhage in the brain and spinal cord occurred in dogs at doses greater than or equal to 15 mg/kg/day (approximately 9.0, 1.8 and 0.8 times the human exposure based on AUC at 25 mg, 200 mg and 300 mg dose once daily, respectively) and choroid plexus oedema in the brain occurred in dogs at doses greater than or equal to 7.5 mg/kg/day (approximately 4.7, 1.0 and 0.4 times the human exposure based on AUC at the clinical dose of 25 mg, 200 mg and 300 mg once daily, respectively). Rats manifested convulsions, which was potentially secondary to inhibition of Nav 1.2 at systemic exposures ≥ 96, 12 and ≥ 8-fold higher than the exposure in patients at the clinical dose of 25 mg, 200 mg and 300 mg once daily.

In a 6 month repeat dose toxicology study in rats, rats manifested haemorrhagic and cystic degeneration of the ovarian corpus lutea and vaginal mucification at dose levels greater or equal to 3 mg/kg/day with exposure margins of 15, 3 and 1.3 times the human exposure based on AUC at 25 mg, 200 mg and 300 mg, respectively. In a 9 month repeat dose toxicology study in dogs, hypospermatogenesis (3/4 males) was observed at the highest dose tested, 5 mg/kg/day (5.7, 1.2 and &lt;1 times the human exposure (AUC) at 25 mg, 200 mg and 300 mg dose, respectively).

## Genotoxicity

The results of a new in vivo mammalian alkaline Comet assay in rat were presented. The previous one was submitted in the (variation EMEA/H/C/5208/X/004/G). Both assays followed a similar protocol. Animals were treated for 2 days by oral gavage and the doses were 37.5, 75, 150 mg/kg/day for males and 25, 50, 100 mg/kg/day for females. The only difference was the batch used, being for this new assay Batch 119200T9009 instead of 0285/02.

It was concluded that avapritinib was negative under the conditions of the study, given that no DNA damage in the liver was induced after oral administration at 0 and 24 hours.

## Carcinogenicity

Previous to the definitive 6-month carcinogenicity study, a 5-day and 28-day oral toxicity study was conducted in mice (CByB6F1 wild-type mouse (non-TG mouse)). After 4 weeks of avapritinib treatment on a daily basis (10, 30 or 100 mg/Kg/day), adverse microscopic findings and correlating haematology changes at ≥ 30 mg/kg/day were observed. The NOAEL was established at 10 mg/kg/day, resulting in a mean AUC0-24hr value of 40,200 hr*ng/mL and a mean Cmax value of 2790 ng/mL for males and females combined on Day 28.

In the definitive study, avapritinib was administered to transgenic mice (CByB6F1/Tg rasH2 hemizygous) by oral gavage on a daily basis for 26 weeks (3, 10 or 20 mg/Kg/day). The study report indicated no avapritinib-related effects on survival. Clinical observations included skin pallor and discoloration/fur staining (white and/or pale) at ≥ 10 mg/kg/day group males and/or females. Regarding organ weights, lower thymus weights at ≥ 10 mg/kg/day group males and females were reported, microscopically corresponded with lower cellularity of the thymic cortex in both groups.

No significant difference in terms of systemic exposure was found between males and females. No accumulation was observed after comparison exposure on days 1 and 182. The exposure levels quantified at the highest dose evaluated (20 mg/kg/day at day 182) were: mean AUC(0-24) value of 72,300 ng*hr/mL and mean Cmax value of 4550 ng/mL.

<div style=\"page-break-after: always\"></div>

| Dose         | AUC(0-24) (nghr/mL)   | AUC(0-24) (nghr/mL)   | Cmnx (mg/mL)   | Cmnx (mg/mL)   | tmax (hr)   | tmax (hr)   |
|--------------|-----------------------|-----------------------|----------------|----------------|-------------|-------------|
|              | Day 1                 | Day182                | Day 1          | Day182         | Day 1       | Day 182     |
| Males        |                       |                       |                |                |             |             |
| 3 mg/kg/day  | 9320                  | 11,300                | 668            | 696            | 2           | 4           |
| 10 mg/kg/day | 32,800                | 38,200                | 2390           | 2190           | 2           | 4           |
| 20 mg/kg/day | 67,000                | 77,000                | 4270           | 4630           | 2           | 8           |
| Females      |                       |                       |                |                |             |             |
| 3 mg/kg/day  | 9210                  | 7540                  | 702            | 475            | 4           | 1           |
| 10 mg/kg/day | 30,400                | 29,000                | 2140           | 1930           | 4           | 4           |
| 20 mg/kg/day | 68,600                | 66,500                | 4790           | 4620           | 1           | 4           |
| Ser Combined |                       |                       |                |                |             |             |
| 3 mg/kg/day  | 9270                  | 9410                  | 667            | 566            | 2           | 4           |
| 10 mg/kg/day | 31,600                | 33,600                | 2190           | 2060           | 2           | 4           |
| 20 mg/kg/day | 67,800                | 72,300                | 4300           | 4550           | 2           | 4           |

In addition to these studies, a carcinogenic risk assessment based on a weight of evidence (WoE) approach was presented by the MAH, in line with the addendum 'Testing for Carcinogenicity of Pharmaceuticals' (ICH S1B[R1], 2022). A long-term carcinogenicity study with avapritinib is ongoing.

## Reproduction toxicity

No new data related to reproduction toxicity have been presented in this variation. Nevertheless, the MAH reconsidered the information included in the SmPC regarding the potential effect of treatment with AYVAKYT on male and female fertility and has amended SmPC sections 4.6 and 5.3 accordingly.

The nonclinical data informing on fertility in humans comprises a dedicated combined male and female fertility and early embryonic development study conducted in rats at oral avapritinib doses of 3, 10, and 30 mg/kg/day for males, and 3, 10, and 20 mg/kg/day for females.

The MAH stated that no direct effects on male or female fertility were noted at the highest dose levels tested in this study (100.8 and 62.6 times the human exposure (AUC) at 25 mg, 20.3 and 9.5 times the human exposure (AUC) at 200 mg and 8.7 and 4.1 times the human exposure (AUC) at 300 mg).

Reduction in sperm production and relative testicular weight were observed in male rats administered avapritinib at exposures of 7 and 30 times, 1 and 5 times, and 0.6 and 3 times the 25 mg, 200 mg, and 300 mg human doses, respectively. Nevertheless, hypospermatogenesis (3/4 males) was observed in the 9 month repeat-dose toxicology study in dogs at the highest dose tested, 5 mg/kg/day (5.7, 1.2 and &lt;1 times the human exposure (AUC) at 25 mg, 200 mg and 300 mg dose, respectively).

Regarding female fertility, the 6 month repeat dose rat toxicity study revealed haemorrhagic and cystic degeneration of the ovarian corpus lutea and vaginal mucification at dose levels greater or equal to 3 mg/kg/day with exposure margins of 15, 3 and 1.3 times the human exposure based on AUC at 25 mg, 200 mg and 300 mg, respectively.

The MAH has included wording in SmPC section 4.6 and section 5.3 to inform on the potential effect of treatment with AYVAKYT on male and female fertility at doses of 200 mg or greater.

## Toxicokinetic data

Toxicokinetic data of the 6-month carcinogenicity study are shown in the section above.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Ecotoxicity/environmental risk assessment

The MAH has submitted additional information related to ERA of avapritinib, resulting in the absence of significant increase of PEC surface-water parameter, which is below the trigger value of 0.01 μ g/L. Consequently, no phase II would be required.

## 2.2.5. Discussion on non-clinical aspects

Avapritinib was initially approved for the indication of GIST and then extended to AdvSM. It showed broad inhibitory activity against both primary and secondary KIT and PDGFRA mutants, especially against mutations in exons 17 and 18 including the D816V mutant in KIT (IC50 = 0.27 nM) and the D842V mutant in PDGFRA (IC50 = 0.24 nM). For this new indication, no additional pharmacological studies have been conducted, which was considered acceptable.

An exploratory brain analysis from samples of the 3-month repeat dose toxicology studies in dogs has been provided with this variation procedure. No effect was reported in animals treated at 30 mg/Kg/day compared to control individuals. It is noted that due to the limited number of animals, no effect of treatment or sex for microglia present in the brain could be concluded. No update of the SmPC was deemed necessary.

In terms of potential genotoxicity of avapritinib, the results reported from a new in vivo Comet assay confirmed those obtained in the initial similar study. It is noted that the only difference between both assays is the batch used with no other differences reported. The information obtained is already included in the section 5.3 of the SmPC, and no modification is considered at this point, which was agreed.

With regards to the carcinogenicity profile of avapritinib, the MAH has presented a carcinogenic risk assessment based on a WoE approach. It should be noted that the MAH anticipates that a  carcinogenic potential of avapritinib in humans is unlikely. It is noted that a previous scientific advice to conduct the 2year carcinogenicity study in rats was not followed by the MAH.

As part of the carcinogenic risk assessment, the results of the short-term carcinogenicity study (6-month in CByB6F1/Tg rasH2 Hemizygous Mice) were shown and have been added to the section 5.3 of the SmPC. In this study, clinical observations were noted in the skin and microscopic findings of decreased cortical cellularity with corresponding reduction in thymus weights were reported at ≥ 10 mg/kg/day. It is noted that the selection of dose levels for this study was based on a 28-day study, in which clinical signs were limited to thin fur cover of the forepaw and hind paws (left and right) in females of the 30 and 100 mg/kg/day groups with no changes in body weight or food consumption. Histopathological changes were reported at ≥ 30 mg/Kg/day (sternal bone ma rrow and thymus). The MAH selected a maximum dose of 20 mg/Kg/day (54.4-fold humans at the dose of 25 mg) for the 6-month study in transgenic mice based on the 50-fold plasma AUC exposure ratio (rodent:human) criterion. However, given that a higher dose level used in the 28-day study (30 mg/Kg/day) had shown a limited toxicity in the previous study, it is anticipated a low (almost negligible) toxic effect in the 6-month study for the 20 mg/Kg/day dose level. Similarly, dose level of 30 mg/Kg QD was described as well-tolerated (not even body weight was affected) in primary pharmacodynamic studies after 27 days of treatment (Pharmacology written summary, initial MAA), also anticipating the absence of a dose-limiting toxicity in the 6-month carcinogenic study. This was confirmed in the 6-month study, in which any change was observed in all tissues analysed. Based on the results of the 6-month transgenic mice study, the MAH concluded no carcinogenic effect of avapritinib.

As for the histopathology data, the MAH mentioned NOAEL values, indicating the absence of hyperplasia or hypertrophy at these NOAEL values in the repeat dose toxicology studies. However, higher doses produced changes in organ weights, bone growth effects in rats and histopathologic findings in dogs

<div style=\"page-break-after: always\"></div>

(bone marrow, spleen and testis) even at the recovery euthanasia.

With regards to the hormonal perturbation analysis, the MAH noted that findings were not indicative of direct hormonal changes. However, taking into account that KIT is described to regulate mammalian spermatogenesis along with the effect observed in testis, it should be reconsidered in terms of potential hormonal perturbation. Indeed, effects on adrenal and prostate glands, vagina and ovaries as well as hypospermatogeneis have been reported in repeat dose toxicology studies.

In the assessment of potential for immune modulation, it is noted that immune systems changes were reported in toxicity studies and that dedicated immunotoxicity studies were not conducted with avapritinib.

Finally, additional supportive clinical data were submitted by the MAH but no information related to the treatment duration of the reported cases has been shown.

Taking together these all factors mentioned above, it can be concluded that a 2-year rat study would add value to the assessment of human carcinogenicity risk, given that carcinogenic potential in humans cannot be ruled out. Also, it should be considered that this new indication (ISM) is not an advanced cancer and patients are likely to have a normal life expectancy. The MAH stated that a 2-year carcinogenicity study with avapritinib in rats is currently ongoing. The final report is expected to be available in March 2026 and the information for the long-term carcinogenicity study has been accordingly modified in SmPC section 5.3.

As this is a new therapeutic indication and in line with current ERA guideline (CPMP/SWP/4447/00), environmental risk update was included. As PEC surfacewater was below the action limit, no additional studies are required.

As previously mentioned, new non-clinical data have been produced from the last variation of Ayvakyt submitted by the MAH. Additional estimations of the safety exposure margin based on the clinical dose (25 mg) for the novel indication, in addition to those estimated for previous indication (300/250 mg for GIST/AdvSM, respectively) have been incorporated in the section 5.3 of SmPC. In addition, based on nonclinical finding in animals, male and female fertility may be compromised by treatment with avapritinib. SmPC sections 4.6 and 5.3 have been updated.

Considering that patients with ISM tend to be younger than patients with AdvSM or GIST and may be more likely to want to pursue pregnancy, the MAH proposes to follow a conservative approach and based on CFTG guidance for drugs with suspected human fetotoxicity, proposes that an extension of the use of effective contraception by 2 weeks is recommended for women (i.e. from 1 month to 6 weeks). Based on the half-life of avapritinib, a 2 week washout period is adequate for the drug washout, in line with the proposed recommendation for contraceptive use in men with female partners of childbearing potential after the last dose of avapritinib.  The information regarding the need for contraception (in men and women) in section 4.6 of the SmPC was updated accordingly.

## 2.2.6. Conclusion on the non-clinical aspects

The non-clinical data are sufficient to support the extension of indication to include treatment of adult patients with indolent systemic mastocytosis. Updated information has been reflected in the SmPC sections 4.6 and 5.3.

The updated ERA data submitted show that the use  in ISM patients does not lead to a significant increase in environmental exposure. Considering the above data, avapritinib is not expected to pose a risk to the environment.

The following measures are considered necessary to address non-clinical issues:

<div style=\"page-break-after: always\"></div>

- The MAH will perform a 2-year carcinogenicity study in rats following the recommendation of the CHMP.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

- Tabular overview of clinical studies

| Type of Study      | Study Identifier   | Location of Study Report   | Objective(s) of the Study                                                                            | Study Design and Type of Control                         | Test Product(s); Dosage Regimen; Route of Administration                                                                                                   | Number of Subjects/ Patients   | Healthy Subjects or Diagnosis of Patients   | Study Status; Type of Report    |
|--------------------|--------------------|----------------------------|------------------------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|---------------------------------------------|---------------------------------|
| Food Effect        | BLU-285- 0102      | 5.3.1.1                    | Food effect,compare PKof avapritinibwith or without food (standardized high- fat, high-calorie meal) | Open-label, randomized, single dose, 2-way crossover     | Avapritinib; Tablet: 2x100 mg; Oral, fed or fasted                                                                                                         | 30                             | Healthy Volunteers                          | Complete; Clinical Study Report |
| BA                 | BLU-285- 0101      | 5.3.1.2                    | Relative bioavailability, avapritinib tablet versus capsule formulations                             | Open-label, randomized, single dose, 2-way crossover     | Avapritinib; Capsule: 2x100 mg Tablet: 1x200 mg; Oral, fasted                                                                                              | 30                             | Healthy Volunteers                          | Complete; Clinical Study Report |
| BE                 | BLU-285- 0105      | 5.3.1.2                    | Bioequivalence between 400 mg and 100 mg tablets                                                     | Open-label, randomized, single dose, 2- period crossover | Avapritinib; Tablet: 4x100 mg Tablet: 1x400 mg; Oral, fasted                                                                                               | 62                             | Healthy Volunteers                          | Complete; Clinical Study Report |
| DDI, PK            | BLU-285- 0104      | 5.3.2.2                    | PK in the presence and absence of itraconazole or rifampin                                           | 2-Part, open- label; fixed sequence                      | Avapritinib single dose: 2×100mg tablet ±itraconazole 200 mg QD (BID on Day 1) Avapritinib single dose: 4×100 mg tablet ± rifampin 600 mg QD; Oral, fasted | Part 1: 20 Part 2: 20          | Healthy Volunteers                          | Complete; Clinical Study Report |
| ADME, Mass Balance | BLU-285- 0103      | 5.3.3.1                    | ADME and mass balance of avapritinib                                                                 | Open-label, single dose                                  | Avapritinib; Tablet:3x100 mg Capsule: 1x ~17 mg [14C]avapriti nib O(100 μCi); Oral, fasted                                                                 | 6                              | Healthy Volunteers                          | Complete; Clinical Study Report |

<div style=\"page-break-after: always\"></div>

| Hepatic Impair- ment   | BLU-285- 0107   | 5.3.3.3   | Effect ofsevere hepaticimpairment on the PK of avapritinib   | Open-label, single dose                                                                                                                                                                       | Avapritinib; Tablet:1 x 100 mg Oral, fasted                                                                                                                                                                                            | 16                                                              | Healthy Volunteers 8 with severe hepatic impairment 8 matched controls   | Complete; Clinical Study Report   |
|------------------------|-----------------|-----------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------|
| Efficacy, Safety, PK   | BLU-285- 2203   | 5.3.5.1   | Efficacy, Safety, PK, and QOL                                | A 3-part, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib inISM and SSM with symptoms inadequately controlled with standard therapy | Part 1: Avapritinib 25, 50,or100 mg or matching placebo PO,QD in continuous 28-day cycles Part 2: avapritinib 25 mg or matching placebo PO, QD in continuous 28- day cycles Part 3 avapritinib 25 mg PO,QD in continuous28- day cycles | Part 1: 39 Part 2: 212 Part 3 (rollover from Part 1 and 2): 235 | Patients with ISM                                                        | Ongoing; Clinical Study Report    |

AdvSM=advanced systemic mastocytosis;DLP= data lock point;GIST=gastrointestinal stromal tumor;ISS=integrated summary of safety;PD= pharmacodynamics;PK= pharmacokinetics;PDGFRA=platelet derived growth factorreceptor alpha;PO= oral dosing;QD= once daily;QOL=quality of life;RP2D=recommendedPhase 2 dose

## 2.3.2. Pharmacokinetics

## Pharmacokinetics in the target population

The clinical pharmacology of avapritinib was further characterized in an efficacy and safety study in patients with ISM (BLU-285-2203).

Table 5. Overview of New Studies Contributing Clinical Pharmacology Data

<!-- image -->

| Study Identifier Status                                                           | Study Objective                                                                                                                                                                           |                                                 | Treatments (Dose, Dosage Form)                                                                                                                   | Subjects Treated: Age: Mean [Range]                                                                                                                                                                                                                           | Route                     | Avapritinib Formulation   | DataIncludedin CurrentSubmission   | DataIncludedin CurrentSubmission   | DataIncludedin CurrentSubmission   | Location in Module 2.7                                                                                   |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|------------------------------------|------------------------------------|------------------------------------|----------------------------------------------------------------------------------------------------------|
| Location of CSR                                                                   |                                                                                                                                                                                           | Study Design                                    |                                                                                                                                                  | No. (MI/F) Iype                                                                                                                                                                                                                                               |                           |                           | NCA PK                             | Pop PK                             | E-R                                | Location in Module 2.7                                                                                   |
| StudiesinPatientswithISMI                                                         | StudiesinPatientswithISMI                                                                                                                                                                 | StudiesinPatientswithISMI                       | StudiesinPatientswithISMI                                                                                                                        | StudiesinPatientswithISMI                                                                                                                                                                                                                                     | StudiesinPatientswithISMI | StudiesinPatientswithISMI | StudiesinPatientswithISMI          | StudiesinPatientswithISMI          | StudiesinPatientswithISMI          | StudiesinPatientswithISMI                                                                                |
| BLU-285- 2203 Part l: complete Part 2: complete Part 3: ongoing CSR BLU-285- 2203 | Part l: recommended Phase 2dose,PK safety, and efficacy of avapritinib Part 2: efficacy and avapritinib safety of compared to placebo Part 3: long-term safety andefficacy of avapritinib | Double-blind, placebo- controlled, 3-part study | Part l: avapritinib 25, 50, or 100 mg QD+BSCor placebo +BSC Part 2: avapritinib 25 mg QD + BSC or placebo+BSC Part 3: avapritinib 25 mg QD + BSC | Part l: 39 (9M/30F) patients with ISM 49.2 years, [21-75 years] 25 mg QD: 10 50 mg QD: 10 100 mg QD:10 Placebo: 9 Part 2: 212 patients with ISM 25 mg QD + BSC:141 (41M/100F) 48.7 years, [18-77 years] Placebo + BSC: 71 (17M/54F) 52.2 years, [26-79 years] | Oral, fasted              | 25 and 100 mg tablets     | Yes                                | Yes                                | Yes (E, S)                         | Module 2.7.2 Section 2.1.1 (NCA PK) Module 2.7.2 Section 2.5.1 (Pop PK) Module 2.7.2 Section 2.5.2 (E-R) |

Abbreviations:BSC=best supportive care;CSR=clinical study report；E=efficacy;E-R=exposure-response;F=female;ISM=indolent systemic mastocytosis; M=male; NCA =noncompartmental analysis;No.=number;PK =pharmacokinetic(s);Pop PK=population pharmacokinetics; QD= once daily; S = safety.

<div style=\"page-break-after: always\"></div>

The  clinical  pharmacokinetics  (PK)  of  avapritinib  were  investigated  in  patients  with  Indolent  systemic mastocytosis (ISM) to assess:

- Analysis of the PK of avapritinib and the constitutive enantiomers BLU111207 and BLU111208 of its pharmacologically active metabolite M499 (BLU136707) using NCA methods, based on data obtained on C1D1 (single-dose PK) for Part 1 and Part 2 of the study, and on C1D15 (Part 1) or C2D1 (repeatdose PK) for Part 2 of the study.
- Population analysis of avapritinib PK, including data submitted previously from Study BLU-285-2101 and Study BLU-285-2202 in patients with AdvSM, Study BLU-285-1101 in patients with GIST, and Studies  BLU-285-0101,  BLU-285-0102,  and  BLU-285-0105  in  healthy  subjects,  with  a  covariate analysis to determine whether patient demographics and other factors can be used to explain interindividual variability in PK parameters.

## Study BLU-285-2203

Study BLU-285-2203 is an ongoing, double-blind, placebo-controlled study to investigate the efficacy and safety of avapritinib in combination with BSC administered orally in adult patients with ISM.

The study includes 3 parts:

- In Part 1, the 25 mg QD RP2D of avapritinib was determined based on the administration of avapritinib at doses of 25, 50, and 100 mg QD and the evaluation of efficacy, safety, and PK at each dose level (Table 5).
- In Part 2, the efficacy of the RP2D (25 mg QD) in combination with BSC was compared with placebo in combination with BSC.
- In  the  ongoing Part 3 of the study, patients who had completed treatment in Part 1 or Part 2 are participating in a long-term extension, receiving 25 mg QD avapritinib in combination with BSC. As of the  data  cutoff  date  for  the  current  submission  (23  June  2022),  251  patients  were  treated  with avapritinib or placebo (39 in Part 1, 212 in Part 2, and 235 in Part 3).

The PK parameters for avapritinib and the constitutive enantiomers of the M499 metabolite (BLU111207 and BLU111208) after single (C1D1) and repeat (QD) dosing (C1D15 or C2D1) of avapritinib were estimated using NCA methods. Only samples from Part 1 and Part 2 of the study were analysed. No PK samples were analysed from Part 3.

The sampling schemes for PK analysis are outlined in Table 6.

## Table 6: Summary of Pharmacokinetic Sampling Schemes in Study BLU-285-2203

<div style=\"page-break-after: always\"></div>

| Avapritinib Dose (Formulation)                |   N (Treated) | Pharmacokinetic Sampling                                                                                                                                                                                                                   |
|-----------------------------------------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Part 1 25, 50, 100 mg QD (tablet), or placebo |            39 | Part 1 (Intensive) a C1D1: Predose, 0.5, 1, 2, 4, 8, 24, 48, 72 hour's postdose C1D15: Predose, 0.5, 1, 2, 4, 8, 24, 48 hours postdose C2D1-C4D1: Predose, 1 time point between 1-8 hours postdose                                         |
| Part 2 25 mg QD (tablet) or placebo           |           212 | Part 2 (Intensive) C1D1: Predose, 1, 4, 6-8 hours postdose C2D1: Predose, 1, 4, 6-8 hours postdose C3D1-C7D1: Predose, 1 time point between 1-8 hours postdose Part 2 (Sparse) C1D1-C7D1: Predose, 1 time point between 1-8 hours postdose |

Abbreviations: CxDy = Cycle x Day y; CxD1-CyD1 = Day 1 of Cycle x through Cycle y; N = number of patients; QD = once daily.

a In Part 1, the C1D2, C1D3, and C1D16 doses were not administered to allow for collection of the 48- and 72-hour postdose samples.

PK Parameter Estimation Set was defined as all patients who received a dose of avapritinib and had at least 3 quantifiable concentrations post-dose. NCA was performed for this group of patients. Patients enrolled in Part 2 with sparse sampling had their exposure metrics derived using population pharmacokinetic methods.

## PK Population

PK population was defined as all patients who received at least one dose of avapritinib and had at least one plasma sample collected, and was used for concentration-time listings.

A flowchart detailing the PK Population and PK Estimation Set is shown in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure  1.  Exclusion  of  Patients  from  the  Pharmacokinetic  Population  and  Pharmacokinetic Estimation Set

<!-- image -->

There were 98 patients in Part 2 with sparse PK sampling, NCA was not performed for these patients. As a result of these exclusions there were 72 patients in the PK Population.

## Avapritinib Pharmacokinetics

The summary avapritinib PK parameters by dose and day are displayed in Tables 7 and 8, for Part 1 and in Table 9 and 10 for Part 2.

<div style=\"page-break-after: always\"></div>

Table 7. Summary of Avapritinib Pharmacokinetic Parameters on C1D1 by Dose - Part 1

| mg   | DoseSummaryStatistic   |   Cmax ng/ml | Tmax h   | Tlast h   |   Ctrough ng/mL |   t1/2 h |   AUCo-last ng.h/mL. |   AUCo-24h ng.h/mL |   ng.h/mL |   CL/F L/h |   Vz/F L |
|------|------------------------|--------------|----------|-----------|-----------------|----------|----------------------|--------------------|-----------|------------|----------|
| 25   | N                      |         9    | 9        | 9         |            9    |      8   |                  9   |                9   |       8   |       8    |      8   |
|      | Mean                   |        26.1  | 一        |           |            7.04 |     37.9 |                732   |              398   |    1130   |      26.8  |   1400   |
|      | SD                     |        11.5  |          | 一         |            2.54 |     11   |                352   |              132   |     449   |      14.6  |    829   |
|      | CV%                    |        44    |          |           |           36.1  |     29   |                 48   |               33.2 |      39.8 |      54.5  |     59.1 |
|      | GeoMean                |        23.6  |          | 一         |            6.64 |     36.3 |                639   |              372   |    1040   |      24.1  |   1260   |
|      | GeoMean CV%            |        55.1  |          |           |           38.1  |     33.5 |                 65.2 |               44.7 |      49.9 |      49.9  |     46.5 |
|      | Min                    |         7.67 | 1.93     | 24.0      |            3.46 |     19.1 |                237   |              138   |     445   |      13.4  |    872   |
|      | Median                 |        23.8  | 3.98     | 71.1      |            6.2  |     37.9 |                816   |              421   |    1160   |      21.5  |   1140   |
|      | Max                    |        48.3  | 8.00     | 72.3      |           11.4  |     53.7 |               1210   |              574   |    1860   |      56.2  |   3370   |
| 50   | N                      |         9    | 9        | 9         |            9    |      9   |                  9   |                9   |       9   |       9    |      9   |
|      | Mean                   |        66.5  |          |           |           14.6  |     44.9 |               1630   |              819   |    2610   |      22.9  |   1420   |
|      | SD                     |        31.3  | 一        | 一         |            7.02 |     12.7 |                611   |              328   |    1140   |      10.5  |    649   |
|      | CV%                    |        47.1  | 一        | 一         |           48.1  |     28.3 |                 37.4 |               40.1 |      43.8 |      45.9  |     45.8 |
|      | GeoMean                |        58.6  | 一        | 一         |           12.9  |     43.2 |               1530   |              753   |    2390   |      20.9  |   1300   |
|      | GeoMeanCV%             |        62.4  | 一        |           |           60.1  |     30.7 |                 41   |               47.6 |      47.8 |      47.8  |     45.5 |
|      | Min                    |        19.1  | 1.00     | 47.9      |            5.82 |     26.5 |                820   |              381   |    1200   |      11    |    681   |
|      | Median                 |        67.5  | 2.00     | 71.5      |           15.2  |     46.2 |               1670   |              824   |    2680   |      18.7  |   1240   |
|      | Max                    |       116    | 4.13     | 72.0      |           22.2  |     64.3 |               2490   |             1290   |    4530   |      41.6  |   2620   |
| 100  | N                      |        10    | 10       | 10        |           10    |      9   |                 10   |               10   |       9   |       9    |      9   |
|      | Mean                   |       120    | 一        | 一         |           33.7  |     45.4 |               3650   |             1830   |    5810   |      19.9  |   1210   |
|      | SD                     |        45.3  |          |           |           17.6  |     11   |               1210   |              534   |    1970   |       9.89 |    329   |
|      | CV%                    |        37.8  |          |           |           52.3  |     24.2 |                 33.2 |               29.1 |      33.8 |      49.7  |     27.2 |
|      | GeoMean                |       111    | 一        | 一         |           29.9  |     44.1 |               3460   |             1750   |    5450   |      18.3  |   1170   |
|      | GeoMeanCV%             |        46    |          |           |           57.2  |     26.5 |                 37   |               34.3 |      42.3 |      42.4  |     28.7 |
|      | Min                    |        42.5  | 1.98     | 24.0      |           10.4  |     25.5 |               1920   |              842   |    2300   |      11.1  |    794   |
|      | Median                 |       113    | 3.92     | 71.6      |           31.6  |     46.9 |               3570   |             1840   |    6030   |      16.6  |   1290   |
|      | Max                    |       183    | 7.83     | 72.5      |           75.4  |     65.6 |               5610   |             2560   |    8980   |      43.5  |   1700   |

Parameter exclusions: t12 was excluded if lz was unreliable (defined in Section 8.1.1). AUCo-w, CL/F, and Vz/F were excluded if Ay was unreliable or %AUCex was &gt;30%.

Table 8. Summary of Avapritinib Pharmacokinetic Parameters on C1D15 by Dose - Part 1

| Dose mg   | SummaryStatistic   |   Cmax.ss ng/mL | Tmax h   | Tlast h   |   Ctrough,ss ng/ml |   AUCo-1ast.ss ng.h/mL. |   AUCo-- ng.h/mL |   CLs/F L/h |   Rac.AUCO-24h |   Rac.Cmax |
|-----------|--------------------|-----------------|----------|-----------|--------------------|-------------------------|------------------|-------------|----------------|------------|
| 25        | N                  |             9   | 9        | 9         |               9    |                     9   |              9   |        9    |          9     |      9     |
|           | Mean               |            80   | 一        | 一         |              38    |                  2570   |           1520   |       21.6  |          4.06  |      3.36  |
|           | SD                 |            38.2 | 一        | 一         |              24    |                  1330   |            750   |       12.5  |          2.2   |      1.78  |
|           | CV%                |            47.8 |          |           |              63.2  |                    51.7 |             49.5 |       58.1  |         54.3   |     52.9   |
|           | GeoMean            |            70.2 |          |           |              30    |                  2220   |           1330   |       18.7  |          3.59  |      2.98  |
|           | GeoMeanCV%         |            62.7 |          |           |              93.1  |                    65.2 |             60.7 |       60.7  |         56.3   |     55.5   |
|           | Min                |            29.8 | 1.95     | 47.2      |               7.65 |                   935   |            608   |        9.06 |          1.7   |      1.48  |
|           | Median             |            85.1 | 3.97     | 47.8      |              40.8  |                  2620   |           1460   |       17.1  |          3.48  |      3.39  |
|           | Max                |           137   | 8.00     | 48.9      |              76.3  |                  4550   |           2760   |       41.1  |          8.65  |      7.14  |
| 50        | N                  |            10   | 10       | 10        |              10    |                    10   |              9   |        9    |          9     |      9     |
|           | Mean               |           147   |          |           |              89.6  |                  4890   |           2820   |       19.9  |          3.9   |      2.97  |
|           | SD                 |            40.8 |          |           |              36.5  |                  1600   |            904   |        8.13 |          2.07  |      2.37  |
|           | CV%                |            27.7 |          | 一         |              40.7  |                    32.8 |             32   |       40.8  |         53     |     79.8   |
|           | GeoMean            |           141   | 一        |           |              83.1  |                  4640   |           2670   |       18.7  |          3.55  |      2.35  |
|           | GeoMeanCV%         |            35.3 | 一        | 一         |              43.3  |                    35.6 |             37.8 |       37.9  |         45.5   |     84.8   |
|           | Min                |            66.4 | 1.88     | 23.0      |              42.4  |                  2570   |           1360   |       12.8  |          1.9   |      0.572 |
|           | Median             |           162   | 4.00     | 48.0      |              86.4  |                  4740   |           3170   |       15.8  |          3.33  |      2.35  |
|           | Max                |           189   | 8.00     | 48.8      |             157    |                  7330   |           3900   |       36.9  |          8.88  |      8.74  |
| 100       | N                  |             8   | 8        | 8         |               8    |                     8   |              8   |        8    |          8     |      8     |
|           | Mean               |           284   |          | 一         |             162    |                  9630   |           5560   |       20.8  |          3.25  |      2.7   |
|           | SD                 |           115   | 一        | 一         |              59.9  |                  3850   |           1880   |        9.74 |          0.583 |      0.688 |
|           | CV%                |            40.5 | 一        |           |              36.9  |                    40   |             33.9 |       46.9  |         18     |     25.5   |
|           | GeoMean            |           260   |          |           |             151    |                  8620   |           5220   |       19.2  |          3.2   |      2.61  |
|           | GeoMeanCV%         |            49.7 |          |           |              45.9  |                    61.7 |             42.7 |       42.7  |         19.9   |     28.6   |
|           | Min                |           119   | 1.93     | 24.8      |              67.7  |                  2660   |           2580   |       13.2  |          2.11  |      1.5   |
|           | Median             |           310   | 4.08     | 47.9      |             165    |                 10700   |           6050   |       16.5  |          3.26  |      2.76  |
|           | Max                |           458   | 8.05     | 48.6      |             228    |                 13200   |           7600   |       38.8  |          3.97  |      3.74  |

Accumulationratios were determined by dividing the CiD15(steady-state)value by the CiD1value.

Table 9. Summary of Avapritinib Pharmacokinetic Parameters on C1D1 - Part 2

| Dose mg   | Summary Statistic   |   Cmax ng/mL. | EUL h   | h    |   AUCo-last ng.h/mL |
|-----------|---------------------|---------------|---------|------|---------------------|
| 25        | N                   |          23   | 23      | 23   |                23   |
|           | Mean                |          33.5 |         |      |               138   |
|           | SD                  |          19.5 |         |      |               104   |
|           | CV%                 |          58.3 |         |      |                75.8 |
|           | GeoMean             |          30.4 |         |      |               120   |
|           | GeoMean CV%         |          43.5 |         |      |                49.7 |
|           | Min                 |          10.9 | 0.933   | 4.98 |                43.9 |
|           | Median              |          29.1 | 4.00    | 5.98 |               115   |
|           | Max                 |         116   | 6.17    | 6.17 |               592   |

<div style=\"page-break-after: always\"></div>

Table 10. Summary of Avapritinib Pharmacokinetic Parameters on C2D1 - Part 2

| Dose mg   | SummaryStatistic   |   Cmax.ss ng/mL | Tmax h   | h    |   AUCo-last.ss ng.h/mL |   Rac,AUCO-last |   Rac.Cmax |
|-----------|--------------------|-----------------|----------|------|------------------------|-----------------|------------|
| 25        | N                  |            29   | 29       | 29   |                   29   |          17     |      17    |
|           | Mean               |            80.3 |          |      |                  388   |           2.9   |       3.63 |
|           | SD                 |            35.3 |          |      |                  160   |           0.766 |       1.08 |
|           | CV%                |            44   |          |      |                   41.2 |          26.4   |      29.8  |
|           | GeoMean            |            73.5 |          |      |                  357   |           2.82  |       3.5  |
|           | GeoMeanCV%         |            45.5 |          |      |                   44.4 |          23.9   |      27.4  |
|           | Min                |            23.3 | 3.85     | 5.83 |                  118   |           2.03  |       2.22 |
|           | Median             |            73.2 | 4.00     | 6.00 |                  363   |           2.73  |       3.36 |
|           | Max                |           205   | 6.00     | 6.67 |                  910   |           5.16  |       6.55 |

Accumulationratiosweredeterminedbydividing theC2D1(steady-state)value by the CiD1value.

## Dose proportionality

In Part 1, a dose-proportional increase in systemic exposure to avapritinib was observed across the dose range of 25 to 100 mg after single-dose administration (C1D1) and at steady state (C1D15) for Cmax and AUC (Figure 2 and Table 7).

Figure 2. Dose Proportionality Analysis of Avapritinib Systemic Exposure After Administration of 25 to 100 mg in Patients with ISM (Study BLU-285-2203, Part 1)

<!-- image -->

Abbreviations: AUCo∞ = area under the plasma concentration-time curve from time O extrapolated to infinity, AUCo- = area under the plasma concentration-time curve over the dosing interval (t = 24 hours); C1D1 =Cycle 1 Day 1; C1D15 = Cycle 1 Day 15; CI = confidence interval; Cmax = maximum plasma concentration; ISM = indolent systemic mastocytosis, n = number of patients in each group.

Note: Both axes are on a log scale. Open circles represent individual values of exposure metric (C1D1: Cmax Or AUCo-o, C1D15: Cmax or AUCo-t), shaded area = 90% CI of the slope, blue line = linear regression.

<div style=\"page-break-after: always\"></div>

Table  11.  Analysis  of  Dose  Proportionality  for  Avapritinib  Pharmacokinetic  Parameters  After Administration of 25 to 100 mg in Patients with ISM (Study BLU-285-2203, Part 1)

| Cycle   | Parameter   |   βest | 90% CI     | Critical Interval   | Conclusion   |
|---------|-------------|--------|------------|---------------------|--------------|
| C1D1    | C max       |   1.11 | 0.83, 1.4  | 0.50-1.50           | Proportional |
|         | AUCo        |   0.96 | 0.542,1.37 | 0.50-1.50           | Proportional |
| C1D15   | Cmax        |   0.95 | 0.671,1.22 | 0.50-1.50           | Proportional |
|         | AUCo--      |   0.98 | 0.717,1.25 | 0.50-1.50           | Proportional |

Abbreviations: AUCo-o = area under the plasma concentration-time curve from time O extrapolated to infinity;

AUCo-= area under the plasma concentration-time curve over the dosinginterval (t=24 hours);

pest =proportionality constant; C1D1 =Cycle 1 Day 1; C1D15=Cycle 1 Day 15; CI=confidence interval;

Cmax = maximum plasma concentration; ISM = indolent systemic mastocytosis.

Note: The critical interval is the prespecified acceptable 90% CI of the slope.

## BLU111207 Pharmacokinetics

The summary BLU111207 PK parameters by dose and day are displayed in Tables 12 and 13, for Part 1 and in Table 14 and 15 for Part 2.

Table 12. Summary of BLU111207 Pharmacokinetic Parameters on C1D1 by Dose - Part 1

| mg   | DoseSummaryStatistic   |   Cmax ng/mL | Tmax h   | Tiast h   |   Ctrough ng/mL. |   t1/2 h |   AUCo-last ng.h/mL. |   AUCo-24h ng.h/mL |   AUCo-∞ ng.h/mL |
|------|------------------------|--------------|----------|-----------|------------------|----------|----------------------|--------------------|------------------|
| 25   | N                      |        9     | 9        | 9         |            9     |     2    |                  9   |                9   |              2   |
|      | Mean                   |        1.94  |          |           |            0.984 |    39.6  |                 73.2 |               31.8 |            127   |
|      | SD                     |        1.15  |          |           |            0.445 |     8.41 |                 41   |               14.2 |            133   |
|      | CV%                    |       59.1   |          |           |           45.2   |    21.3  |                 56.1 |               44.6 |            104.1 |
|      | GeoMean                |        1.7   |          |           |            0.822 |    39.1  |                 62.2 |               29.2 |             86.2 |
|      | GeoMean CV %           |       56.9   |          |           |           88.8   |    21.7  |                 70.6 |               47.7 |            221.2 |
|      | Min                    |        0.717 | 1.93     | 24.0      |            0.152 |    33.6  |                 26.3 |               12.2 |             33.6 |
|      | Median                 |        1.48  | 4.02     | 71.2      |            1.06  |    39.6  |                 79.9 |               28.1 |            127   |
|      | Max                    |        4.36  | 71.2     | 72.3      |            1.44  |    45.5  |                146   |               60.1 |            221   |
| 50   | N                      |        9     | 9        | 9         |            9     |     5    |                  9   |                9   |              5   |
|      | Mean                   |        4.79  |          | 一         |            1.28  |    44.1  |                123   |               51.1 |            145   |
|      | SD                     |        3.66  | 一        | 一         |            0.853 |    27.1  |                 74   |               26.3 |            116   |
|      | CV%                    |       76.5   |          |           |           66.5   |    61.4  |                 60.3 |               51.5 |             79.7 |
|      | GeoMean                |        3.65  |          |           |            0.906 |    38.5  |                104   |               45.7 |            112   |
|      | GeoMean CV %           |       93     |          |           |          133.9   |    61.3  |                 67.6 |               52.5 |             93.5 |
|      | Min                    |        1.44  | 1.00     | 48.0      |            0.208 |    20.5  |                 47.9 |               24.9 |             56.3 |
|      | Median                 |        4.22  | 4.00     | 71.7      |            1.71  |    33.8  |                 91.2 |               38.3 |             76.7 |
|      | Max                    |       11.5   | 71.5     | 72.0      |            2.36  |    88.5  |                234   |               95   |            313   |
| 100  | N                      |       10     | 10       | 10        |           10     |     5    |                 10   |               10   |              5   |
|      | Mean                   |        9.44  |          |           |            4.15  |    71    |                344   |              143   |            787   |
|      | SD                     |        5.71  | 一        | 一         |            1.61  |    13    |                158   |               70.7 |            273   |
|      | CV%                    |       60.4   |          | 一         |           38.8   |    18.3  |                 46   |               49.5 |             34.6 |
|      | GeoMean                |        8.1   |          |           |            3.78  |    70.1  |                307   |              127   |            754   |
|      | GeoMean CV %           |       64.5   |          |           |           52.7   |    17.2  |                 58.1 |               56.9 |             33.3 |
|      | Min                    |        2.63  | 1.98     | 24.0      |            1.22  |    58.7  |                119   |               47.4 |            533   |
|      | Median                 |        7.7   | 3.06     | 71.6      |            4.32  |    66.8  |                324   |              129   |            778   |
|      | Max                    |       20.7   | 71.0     | 72.5      |            5.88  |    93    |                629   |              273   |           1230   |

Parameter exclusions: ti2 was excluded if Az was unreliable (defined in Section 8.1.1).

<div style=\"page-break-after: always\"></div>

Table 13. Summary of BLU111207 Pharmacokinetic Parameters on C1D15 by Dose - Part 1

| Dose mg   | Summary Statistic   |   Cmax,.ss ng/mL | Tmax h   | Tlast h   |   Ctrough.ss ng/ml. |   AUCo-last.ss ng.h/mL. |   AUCo-T ng.h/mL |   Rac,AUCO-24h |   Rac.Cmax |
|-----------|---------------------|------------------|----------|-----------|---------------------|-------------------------|------------------|----------------|------------|
| 25        | N                   |             9    | 9        | 9         |               9     |                     9   |              9   |           9    |      9     |
|           | Mean                |            10.3  |          |           |               5.56  |                   339   |            187   |           5.99 |      5.51  |
|           | SD                  |             6.48 |          |           |               3.78  |                   211   |            115   |           4.08 |      3.68  |
|           | CV%                 |            63.1  |          |           |              67.9   |                    62.3 |             61.7 |          68    |     66.8   |
|           | GeoMean             |             7.64 |          |           |               3.84  |                   247   |            138   |           4.74 |      4.49  |
|           | GeoMean CV%         |           117.3  |          |           |             147.4   |                   126.2 |            119.9 |          89.1  |     77.9   |
|           | Min                 |             1.46 | 0.967    | 47.2      |               0.57  |                    51.2 |             31.1 |           1.25 |      1.76  |
|           | Median              |            12.3  | 3.98     | 47.8      |               5.59  |                   466   |            241   |           4.99 |      4.41  |
|           | Max                 |            18.1  | 23.2     | 48.9      |              11.5   |                   574   |            307   |          13.4  |     12.3   |
| 50        | N                   |            10    | 10       | 10        |              10     |                    10   |              9   |           9    |      9     |
|           | Mean                |            17.8  |          |           |              10.6   |                   584   |            339   |           6.81 |      6.1   |
|           | SD                  |            12.9  | 一        |           |               9.3   |                   495   |            273   |           6.23 |      6.18  |
|           | CV%                 |            72.4  |          |           |              87.4   |                    84.7 |             80.6 |          91.5  |    101.3   |
|           | GeoMean             |            12.6  |          |           |               6.39  |                   368   |            214   |           4.68 |      3.36  |
|           | GeoMean CV%         |           129.9  |          |           |             186.8   |                   162   |            167.8 |         120.5  |    230.5   |
|           | Min                 |             2.32 | 0.500    | 23.0      |               0.824 |                    66.7 |             42.2 |           1.1  |      0.202 |
|           | Median              |            18    | 2.00     | 48.0      |               9.66  |                   518   |            376   |           4.38 |      2.99  |
|           | Max                 |            39.4  | 23.0     | 48.8      |              28.2   |                  1400   |            771   |          20.4  |     19.1   |
| 100       | N                   |             8    | 8        | 8         |               8     |                     8   |              8   |           8    |      8     |
|           | Mean                |            41.1  | 一        | 一         |              34.7   |                  1700   |            872   |           7.85 |      6.05  |
|           | SD                  |            20.8  | 一        |           |              17.4   |                   915   |            436   |           3.37 |      3.05  |
|           | CV%                 |            50.7  | 一        |           |              50.2   |                    53.9 |             50   |          42.9  |     50.5   |
|           | GeoMean             |            37    |          |           |              30.4   |                  1440   |            779   |           6.91 |      5.17  |
|           | GeoMean CV%         |            50.7  |          |           |              63.2   |                    74.8 |             54.9 |          68.5  |     76     |
|           | Min                 |            20.6  | 2.00     | 24.8      |              12.8   |                   424   |            413   |           1.73 |      1.24  |
|           | Median              |            32.8  | 4.00     | 47.9      |              32.6   |                  1480   |            729   |           8.12 |      5.7   |
|           | Max                 |            77.4  | 7.98     | 48.6      |              59.3   |                  2950   |           1520   |          12.8  |     11     |

Accumulation ratios were determined by dividing the CiD15 (steady-state) value by the CiD1 value.

Table 14. Summary of BLU111207 Pharmacokinetic Parameters on C1D1 - Part 2

| Dose mg   | Summary Statistic   |   Cmax ng/mL | h    | Tiast h   |   AUCo-iast ng.h/mL |
|-----------|---------------------|--------------|------|-----------|---------------------|
| 25        | N                   |       28     | 28   | 28        |               28    |
|           | Mean                |        2.82  |      |           |               11.4  |
|           | SD                  |        1.44  |      |           |                6.28 |
|           | CV%                 |       51.2   |      |           |               55.2  |
|           | GeoMean             |        2.46  |      |           |                9.79 |
|           | GeoMean CV%         |       61     |      |           |               64.7  |
|           | Min                 |        0.553 | 1.08 | 4.98      |                1.99 |
|           | Median              |        2.74  | 4.00 | 6.00      |               10.8  |
|           | Max                 |        7.51  | 6.00 | 6.17      |               31.4  |

Table 15. Summary of BLU111207 Pharmacokinetic Parameters on C2D1 - Part 2

| Dose mg   | SummaryStatistic   |   Cmax.ss ng/mL | Tmax h   | Tiast h   |   AUCo-last.ss ng.h/ml |   Rac,AUCO-1ast |   Rac.Cmax |
|-----------|--------------------|-----------------|----------|-----------|------------------------|-----------------|------------|
| 25        | N                  |           30    | 30       | 30        |                  30    |           23    |      23    |
|           | Mean               |           11.5  |          |           |                  58    |            4.94 |       6.4  |
|           | SD                 |            5.38 |          |           |                  28.3  |            2.66 |       3.59 |
|           | CV%                |           46.9  |          |           |                  48.9  |           53.7  |      56.1  |
|           | GeoMean            |            9.93 |          |           |                  49.5  |            4.28 |       5.45 |
|           | GeoMean CV%        |           67.4  |          |           |                  71    |           61.5  |      66.9  |
|           | Min                |            1.5  | 0.933    | 5.83      |                   7.25 |            1.32 |       1.41 |
|           | Median             |           11    | 4.00     | 6.00      |                  55.3  |            4.31 |       5.9  |
|           | Max                |           22.5  | 6.67     | 6.67      |                 108    |           12    |      15.2  |

AccumulationratiosweredeterminedbydividingtheC2D1(steady-state)valuebytheCiD1value.

The Rmet for BLU111207 (as assessed by AUC) did not appear to be dose dependent but increased slightly between observation periods, the mean ranges were 6.1% - 7.8% and 8.0% - 15% on C1D1 and C1D15, respectively (Table 16).

<div style=\"page-break-after: always\"></div>

Table 16. Summary of BLU111207 to Avapritinib Ratio on C1D1 by Dose - Part 1

| Visit   | AvapritinibDose (mg)   | N GeometricMeanAUC   | N GeometricMeanAUC   | Rmet (%) BLU111207/Avapritinib   |
|---------|------------------------|----------------------|----------------------|----------------------------------|
| Visit   | AvapritinibDose (mg)   | Avapritinib          | BLU111207            | Rmet (%) BLU111207/Avapritinib   |
| C1D1    | 25                     | 9 372                | 29.1                 | 7.82                             |
| C1D1    | 50                     | 9 753                | 45.7                 | 6.05                             |
| C1D1    | 100                    | 10 1750              | 127                  | 7.23                             |
| CID15   | 25                     | 9 1340               | 138                  | 10.3                             |
| CID15   | 50                     | 9 2670               | 214                  | 7.98                             |
| CID15   | 100                    | 8 5220               | 779                  | 14.9                             |

AUCo-24 and AUC, were reported on C1D1 and CiD15, respectively. Only patients with valid AUCs for both analytes on the same visitwereincluded.

## BLU111208 Pharmacokinetics

The summary BLU111208 PK parameters by dose and day are displayed in Tables 17 and 18, for Part 1 and in Table 19 and 20 for Part 2.

Table 17. Summary of BLU111208 Pharmacokinetic Parameters on C1D1 by Dose - Part 1

| mg   | DoseSummaryStatistic   |   Cmax ng/mL | Tmax h   | Tlast h   |   ng/mL |   t1/2 h |   AUCo-last ng.h/mL |   AUCo-24h ng.h/mL |   ng.h/mL |
|------|------------------------|--------------|----------|-----------|---------|----------|---------------------|--------------------|-----------|
| 25   | N                      |        9     | 9        | 9         |   9     |      3   |                 9   |                9   |       3   |
|      | Mean                   |        2.39  |          |           |   1.23  |     57.5 |                92.6 |               38.7 |     252   |
|      | SD                     |        1.7   |          |           |   0.56  |     13.1 |                63.4 |               22.2 |     190   |
|      | CV%                    |       71.1   |          |           |  45.7   |     22.7 |                68.5 |               57.4 |      75.3 |
|      | GeoMean                |        1.99  |          |           |   1.05  |     56.5 |                73   |               34.1 |     176   |
|      | GeoMeanCV%             |       67.8   |          |           |  76.5   |     24.8 |                89.2 |               57   |     179.4 |
|      | Min                    |        0.766 | 2.00     | 24.0      |   0.224 |     42.7 |                27.2 |               13.5 |      44.8 |
|      | Median                 |        1.71  | 4.02     | 71.2      |   1.2   |     62.6 |                87.7 |               32   |     294   |
|      | Max                    |        6.08  | 71.3     | 72.3      |   2.08  |     67.3 |               215   |               85.1 |     417   |
| 50   | N                      |       10     | 10       | 10        |  10     |      5   |                10   |                9   |       5   |
|      | Mean                   |        5.85  |          |           |   2.13  |    116   |               154   |               65.7 |     430   |
|      | SD                     |        4.97  |          | 一         |   1.37  |    153   |               108   |               33.4 |     513   |
|      | CV%                    |       84.8   |          |           |  64.3   |    132.5 |                69.9 |               50.7 |     119.3 |
|      | GeoMean                |        4.47  |          |           |   1.57  |     68.1 |               114   |               58.5 |     227   |
|      | GeoMeanCV%             |       87.8   |          |           | 120.2   |    140.1 |               113.8 |               54.8 |     199.8 |
|      | Min                    |        1.53  | 1.00     | 7.92      |   0.379 |     33   |                16.2 |               28.5 |      82.5 |
|      | Median                 |        4.69  | 4.02     | 71.6      |   2.25  |     37.2 |               130   |               50.2 |     108   |
|      | Max                    |       18.1   | 71.5     | 72.0      |   4.1   |    387   |               313   |              115   |    1250   |
| 100  | N                      |       10     | 10       | 10        |  10     |      3   |                10   |               10   |       3   |
|      | Mean                   |       12     |          | 一         |   6.64  |     82.8 |               509   |              194   |    1540   |
|      | SD                     |        6.41  |          | 一         |   2.12  |     12.1 |               213   |               89.9 |     497   |
|      | CV%                    |       53.4   |          | 一         |  32     |     14.7 |                41.9 |               46.4 |      32.4 |
|      | GeoMean                |       10.7   |          |           |   6.18  |     82.2 |               458   |              175   |    1490   |
|      | GeoMeanCV%             |       54.6   |          |           |  47.3   |     14.7 |                56.5 |               52.1 |      31.1 |
|      | Min                    |        4.23  | 1.98     | 24.0      |   1.92  |     71.3 |               156   |               73.7 |    1220   |
|      | Median                 |        9.66  | 3.06     | 71.6      |   6.67  |     81.6 |               518   |              174   |    1280   |
|      | Max                    |       25.4   | 71.0     | 72.5      |   9.32  |     95.5 |               861   |              339   |    2110   |

Parameter exclusions: ti2 was excluded if Az was unreliable (defined in Section 8.1.1).

<div style=\"page-break-after: always\"></div>

Table 18. Summary of BLU111208 Pharmacokinetic Parameters on C1D15 by Dose - Part 1

| Dose mg   | SummaryStatistic   |   Cmax.ss ng/mL | Tmax h   | Tlast h   |   Ctrough.ss ng/mL. |   AUCo-last,ss ng.h/mL |   ng.h/mL |   Rac.AUCO-24h |   Rac.Cmax |
|-----------|--------------------|-----------------|----------|-----------|---------------------|------------------------|-----------|----------------|------------|
| 25        | N                  |            9    | 9        | 9         |                9    |                    9   |       9   |           9    |      9     |
|           | Mean               |           15.8  | 一        | 一         |                9.99 |                  577   |     312   |           8.38 |      7.23  |
|           | SD                 |            9.21 |          |           |                6.49 |                  354   |     190   |           4.99 |      4.13  |
|           | CV%                |           58.1  |          |           |               65    |                   61.4 |      60.9 |          59.5  |     57.1   |
|           | GeoMean            |           12.4  |          |           |                6.81 |                  419   |     234   |           6.86 |      6.23  |
|           | GeoMean CV%        |          100.7  |          |           |              158.1  |                  130.4 |     117.2 |          84    |     64.3   |
|           | Min                |            3.23 | 2.00     | 47.2      |                1.07 |                   72   |      47   |           1.58 |      2.37  |
|           | Median             |           19.8  | 4.00     | 47.8      |               11.4  |                  801   |     405   |           6.16 |      5.6   |
|           | Max                |           26.6  | 23.2     | 48.9      |               17.9  |                  899   |     519   |          15    |     13.8   |
| 50        | N                  |           10    | 10       | 10        |               10    |                   10   |       9   |           9    |     10     |
|           | Mean               |           26.9  |          |           |               19    |                  954   |     518   |           8.22 |      7.2   |
|           | SD                 |           17.5  |          |           |               14.5  |                  706   |     387   |           7.13 |      6.22  |
|           | CV%                |           65    |          |           |               76.6  |                   74   |      74.6 |          86.8  |     86.4   |
|           | GeoMean            |           19.7  |          |           |               12.2  |                  652   |     348   |           5.94 |      4.41  |
|           | GeoMean CV%        |          119.8  |          |           |              164.2  |                  140.2 |     147.6 |         105.7  |    200.1   |
|           | Min                |            4.24 | 0.500    | 23.0      |                1.96 |                  134   |      73.4 |           1.46 |      0.234 |
|           | Median             |           29.6  | 1.98     | 48.0      |               18.2  |                  920   |     560   |           5.04 |      4.92  |
|           | Max                |           52.8  | 4.00     | 48.8      |               41.5  |                 2020   |    1080   |          23    |     19.1   |
| 100       | N                  |            8    | 8        | 8         |                8    |                    8   |       8   |           8    |      8     |
|           | Mean               |           61.2  |          |           |               55.1  |                 2610   |    1330   |           8.85 |      6.77  |
|           | SD                 |           26.2  | 一        | 一         |               22.8  |                 1210   |     544   |           3.59 |      3     |
|           | CV%                |           42.7  | 一        | 一         |               41.3  |                   46.5 |      40.8 |          40.6  |     44.3   |
|           | GeoMean            |           56.7  |          |           |               50.5  |                 2300   |    1230   |           7.88 |      5.94  |
|           | GeoMean CV%        |           43.4  |          |           |               49.2  |                   64.2 |      44.5 |          64.5  |     68.8   |
|           | Min                |           33.5  | 1.97     | 24.8      |               25.6  |                  735   |     709   |           2.09 |      1.52  |
|           | Median             |           56    | 4.04     | 47.9      |               55.2  |                 2460   |    1220   |           9.3  |      6.9   |
|           | Max                |          106    | 23.8     | 48.6      |               87.6  |                 4190   |    2120   |          13.6  |     11.2   |

Accumulation ratios were determined by dividing the CiD15 (steady-state)value by the CiD1 value.

Table 19. Summary of BLU111208 Pharmacokinetic Parameters on C1D1 - Part 2

| Dose mg   | Summary Statistic   |   Cmax ng/mL | EUL h   | Tiast h   |   AUCo-last ng.h/mL |
|-----------|---------------------|--------------|---------|-----------|---------------------|
| 25        | N                   |        26    | 26      | 26        |               26    |
|           | Mean                |         3.12 |         |           |               12.8  |
|           | SD                  |         1.69 |         |           |                7.28 |
|           | CV%                 |        54.1  |         |           |               57.1  |
|           | GeoMean             |         2.7  |         |           |               10.9  |
|           | GeoMean CV%         |        61.6  |         |           |               65.1  |
|           | Min                 |         0.6  | 1.08    | 4.98      |                2.21 |
|           | Median              |         2.98 | 4.00    | 5.99      |               10.9  |
|           | Max                 |         8.54 | 6.00    | 6.17      |               35.6  |

Table 20. Summary of BLU111208 Pharmacokinetic Parameters on C2D1 - Part 2

| Dose mg   | SummaryStatistic   |   Cmax.ss ng/mL | Tmax h   | Tlast h   |   AUCo-last.ss ng.h/mL |   Rac,AUCO-1ast |   Rac.Cmax |
|-----------|--------------------|-----------------|----------|-----------|------------------------|-----------------|------------|
| 25        | N                  |           30    | 30       | 30        |                   30   |           22    |      22    |
|           | Mean               |           16.4  |          |           |                   83.4 |            6.56 |       8.52 |
|           | SD                 |            6.99 |          |           |                   37   |            3.53 |       4.74 |
|           | CV%                |           42.7  |          |           |                   44.4 |           53.8  |      55.6  |
|           | GeoMean            |           14.5  |          |           |                   73.2 |            5.65 |       7.25 |
|           | GeoMeanCV%         |           60.5  |          |           |                   62.9 |           63.8  |      67.7  |
|           | Min                |            2.52 | 0.933    | 5.83      |                   12.7 |            1.55 |       1.78 |
|           | Median             |           15.1  | 4.05     | 6.00      |                   76.8 |            5.93 |       8.32 |
|           | Max                |           31.4  | 6.67     | 6.67      |                  154   |           14.9  |      19.2  |

Accumulationratiosweredetermined by dividingtheC2D1 (steady-state)value by the CiD1value.

The Rmet for BLU111208 (as assessed by AUC) did not appear to be dose dependent but increased slightly between observation periods, the mean ranges were 7.8% - 10% and 13% - 24% on C1D1 and C1D15, respectively (Table 21).

<div style=\"page-break-after: always\"></div>

Table 21. Summary of BLU111208 to Avapritinib Ratio on C1D1 by Dose - Part 1

| Visit   | AvaprilinibDose (mg)   | N GeometricMeanAUC   | N GeometricMeanAUC   | Rmet (%) BLU111208/Avapritinib   |
|---------|------------------------|----------------------|----------------------|----------------------------------|
| Visit   | AvaprilinibDose (mg)   | Avapritinib          | BLU111208            | Rmet (%) BLU111208/Avapritinib   |
| CID1    | 25                     | 9 372                | 34.1                 | 9.14                             |
| C1D1    | 50                     | 9 753                | 58.5                 | 7.76                             |
| C1D1    | 100                    | 10 1750              | 175                  | 9.96                             |
| CID15   | 25                     | 9 1340               | 234                  | 17.5                             |
| C1D15   | 50                     | 9 2670               | 348                  | 13.0                             |
| C1D15   | 100                    | 8 5220               | 1230                 | 23.6                             |

AUCo-24 and AUC, were reported on C1D1 and CiD15, respectively. Only patients with valid AUCs for both analytes on the same visitwereincluded.

## Population Pharmacokinetic Analysis

The  overall  objective  of  the  analysis  was  to  update  the  population  pharmacokinetic  (PK)  model  to characterize  avapritinib  exposure  as  a  function  of  dose,  time  after  dosing,  and  patient  characteristics, including the variability between and within patients with indolent systemic mastocytosis (ISM). To achieve this the following sub-objectives were set:

1. Perform exploratory graphical analysis of the plasma concentration-time profile of avapritinib in study BLU-285-2203.

2. Evaluate and update the previously developed population PK model for avapritinib in healthy volunteers (HVs),  patients  with  gastrointestinal  stromal  tumours  (GIST),  and  patients  with  advanced  systemic mastocytosis (AdvSM) to describe the plasma concentration-time data from clinical study BLU-285-2203 in patients with ISM.

(a) Quantify population PK parameters, including typical parameter values and random inter-individual and residual variability.

(b) Identify and quantify covariate effects which describe variability in the PK ofavapritinib.

3. Estimate the maximum plasma concentration at steady state (Cmax,ss) and the area under the plasma concentration-time curve from time 0 to 24 hours at steady state (AUC0-24,ss) for patients recruited in study BLU-285-2203 Part 2, on cycle 1 day 15 (C1D15, steady state) where only sparse PK samples were collected.

The PK Model was updated in a step-wise manner as follows:

1. Previously developed population PK model was fitted to the data from only study BLU-285-2203 without parameter estimation, in a process known as Bayesian feedback. Any biases or changes specific to the ISM population were then compared to the previous analysis populations to inform the model update in the next step.

2. Data from other studies were included in the model with full parameter estimation.

3. Covariate effects were evaluated through visual inspection of covariate-eta relationships for any obvious trends.

<div style=\"page-break-after: always\"></div>

Figure 3. Model Development Flowchart

<!-- image -->

- ** Only fasted observations from study BLU-285-0102 were included in the analysis

A summary of the available studies included in the final analysis dataset is presented in Table 22.

Table 22. Summary of Data Available for the Model Building

<!-- image -->

| Study        | Study Description                                                                                                                                                                | Dose (Formulation Process)                                                                                                           |     | PK Sampling                                                                                    |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------|
| BLU-285-0101 | An open-label, randomized, single- dose, 2-way crossover study to evaluate therelativebioavailabilityofavapritinib (tablet vs capsule) in healthy adult male subjects            | 1 x 200 mg (tablet) fasted state: 10h before, & 4h after dosing 2 x 100 mg (capsule) fasted state: 10h before, & 4h after dosing     | 30  | Predose, 0.5, 1, 1.5, 2, 2.5, 3.25, 4, 4.75,5.5, 6, 8,10, 12, 24, 48, & 72h                    |
| BLU-285-0102 | An open-label, randomized, single- dose, 2-way crossover study to evaluate the e ect of food on the pharmacokinet- ics of avapritinib in healthy adult male subjects             | 2 x 100 mg (tablet) following an overnight fast 2 x 100 mg (tablet) overnight fast, followed by a high-fat meal 30 min before dosing | 30* | Predose,0.5,1,1.5,2,2.5,3.25,4,4.75,5.5,6, 8,10,12,24,48,72,96,120,&168h                       |
| BLU-285-0105 | An open-label, randomized, single- dose， 2-period crossover, bioequiva- lence study comparing one 400 mg tablet with four 100 mg tablets of avapritinibin healthy adult subjects | 4 x 100 mg (tablet) following an overnight fast 1 x 400 mg (tablet) following an overnight fast                                      | 62  | Predose,0.5,1,1.5,2,2.5,3.25,4,4.75,5.5, 6.25,8,10,12,24,36,48,72,96,120,144,168, 192,216&240h |

In studyBLU-285-2101,Part 2,and studyBLU-285-2202(intensive sampling),the Cycle1Day2 and Day16 dose were not administered to allowfor collection of the 48-hour postdose sample on Day 3 and Day 17, respectively. Includes patients from Parts 1 &amp; 2. In study BLU-285-2203 (Part 1), the Cycle 1 Day 2, Cycle 1 Day 3, and Cycle 1 Day 16 dose were not administered to allow for collection of the 48 and 72-hour postdose samples. nnumber of subjects included in the analysis.

<div style=\"page-break-after: always\"></div>

| Study        | StudyDescription                                                                                                     | Dose (Formulation Process)                                                                                                                        | n     | PK Sampling                                                                                                                                                             |
|--------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BLU-285-1101 | Phase I, open-label, first-in-human study in patients with GIST & other relapsedrefractory solid tumours             | Dose-Escalation (Part 1) 30,60,90,135,200,300,400,600 mg (capsule ortablet) once daily fasted 2h before & until 1h after dosing                   | 43    | Dose-Escalation (Part 1) Lead-in:Predose,0.5,1,2,4,8,10,24,48,72h C1D15:Predose,0.5,1,2,4,8h C2-4: Predose                                                              |
|              |                                                                                                                      | Dose-Expansion (Part 2: 3groups) 400, 300 mg (capsule or tablet) once daily fasted 2h before & until 1 hr after dosing Group 1i Group 2i Group 35 | 178   | Dose-Expansion (Part 2) IntensiveSamplingSchedule C1:Predose,0.5,1,2,4,8,24h C1D15:Predose,0.5,1,2,4,8h C2-4: Predose SparseSamplingSchedule C1D15: Predose, 1, 4, 6-8h |
| BLU-285-2101 | Phase 1, open-label, first-in-human study in patients with AdvSM and re- lapsed or refractory myeloid malignan- cies | Dose-Escalation (Part 1) 30,60,100,130,200,300,400mg (capsule ortablet) once daily fasted 2h before & until 1h after dosing                       | 32    | Dose-Escalation (Part 1) C1D1: Predose,0.5,1,2,4,8,24h C1D15:Predose,0.5,1,2,4,8h C2-4: Predose                                                                         |
|              |                                                                                                                      | Dose-Expansion (Part 2) 300 or 200 mg (capsule ortablet) once daily fasted 2h before & until 1h after dosing                                      |       | Dose-Expansion (Part 2) Cohort 1: C1D1: Predose,0.5,1,2,4,8, 24h CID15: Predose, 0.5, 1,2,4, 8h C2-4: Predose                                                           |
|              |                                                                                                                      | Cohort 1 Cohort 2**                                                                                                                               | 37 17 | Cohort 2: C1D1:Predose,0.5,1,2,4,8,10,24,48h C1D15:Predose,0.5,1,2,4,8,10,24,48h C2-4: Predose                                                                          |

Continued on next page. Intensive PK sampling, ~ Sparse PK sampling, Fed subjects from study BLU-285-0102 were not included in the population PK analysis.1 In study BLU-285-2101, Part 2, and study BLU-285-2202 (intensive sampling), the Cycle 1 Day 2 and Day 16 dose were not administered to allow for collection of the 48-hour postdose sample on Day 3 and Day 17,respectively.Includes patients from Parts 1 &amp; 2. In study BLU-285-2203 (Part 1), the Cycle 1 Day 2, Cycle 1 Day 3, and Cycle 1 Day 16 dose were not administered to allow for collection of the 48 and 72-hour postdose samples. nnumber of subjects included in the analysis.

| Study        | StudyDescription                                                                                                                       | Dose (Formulation Process)                                                                                       |   n | PK Sampling                                                                                                                                                                                                                                                                                    |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BLU-285-2202 | An open-label, single arm, Phase 2 study to evaluate e cacy and safety of avapritinib in patients with A dvSM                          | 200 mg (tablet) once daily fasted 2h before & until 1h after dosing                                              |  58 | Intensive Sampling (n 15)** C1D1:Predose,0.5,1,2,4,8,10,24,48h C1D15:Predose,0.5,1,2,4,8,10,24,48h C2,C3,C5:Predose,1 time point between 1-8h StandardSampling(allotherpatients) CID1: Predose, 1 time point between 1-8h CID15: Predose, 1,4, 6-8h C2,C3,C5:Predose,1 time point between 1-8h |
| BLU-285-2203 | A 3-part, randomized,double-blind, placebo-controlled Phase 2 study to evaluate ecacy and safety of avapri- tinib in patients with ISM | Part 1 25,50,100 mg (tablet) once daily for 16 weeks fasted 2h before & until 1h after dosing                    |  30 | Part 1 (Intensive) C1D1:Predose,0.5,1,2,4,8,10,24,48,72h C1D15:Predose, 0.5,1,2,4,8,10, 24,48h C2D1, C3D1, C4D1: Predose, 1 time point between 1-8h                                                                                                                                            |
|              |                                                                                                                                        | Part 2 25 mg (tablet) once daily for 6 cycles fasted 2h before & until 1h after dosing                           | 139 | Part2 (Intensive,n 40) CID1: Predose, 1,4, 6-8h C2D1: Predose, 1, 4, 6-8h C3D1-C7D1: Predose, 1 time point between 1-8h Part 2 (Sparse)                                                                                                                                                        |
|              |                                                                                                                                        | Part3 (Open-Label Extension) 25 mg (tablet) once daily forup to 5 years fasted 2h before & until 1h after dosing | 235 | Part3 No PKSamples                                                                                                                                                                                                                                                                             |

2, and study BLU-285-2202 (intensive sampling), the Cycle 1 Day 2 and Day 16 dose were not administered to allow for collection of the 48-hour postdose sample on Day 3 and Day17,respectively.Includes patients fromParts 1&amp; 2.In study BLU-285-2203(Part 1),the Cycle 1 Day 2,Cycle 1 Day 3,and Cycle 1 Day16 dose were not administered to allow for collection of the 48 and 72-hour postdose samples. nnumber of subjects included in the analysis.

<div style=\"page-break-after: always\"></div>

The PK analysis population included all subjects and patients that received at least one dose of avapritinib with valid avapritinib concentrations from studies shown in Table 22.

## Dataset

A total of 3579 observations in the NONMEM dataset were excluded from the analysis. The majority of these data had dose time related to the samples not known accurately (12.6%), were either BLQ (8.5%) or were associated with the 'fed' treatment arm in BLU-285-0102 (4.1%). A detailed summary of the excluded data is shown in Table 23.

Table 23. Summary of Data in the NONMEM Dataset which were Excluded from Analysis

|                                | BLU-285-0101   | BLU-285-0102   | BLU-285-0105   | BLU-285-1101   | BLU-285-2101   | BLU-285-2202   | BLU-285-2203   | Total        |
|--------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------|
| Originalobservations           | 1020           | 1200           | 3100           | 3264           | 1433           | 574            | 2693           | 13284        |
| InvalidDatetime                | 0              | 0              | 0              | 0              | 0              | 2 (0.3%)       | 23 (0.9%)      | 25 (0.2%)    |
| Duplicate PKmeasures           | 0              | 0              | 0              | 0              | 24 (1.7%)      | 0              | 0              | 24 (0.2%)    |
| PredoseBLQexclusions           | 30 (2.9%)      | 30 (2.5%)      | 62 (2%)        | 197 (6%)       | 84 (5.9%)      | 60 (10.5%)     | 154 (5.7%)     | 617 (4.6%)   |
| Missingconcentrations          | 0              | 1 (0.1%)       | 0              | 0              | 0              | 0              | 0              | 1 (0%)       |
| PostdoseBLQexclusions          | 57 (5.6%)      | 64 (5.3%)      | 70 (2.3%)      | 122 (3.7%)     | 51 (3.6%)      | 9 (1.6%)       | 145 (5.4%)     | 518 (3.9%)   |
| Concentrationspriortofirstdose | 0              | 0              | 0              | 3 (0.1%)       | 1 (0.1%)       | 0              | 2 (0.1%)       | 6 (0%)       |
| Imprecisereferencedosetime     | 0              | 0              | 0              | 705 (21.6%)    | 45 (3.1%)      | 71 (12.4%)     | 882 (32.8%)    | 1703(12.8%)  |
| Fed trealment arm              | 0              | 541 (45.1%)    | 0              | 0              | 0              | 0              | 0              | 541 (4.1%)   |
| Anomalousconcentrations*       | 3 (0.3%)       | 2 (0.2%)       | 13 (0.4%)      | 0              | 11 (0.8%)      | 0              | 1 (0%)         | 30 (0.2%)    |
| Subjectswithoutusableconcdata  | 0              | 0              | 0              | 36 (1.1%)      | 0              | 0              | 0              | 36 (0.3%)    |
| Duplicateconcentrationrecords  | 0              | 0              | 0              | 0              | 0              | 0              | 74 (2.7%)      | 74 (0.6%)    |
| Unresolveddate timeissues      | 0              | 0              | 0              | 0              | 0              | 0              | 4 (0.1%)       | 4 (0%)       |
| Analysisobservations           | 930 (91.2%)    | 562 (46.8%)    | 2955 (95.3%)   | 2201 (67.4%)   | 1217 (84.9%)   | 432 (75.3%)    | 1408 (52.3%)   | 9705 (73.1%) |

BLQ-belowthelimit of quantitation.Note:thefedtreatment armfromstudyBLU-285-0102isexcludedfromthedata analysis.

Furtherexplanationfor theseexclusions is includedinAppendix17.2.1.

A full summary of the demographics for all data are provided in Tables 24 and 25.

Table 24. Categorical Covariates for All Subjects in the Model Build Data

| xaS                                   | Race                                                                                 | Form                                    | Patient Population                                                       | PPI Use                                 | H2RA Use                                 | CYP3A4Inhib.                           | CYP3A4 Ind.                            |
|---------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------|--------------------------------------------------------------------------|-----------------------------------------|------------------------------------------|----------------------------------------|----------------------------------------|
| Male: 371 (56.6%) Female: 285 (43.49) | White: 515 (78.5%) Black: 27 (4.1%) Asian: 26 (49) Other: 59 (966) Unknown:29 (4.4%) | Tablet:487 (74.2%) Capsule: 169 (25.8%) | Healthy: 122 (18.69%) GIST:221 (33.7%) AdvSM:144 (22%) ISM: 169 (25.896) | Not Used: 464 (70.7%) Used: 192 (29.39) | Not Used: 434 (66.296) Used: 222 (33.8%) | Not Used: 616 (93.996) Used: 40 (6.1%) | Not Used: 567 (86.4%) Used: 89 (13.6%) |

PPI proton pump inhibitor,H2RA Hz-receptor antagonist, Inhib. inhibitor use,Ind. inducer use,Form formulation.Note: 'Not Used' is defined as 0 to 5 days of consecutive use (See Section 9.3).

Table 25. Continuous Covariates for All Subjects in the Model Build Data

|        |   Age (years) |   Weight (kg) |   Height (cm) |   LBW (kg) |   ALB (g L) |   ALP (IU L) |   ALT (IU L) |   AST (IU L) |   Bilirubin mol L) |   CrCI (mL min) |   eGFR （mL.min 173m²) |
|--------|---------------|---------------|---------------|------------|-------------|--------------|--------------|--------------|--------------------|-----------------|-----------------------|
| N      |         656   |         656   |        656    |      999   |      656    |          656 |        656   |        656   |             656    |           656   |                 656   |
| Mean   |          54   |          78   |        171    |       53.3 |       40.9  |          131 |         24.6 |         23.6 |              10.3  |           107   |                  89.3 |
| SD     |          14.4 |          18   |          9.47 |       11.9 |        5.89 |          147 |         17.9 |         14.4 |               6.2  |            37.4 |                  24.4 |
| CV%    |          26.6 |          23.1 |          5.55 |       22.4 |       14.4  |          112 |         73   |         61.1 |              60.2  |            35   |                  27.3 |
| Median |          54   |          76.8 |        170    |       54   |       42    |           86 |         20   |         21   |               8.55 |           104   |                  88.2 |
| Min    |          18   |          39.5 |        142    |       28   |       12.7  |           27 |          3   |          5   |               1.71 |            27.6 |                  33.2 |
| Max    |           6   |         156   |        207    |       85.5 |       55    |         1750 |        215   |        182   |              52    |           329   |                 273   |

LBW - Lean body weight, ALB Albumin, ALP Alkaline phosphatase, ALT Alanine transaminase,AST Aspartate transaminase, CrCL Creatinine clearance,eGFR Estimatedglomerular filtrationrate.

A full summary of the demographics for patients with ISM are provided in Tables 26 and 27.

<div style=\"page-break-after: always\"></div>

Table 26. Categorical Covariates for the Patients with ISM in the Model Build Data

| Sex                                 | Race                                                      | Form               | PPI Use                                | H2RA Use                               | CYP3A4Inhib                          | CYP3A4Ind                             |
|-------------------------------------|-----------------------------------------------------------|--------------------|----------------------------------------|----------------------------------------|--------------------------------------|---------------------------------------|
| Male: 48 (28.4%) Female:121 (71.6%) | White: 134 (79.3%) Black:1 (0.6%) Asian:1 (0.6%) Other: 4 | Tablet: 169 (100%) | Not Used: 123 (72.89) Used: 46 (27.2%) | Not Used: 53 (31.49) Used: 116 (68.6%) | Not Used: 162 (95.99) Used: 7 (4.1%) | Not Used: 154 (91.1%) Used: 15 (8.9%) |

PPI proton pump inhibitor, H2RA H-receptor antagonist, Inhib. inhibitor use, Ind. inducer use,Form formulation. Note: Not Used' is defined as 0 to 5 days of consecutive use (See Section 9.3).

Table 27. Continuous Covariates for the Patients with ISM in the Model Build Data

|        |   Age (years) |   Weight (kg) |   Height (cm) |   LBW (kg) |   ALB (g L) |   ALP (IU L) |   ALT (IU L) |   AST (IU L) |   Bilirubin (mol L) |   CrCI (mL. min) |   eGFR (mL. min 1 73m²) |
|--------|---------------|---------------|---------------|------------|-------------|--------------|--------------|--------------|---------------------|------------------|-------------------------|
| N      |         169   |         169   |        169    |      169   |      169    |        169   |        169   |        169   |              169    |            169   |                   169   |
| Mean   |          48.8 |          80.6 |        169    |       50.9 |       43.9  |         83.6 |         23.6 |         19.9 |                7.9  |            118   |                    88.5 |
| SD     |          12   |          17.7 |          9.79 |       11.7 |        3.68 |         30.8 |         17.1 |         14.5 |                4.5  |             32.8 |                    18.8 |
| CV%    |          24.5 |          22   |          5.8  |       23   |        8.36 |         36.9 |         72.6 |         73.1 |               57    |             27.9 |                    21.3 |
| Median |          50   |          79.4 |        167    |       47.6 |       44    |         77   |         19   |         18   |                6.84 |            114   |                    88.2 |
| Min    |          18   |          45   |        142    |       31.4 |       35    |         39   |          7   |          7   |                1.71 |             44.8 |                    36   |
| Max    |          77   |         126   |        196    |       81   |       55    |        219   |        112   |        182   |               29.1  |            218   |                   143   |

LBW Lean body weight, ALB Albumin, ALP Alkaline phosphatase, ALT Alanine transaminase, AST Aspartate transaminase, CrCL.( Creatinine clearance, eGFR Estimated glomerular filtration rate.

## Previously Developed PK Model for Avapritinib

The analysis was performed by updating the previously developed population PK model in HVs, patients with  GIST,  and  patients  with  AdvSM,  with  data  from  patients  with  ISM.  The  PK  model  was  a  twocompartment  disposition  model  with  absorption  modelled  via  4  or  5  transit  compartments  that  was dependent on the formulation.

A schematic of the previously developed population PK model for avapritinib is shown in Figure 4, and the parameter estimates of the model are shown in Table 28.

<div style=\"page-break-after: always\"></div>

Figure 4. Schematic of the Previously Developed Population PK model for Avapritinib

<!-- image -->

Abbreviations: CL/F = apparent oral clearance, unadjusted for bioavailability; KTRc = absorption transit rate constant for capsules; KTRr = absorption transit rate constant for tablets; Q/F = apparent intercompartmental clearance; V/F = apparent volume of distribution for the central compartment; Vp/F = apparent volume of distribution for the peripheral compartment.

Table 28. Parameter Estimates for the Previously Developed Population PK Model

| Parameter Name                                                                          | Estimated Value (95% C1)   |
|-----------------------------------------------------------------------------------------|----------------------------|
| Apparent Clearance (CL/F, L/h)                                                          | 16(15.3 - 16.8)            |
| Maximum Time-dependent Decrease of CL/F for AdvSM Patients (Fold)                       | 0.386 (0.318 - 0.445)      |
| Time at Half Maximum Decrease of CL/F for AdvSM Patients (h)                            | 200 (120-314)              |
| Covariate Effect of AdvSM on CL/F (Fold)                                                | 1.32 (1.17 - 1.48)         |
| Apparent Central Volume of Distribution (V/F, L)                                        | 999 (953 - 1060)           |
| Covariate Effect of LBW onV/F                                                           | 0.336 (0.114 - 0.533)      |
| Apparent Peripheral Volume of Distribution (Vp/F, L)                                    | 233 (210-256)              |
| Apparent Inter-compartmental Clearance (Q/F, L/h)                                       | 13.7 (10.8-17.2)           |
| Rate of Transit Absorption for Tablets (KTRT, 1/h)                                      | 3.31 (3.23 - 3.4)          |
| Rate of Transit Absorption for Capsules (KTRc, 1/h)                                     | 3.79 (3.65 - 3.93)         |
| Covariate Effect of AdvSM on KTR (Fold)                                                 | 1.23 (1.15 - 1.31)         |
| Covariate Effect of PPI Use on KTR (Fold)                                               | 0.845 (0.786 - 0.906)      |
| Relative Bioavailability for AdvSM Patients (Fold)                                      | 0.65 (0.607 - 0.703)       |
| Relative Bioavailability for GIST Patients (Fold)                                       | 0.819 (0.777 - 0.87)       |
| CovariateEffect of PPI Comedication on F (Fold)                                         | 0.837 (0.784 -0.896)       |
| Between Subject Variability for CL/F (%)                                                | 43.3 (39.8 - 46.5)         |
| Between Subject Variability for Ve/F (%)                                                | 47.8 (44.2-52.5)           |
| Correlation between CL/F-V/F (-)                                                        | 0.623 (0.563 - 0.641)      |
| Between Subject Variability for Rate of Transit Absorption (%)                          | 26.7 (20.7 - 31.4)         |
| Between-occasion Variability for Bioavailability (%)                                    | 25.1 (23 - 27.4)           |
| Between-occasion Variability for Rate of Transit Absorption (%)                         | 30.8 (26.9- 34.6)          |
| Residual Unexplained Variability for Study BLU-285-0101/BLU-285-0102 (Proportional) (%) | 17.1 (16.3-18)             |
| Residual Unexplained Variability for Study BLU-285-0105 (Proportional) (%)              | 18.4 (17.8- 19.2)          |
| Residual Unexplained Variability for Study BLU-285-2101/BLU-285-2202 (Proportional) (%) | 23 (21.9 - 24.2)           |
| Residual Unexplained Variability for Study BLU-285-1101 (Proportional) (%)              | 26.2 (25 - 27.4)           |

## Covariate Model Development

The covariates that were considered are presented in Table 29. All covariates that have been identified in the previously developed population PK model were included a priori in the model update.

<div style=\"page-break-after: always\"></div>

Table 29. Covariates Assessed in the Population PK Model Update

<!-- image -->

| Covariate                                                                              |                                                                                        | Value                                        | Parameters                                   |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|
| Age at baseline (yr)                                                                   | AGE                                                                                    | Continuous                                   | CL E, V, F                                   |
| Total body weight at baseline (kg)                                                     | WT                                                                                     | Continuous                                   | CL F V。 F                                    |
| Lean body weight at baseline (kg)                                                      | LBW                                                                                    | Continuous                                   | CL F V。 F                                    |
| bCreatinine clearance at baseline (mL min)                                             | CRCL                                                                                   | Continuous                                   | CLF                                          |
| Estimated glomerular filtration rate at baseline (mL min 1.73 m²)                      | EGFR                                                                                   | Continuous                                   | CLF                                          |
| Alanine aminotransferase at baseline (IU L)                                            | ALT                                                                                    | Continuous                                   | CLF                                          |
| Aspartate aminotransferase at baseline (IU L)                                          | AST                                                                                    | Continuous                                   | CLF                                          |
| Bilirubin at baseline ( mol L)                                                         | BILI                                                                                   | Continuous                                   | CL F                                         |
| Albumin at baseline (g L)                                                              | ALB                                                                                    | Continuous                                   | CLF                                          |
| Sex                                                                                    | SEX                                                                                    | Categorical                                  | CL E V F                                     |
| Race                                                                                   | RACE                                                                                   | Categorical                                  | CL E, V, F                                   |
| Concomitant CYP3A4 inhibitor                                                           | CYPINB                                                                                 | Categorical                                  | CLE F                                        |
| Concomitant CYP3A4 inducer                                                             | CYPIND                                                                                 | Categorical                                  | CLE F                                        |
| Concomitant PPI                                                                        | PPI                                                                                    | Categorical                                  | CL F, KTR, F                                 |
| Concomitant H2RA                                                                       | H2RA                                                                                   | Categorical                                  | CL E,KTR, F                                  |
| Formulation (capsule, tablet)                                                          | FORM                                                                                   | Categorical                                  | CL E, KTR, F                                 |
| Disease Subpopulation (HV GIST SM)                                                     | DSSTAT                                                                                 | Categorical                                  | CL.EVE,KTR,F                                 |
| CLF apparent clearance,VF apparent central volume of distribution, KTR bioavailability | CLF apparent clearance,VF apparent central volume of distribution, KTR bioavailability | absorption transit rate constant, F relative | absorption transit rate constant, F relative |

## Exploratory Graphical Analysis (Objective 1)

Dose-normalized concentration-time profiles for the HV (studies BLU-285-0101, BLU- 285-0102, and BLU285-0105), patients with GIST (BLU-285-1101), patients with AdvSM (studies BLU-285-2101 and BLU-2852202), and patients with ISM (study BLU- 285-2203) at C1D1 and at C1D15 are displayed in Figures 5 and 6.

<div style=\"page-break-after: always\"></div>

Figure  5.  Dose-Normalized  Plasma  Concentration-Time  Profiles  for  Avapritinib  in  Healthy Volunteers and Patients with GIST, AdvSM or ISM (C1D1)

<!-- image -->

Disease Status

The solid lines show the median,with the filled circles representing he observed dataThp Panet Concenlration-time profiles for the first 48hoursposidose.X-axis andY-axison log-scale.Bottlom Panel:Concentration-time profiles forup to72 hours postdose.Y-axis on log-scal. Data below the LL0Q (2.00 ng mL) were excluded CiD1 Cyce 1 Day 1.

<div style=\"page-break-after: always\"></div>

Figure 6. Dose-Normalized Plasma Concentration-Time Profiles for Avapritinib in Patients with ISM, GIST, or AdvSM (C1D1 &amp; C1D15)

<!-- image -->

The solid lines show the median, with the filed circles representing the observed data. Top Panel: Concentralion-time profiles for up to 72 hours posldose (CiD1). Botlom Panel: Concentralion-time profiles for the first 48 hours postdose (CID15). Data below the LLOQ (2.00 ng mL) were excluded. Y-axis on log-scale. CiD1 Cycle 1 Day 1, CiDi5 Cycle 1 Day 15.

## Population Pharmacokinetic Model Development (Objective 2)

The final updated model comprised the same structure and covariate effects as the previous model. No additional  covariates  were  included  in  the  model  based  on  visual  inspection  of  the  covariate-eta relationships. Table 30 reports the updated parameter estimates of the model.

<div style=\"page-break-after: always\"></div>

Table 30. Parameter Estimates for the Final Population PK Model

| ParameterName                                                                           | EstimatedValue(%RSE,95%CI)   |
|-----------------------------------------------------------------------------------------|------------------------------|
| Apparent Clearance (CL F, L h)                                                          | 16.9 (2.2, 16.1 - 17.6)      |
| Maximum Time-dependent Decrease of CL F for AdvSM Patients (Fold)                       | 0.394 (9.7, 0.319-0.469)     |
| Time at Half Maximum Decrease of CL F for Adv SM Patients (h)                           | 190 (26.9,90-291)            |
| Covariate E ect ofAdvSM on CLF (Fold)                                                   | 1.3 (5.5, 1.16 - 1.44)       |
| Apparent Central Volume of Distribution (Ve F, L)                                       | 971 (2.7, 920-1020)          |
| Covariate E ect ofLBWonVe F                                                             | 0.354 (39.9, 0.077 -0.631)   |
| Apparent Peripheral Volume of Distribution (V, F, L)                                    | 228 (8.9,188-268)            |
| Apparent Inter-compartmental Clearance (Q F, L h)                                       | 15.8 (17.4, 10.4 -21.2)      |
| Rate of TransitAbsorption for Tablets (KTRt,1 h)                                        | 3.41 (1.3, 3.33 - 3.5)       |
| Rate of Transit Absorption for Capsules (KTRc, 1 h)                                     | 3.78 (2.0, 3.63 - 3.93)      |
| Covariate E ectofAdvSM on KTR (Fold)                                                    | 1.19 (3.2, 1.11 - 1.26)      |
| Covariate E ect of PPI Use on KTR (Fold)                                                | 0.869 (3.4, 0.81 -0.928)     |
| RelativeBioavailabilityforAdvSM Patients (Fold)                                         | 0.667 (4.1, 0.614 -0.721)    |
| Relative Bioavailability for GIST Patients (Fold)                                       | 0.856 (3.1, 0.804 -0.908)    |
| CovariateE ect of PPI Comedication onF (Fold)                                           | 0.833 (3.4,0.777 -0.889)     |
| Between Subject Variability for CL F (%)                                                | 44.4 (4.0, 40.5 -48.1)       |
| BetweenSubjectVariabilityforVF (%)                                                      | 50.1 (4.6, 44.9 -55)         |
| Correlation between CL F-V, F ()                                                        | 0.634 (5.8, 0.589 -0.666)    |
| Between Subject Variability for Rate of Transit Absorption(%)                           | 24.6 (14.4, 16.1 - 31)       |
| Between-occasionVariabilityforBioavailability(%)                                        | 25.3 (4.6,22.8-27.5)         |
| Between-occasionVariability for Rate of Transit Absorption (%)                          | 32.9 (7.7,27.3-37.8)         |
| Residual UnexplainedVariability for Study BLU-285-0101BLU-285-0102(Proportional) (%)    | 17.2 (6.5, 14.9- 19.3)       |
| Residual Unexplained Variability for Study BLU-285-0105(Proportional) (%)               | 18.3 (4.6,16.6-19.9)         |
| Residual Unexplained Variability for Study BLU-285-2101 BLU-285-2202 (Proportional) (%) | 23.3 (23,21.2-25.3)          |
| Residual Unexplained Variability for Study BLU-285-1101 (Proportional) (%)              | 26.6 (4.0, 24.4 -28.7)       |
| Residual Unexplained Variability for Study BLU-285-2203(Proportional) (%)               | 27 (12.6, 19.1-33.3)         |

%RSE relative standarderror, CIconfidence interval.Covariate relationships are described in detail inSection 12.2.3.

Evaluation of Covariates in the Final Population PK Model

## Impact of Lean Body Weight on Avapritinib PK

LBW was included a priori as a covariate on Vc/F, which was the same as previously described in the population PK model for HVs, patients with GIST and patients with AdvSM.

The expression in the final population PK model is shown in Equation 7:

<!-- formula-not-decoded -->

Where 0.354 was the estimated covariate effect of LBW on Vc/F (note that the median LBW of patients with ISM in the analysis population was 47.6 kg). A graphical representation of the relationship between LBW and Vc/F is shown in Figure 7.

<div style=\"page-break-after: always\"></div>

Figure 7. Model Predicted Effect of Lean Body Weight

<!-- image -->

Solid lines represent simulated median concentration-time profiles assuming a patient withISM with median lean body weight of 47.6 kg receiving 25 mg avapritinib(as tablet formulation) QD.

## Impact of Proton Pump Inhibitor (PPI) Use on Avapritinib PK

Concomitant PPI use was included a priori as a covariate on bioavailability (F) and KTR. The expressions in the final population PK model is shown in Equation 8 and 9:

F = GISTF * SMF * PPIF  Equation 8

KTR = 3.41 (if Tablets) or 3.78 (if Capsules)  SMKTR  PPIKTR   Equation 9

where GISTF and SMF are the covariate effects of being a GIST or AdvSM patient on F, respectively, and PPIF is the estimated covariate effect of concomitant PPI use, where it is 1 if there was no concomitant PPI use (0 to less than 5 consecutive days of PPI use prior to the PK sample), and 0.833 if there was equal or more than 5 consecutive days of PPI use prior to the PK sample. For the effect on KTR (Equation 9, PPIKTR), it is 1 if there was no concomitant PPI use, and 0.869 if there was equal or more than 5 consecutive days of PPI use prior to the PK sample collection.

<div style=\"page-break-after: always\"></div>

Figure 8. Model Predicted Effect of Concomitant PPI

<!-- image -->

Solid lines represent simulated median concentration-time profiles assuming a patient with ISM with median lean body weight of 47.6 kg receiving 25 mg avapritinib (as tablet formulation) QD.

## Impact of Patient Population on Avapritinib PK

The  covariate  effect  of  patient  population  on  F  is  shown  in  Equation  8.  Patients  with  ISM  had  overall exposure comparable to HVs and the relative F for patients with ISM and HVs were fixed to 1. As previously reported, patients with GIST had a reduced F compared to HVs and GISTF was estimated to be 0.856 (GISTF was fixed to 1 for other patient populations). Similarly patients with AdvSM had the lowest overall exposure compared to the other patient populations and SMF was estimated to be 0.667 (SMF was fixed to 1 for other patient populations).

Patients with AdvSM was also found to have higher KTR previously and this relationship was included in the model a priori. The covariate effect of patient population on KTR is shown in Equation 9, where KTR is dependent on the formulation, and SMKTR was to be 1.19 for patients with AdvSM (SMKTR was fixed to 1 for other patient populations).

As previously reported, patients with AdvSM exhibited time-dependent reduction in CL/F, which is shown in Equations 10-11

CL F=16.9*SMCL*TIMCL     Equation 10

TIMCL=1 (if Healthy or GIST)  or 1-  (Time (h)*0.394)/(190*Time(h))   (if AdvSM)    Equation 11

where SMCL is the covariate effect of AdvSM on CL/F and estimated to be 1.3. TIMCL is a time-dependent decrease in CL/F for patients with AdvSM, where the maximum decrease in CL/F compared to other patient population was 39.4%, and the time at half maximum decrease of CL/F was estimated to be 190 hours since the first dose. A graphical representation of the overall effect of patient population on avapritinib is shown in Figure 9.

<div style=\"page-break-after: always\"></div>

Figure 9. Model Predicted Effect of Different Patient Population

<!-- image -->

Solid lines represent simulated median concentration-time profiles assuming a patient with ISM with median lean body weight of 47.6 kg receiving 25 mg avapritinib (as tablet formulation)QD.

## Impact of Oral Formulation on Avapritinib PK

Formulation of avapritinib was included a priori as a covariate on KTR, as shown in Equation 9, where KTR was dependent upon formulation of the administration i.e. tablets or capsules. A graphical representation of the relationship between formulation and KTR is shown in Figure 10.

Figure 10. Model Predicted Effect of Different Oral Formulation

<!-- image -->

Solid lines represent simulated median concentration-time profiles assuming a patient with ISM with median lean body weight of 47.6 kg receiving 25 mg avapritinib (as tablet formulation) QD.

Forest Plot Investigating the Impact of Covariate Effects on Avapritinib Exposure

<div style=\"page-break-after: always\"></div>

The impact of covariates on the exposure metrics (AUC0T,ss and Cmax,ss) are summarized in Figures 11 and 12.

Figure 11. Model Predicted Effect of Covariates on AUC0-T,ss

<!-- image -->

Thesolidblacklinerepresentsnoimpactofthecovariatewith thereferencesubjectreferringto apatientwithISMwithmedian lean bodyweight of the47.6kgreceiving25mg dose of avapritinib（tablet formulation)QD,sampled every hour onDay 15 （steady state）. to97.5percentiles of the simulations)prediction intervals(PI) of the covariateeffectbased on1000 simulated subjectswithineach groupincludinguncertaintyonthefixedeffect.

<div style=\"page-break-after: always\"></div>

Figure 12. Model Predicted Effect of Covariates on Cmax,ss

<!-- image -->

The solid black line represents no impact of the covariate with the reference subject referring to a patient with ISMwith median lean bodyweight of the47.6kg receiving25mg dose of avapritinib(tablet formulation)QD,sampledevery hour onDay15(steady state). Dashed red lines represent the 80-125% range of the reference subject. The blue dots and error bars represent the median and 95% (2.5th to 97.5th percentiles of the simulations) prediction intervals (Pl) of the covariate e ect based on 1000 simulated subjects within each groupincluding uncertainty on the fixedeect.

Evaluation of the Final Population PK Model

Plots  of  observed  versus  population  predicted  plasma  concentrations  and  observed  versus  individual predicted plasma concentrations are presented below in Figure 13.

<div style=\"page-break-after: always\"></div>

Figure 13. Goodness of Fit Plots for the Final Population PK Model

<!-- image -->

The solid blue lines represent the line of unity, the solid red lines represent the trend in the data (Loess smooth), the dashed orange line represent the LL0Q (p00 ng mL), and shrinkage for the residual wariability ( sh) 11.4% . Top Panel: all data. Bottom Panel: data from patients with ISM only (study BLU-285-2203).

Additional diagnostic plots of CWRES are shown in Figure 14.

<div style=\"page-break-after: always\"></div>

Figure 14. CWRES Plots for the Final Population PK Model

<!-- image -->

The solid ble lines represents the line of identity or zero, the red lines represents the tend in the data (Loess smooth) or the mean.

The trend at lower concentrations where the model under-predicts the lower observed concentrations is expected given censoring of data at the LLOQ (2.00 ng/mL). Additionally, the apparent bias at the low population predicted values which occurred during the early absorption phase was evaluated separately using VPCs (Figures 15 - 18).

<div style=\"page-break-after: always\"></div>

Figure 15. pvcVPC for the Final Population PK Model: Patients with ISM (C1D1 &amp; C1D15)

<!-- image -->

Open circlesindividual observed, dashed blue lines observed 10lh&amp; go percentiles of the observed data,solid blue lineobserved median concentration, shaded areas 95% confidence interval around the model predicted 10h, 50h, &amp; 9o percentiles. Top Panel: CID1. Bottom Panel: CiD15: Nole: Log-log scale is used. CID1 Cyce 1Day 1, CiD15 Cycle 1 Day 15

<div style=\"page-break-after: always\"></div>

Figure 16. pvcVPC for the Final Population PK Model: HV

<!-- image -->

Opencirclesindividual observed, dashed blue lines observed 10h &amp; 9o percentiles of the observed data, solid blueline observed median concentation, shadd areas  95% prediction interval around the model predicted 10h, 50, &amp; 90* percentiles Note: Log-log scale isused. CiD1 Cycb 1Day 1,CiDi5 Cycle 1Day 15

<div style=\"page-break-after: always\"></div>

Figure 17. pvcVPC for the Final Population PK Model: Patients with AdvSM (C1D1 &amp; C1D15)

<!-- image -->

Opencirclesindividual observed, dashed blue linesobserved 10h &amp; 9o percentiles of the observed data, solid blue line observed median concentration, shaded areas 95% confidence interval around the model predicted 10h, 50h, &amp; 9o percentiles. Top Panel: CiD1. Boltom Panel: CID15: Note: Log-log scale is used. CID1 Cycle 1 Day 1, CiDi5 Cycle 1 Day 15

<div style=\"page-break-after: always\"></div>

Figure 18. pvcVPC for the Final Population PK Model: Patients with GIST (C1D1 &amp; C1D15)

<!-- image -->

Opencirclesindividual observeddashed blue lines observed 10h&amp; go percentiles of the observed data,solid bluelineobserved median concentration, shaded areas  95% confidence interval around the model pedicted 10h, 50h, &amp; 9o percentiles. Top Panel: CiDi. Boltom Panel: CiDi5: Note: Log-log scale is used. CiD1 Cycle 1 Day 1, CiDi5 Cycle 1 Day 15

## Predicted Exposure Metric for Patients in Study BLU-285-2203, Part 2 (Objective 3)

The model predicted exposure metrics (AUC0-24,ss, Cmax,ss and trough plasma concentration at steady state  (Ctrough,ss))  are  summarized  in  Table  31.  The  geometric  mean  of  AUC0-24,ss,  Cmax,ss  and Ctrough,ss were 1320 ng h/mL, 65.3 ng/mL and 45.4 ng/mL, respectively and were consistent with the values reported by non-compartmental analysis (NCA) methods.

<div style=\"page-break-after: always\"></div>

## Table 31. Summary of Model Predicted Exposure Metrics for Patients in Study BLU-285-2203, Part 2 C1D15

|                        |   AUC-24,ss (ng.h mL) |   Cmar ps (ng mL) |   Ctrough,ss (ng mL) |
|------------------------|-----------------------|-------------------|----------------------|
| N                      |                 139   |            139    |               139    |
| Mean                   |                1460   |             71.7  |                50.7  |
| Geometric Mean         |                1320   |             65.3  |                45.4  |
| CV% for geometric mean |                   0.5 |              0.48 |                 0.53 |
| Minimum                |                 283   |             14.8  |                 8.99 |
| Median                 |                1450   |             70.4  |                49.9  |
| Maximum                |                3440   |            161    |               127    |
| Lower 95% CI           |                 420   |             22.7  |                13.7  |
| Upper 95% CI           |                2880   |            137    |               104    |

## 2.3.3. Pharmacodynamics

## 2.3.4. PK/PD modelling

Given the non-malignant nature of ISM and the difference between the recommended avapritinib dose for patients with ISM (25 mg QD) and the higher recommended doses for patients with AdvSM (200 mg QD) or  GIST  (300  mg QD), together with the anticipated differences in benefit-risk considerations, the E-R analysis of efficacy and safety outcomes included only data from patients with ISM from Study BLU-2852203.

The objectives of this analysis were to:

1. Graphically evaluate the effect of avapritinib exposure on selected measures of efficacy and safety in ISM patients from study BLU-285-2203.

2. Present an ER model for the primary efficacy endpoint in ISM patients from study BLU-285-2203.
3. Perform additional descriptive analyses to support dose evaluation.

Analysis Populations

- Efficacy Population

The efficacy analysis was conducted in patients on placebo or active treatment up to at least C7D1.

- Safety population

The  safety  analysis  was  conducted  in  all  patients  who  were  enrolled  and  received  at  least  1  dose  of avapritinib. Additionally, patients on placebo were also included in the safety analyses.

## Efficacy Endpoints

The following measures of efficacy were evaluated:

- Activity of avapritinib as measured by change ( Δ) in TSS from baseline to C7D1 (or equivalent for patients from Part 1).
- Activity of avapritinib as measured by a ≥30% reduction in TSS from baseline.
- Activity of avapritinib as measured by a ≥50% reduction in TSS from baseline.
- Activity of avapritinib as measured by a ≥50% reduction in serum tryptase from baseline.

<div style=\"page-break-after: always\"></div>

## Safety Endpoints

The following measures of safety were evaluated:

- All Grade ≥3 adverse events (AEs).
- Grade ≥1 cognitive effects.
- Grade ≥1 edema.
- Grade ≥2 total bilirubin.
- Grade ≥2 hemoglobin.
- Grade ≥1 weight gain/increase.

Each safety endpoint was dichotomized as experiencing zero or ≥ 1 occurrence/event, where only the first onset of an event per patient (and corresponding time to that event) was considered in the analysis (ie, repeat events were not analyzed). If an event occurred either 2 days after the last dose, or after the end of study participation (whichever occurred first), the event was declared as censored.

## Exposure Parameters

The  final,  updated  population  pharmacokinetic  (PK)  model  of  avapritinib  was  used  to  derive  individual estimates of avapritinib exposure.

Cave was derived empirically for each individual using their observed dosing records and empirical Bayes estimates (EBEs) from NON linear Mixed Effects Modelling software (NONMEM). More specifically, for Δ TSS, Cave was computed from the start of treatment until C7D1 (or equivalent for patients in Part 1). For the dichotomous efficacy and safety endpoints, Cave was computed from the start of treatment until the first occurrence of an event or censoring.

## Summary of Exposures

Figure 19 displays the distribution of Cave computed up to C7D1 by treatment arm. The PK of avapritinib in ISM patients from study BLU-285-2203 was approximately linear across the dose range of 25 mg to 100 mg.

<div style=\"page-break-after: always\"></div>

Figure 19. Cave by Treatment Arm

<!-- image -->

C7D1 = Cycle 7, Day 1. The open circles represent the observed data. The thick solid black lines represent the median of the data, the hinges (top and bottom of the boxes) represent the 25* and 75* percentiles (ie., the interquatile range, or IQR). the top and bottom whiskers extend to the largest and smallest values that are within 1.5 * IQR of the hinges respectively, and values outside the whiskers are represented with dots.

## Efficacy

A total of 249 patients were included in the efficacy population. Fifteen of these patients had missing values for Δ TSS (i.e., 2 patients from Part 1 and 13 patients from Part 2); therefore, 234 patients were included in analyses of Δ TSS.

Figure 20 displays the relationship between Δ TSS and Cave. The average Δ TSS was approximately -9.65 points in patients on placebo. For patients on active treatment, the average Δ TSS was approximately -17.0 points across the exposure range.

<div style=\"page-break-after: always\"></div>

Figure 20. Δ TSS vs. Cave

<!-- image -->

The circles represent observed values, the solid bladk square indicates the avernge ATSS for the placebo groups, the solid black line Yish aq sajeoipu toteai papeys Ara ap pue quamean aagoe to spuayed oi pang lapom reaut e mog suoupipand aq sjuasandar Confidence interval for the linear modelpredictions. The dashed black line indicates ATSS of O (ie., no change from baseline).

Δ TSS was analyzed in a linear model framework:

<!-- formula-not-decoded -->

In Equation 1, Placeboi indicates placebo or active treatment for individual i (i.e., 0 = active treatment, 1 = placebo), and TSSbaseline, i indicates the baseline value of TSS for individual i.

Due to a change in scope of the originally planned ER analyses, covariate modelling and simulation for Δ TSS was not performed.

Table 32 reports the parameter estimates from the model described in Equation 1. After adjustment for baseline TSS, there was no evidence for a Cave effect (p = 0.922), suggesting that the expected average ΔTSS  was  ≈ -16.7  points  across  the  exposure  range  in  patients  on  active  treatment.  There  was  also evidence that patients on placebo experienced less reduction in TSS at C7D1 from baseline compared to patients on active treatment (p = 0.002).

Additionally, there was evidence that patients with higher baseline TSS experienced greater reductions in TSS at C7D1 (p &lt;0.001; median TSS at baseline was 48.6 points).

Table 32: Parameter Estimates from the Δ TSS Model

|                        |   Estimnte | 95%6 C1       |   P-vnhue |
|------------------------|------------|---------------|-----------|
| Imtercept              |    -16.7   | -20.9.-12.51  |     0.001 |
| Placebo (vs.Active)    |      8.44  | (3.1, 13.8)   |     0.002 |
| Slope for! C.          |      0.002 | (-0.05,0.05)  |     0.922 |
| Slope for baseline TSS |     -0.31  | (-0.41,-0.21] |    20.001 |

Figure 21 displays key diagnostic plots of the Δ TSS model. The plots suggest that the model provided an acceptable fit to the data.

<div style=\"page-break-after: always\"></div>

Figure 21. Diagnostic Plots of the Δ TSS Model

<!-- image -->

The solid circles represent observed data. In the left panel, the solid blue line indicates fits from a nonparametric smoother and the gray shaded region displays the coresponding 95% confidence interval.

Figures 22 and 23 display KM plots for ≥30% and ≥50% reduction in TSS from baseline (respectively) stratified by Cave quartile. For both endpoints the active treatment groups experienced faster onset of response compared to patients on placebo.

Figure 22. ≥30% Reduction in TSS from Baseline vs. Cave

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 23. ≥50% Reduction in TSS from Baseline vs. Cave

<!-- image -->

Prob = probability. Solid lines = Kaplan-Meier cuves, pluses =observed censoring. The shaded regions represent the 95% CIs forthe Kaplan-Meiercurves.

Figure 24 displays a KM plot for a ≥50% reduction in serum tryptase from baseline stratified by Cave quartile. There was evidence that higher levels of exposure were associated with faster onset of ≥50% reduction in serum tryptase.

<div style=\"page-break-after: always\"></div>

Figure 24. ≥50% Reduction in Serum Tryptase from Baseline vs. Cave

<!-- image -->

Prob=probability.Solid lines=Kaplan-Meiercuves,pluses=observedcensoring.The shadedregionsrepresentthe 95% CIs forthe Kaplan-Meier cuves.

## Safety

All 249 patients were included in the safety analyses. Figures 25, 26, and 27 show KM plots for all Grade ≥3 AEs, Grade ≥1 cognitive effects, and Grade ≥1 weight gain (respectively) stratified by Cave quartile.

Incidences of all Grade ≥3 AEs, Grade ≥1 cognitive effects, and Grade ≥1 weight gain were very low in patients  on  active  treatment  (corresponding  percentages  of  5.3%,  7.7%,  and  2.4%)  or  placebo (corresponding percentages of 2.5%, 5.0%, and 2.5%).

<div style=\"page-break-after: always\"></div>

Figure 25. All Grade ≥3 AEs vs. Cave

<!-- image -->

Prob=probability.Solid lines=Kaplan-Meiercurves.pluses=observed censoring.The shaded regionsrepresent the 95%CIs forthe Kaplan-Meier curves.

Figure 26. Grade ≥1 Cognitive Effects vs. Cave

<!-- image -->

<!-- image -->

Prob =probability. Solid lines =Kaplan-Meier cuves, pluses =observed censoring.The shaded regions represent the 95% CIs for the Kaplan-Meier cwves.

<div style=\"page-break-after: always\"></div>

Figure 27. Grade ≥1 Weight Gain vs. Cave

<!-- image -->

Figure 28 displays the KM plot for Grade ≥1 edema stratified by Cave quartile. There was statistical evidence for  a  trend,  with  45  and  7  occurrences  in  the  active  and  placebo  groups,  respectively  (corresponding percentages of 26.6% and 8.8%). This trend appeared driven by the 4th quartile of Cave, for which faster onset was observed compared to the other quartiles.

<div style=\"page-break-after: always\"></div>

Figure 28. Grade ≥1 Edema vs. Cave

<!-- image -->

Prob = probability. Solid lines = Kaplan-Meier curves, pluses = observed censoring. The shaded regions represent the 95% CIs for the Kaplan-Meier curves.

Lastly,  there  were  no  occurrences  of  Grade  ≥2  hemoglobin  or  Grade  ≥2  total  bilirubin,  thus  graphical evaluations of these endpoints are not shown.

## 2.3.5. Discussion on clinical pharmacology

Avapritinib  for  the  treatment  of  indolent  systemic  mastocytosis  (ISM)  in  adults  was  evaluated  in  the placebo-controlled phase 2 study BLU-285-2203.

Non-Compartmental Analysis (NCA) of the data from study BLU-285-2203 reveals dose proportionality between 25 mg and 100 mg in patients with ISM at Day 1 and Day 15 of cycle 1 (C1D15), as the 90% CI ranges  within  the  accepted  critical  interval  of  0.5-1.5  and  the  graphical  representation  shows  the proportional relationship among dose levels. In addition, the impact of time-dependency processes on the avapritinib PK properties for the 25 mg QD dose between single dose and steady state conditions (C1D15 Part 1) revealed an AUC0-24 accumulation ratio of 3.59 (geometric mean), which is similar across the different  indications  and  doses  previously  evaluated.  Accumulation  of  BLU111207  and  BLU111208 enantiomers was observed after repeated once daily dosing of 25 mg of avapritinib. At steady-state the metabolite to parent ratio of BLU111207 and BLU111208 was 10.3 and 17.5%, respectively, which is slightly lower compared to the ratios observed for patients with AdvSM at Cycle 1 Day 15 (20.5-29.9% and 25.934.4%, respectively).

For ISM, the recommended dose of avapritinib is 25 mg orally once daily, on an empty stomach (see Method of administration). This once daily 25 mg dose is also the maximum recommended dose that must not be exceeded  in  patients  with  ISM.  Treatment  of  ISM  should  be  continued  until  disease  progression  or unacceptable toxicity occurs.

The population PK analysis was based on a pooled dataset from 7 studies, which includes data of avapritinib in healthy volunteers (Study BLU-285-0101, Study BLU-285-0102 and Study BLU-285-0105), in patients

<div style=\"page-break-after: always\"></div>

with Gastrointestinal Stromal tumor (GIST) and other relapsed refractory solid tumours (Study BLU-2851101),  in  patients  with  Advanced  Systemic  Mastocytosis  (AdvSM)  and  relapsed  or  refractory  myeloid malignancies (Study BLU-285-2101, and Study BLU-285-2202) and in patients with ISM.

The final dataset for the current Population PK model development included a total of 9705 observation records from 656 subjects, which includes 1408 records from 169 subjects with ISM. Post-dose PK samples below limit of quantification (BLQ) were low and were excluded from the analysis. M1 method for handling BLQ-data is considered acceptable. The final popPK model was developed using 169 ISM patients, which is accepted,  but  only  1408  PK  observations.  The  evaluation  of  the  excluded  samples  was  conducted, demonstrating the adequacy of the current population PK model to account for the excluded samples due to  imprecise  reference  dose  time.  Although  the  excluded  samples  are  below  the  corresponding  95% prediction intervals of the 10 th , 50 th  and 90 th  percentiles at C1D15, it could be partially a consequence of the  imprecise  reference  dose  time.  Therefore,  an  adequate  predictive  capacity  of  the  PK  model  was demonstrated.

The population PK model development includes the re-use of the previously developed model to characterize the PK of Avapritinib in healthy subjects, patients with GIST and patients with AdvSM. The structural and covariate effects were maintained and no further modification was included.

Avapritinib  PK  was  described  using  a  linear,  2-compartment  model  with  4  or  5  absorption  transit compartments for tablet or capsule formulation respectively. The full PK model contains 7 covariates effects including LBW on Vc/F, concomitant PPI use on KTR and F, lower F in patients with GIST, lower F, lower KTR and time-dependent decrease in CL/F in patients with AdvSM.

A forest plot has been provided to assess the clinical relevance of the covariates selected based on the change on the exposure (AUC,ss and Cmax,ss). The analysis revealed no clinically relevant changes in exposure  except  for  AdvSM  patients,  which  is  expected  based  on  the  time  decrease  in  clearance  and decrease  bioavailability  of  this  sub-group  of  patients.  Therefore,  no  dose  adjustment  of  avapritinib  is required based on the covariates included in the population PK model.

An Exposure-Response analysis of efficacy and safety was performed including only data from patients with ISM from Study BLU-285-2203.

Change ( Δ) in TSS from baseline to C7D1 was used as the efficacy outcome and Cave was computed until C7D1 or the occurrence of an event and was used as the exposure metric in the exposure efficacy analysis. Δ TSS was analysed in a linear model and the results showed a slight improvement in Δ TSS in patients on active treatment compared to patients in the placebo group but not differences between the different doses where found. No exposure-efficacy relationships was established across the different dose levels evaluated (25-100 mg QD). Therefore, it is not possible to establish the optimal dosing regimen of avapritinib in patients with ISM from the presented exposure-efficacy relationship.

Regarding the safety endpoints, Kaplan-Meier curves stratified by quartiles of Cave were presented. The results showed a statistically difference in the occurrence of grade ≥1 oedema between the active and placebo groups. This result was expected as fluid retention is a frequent adverse effect related to the use of  avapritinib.  However,  no  exposure-safety  relationship  was  established  across  the  exposure  range  of avapritinib. Therefore, it is not possible to establish the optimal dosing regimen of avapritinib in patients with ISM from the presented exposure-safety relationship.

The metabolism of avapritinib is predominantly mediated by CYP3A4/CYP3A5, so the concomitant treatment with  drugs  that  are  strong  or  moderate  CYP3A  inhibitors  or  inducers  can  increase  (with  inhibitors)  or decrease (with inducers) the exposure to avapritinib, as confirmed by a clinical study with concomitant administration of avapritinib with itraconazole (a potent CYP3A  inhibitor) or rifampin (a potent CYP3A inducer). The dosing recommendation for avapritinib is therefore to avoid the concomitant use of strong or moderate CYP3A inhibitors or inducers.

<div style=\"page-break-after: always\"></div>

The MAH provided the report of the clinical DDI study report (BLU-285-0108) that aims to assess the potential  interaction  of  avapritinib  in  combination  with  oral  contraceptives  and  to  provide  dosing recommendations if required. The combination LNG/EE was selected as this represents a widely used oral contraceptive. The clinical significant bounds of 90% confidence intervals (CIs) selected for this study were 80.00%  -  140.00%  for  AUC0-inf  taking  into  account  the  doses  used  in  the  study  and  other  labelling recommendations and for Cmax an upper clinical significant bound less than 140% as decrease in Cmax is not supposed to affect the clinical efficacy.

Sixteen  women  were  enrolled  in  the  study  and  15  of  them  completed  the  study  and  one  of  them discontinued due to an adverse event (vision blurred).

Following coadministration of 25 mg of avapritinib QD with a single dose of oral contraceptives 0.15 mg LNG/0.03 mg EE, based on GMR, LNG Cmax, AUC0-t and AUC0-inf were 7%, 13% and 16% higher that when LNG was administered as the combination of OC alone. The 90 % CI of LNG Cmax falls below the 140% upper bound and the AUC0-inf falls within the 80-140% clinical significance bounds. On the other hand, based on GMR, EE Cmax, AUC0-t and AUC0-inf were 45.81%, 16.55% and 15.48% higher than when EE  was  administered  as  the  combination  of  OC  alone.  The  AUC0-inf  falls  within  the  80-140%  clinical significance bounds, however, the 90 % CI of LNG Cmax falls above the 140% upper (CI 17.16%-81.46%).

Despite the slightly higher EE Cmax (45%) , very similar exposures of avapritinib at the proposed dosing regimen  at  single  and  steady-state  conditions  were  predicted  when  a  single  dose  of  LNG/EE  was coadministered. Therefore, no relevant differences in efficacy/safety are expected since no relevant changes in exposure were predicted.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology properties of avapritinib in patients with ISM have been adequately characterized based on a totality of population PK model analysis developed in patients with AdvSM and GIST. The exposure-response analyses were not clinically relevant and the proposed dosing regimen seems adequate for the studied population and included accordingly in the SmPC.

## 2.4. Clinical efficacy

The primary evidence of efficacy and safety of avapritinib in the treatment of ISM comes from Study BLU285-2203. This study was conducted in patients from North America, countries in the EU, and the UK.

The focus for efficacy analyses in the current procedure is on patients with ISM treated with avapritinib at a dose of 25 mg QD.

<div style=\"page-break-after: always\"></div>

Table 33. Overview of Clinical Studies

| Study Identifier/ Status                                                                                                                                                                 | Number of Study Center's/ Countries                                                                                                  | Study Objective(s)                                                                                                                                                                                                                                                                                                        | Study Design                                                         | DiseasePopulation                                                                                                                                                                                                 | Dose/Dosing Regimen                                                                                                                                                                                                                                                                                       | Number of Patients                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Indolent Systemic Mastocytosis                                                                                                                                                           | Indolent Systemic Mastocytosis                                                                                                       | Indolent Systemic Mastocytosis                                                                                                                                                                                                                                                                                            | Indolent Systemic Mastocytosis                                       | Indolent Systemic Mastocytosis                                                                                                                                                                                    | Indolent Systemic Mastocytosis                                                                                                                                                                                                                                                                            | Indolent Systemic Mastocytosis                                                                                           |
| BLU-285-2203 (IND number: 124159, EudraCT number: 2018- 000588-99, NCT03731260) Part 1: Complete Part 2: Complete Part 3: Ongoing. enrollment complete; data cutoff date of 23 June 2022 | 42 centers/ 13 countries (Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK, US) | Theprimary objectives of thestudywere: Part 1 Todetermine theRP2Dof avapritinibin patients with ISM for use in Part 2 and Part 3 of the study. Part 2 TodeterminemeanchangeinISM-SAF TSS from baseline to C7D1, compared to placebo. Part3 To assess thelong-term safety and efficacy of avapritinibin patients with ISM. | 3-part, Phase 2, randomized, double-blind, placebo- controlled study | Male and female patients ≥18 years old, with centrally diagnosis ofISM confirmed WHO and moderate to severesymptoms based on the average TSS of ≥28 on the ISM- SAF over the 14-day eligibility screening period. | Part l: Avapritinib 25, 50,or 100 mg or matching placebo administered orally QD for at least 12weeks. or matching Part 2: Avapritinib 25 mg placebo administered orally, QD for 6 cycles (24 weeks). Part 3: Avapritinib 25 mg administered orally, QD for up to 5 years, inclusive of Part 1 and Part 2. | Part l: 39 patients. 212 patients. Part 2: Part 3: 235 patients from Part 1 and Part 2 participated in Part3ofthe study. |

Abbreviations:C7D1 =Cycle 7 Day 1; ISM =indolent systemic mastocytosis;ISM-SAF=Indolent Systemic Mastocytosis-Symptom Assessment Form; QD=once daily; RP2D =recommended Phase 2 dose; TSS =total symptom score; UK =United Kingdom; US =United States; WHO =World Health

Organization.

## 2.4.1. Dose response studies

Part 1 of the main study BLU 285-2203 had as main objective determining the RP2D of avapritinib in patients with ISM for use in Part 2 and Part 3 of the study.

This Part 1 is presented below under the main study BLU 285-2203 section.

## 2.4.2. Main study

Study BLU 285-2203 is a 3-part, randomised, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib (BLU 285) in patients with indolent and smouldering systemic mastocytosis with symptoms inadequately controlled with standard therapy.

## Methods

Study BLU-285-2203 is a 3-part, Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib in combination with best supportive care (BSC) to placebo in combination with BSC in patients with ISM whose symptoms were not adequately controlled by BSC.

The study was conducted in 3 parts:

- In Part 1 , the optimal dose of avapritinib (RP2D) was identified in patients with ISM.
- In Part 2 , patients with ISM were randomly assigned in 2:1 ratio to the avapritinib RP2D identified in Part 1 in combination with BSC, or to placebo in combination with BSC.
- In Part 3 , patients who complete treatment in Part 1 or Part 2 of the study can participate in a long-term extension, receiving avapritinib at the RP2D in combination with BSC.

<div style=\"page-break-after: always\"></div>

Figure 29. Overall study design

<!-- image -->

Abbreviations: BSC = best supportive care; CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; RP2D = recommended Phase 2 dose; TSS = total symptom score. Patients who received placebo in Part 2 rolled over to avapritinib treatment in Part 3.

All patients who complete Part 1 or Part 2 were given the opportunity to receive avapritinib at a RP2D to assess long-term efficacy and safety.

## Study participants

| Main inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Main exclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Patient must be ≥ 18 years of age. 2. Patient must have SM, confirmed by Central Pathology Review of BM biopsy, and central review of B- and C-findings by WHO diagnostic criteria. 3. Patient must have moderate-to-severe symptoms based on minimum mean total symptom score (TSS) over the 14-day eligibility screening period for assessment of TSS. Minimum TSS for eligibility is ≥ 28. 4. Patient must have failed to achieve adequate symptom control for 1 or more baseline symptoms as determined by the Investigator, with at least 2 of the following symptomatic therapies: • H1 blockers. • H2 blockers. • Proton-pump inhibitors. • Leukotriene inhibitors. • Cromolyn sodium. | 1. Patient has been diagnosed with any of the following WHO SM sub-classifications: • Cutaneous mastocytosis (CM) only (ie, without documentation of systemic involvement). • SSM • SM-AHN. • ASM. • MCL. • MC sarcoma. 2. Patient has been diagnosed with another myeloproliferative disorder (eg, myelodysplastic syndrome, myeloproliferative neoplasm). 3. Patient has any of the following organ damage C- findings attributable to SM: • Cytopenia. • Hepatomegaly with ascites and impaired liver function. |

<div style=\"page-break-after: always\"></div>

| • Corticosteroids. • Omalizumab. 5. The patient's symptomatic SM therapies (eg, H1 and H2 blockers) must be stable (same dose, no new medications ≥14 days before beginning the 14 -day ISM SAF eligibility TSS assessment.). 6. For patients receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or equivalent, and the dose must be stable for ≥ 14 days before starting the ISM SAF for the determination of eligibility. 7. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2. 8. Patient must give written informed consent.   | - • Palpable splenomegaly with hypersplenism. • Malabsorption with hypoalbuminemia and significant weight loss. • Skeletal lesions: large osteolytic lesions with pathologic fractures. • Life-threatening organ damage in other organ systems that is caused by MC infiltration in tissues. 4. Patient meets any of the following laboratory criteria: • Aspartate aminotransferase or alanine aminotransferase > 3.0 × upper limit of normal (ULN). • Total bilirubin > 1.5 × ULN; > 3.0 × ULN if due to Gilbert's disease. • Albumin < 1 × LLN. • Estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease equation) < 30 mL/min/1.73 m 2 or creatinine > 1.5 × ULN. • Absolute neutrophil count < 1.5 × 10 9 /L. • Hemoglobin < 10 g/dL. • Platelet count < 100 × 10 9 /L. 5. Patient has received any of the following medications, therapies, or procedures in the timeframes listed: • Any prior treatment with avapritinib. • Any TKI, including but not limited to masitinib and midostaurin, or investigational agent for < 14 days or 5 half-lives of the drug (whichever is longer) before beginning the 14-day ISM-SAF eligibility TSS assessment. • Any antineoplastic drug therapy (including but not limited to cladribine and interferon alpha, pegylated interferon, or antibody therapy) < 28 days or 5 half-lives of the drug (whichever is longer) before beginning the 14-day ISM-SAF eligibility TSS assessment. • Radiotherapy or psoralen and ultraviolet A (PUVA) therapy < 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment. • Any hematopoietic growth factor < 14 days before starting the ISM-SAF for determination of eligibility. • Any major surgical procedure (minor surgical procedures such as central venous catheter placement, BM biopsy, and feeding tube placement are not considered major surgical   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

## Treatments

## Part 1

Avapritinib (at a dose of 25, 50, or 100 mg QD) or matching placebo was administered orally in 28-day cycles for at least 12 weeks before rolling over to Part 3. Under the original protocol a 200 mg group was also included, however, based on a review of safety and efficacy data from the BLU-285-2101 Phase 1

procedures) &lt; 14 days before starting the ISMSAF for determination of eligibility.

6. Patient requires therapy with a concomitant medication that is a strong inhibitor or strong inducer of cytochrome P450 3A4 (CYP3A4).
7. Patient has a history of a malignancy that has been diagnosed or required therapy within 3 years before the first dose of study drug. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational agent may be included after approval by medical monitor.
8. Patient has a QT interval corrected using Fridericia's formula (QTcF) &gt; 480 msec.
9. Patient has a history of a seizure disorder (eg, epilepsy) or requires antiseizure medication.
10. Patient has a history of a cerebrovascular accident or transient ischemic attacks within 12 months before the first dose of study drug.
11. Patient has a known risk or recent history (12 months before the first dose of study drug) of intracranial bleeding (eg, brain aneurysm).
12. Patient has a primary brain malignancy or metastases to the brain.
13. Patient has clinically significant, uncontrolled cardiovascular disease, including Grade III or IV congestive heart failure according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months; clinically significant, uncontrolled arrhythmias, or uncontrolled hypertension.
14. Patient is unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures, including mandatory BM and skin biopsies, and study restrictions.

<div style=\"page-break-after: always\"></div>

study, the 200 mg dose group in this study was removed and no patients received the 200 mg dose within this study.

## Part 2

Avapritinib RP2D (25 mg) or matching placebo was administered orally, QD in Part 2 in 28-day cycles for 6 cycles. After completion of 6 cycles (24 weeks) of treatment (C7D1) and all post-C7D1 study procedures, patients rolled over to Part 3 of the study where all patients had the opportunity to receive avapritinib 25 mg QD in an open-label fashion.

## Part 3

Avapritinib 25 mg was administered orally, QD for up to 5 years, in 28-day cycles, inclusive of Part 1 and Part 2. The study drug was administered at the same dosing frequency as the last cycle in Part 1 or Part 2. The dose administered could be modified under certain circumstances.

In Part 2, dose escalations above 25 mg QD (placebo or avapritinib) were not permitted.

In Part 3 open-label extension, dose escalation from 25 mg QD to 50 mg QD was permitted, if patients met the required criteria as indicated in the protocol.

All patients continued to receive BSC throughout the study.

<div style=\"page-break-after: always\"></div>

## Objectives

| Objectives                                                                                                                                                                                                                                                        | Endpoints                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |
| Part 1                                                                                                                                                                                                                                                            |                                                                                                                                                                                               |
| To determine the RP2D of avapritinib in patients with ISM for use in Part 2 and Part 3 of the study                                                                                                                                                               | The RP2D in patients with ISM                                                                                                                                                                 |
| Part 2                                                                                                                                                                                                                                                            |                                                                                                                                                                                               |
| To determine mean change in ISM-SAF TSS from baseline to C7D1, compared to placebo                                                                                                                                                                                | Mean change in ISM-SAF TSS, from baseline to C7D1                                                                                                                                             |
| Part 3                                                                                                                                                                                                                                                            |                                                                                                                                                                                               |
| To assess the long-term safety and efficacy of avapritinib n ISM patients                                                                                                                                                                                         | The long-term safety and eficacy of avapritinib                                                                                                                                               |
| Key Secondary (Part 2 Only)                                                                                                                                                                                                                                       |                                                                                                                                                                                               |
| To determine the proportion of avapritinib-treated patients with ISM with a ≥ 50% reduction in senum tryptase firom baseline to C7D1, compared to placebo                                                                                                         | Proportion of patients with a ≥ 50% reduction in sennm tryptase from baseline to C7D1                                                                                                         |
| To determine the proportion of avapritinmib-treated patients with ISM with a ≥ 50% reduction in peripheral blood KIT D816V allele fiaction from baseline to C7D1 or tmdetectable (< 0.02%) for patients with detectable mutation at baseline, compared to placebo | Proportion of patients with a ≥ 50% reduction in peripheral blood KIT D816V allele fiaction from baseline to C7D1 or umdetectable (< 0.02%) for patients with detectable mutation at baseline |
| To determine the proportion of avapritinib-treated patients with ISM achieving ≥ 50% reduction in ISM-SAF TSS from baseline to C7D1, compared to placebo.                                                                                                         | Proportion of patients with ≥ 50% reduction in ISM-SAF TSS from baseline to C7D1.                                                                                                             |
| To determine the proportion of avapritinib-treated patients with ISM achieving 2 30% reduction in ISM-SAF TSS from baseline to C7D1, compared to placebo.                                                                                                         | Proportion of patients with ≥ 30% reduction in ISM-SAF TSS from baseline to C7D1.                                                                                                             |
| To determine the proportion of avapritinib-treated patients with a ≥ 50% reduction in bone mairow mast cells from baseline to C7D1 or no aggregates for patients with aggregates at baseline, compared to placebo                                                 | Proportion of patients with a ≥ 50% reduction in bone mairow mast cells from baseline to C7D1 or no aggregates for patients with aggregates at baseline                                       |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                                                                                                           | Endpoints                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Additional Secondary                                                                                                                                                                                                 | Additional Secondary                                                                                                                                                                                     |
| Parts l and 2                                                                                                                                                                                                        |                                                                                                                                                                                                          |
| Assess change in the following measures of mast cell burden in each treatment cohort from baseline to C4D1 (Part 1) and C7D1 (Part 2): Sernum tryptase KIT D816V allele burden in blood Bone marrow mast cells       | Change in measures of mast cell burden from baseline to C4D1 (in Part 1) and to C7D1 (in Pait 2): Serum tryptase KIT D816V allele buwdenin blood Bone manrow mast cells                                  |
| Assess change in BSC usage for SM symptoms                                                                                                                                                                           | Change in BSC usage                                                                                                                                                                                      |
| Assess change in GI and skin domains, neurocognitive symptom cluster (brain fog. headache and dizziness), and individual symptom scores ofISM-SAF                                                                    | Change in GI and slin domains, neurocognitive symptom cluster (brain fog, headache and dizziness), and individual symptom scores of ISM-SAF                                                              |
| and \"lead (most severe) domain/symptom cluster score (ie, individual symptom and domain/symptom cluster with highest mean score at baseline in each patient) of ISM-SAF                                              | pue uodus (aanas psow) pee., u siue \"lead (most severe) domain/symptom cluster score ofISM-SAF                                                                                                           |
| Assess change in other PROs and QoL measures based on the MC-QoL, PGIS, SF-12, PGIC, and EQ-5D-5L questiomaire                                                                                                       | Change in MC-QoL, PGIS, SF-12, PGIC, and EQ-5D-5L                                                                                                                                                        |
| Assess the safety and tolerability of avapritinib, as assessed by AEs, vital sigus, ECGs, and laboratory tests                                                                                                       | Safety and tolerability of avapritinib, as assessed by AEs, vital signs, ECGs, and laboratory tests                                                                                                      |
| Assess the PK of avapritinib                                                                                                                                                                                         | PK of avapritinib                                                                                                                                                                                        |
| Correlate avapritinib exposure with safety and efficacy endpoints                                                                                                                                                    | Correlations between avapritinib exposure and safety and efficacy endpoints                                                                                                                              |
| Additional Secondary                                                                                                                                                                                                 |                                                                                                                                                                                                          |
| Part 3                                                                                                                                                                                                               |                                                                                                                                                                                                          |
| Assess chamges in the following measures of mast cell burden: Sernm tryptase KIT D816V allele burden in blood Bone marrow mast cells (optional at approximately 1 year after the biopsy at the end of Parts 1 and 2) | Change in the following measures of mast cell burden: Serum tryptase KIT D816V allele buuden in blood Bone marow mast cells (optional at approximately 1 year after the end of Part 1 and Part 2 biopsy) |
| Assess change in BSC usage for SM symptoms                                                                                                                                                                           | Change in BSC concomitant medication usage                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                                                                                                                                              | Endpoints                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| and \"lead (most severe) domain/symptom cluster score (ie, individual symptom and domain/symptom cluster with highest mean score at baseline in each patient) of ISM-SAF                                                                                 | pue .uods (aanas pso) peap., ur saeuo score ofISM-SAF\"                                                                                                                                                                                                        |
| Assess the proportion of avapritinib-treated patients with ISM achieving 2 50% reduction in TSS at 1 year after initiation of avapritinib therapy                                                                                                       | Proportion of avapritinib-treated patients with ISM achieving ≥ 50% reduction in TSS at 1 year from Pait 3 baseline (and Part 1 or Part 2 baseline for patients on same dose of avapritinib in both parts of the study).                                      |
| Assess the proportion of avapritinib-treated patients with ISM achieving ≥ 30% reduction in TSS at 1 year after initiation of avapritinib therapy                                                                                                       | Proportion of avapritinib-treated patients with ISM achieving ≥ 30% reduction in TSS at 1 year from Pait 3 baseline (and Part 1 or Part 2 baseline for patients on same dose of avapritinib in both paits of the study).                                      |
| Assess change in TSS, symptom cluster, domain scores, and individual symptom scores of ISM-SAF from Part 3 baseline (and Part 1 or Part 2 baseline for patients on same dose of avapritinib im both parts of the study) to C4D1. C7D1, C11D1, and C13D1 | Change in TSS, symptom cluster, domain scores, and individual symptom scores of ISM-SAF from Part 3 baseline (and from Part 1 and Part 2 baseline for patients receiving same dose of avapritimib in both study parts) to Part 3 C4D1, C7D1, C11D1, and C13D1 |
| Assess change in other PROs and QoL measures based on the MC-OoL, PGIS, SF-12, PGIC, and EQ-5D-5L questiommaires                                                                                                                                        | Change in MC-QoL, PGIS, SF-12, PGIC, and EQ-5D-5L                                                                                                                                                                                                             |
| Assess the safety and tolerability of avapritinib, as assessed by AEs, vital signs, ECGs, and laboratory tests                                                                                                                                          | Safety and tolerability of avapritinib, as assessed by AEs, vital signs, ECGs, and laboratory tests                                                                                                                                                           |
| Exploratory (Parts1, 2, and 3)                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                               |
| Explore potential correlations between the ISM-SAF and other PRO and QoL meastures and individual measures of mast cell burden                                                                                                                          | Potential correlations between ISM-SAF, PGIS. other PR.O and QoL measures, and individual measures of mast cell burden                                                                                                                                        |
| Assess conrelation of clinical features (eg. demographics, laboratory tests, concomitant medications, AEs, concomitant mutations) with activity against ISM                                                                                             | Correlation of clinical features (eg, demographics, laboratory exams, concomitant medications, AEs. concomitant mutations, etc.) with activity against ISM                                                                                                    |
| Identify potential new biomarkers (DNA, RNA. senum protein) in blood for pharmacodynamic effects and safety of avapritinib                                                                                                                              | Status of exploratory biomarkers (DNA, RNA. senum protein) in blood with respect to efficacy or safety related endpoints for avapritinib                                                                                                                      |
| Assess whether avapritinib can affect platelet aggregation as a possible mechamistic contributor to bleeding events                                                                                                                                     | Platelet aggregation studies at baseline and during treatment, including at the time of bleeding events                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                                          | Endpoints                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Assess change in bone density by DXA/bone densitometry scan (optional, performed at the Investigator's discretion)                                  | Change in bone density (optional, performed at the Investigator's discretion)                                                                                                                                             |
| Assess changes in skin lesions by photography in patients with baseline mastocytosis in skin from baseline to C4D1 (in Part 1) and C7D1 (in Part 2) | Change in percent fractional body suface area involved by mastocytosis in skin, change in lesion mumber, and change in pigmentation of cutaneous lesions in patients with baseline mastocytosis in skin                   |
| Assess changes in skin lesions by photography im patients with new mastocytosis im skin from baseline (Part 3) to C7D1 (Pait 3)                     | Change in percent fractional body suface area involved by mastocytosis in skin, change im lesion mumber, and change in pigmentation of cutaneous lesions in patients with new mastocytosis in slin at baseline of Part 3. |
| Assess changes in mast cells in skin biopsies in patients with baseline mastocytosis in skin                                                        | Change in skin mast cells in patients with baseline mastocytosis in skin from baseline to C4D1 (in Part 1) and to C7D1 (in Part 2) and at C13D1 (in Part 3, optional).                                                    |
| Assess change in the frequency of anaphylactic episodes based on epinephrine uise                                                                   | Change in number of episodes of anaphylaxis. based on epinephrine use                                                                                                                                                     |

Abbreviations: AE = adverse event; BSC = best supportive care; CXDX = Cycle X Day X; DNA = deoxyribonucleic acid; DXA = dual xray energy assessment; ECG = electrocardiogram; EQ-5D-5L = Fivelevel EuroQuol 5D; GI = gastrointestinal; ISM = indolent systemic mastocytosis; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; MC- QoL= Mastocytosis Quality of Life Questionnaire; PGIC = Patients' Global Impression of Change; PGIS = Patient's Global Impression of Symptom Severity; PK = pharmacokinetic(s); PRO = patient-reported outcome; QoL = Quality of Life; RNA = ribonucleic  acid; RP2D = recommended Phase 2 dose; SF-12 = Twelve-item Short Form Health Survey; SM = systemic mastocytosis; TSS = Total symptom score.

## ISM-SAF questionnaire

The Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF) is a 12-item PRO employed for the daily PRO assessment on an eDiary to assess symptoms in patients with ISM. Eleven items (bone pain, abdominal pain, nausea, the spots on the skin, itching, flushing, fatigue, dizziness, brain fog, headache, diarrhoea) that assess the severity of symptoms are graded on an 11-point scale (0 to 10, none to maximum severity), and one item (diarrhoea) assesses the frequency. The ISM-SAF generates scores for each item, for skin domain, GI domain, neurocognitive domain and a TSS. The skin domain includes subscales of the spots on the skin, itching, and flushing, ranging from 0 to 30. The GI domain includes subscales of abdominal pain, nausea, and diarrhoea, ranging from 0 to 30. The neurocognitive domain includes subscales of brain fog, headache, and dizziness, ranging from 0 to 30. The TSS is the sum of the 11 severity items ranged from 0 to 110. For all levels, higher scores represent increased sign and symptom severity. If any item score is missing, the corresponding domain and TSS score will be set as missing on a given day.

The patient will complete the ISM-SAF daily for 4 weeks beginning at the time of informed consent, during which time BSC medications are optimized and stabilized. The ISM-SAF will be completed daily for an additional 2 weeks (14 days) to calculate eligibility TSS score to determine patient eligibility based on the ISMSAF symptom threshold (≥28 vs. &lt;28). Baseline symptoms will be collected for the 14 days immediately preceding the first dose of study drug or placebo. These data will be used to derive a Baseline TSS. Thereafter the ISM-SAF TSS will be calculated on a daily and bi-weekly basis. A daily TSS is

<div style=\"page-break-after: always\"></div>

created by summing the scores for each of the 11 items on a given assessment day, and a bi-weekly TSS (14-day average TSS) is created by averaging the summed daily scores over a pre-specified 14-day period and dividing by the number of non-missing days. A bi-weekly TSS is derived only if the subject completes the ISM-SAF on seven or more of the 14 days, otherwise it will be considered missing for the patient. The average of summed daily scores over a 14-day period, was calculated and used to assess eligibility for inclusion in BLU-285-2203 as well as treatment efficacy at each study timepoint.

The primary efficacy endpoint for Part 2 is the mean change is ISM-SAF TSS from Baseline to Cycle 7 Day 1 (C7D1). Change in TSS from Baseline to C7D1 is defined as (C7D1 TSS - Baseline TSS).

The threshold for baseline ISM moderate vs. severe is 42.

Table 34. Conceptual framework for the ISM-SAF

| Item                                                                                   | Concept            | Domain                           | General concept                 |
|----------------------------------------------------------------------------------------|--------------------|----------------------------------|---------------------------------|
| Item 2. 0ver the past 24 hours, how severe was your worst abdominal pain?              | Abdominal pain     | Gl sign and symptom severityt    | Total sign and symptom severity |
| Item 3. 0ver the past 24 hours, how severe was your worst nausea?                      | Nausea             | Gl sign and symptom severityt    | Total sign and symptom severity |
| Item 12. 0ver the past 24 hours, how severe was your worst diarrhea?                   | Diarrhea           | Gl sign and symptom severityt    | Total sign and symptom severity |
| Item 4. 0ver the past 24 hours, how severe were the spots on your skin at their worst? | Spots              | Skin sign and symptom severity   | Total sign and symptom severity |
| Item 5. 0ver the past 24 hours, how severe was your worst itching?                     | Itching            | Skin sign and symptom severity   | Total sign and symptom severity |
| Item 6. 0ver the past 24 hours, how severe was your worst flushing?                    | Flushing           | Skin sign and symptom severity   | Total sign and symptom severity |
| Item 1. 0ver the past 24 hours, how severe was your worst bone pain?                   | Bone pain          | Bone pain                        | Total sign and symptom severity |
| Item 7. 0ver the past 24 hours, how severe was your worst fatigue?                     | Fatigue            | Fatigue                          | Total sign and symptom severity |
| Item 8. 0ver the past 24 hours, how severe was your worst dizziness?                   | Dizziness          | Neurocognitive symptom severityt | Total sign and symptom severity |
| Item 9. Over the past 24 hours, how severe was your worst brain fog?                   | Brain fog          | Neurocognitive symptom severityt | Total sign and symptom severity |
| Item 10. 0ver the past 24 hours, how severe was your worst headache?                   | Headache           | Neurocognitive symptom severityt | Total sign and symptom severity |
| Item 11. 0ver the past 24 hours, how many times did you have diarrhea?                 | Diarrhea frequency | Diarrhea frequency               | Diarrhea frequency              |

Abbreviations: Gl=gastrointestinal

'These reflect non-specific symptoms and intended to be assessed and scored on an item-level basis only (i.e., unlike Gl, skin, and neurocognitive symptoms, no domain is hypothesized)

Though the focus of this dossier is on the ISM-SAF TSs, it is important to note that content validity and psychometric analysis provided herein also support use of the Gl Symptom, Skin Symptom, and Neurocognitive Symptom domain scores in the target patient population.

## Development of the ISM-SAF PRO questionnaire

The qualitative activities undertaken during the development of the ISM-SAF included a review of empirical literature, advice meetings with therapeutic area experts, qualitative concept elicitation interviews with patients with ISM (n=13) or SSM (n=3), concept selection and questionnaire development, and qualitative cognitive debriefing interviews with patients with ISM.

<div style=\"page-break-after: always\"></div>

A translatability assessment was conducted by an independent translation services provider. The following eight languages were selected for the evaluation: Danish (for Denmark), Dutch (for Netherlands and Belgium), Spanish (for Spain), French (for France), German (for Germany), Italian (for Italy), and Swedish (for Sweden).

Qualitative cognitive debriefing interviews were conducted with patients with ISM to evaluate the ISMSAF for readability, comprehensibility, relevance, and comprehensiveness.

The psychometric performance of ISM-SAF scores was evaluated in an observational study (n=103), during part 1 of study BLU-285-223 (n=38) and in part 1 + part 2 of study BLU-285-223 (n=243).

## Identification of severity thresholds in the observational study

As stated above, a prospective, observational study was performed to (1) generate cross-sectional psychometric data for ISM-SAF scores, (2) inform the use of the ISM-SAF as a clinical trial screening tool in BLU-285-2203, and (3) identify TSS cut-off scores capable of distinguishing patients with moderate to severe symptoms from those with mild symptoms.

The observational study utilized an online survey of patients in the US diagnosed with ISM or SSM, who completed clinical outcome assessments using a web-based electronic platform over the course of 15 days. In addition to the ISM-SAF, clinical outcome assessments included the Patient Global Impression of Symptom Severity (PGIS), 12-Item Short Form Survey, Version 2 (SF-12v2®), Mastocytosis Quality of Life Questionnaire (MC-QoL), and Functional Assessment of Cancer Therapy - Cognitive Function (FACTCog).

A total of 116 eligible adult patients were screened into the study; 103 were included in the Self-reported Diagnosis Cohort, and 58 were able to provide medical documentation of diagnosis from their physician and were included in the Medically Documented Diagnosis Cohort.

Based on the findings of both the ROC and contingency analyses, using the PGIS as an anchor, a biweekly ISM-SAF TSS cut-off value of between 21 and 28 to identify patients with at least moderate symptoms was indicated for screening purposes in the BLU-285-2203 study. The upper value of 28 was selected as a more conservative estimate, and it was assumed that the use of this cut-off would retain a large enough sample to meet clinical study goals. These same analyses based on observational study data were used to establish a TSS cut-off value of 42 to distinguish patients with severe symptoms from those with moderate symptoms.

Results from the observational study and from Part 1 of BLU-285-2203 were shared with the FDA and EMA, and are understood by the MAH to support the conclusion that the ISM-SAF produces reliable and construct valid scores when administered to patients in the target population. To provide further evidence of the reliability and validity of the ISM-SAF, the MAH conducted psychometric analyses based on pooled data from Part 1 and Part 2 of BLU-285-2203. A total of 243 patients from Cohort 1 and Cohort 2 with ISM-SAF data at C1D1 and at C3D1, C4D1, or C7D1 were included in the psychometric analysis population (PsAP) for Part 1 and Part 2. Nearly all patients had bi-weekly scores for all ISM-SAF items throughout the study: 100.0% at Baseline, 98.8% at C3D1, 98.3% at C4D1, 99.2% at C6D1, and 97.9% at C7D1.

## Score interpretation and clinical relevance

Researchers are using different nomenclature including the clinically important difference (CID) between groups and clinically important response, most recently referred to as meaningful within-patient change

<div style=\"page-break-after: always\"></div>

(MWPC). The CID reflects the difference in scores between two treatment groups that can be considered clinically relevant and distinguishes between-groups change from measurement error. In contrast, the MWPC is the amount of change an individual would have to report to support the conclusion that a treatment benefit has been observed.

To assist in the interpretation of scores of the ISM-SAF, distribution-based methods, anchor-based methods, empirical cumulative distribution function (eCDF) curves, and probability density function (PDF) curves were employed.

Anchor-based analyses from Part 1 Cycle 4 of BLU-285-2203 (based on a PGIS reduction of one or two points from baseline) were used to inform the conclusion that a 30% reduction in the TSS reflects an MWPC, a threshold that aligns with the treatment respons e criteria of ≥30% proposed by the European Competence Network on Mastocytosis (ECNM) and the American Initiative on Mast Cell Diseases (AIM) Consortium. Score interpretation conclusions from Part 1 were confirmed by the pooled Part 1 and 2 data. Additionally, CID estimates to facilitate the meaning of observed group differences using distribution based methods were proposed by the MAH. The range was generated using two independent distributionbased methods ('1/2 standard deviation at baseline' and the 'standard error of measurement') as defined in the psychometric analysis SAP. CID range for the TSS was based on pooled Part 1 and 2 data, and confirmed the difference range previously observed for Part 1.

## Sample size

## Part 1

The sample size for Part 1 of the study is not determined based on a specific statistical hypothesis; rather, it is chosen to allow analysis of ISM-SAF TSS, PK parameters, safety, and objective measures of MC burden for a range of avapritinib doses in the study population to enable further study of a RP2D in Part 2.

## Part 2

Mean change in ISM-SAF TSS from Baseline to C7D1:

With a 1:2 (placebo:avapritinib 25mg) randomization ratio, assuming the null hypothesis is the mean change of TSS of negative 10 in the placebo group, versus the alternative hypothesis of the mean change of TSS of negative 19.7 in the avapritinib group, the standard deviation of mean change of TSS is assumed to be 20, and a 1- sided type I error rate of 0.025, a total of 204 patients will have &gt; 90% power using a 2-sample t-test.

Supportive evidence was from analysis results from Part 1 showing -19.7 mean change (standard deviation 20.2, n=10) in patients treated with avapritinib 25 mg, compared to -3.2 mean change (standard deviation 9.0, n=9) in patients treated with placebo. Further, psychometric evaluation of the ISM-SAF in Part 1 using distribution-based methods identified a 10-point threshold as a conservative approach providing guidance for interpreting substantive results when using ISM-SAF for the comparison of treatment group mean difference. Therefore, in Part 2 the assumption of a mean change of negative 10 in the placebo group was used to take a conservative approach to powering the study, while maintaining a difference of approximately 10 between placebo and avapritinib treatment.

To ensure the study is powered for the primary endpoint and all key secondary endpoints, 204 patients is the proposed sample size for Part 2.

## Part 3

<div style=\"page-break-after: always\"></div>

Patients rollover to Part 3 from Part 1 and Part 2. The number of patients in Part 3 will be approximately 39+204= 243 patients.

## Randomisation

The randomization assignment was implemented by the IRT after screening was completed:

## Part 1

Enrolment into Part 1 of the study was randomized in a ratio of 1:1:1:1 to the 3 doses of avapritinib and placebo. Randomization was stratified by presence or absence of mastocytosis in skin at baseline and by baseline serum tryptase level (&lt; 20 vs ≥ 20 ng /mL). All patients received the RP2D when they rolled over to Part 3.

## Part 2

Enrolment into Part 2 of the study was randomized in a ratio of 2:1 to 25 mg avapritinib QD and placebo. All patients received 25 mg avapritinib QD (RP2D) when they roll over to Part 3. Randomization in Part 2 was stratified based on baseline serum tryptas e level (&lt; 20 ng/mL vs ≥ 20 ng/mL).

## Blinding (masking)

The study is double-blinded. Patients, monitors, study centre personnel related to the study, and the Sponsor were blinded to treatment assignment in Part 1 and Part 2 of the study, with the exception of specific unblinded staff involved in safety and pharmacovigilance, and management of the IDMC.

To ensure that the study team members were not unblinded inadvertently, the documentation containing patient treatment assignment information was stored in a pre-identified, secure, limited-access folder or secure network area.

## Statistical methods

The final SAP for Part 2 and Part 3 of study dated 07 June 2022 and the interim analysis SAP for Part 1 of the study dated 03 February 2020.

When analysing overall long-term data, information from Parts 1, 2 and 3 were included in the analyses.

Analyses for Part 1 are presented by treatment group. Continuous variables were summarized by reporting the number of observations (n), mean, SD, median, min, and max.

Categorical variables were summarized using frequency tables showing the number and percentage of patients within a particular category, where the denominator was the total number of non-missing values at the applicable time point (unless otherwise specified). Appropriate 95% CIs were also presented as needed.

All analyses for Part 2 are presented by treatment arm, 'placebo' and '25 mg' for patients who initially enrolled into Part 2 of the study. Part 3 analyses that use the Part 3 baseline are presented by patients' initial treatment arm in Part 1 or Part 2 as the following: 'placebo to 25 mg', '25 to 25 mg', '50 to 25 mg', '100 to 25 mg', 'placebo' or '25 to 25 mg', and 'overall'.

The same layout as Part 3 is used for long-term avapritinib summary tables that use avapritinib baseline and data from Part 1, Part 2, and Part 3 (definitions of baseline provided in Section 9.7.1.2).

<div style=\"page-break-after: always\"></div>

Summary statistics for continuous variables included n (non-missing observations), mean, SD, minimum, median, and maximum. Summary statistics for categorical variables were presented in terms of frequencies and percentages. Time to event data were summarized using KM method, which included the number of events and censors, the estimated median with 95% CIs, minimum, maximum, and 25th and 75th percentiles.

## Analysis populations

- Intent-to-treat (ITT) Population: All randomized patients independent of whether they received the study drug or not. The primary efficacy analysis set is the ITT population.
- Per-Protocol (PP) Population (only for Part 2 and 3) : All randomized patients who met the following criteria:
- -Confirmed to have ISM per WHO diagnostic criteria, including Central Pathology Review of bone marrow.
- -Had no major violations of the inclusion criteria (#2, #3, #6) or exclusion criteria (#1, #5, #18):
- -Part 1 or Part 2 baseline TSS score ≥ 28.
- -Had not received wrong study drug at any time during Part 2 of the study (ie, placebo patient received avapritinib by mistake, or vice versa).
- -Had not received concomitant TKI treatment.
- Safety Population: All patients who received at least 1 dose of avapritinib or placebo.

## Adjustments for covariates

For the primary analysis, an ANCOVA controlling for randomization stratification factor (serum tryptase &lt;20 ng/mL vs ≥ 20 ng/mL) and baseline ISM status (moderate vs severe) was performed to compare avapritinib and placebo.

## Handling of dropouts or missing data

No imputation was made for completely missing date unless otherwise specified.

## Interim analyses and data monitoring

As per protocol, an interim analysis was performed to determine the RP2D, efficacy, and safety once all Part 1 patients had completed C4D1 assessments. No other interim analysis was planned for the study.

## Multiple comparison/multiplicity

The gatekeeping procedure was used to test the primary endpoint and all four key secondary endpoints with the testing order shown in the below Figure 30 to ensure the family-wise type I error is strongly controlled for both the primary endpoint and key secondary endpoints at 1-sided alpha of 0.025.

<div style=\"page-break-after: always\"></div>

Figure 30. Gatekeeping Procedure for Primary Endpoint and Key Secondary Endpoints

<!-- image -->

## Results

Study BLU-285-2203 has enrolled 251 patients with ISM, including 246 patients who have received at least 1 dose of avapritinib.

The study is being conducted in 3 parts:

- Part 1 Tested 3 doses of avapritinib in ISM patients (100, 50, and 25 mg vs placebo) and identified 25 mg as the RP2D with the optimized benefit-risk for patients with ISM (39 patients; duration of treatment: at least 12 weeks)
- Part 2 Conducted after the determination of RP2D, in patients with ISM randomly assigned to the avapritinib RP2D identified in Part 1 in combination with BSC (141 patients) or to placebo in combination with BSC (71 patients), to determine the efficacy and safety of avapritinib in combination with BSC compared with placebo in combination with BSC in patients with ISM with moderate to severe symptoms that could not be adequately controlled by BSC (duration of treatment: 24 weeks)
- Part  3  Is  ongoing  and  is  intended  to  further  characterize  the  safety  and  efficacy  of  long-term treatment in patients receiving the RP2D in combination with BSC. Patients on placebo in Part 1 or 2 will crossover to receive avapritinib, and patients randomized to receive treatment with avapritinib in

<div style=\"page-break-after: always\"></div>

Parts 1 or 2 will continue to receive avapritinib in this open-label extension cohort after completion of Parts 1 or 2. Part 3 duration of treatment: up to 5 years including durations of Parts 1 and 2.

The study included 39 patients (9 patients in placebo, 10 patients in each group of avapritinib 25, 50, and 100 mg) in Part 1 and 212 patients (71 patients in placebo and 141 in the 25 mg Avapritinib Group) in Part 2.

Overall, 235 patients (34 patients from Part 1 and 201 patients from Part 2) rolled over to Part 3 from Part 1 and Part 2 of the study.

## Participant flow

## Patient disposition

Part 1 of the study completed enrolment with 39 patients. All 39 patients were randomized 1:1:1:1 into 1 of 3 avapritinib dose groups or placebo. Patients received a once-daily dose of either placebo (n=9) or avapritinib (25 mg, 50 mg, 100 mg: n=10 for each group).

In Part 1, 2 patients from the 25 mg Avapritinib Group discontinued from the study due to noncompliance and AE, respectively.

In the 50 mg Avapritinib Group, 2 patients discontinued due to non-compliance and AE, respectively.

In the 100 mg Avapritinib Group, 1 patient discontinued due to withdrawal by patient.

A total of 34 patients completed Part 1 of the study and rolled over to Part 3.

Figure 31. Disposition of Patients in Part 1 (Including Those Who Rolled Over to Part 3)

<!-- image -->

Abbreviations: RP2D = recommended Phase 2 dose.

In Part 2 , both the ITT and Safety Populations included 141 patients in the 25 mg avapritinib group and 71 patients in the placebo group.

The PP Population in Part 2 included 123 patients in the 25 mg Avapritinib Group and 67 patients in the Placebo Group. In Part 2, patient disposition was similar in the 25 mg Avapritinib Group and Placebo Group. In the 25 mg Avapritinib Group, 5 patients discontinued from the study for the following reasons: withdrawal of consent (n=2), related AE (n=1), SM clinical progression (n=1), and Investigator's decision (n=1).

In the Placebo Group, 5 patients discontinued from the study (3 patients due to withdrawal of consent

<div style=\"page-break-after: always\"></div>

and 2 patients due to other reasons).

A total of 136 patients (96.5%) treated with 25 mg avapritinib and 66 patients (93.0%) treated with placebo completed Part 2 of the study. Of these, 1 patient in the 25 mg Avapritinib Group completed Part 2 but did not roll over to Part 3. A total of 201 patients completed Part 2 and rolled over to Part 3.

Figure 32. Disposition of patients in Part 2 of the Study (Including those who rolled over to part 3)

<!-- image -->

Abbreviations: AE = adverse event; SM = systemic mastocytosis.

Overall, 235 patients rolled over to Part 3 from Part 1 and Part 2 of the study. At the time of the data cutoff (23 June 2022), 14 patients have discontinued from Part 3 of the study and 221 patients were ongoing. Of these, 5 patients discontinued due to AEs, 2 each due to progressive disease and withdrawal of consent, and 1 each due to investigator decision, patient decision, lost to follow-up, and patient withdrew as they requested dose escalation that was not permitted per protocol. Only 1 patient discontinued from the study drug due to lack of effectiveness. Updated data with a data cut-off date of 07 April 2023 (an additional 10 months of follow-up) were provided during the procedure. At the time of this data cut-off, 24 patients have discontinued from Part 3 of the study and 211 patients were ongoing.

## Recruitment

- Date first patient enrolled (C1D1): 16 April 2019
- Date last patient enrolled (C1D1): 06 January 2022
- Data cut-off date for the interim analysis: 23 June 2022

<div style=\"page-break-after: always\"></div>

Forty-two sites enrolled patients and entered data for this study, including 19 sites in North America, 20 sites in Europe, and 3 sites in the United Kingdom. Two additional sites screened patients but did not enrol any patients.

## Conduct of the study

The original Protocol for Study BLU-285-2203 (dated 15 February 2018) was amended 10 times: 5 were global and 5 were country-specific amendments. The study methodology presented for assessment is in accordance with the latest global protocol amendment 9 (dated 07 June 2022).

Table 35. Major Changes of Global Protocol Amendments

| Ainendment Number   | Amendment Date                                                                                                         | Summary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     | 30 July 2018 First patient screened for the study: 11 January 2019 First patient emrolled in the shudy: 16 April 2019: | Part 1 and 2: Primary endpoint changed from mean percent reduiction in ISM-SAF TSS to mean change in ISM-SAF TSS from baseline to Week 12. Secondary objectives and endpoints updated to proportion of patients with at least 5-, 10-, and 15-point reductions in TSS and domain scores of ISM-SAF from baseline to Week 12. Part 3: Secondary objectives and endpoints updated to reflect the time to achieve 5-, 10-, and 15-poimt reductions in TSS and domain scores |

<div style=\"page-break-after: always\"></div>

| Amendment Nunber   | Amendment Date                                                                                                                              | Sumimary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    |                                                                                                                                             | Added threshold for eligibility based on ISM-SAF TSS to eligibility criteria Removed 200 mg dose group from study Updated duration of patient pauticipation to reflect minimum duration of participation of 26 weeks (Parts 1 and 2) and 8 weeks (Part 3) Updated dosing guidelines in the event of toxicity or ICB.                                                                                                                                                                                                                                                                                                                                                                                        |
| 2                  | 14 Febrnary 2020                                                                                                                            | To reduce the risk of ICB, the following changes were made: Added new dose modifications for moderate thrombocytopenia (< 75,000/μL) Added precautions around concomitant coagulopathy and use of antithrombotic and anticoagulant therapy Added an exploratory objective assessing platelet aggregation Increased monitoring for ICB, including focal neurological history and exam at each visit Revised informed consent Other major changes were: Raised the QTc exclusion threshold from 450 to 480 msec Added exclusion criteria to exclude patients with kmown Added exclusion criteria to exclude patients who participate in another study Added precaution to use clothing and sumscreen to avoid |
| 4                  | 15 Jume 2020 First patient screened for Part 2 of the study: 23 July 2020 First patient enmrolled in Part 2 of the study: 24 September 2020 | Major revisions of Pat 2 (efficacy) prior to staiting Part 2 enrollment included: Confinmed RP2D to be 25 mg QD based on equivalent efficacy but superior tolerability than 50 and 100 mg QD Established climically important response as a ≥ 30% reduction in TSS firom baseline based on the psychometric evaluation of the ISM-SAF in Part 1.                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Anendinent Nunber   | Aimendment Date   | Summary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                   | treated patients with ISM achieving ≥ 30% reduction in TSS from baseline to C7D1, as compared to placebo Added the following 4 key secondary endpoints: To determine the proportion of avapritinib-treated patients with a ≥ 50% reduction in serum tryptase from baseline to C7D1, compared to placebo To determine the proportion of patients with a≥ 50% reduction in peripheral KIT D816V allele fiaction from baseline to C7D1 or undetectable (< 0.02%6) for patients with detectable mutation at baseline To determine mean change in ISM-SAF TSS in patients from baseline to C7D1 To determine the proportion of patients with a ≥ 50% reduction in bone marrow mast cells from baseline to C7D1 or no aggregates for patients with aggregates at baseline Other major changes included: Increased sample size in Paat 2 to approximately 204 patients, imcreasing the total miumber of patients across all parts to approximately 244 patients Added a stratification to treatment assigument randomization in Part 2 Instituted blinding to changes in serum tryptase, bone marow mast cells, and KIT D816V allele faction dhuring Part 2 Limited study population to ISM in Part 2 Clarified exclusion criterion regarding ongoing sigmificant medical conditions that are symptomatically uncontrolled Increased the mumber of sites from approximately 20 to approximately 35 sites Removed dose escalation to > 25 mg QD Updated the dose-modification guidance to recommend intermuption of avapritinmib if platelet levels for a patient fall < 100,000/μL |

<div style=\"page-break-after: always\"></div>

| Ainendment Nunber   | Amendment Date   | Suminary of Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                  | Removed the Paut 2 and 3 weekly safety visits at C1D8 C1D15, and C1D22 Added new appendix to provide guidance on study conduct in case of travel restrictions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 7                   | 01 November 2021 | Added the option of escalating avapritinib dose to 50 mg in Part 3. Specific criteria for this dose escalation added. Extended the schedule of ISM-SAF and OoL assessments beyond C13D1 through to E0T. Clarified use of corticosteroids churing the study. If a patient was not on coiticosteroids at baseline. corticosteroids were not recommended during the study. Similarly, for patients who were on coiticosteroids at baseline, increasing the dosage of these dnugs was not recommended during the shudy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                     | 07 Jume 2022     | Based on FDA feedback receivedin May 2022, the following changes were made: The primary objective for Part 2 was changed from 'the proportion of avapritinib treated patients with ISM achieving ≥ 30% reduction in TSS from baseline to C7D1, compared to placebo' to *mean change in ISM-SAF TSS from baseline to C7D1, compared to placebo'. It enables analyzing symptom reduction as a continuous variable instead of a dichotomous endpoint. The 'proportion of avapritinib treated patients with ISM achieving 2 30% reduiction in TSS from baseline to C7D1, compared to placebo* was changed to a key secondary endpoint for Part 2. An additional key secondary endpoint for Pait 2, the *proportion of avapritinib treated patients with ISM achieving ≥ 50% reduction in TSS fom baseline to C7D1, compared to placebo' was added. Analysis method for the *mean change in ISMI-SAF TSS from baseline to C7D1, compared to placebo' was changed from the two-sample t-test to ANCOVA controlling for randomization stratification factor (tryptase) and baseline ISM status (moderate vs severe). LOCF missing data imputation method was removed. |

Abbreviations: ANCOVA = analysis of covariance; CxDx = Cycle X Day X; EOT = End-of-Treatment; FDA = US Food and Drug Administration; ICB = intracranial bleeding; ISM = indolent systemic mastocytosis; ISM-SAF = Indolent Systemic MastocytosisSymptom Assessment Form; LOCF = last observation carried forward; QD = once daily; QoL = Quality of Life; RP2D = recommended Phase 2 dose; TSS = Total symptom score.

<div style=\"page-break-after: always\"></div>

## Protocol deviations

In Part 1, overall, 10 patients had ≥ 1 major protocol deviation.

The most common major protocol deviation was related to informed consent (7 patients overall).

For patients enrolled in Part 2, 41 (29.1%) patients in the 25 mg Avapritinib Group vs. 7 (9.9%) patients in the Placebo Group had ≥ 1 major protocol deviation during Part 2 of the study.

The most common major protocol deviations are outlined in the Table below. All other major protocol deviations occurred in &lt; 2% of patients in either treatment group.

Table 36. Major deviations in &gt; 2% of patients (Part 2)

| Deviation Type                            | Detail                                                                               | Avapritinib 25 mg n (%)   | Placebo n (%)   |
|-------------------------------------------|--------------------------------------------------------------------------------------|---------------------------|-----------------|
| Missed critical assessment at C7D1a       | Central tryptase                                                                     | 1 (0.7)                   | 1 (1.4)         |
|                                           | Central Bone marrow biopsy                                                           | 6 (4.3)                   | 0               |
|                                           | Central skin biopsy                                                                  | 1 (0.7)                   | 0               |
| ISM-SAF Compliance                        | < 50% completed in a cycle                                                           | 10 (7.1)                  | 3 (4.2)         |
| ICF compliance                            | ICF reconsent available but not signed within 2 study visits or administrative error | 7 (5.0)                   | 1 (1.4)         |
| Prohibited concomitant medication given b | Use of CYP3A4 inhibitor c                                                            | 1 (1.4)                   | 3(2.1)          |
| High dose steroid use                     | Within 7 days prior to C7D1 or for 14 consecutive days during the study              | 3 (2.1)                   | 0               |
| Randomized to incorrect tryptase level    | Tryptase ≥ 20 ng/mL at Screening and randomized to < 20 ng/mL stratification group   | 3 (2.1)                   | 1 (1.4)         |
|                                           | Tryptase < 20 ng/mL at Screening and randomized to ≥ 20 ng/mL stratification group   | 1 (0.7)                   | 0               |
| Dosing compliance                         | < 75% prescribed dose received in a cycle                                            | 5 (3.5)                   | 0               |

a Two of the 11 patients categorized as having missed critical assessments were determined to be minor deviations after database lock and thus were miscategorized, therefore reasons for only 9 patients are listed in this table.

b Two of the 6 patients categorized as having prohibited concomitant medication given were later determined to be minor deviations as the steroid use did not meet the criteria for major deviation (ie, use within 7 days before C7D1 or for 14 consecutive days during the study). Therefore, only 4 patients are listed in this table.

C Five additional patients who had protocol deviations for CYP 3A4 inhibitor use are not included in Table 99.1.2.1.1, as the start date of use was prior to study entry (see listing 16.2.2.1).

Patients with missing TSS at Part 2 C7D1 were excluded from the primary efficacy analysis using ANCOVA method but was included in the sensitivity analysis using Markov chain Monte Carlo (MCMC) imputation method. Likewise, patients who received high dose steroids within C7D1 were excluded from the primary efficacy analysis using ANCOVA method but were included in the sensitivity analysis using MCMC imputation method.

<div style=\"page-break-after: always\"></div>

## Baseline data

## Part 1 of study BLU 285-2203

## Demographic characteristics

In Part 1, the majority of the patients were female (76.9%), &lt; 65 years old (87.2%), White (92.3%), and not Hispanic and Latino (89.7%). Baseline height and weight were similar across treatment groups.

Part l: Demographics and Baseline Characteristics Intent-to-Treat Population

|                                           | Placebo (N=9)   | Avapritinib 25mg (N=10)   | Avapritinib 50 mg (N=10)   | Avapritinib 100 mg (N=10)   | Overall (N=39)   |
|-------------------------------------------|-----------------|---------------------------|----------------------------|-----------------------------|------------------|
| Age (Years)                               |                 |                           |                            |                             |                  |
| n                                         | 9               | 10                        | 10                         | 10                          | 39               |
| Mean (StdDev)                             | 50.2 (11.57)    | 51.1 (16.89)              | 48.0 (8.98)                | 47.6 (14.49)                | 49.2 (12.92)     |
| Median                                    | 51.0            | 52.0                      | 50.5                       | 46.0                        | 51.0             |
|                                           | 29,68           | 23，75                     | 33,61                      | 21,72                       | 21,75            |
| Age， n (名)                                |                 |                           |                            |                             |                  |
| <65                                       | 8 ( 88.9)       | 7 (70.0)                  | 10 (100)                   | 9(90.0)                     | 34 ( 87.2)       |
| >=65                                      | 1 ( 11.1)       | 3 ( 30.0)                 | 0                          | 1 ( 10.0)                   | 5 (12.8)         |
| Sex, n (%)                                |                 |                           |                            |                             |                  |
| Male                                      | 2(22.2)         | 0                         | 4 ( 40.0)                  | 3(30.0)                     | 9(23.1)          |
| Female                                    | 7(77.8)         | 10 (100)                  | 6 (60.0)                   | (70.0)                      | 30 (76.9)        |
| Race, n (&)                               |                 |                           |                            |                             |                  |
| White                                     | (100)           | (100)                     | 8 (80.0)                   | 9 (90.0)                    | 36 (92.3)        |
| Black or African American                 | 0               | 0                         | 1 (10.0)                   | 0                           | 1 2.6)           |
| Asian                                     | 0               | 0                         | 0                          | 0                           | 0                |
| American Indian or Alaska Native          | 0               | 0                         | 0                          | 0                           | 0                |
| Native Hawaiian or Other Pacific Islander | 0               | 0                         | 0                          | 0                           | 0                |
| Other                                     | 0               | 0                         | 0                          | 0                           | 0                |
| Unknown                                   | 0               | 0                         | 1  ( 10.0)                 | 1 ( 10.0)                   | 2（ 5.1)          |

SSS = Skin Symptom Score, SM = Systemic Mastocytosis, ISM = Indolent Systemic Mastocytosis, SSM = Smoldering Systemic Mastocytosis,BsC=Best Supportive Care

Note: Percentages are based on number of patients in the ITT Population.

[l] Baseline Body Mass Index (BMI) is calculated as weight (kg)/ (height (m))^2.

[2] Baseline anaphylaxis event rate is calculated as number of events between Informed Consent to CiDl/(CiDl date -Informed Consent date)

Cross References:Listing 16.2.4.1.1a, 16.2.4.1.2a, 16.2.4.1.3a

Program:t-14-01-03-01a.sas

## Disease characteristics

In Part 1, at baseline, all patients had significant sign and symptom burden as assessed by the ISM-SAF with a mean (SD) TSS of 53.3 (19.34).

Baseline mean (SD) serum tryptase was 83.78 (100.530) ng/mL and 89.7% patients had bone marrow mast cell aggregates.

KIT D816V mutation was detected in peripheral blood in 79.5% of patients at baseline with a mean (SD) allele fraction of 4.274 (8.4802).

## Part 2 of study BLU 285-2203

Demographic characteristics

Table Generation:11MAY2020 13:21

<div style=\"page-break-after: always\"></div>

Table 37. Demographic Characteristics (Part 2 ITT Population)

| Category               | Avapritinib 25 mg N=141   | Placebo N=71          |
|------------------------|---------------------------|-----------------------|
| Age (years) a          |                           |                       |
| Mean (SD)              | 48.7 (11.70)              | 52.2 (12.52)          |
| Median (Min, Max)      | 50.0 (18, 77)             | 54.0 (26, 79)         |
| Age group, n (%)       |                           |                       |
| <65 years              | 132 (93.6)                | 60 (84.5)             |
| ≥65 years              | 9 (6.4)                   | 11 (15.5)             |
| Sex, n (%)             |                           |                       |
| Female                 | 100 (70.9)                | 54 (76.1)             |
| Male                   | 41 (29.1)                 | 17 (23.9)             |
| Ethnicity, n (%)       |                           |                       |
| Hispanic or Latino     | 6 (4.3)                   | 1 (1.4)               |
| Not Hispanic or Latino | 99 (70.2)                 | 58 (81.7)             |
| Not reported           | 22 (15.6)                 | 10 (14.1)             |
| Race, n (%)            |                           |                       |
| Asian                  | 1 (0.7)                   | 0                     |
| White                  | 109 (77.3)                | 61 (85.9)             |
| Unknown                | 27 (19.1)                 | 8 (11.3)              |
| Other                  | 4 (2.8)                   | 2 (2.8)               |
| Height (cm)            |                           |                       |
| n                      | 137                       | 70                    |
| Mean (SD)              | 169.05 (9.726)            | 166.55 (9.073)        |
| Median (Min, Max)      | 167.00 (152.4, 194.0)     | 165.00 (150.2, 195.0) |
| Weight (kg)            |                           |                       |
| n                      | 141                       | 71                    |
| Mean (SD)              | 81.12 (17.915)            | 82.19 (17.796)        |
| Median (Min, Max)      | 80.20 (45.0, 126.4)       | 80.70 (44.4, 134.8)   |
| BMI (kg/m2)b           |                           |                       |
| n                      | 137                       | 70                    |
| Mean (SD)              | 28.31 (5.400)             | 29.46 (5.276)         |
| Median (Min, Max)      | 27.84 (17.6, 42.0)        | 28.99 (19.7, 43.7)    |

Abbreviations: BMI = body mass index; ITT = Intent-to-Treat; Max = maximum; Min = minimum; SD = standard deviation.

a Age at the time of informed consent.

b Baseline BMI was calculated as weight (kg)/(height (m)².

Part 2 ITT population of the study included more female (100 [70.9%] patients in the 25 mg Avapritinib Group; 54 [76.1%] patients in the Placebo Group) than male (41 [29.1%] patients in the 25 mg Avapritinib Group; 17 [23.9%] patients in the Placebo Group).

<div style=\"page-break-after: always\"></div>

Most patients in both groups were &lt; 65 years (93.6% in the 25 mg Avapritinib Group and 84.5% in the Placebo Group), not Hispanic or Latino (70.2% in the 25 mg Avapritinib Group and 81.7% in the Placebo Group), and White (77.3% patients in the 25 mg Avapritinib Group and 85.9% patients in the Placebo Group), and other baseline characteristics (mean height [cm], weight [kg], and body mass index [kg/m2]) were similar in both groups.

## Baseline disease characteristics

Table 38. Baseline Disease Characteristics (Part 2 ITT/Safety Population)

| Category                                                                                              | Avapritinib 25 mg N=141                                                                               | Placebo N=71                                                                                          |
|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Baseline ISM-SAF TSS α (Range: 0-110)                                                                 | Baseline ISM-SAF TSS α (Range: 0-110)                                                                 | Baseline ISM-SAF TSS α (Range: 0-110)                                                                 |
| n                                                                                                     | 139                                                                                                   | 71                                                                                                    |
| Mean (SD)                                                                                             | 50.17 (19.145)                                                                                        | 52.43 (19.823)                                                                                        |
| Median (Min, Max)                                                                                     | 47.86 (12.1, 102.7)                                                                                   | 47.79 (18.0, 104.4)                                                                                   |
| Baseline ISM severity based on ISM-SAF TSS a n (%)                                                    | Baseline ISM severity based on ISM-SAF TSS a n (%)                                                    | Baseline ISM severity based on ISM-SAF TSS a n (%)                                                    |
| ≥42 (Severe)                                                                                          | 87 (61.7)                                                                                             | 45 (63.4)                                                                                             |
| < 42 (Moderate)                                                                                       | 52 (36.9)                                                                                             | 26 (36.6)                                                                                             |
| Baseline Serum Tryptase (ng/mL) b                                                                     | Baseline Serum Tryptase (ng/mL) b                                                                     | Baseline Serum Tryptase (ng/mL) b                                                                     |
| n                                                                                                     | 141                                                                                                   | 71                                                                                                    |
| Mean (SD)                                                                                             | 57.57 (54.371)                                                                                        | 67.57 (74.248)                                                                                        |
| Median (Min, Max)                                                                                     | 38.40 (3.6, 256.0)                                                                                    | 43.70 (5.7, 501.6)                                                                                    |
| Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) b | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) b | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) b |
| n                                                                                                     | 141                                                                                                   | 71                                                                                                    |
| Mean (SD)                                                                                             | 2.570 (6.1287)                                                                                        | 3.570 (7.5691)                                                                                        |
| Median (Min, Max)                                                                                     | 0.390 (0.00, 41.29)                                                                                   | 0.260 (0.00,36.74)                                                                                    |

<div style=\"page-break-after: always\"></div>

| Category                                                                             | Avapritinib 25 mg N=141                                                              | Placebo N=71                                                                         |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Baseline Percent Bone Marrow Mast Cells (Central Pathology Review) b                 | Baseline Percent Bone Marrow Mast Cells (Central Pathology Review) b                 | Baseline Percent Bone Marrow Mast Cells (Central Pathology Review) b                 |
| N                                                                                    | 141                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 11.03 (11.087)                                                                       | 12.23 (12.611)                                                                       |
| Median (Min, Max)                                                                    | 7.00 (1.0, 50.0)                                                                     | 7.00 (1.0, 70.0)                                                                     |
| Baseline GI domain score on ISM-SAF ~(Range: O-30)                                   | Baseline GI domain score on ISM-SAF ~(Range: O-30)                                   | Baseline GI domain score on ISM-SAF ~(Range: O-30)                                   |
| n                                                                                    | 139                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 9.71 (6.202)                                                                         | 10.41 (6.847)                                                                        |
| Median (Min, Max)                                                                    | 8.43 (0.0, 26.8)                                                                     | 9.79 (0.0, 28.0)                                                                     |
| Baseline skin domain score on ISM-SAF ~(Range: 0-30)                                 | Baseline skin domain score on ISM-SAF ~(Range: 0-30)                                 | Baseline skin domain score on ISM-SAF ~(Range: 0-30)                                 |
| N                                                                                    | 139                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 15.50 (7.123)                                                                        | 17.20 (7.612)                                                                        |
| Median (Min, Max)                                                                    | 15.15 (0.0, 30.0)                                                                    | 17.85 (0.0, 30.0)                                                                    |
| Baseline neurocognitive symptom cluster on ISM-SAF * (Range: 0-30)                   | Baseline neurocognitive symptom cluster on ISM-SAF * (Range: 0-30)                   | Baseline neurocognitive symptom cluster on ISM-SAF * (Range: 0-30)                   |
| N                                                                                    | 139                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 13.04 (6.779)                                                                        | 12.71 (6.969)                                                                        |
| Median (Min, Max)                                                                    | 12.62 (0.0, 29.6)                                                                    | 11.29 (0.4, 29.1)                                                                    |
| Baseline lead (most severe) symptom on ISM-SAF c                                     | Baseline lead (most severe) symptom on ISM-SAF c                                     | Baseline lead (most severe) symptom on ISM-SAF c                                     |
| N                                                                                    | 139                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 7.66 (1.693)                                                                         | 7.91 (1.679)                                                                         |
| Median (Min, Max)                                                                    | 7.69 (3.6, 10.0)                                                                     | 8.00 (4.1, 10.0)                                                                     |
| Baseline lead (most severe) domain/neurocognitive symptom cluster score on ISM-SAF d | Baseline lead (most severe) domain/neurocognitive symptom cluster score on ISM-SAF d | Baseline lead (most severe) domain/neurocognitive symptom cluster score on ISM-SAF d |
| N                                                                                    | 139                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 17.51 (6.033)                                                                        | 18.58 (6.397)                                                                        |
| Median (Min, Max)                                                                    | 17.21 (5.6, 30.0)                                                                    | 18.64 (4.8, 30.0)                                                                    |
| Baseline concomitantBSCuse?                                                          | Baseline concomitantBSCuse?                                                          | Baseline concomitantBSCuse?                                                          |
| n                                                                                    | 141                                                                                  | 71                                                                                   |
| Mean (SD)                                                                            | 3.7 (1.94)                                                                           | 3.8 (1.83)                                                                           |
| Median (Min, Max)                                                                    | 3.0 (0, 11)                                                                          | 4.0 (1, 8)                                                                           |
| Category                                                                             | Avapritinib 25 mg N=141                                                              | Placebo N=71                                                                         |
| Mast Cell (counts/mm²) in Skin by Central Lab (Lesional)                             | Mast Cell (counts/mm²) in Skin by Central Lab (Lesional)                             | Mast Cell (counts/mm²) in Skin by Central Lab (Lesional)                             |
| N                                                                                    | 107                                                                                  | 60                                                                                   |
| Mean (SD)                                                                            | 561.2 (399.65)                                                                       | 637.6 (488.71)                                                                       |
| Median (Min, Max)                                                                    | 459.0 (89, 2870)                                                                     | 617.5 (83,2609)                                                                      |
| Mast Cell (counts/mm²) in Skin by Central Lab (Non-lesional)                         | Mast Cell (counts/mm²) in Skin by Central Lab (Non-lesional)                         | Mast Cell (counts/mm²) in Skin by Central Lab (Non-lesional)                         |
| n                                                                                    | 106                                                                                  | 60                                                                                   |
| Mean (SD)                                                                            | 152.2 (76.28)                                                                        | 165.9 (166.00)                                                                       |
| Median (Min, Max)                                                                    | 131.5 (35, 659)                                                                      | 129.0 (59, 1337)                                                                     |

Abbreviations:BSC = best supportive care; CXDX = Cycle X DayX; ddPCR = digital-droplet polymerase chain reaction,GI =gastrointestinal;ISM=indolent systemic mastocytosis;ISM-SAF =Indolent Systemic

Mastocytosis-SymptomAssessmentForm;ITT=Intent-to-Treat;MAF=mutant allelefraction;Max=maximum;

aBaseline TSS score is defined as the14-day average of TSSfrom C1D-14 to C1D-1. Ifa patient is missing more than7days of score betweenC1D-14 and C1D-1, thebaseline score is considered as missingfor thepatient.

Min =minimum; SD= standard deviation,TSS =Total symptom score.

bBaseline refers to the last assessment value prior to CiD1 dosing inPart 2 of the study.

d The \"lead domain/symptom cluster\" score refers to the domain/symptom cluster with highest score at baseline in each patient

° The “lead symptom” score refers to the individual symptom with highest score at baseline in each patient.

eConcomitant BSCmedications arecoded usingWHODrugGlobal B3March 2022.BaselineBSCis the number of BSCtakenonCiD1.

<div style=\"page-break-after: always\"></div>

At Part 2 baseline, patients in both the 25 mg Avapritinib Group and the Placebo Group had significant sign and symptoms burden as assessed by the ISM-SAF with a mean (SD) TSS of 50.17 (19.145) in the 25 mg Avapritinib Group and 52.43 (19.823) in the Placebo Group. The thresholds for moderate symptoms of ISM were a TSS of ≥ 28 to &lt; 42, and for severe symptoms of ISM a TSS of ≥ 42. The percentage of patients with severe symptoms of ISM was balanced between the 25 mg Avapritinib Group (61.7%) and the Placebo Group (63.4%).

Other baseline disease parameters including ISM-SAF domain scores, serum tryptase, KIT D816V MAF, bone marrow mast cells, and concomitant BSC use were similar in the 25 mg Avapritinib Group and the Placebo Group and consistent with characteristics observed in the ISM patient population.

At baseline, 12 of 212 (5.7%) patients tested negative for KIT D816V by both central and local testing (n=2 Placebo Group; n=10 Avapritinib Group).

## Medical and surgical history

All patients in Part 2 had ongoing medical history. The majority of medical and surgical history events reported are commonly observed in patients with ISM and were similar in the 25 mg Avapritinib Group and Placebo Group. The most common medical history events by System Organ Class were Gastrointestinal Disorders (80.9% in the 25 mg Avapritinib Group and 77.5% in the Placebo Group) followed by Musculoskeletal and Connective Tissue Disorders (79.4% in the 25 mg Avapritinib Group and 81.7% in the Placebo Group), and Skin and Subcutaneous Tissue Disorders (78.0% in the 25 mg Avapritinib Group and 73.2% in the Placebo Group).

<div style=\"page-break-after: always\"></div>

Table 39. Ongoing Medical History with Incidence ≥ 10% in Either Treatment Group (Part 2 Safety Population)

<!-- image -->

| System Organ Class Preferred Tern                     | Avapritinib 25 mg N=141 n (%)   | Placebo N=71 n (%)   |
|-------------------------------------------------------|---------------------------------|----------------------|
| Patients with Ongoing Medical History                 | 141 (100.0)                     | 71 (100.0)           |
| Gastrointestinal Disorders                            | 114 (80.9)                      | 55 (77.5)            |
| Diarhoea                                              | 85 (60.3)                       | 35 (49.3)            |
| Abdominal pain                                        | 45 (31.9)                       | 21 (29.6)            |
| Nausea                                                | 39 (27.7)                       | 19 (26.8)            |
| Gastrooesophageal reflux disease                      | 38 (27.0)                       | 10 (14.1)            |
| Abdominal distension                                  | 14 (9.9)                        | 8 (11.3)             |
| Constipation                                          | 13 (9.2)                        | 10 (14.1)            |
| Musculoskeletal and Connective Tissue Disorders       | 112 (79.4)                      | 58 (81.7)            |
| Bone pain                                             | 53 (37.6)                       | 28 (39.4)            |
| Arthralgia                                            | 33 (23.4)                       | 7 (9.9)              |
| Osteopenia                                            | 32 (22.7)                       | 9 (12.7)             |
| Osteoporosis                                          | 27 (19.1)                       | 22 (31.0)            |
| Myalgia                                               | 19 (13.5)                       | 9 (12.7)             |
| Back pain                                             | 18 (12.8)                       | 2 (2.8)              |
| Skin and Subcutaneous Tissue Disorders                | 110 (78.0)                      | 52 (73.2)            |
| s                                                     | 61 (43.3)                       | 31 (43.7)            |
| Urticaria pigmentosa                                  | 50 (35.5)                       | 26 (36.6)            |
| Urticaria                                             | 17 (12.1)                       | 8 (11.3)             |
| Rash maculo-papular                                   | 11 (7.8)                        | 11 (15.5)            |
| General Disorders and Adininistration Site Conditions | 96 (68.1)                       | 39 (54.9)            |
| Fatigue                                               | 67 (47.5)                       | 30 (42.3)            |
| Feeling abnormal                                      | 37 (26.2)                       | 9 (12.7)             |
| Asthenia                                              | 16 (11.3)                       | 4 (5.6)              |
| Nervous System Disorders                              | 95 (67.4)                       | 44 (62.0)            |
| Headache                                              | 52 (36.9)                       | 26 (36.6)            |
| Dizziness                                             | 29 (20.6)                       | 13 (18.3)            |
| Migraine                                              | 22 (15.6)                       | 9 (12.7)             |
| Memory impaiment                                      | 20 (14.2)                       | 8 (11.3)             |
| Disturbance in attention                              | 19 (13.5)                       | 6 (8.5)              |
| Vascular Disorders                                    | 85 (60.3)                       | 48 (67.6)            |
| Flushing                                              | 62 (44.0)                       | 35 (49.3)            |
| Hypertension                                          | 37 (26.2)                       | 15 (21.1)            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| System Organ Class Preferred Tern               | Avapritinib 25 mg N=141 n (%)   | Placebo N=71 (%) u   |
|-------------------------------------------------|---------------------------------|----------------------|
| Metabolism and Nutrition Disorders              | 76 (53.9)                       | 35 (49.3)            |
| Obesity                                         | 39 (27.7)                       | 20 (28.2)            |
| Psychiatric Disorders                           | 69 (48.9)                       | 30 (42.3)            |
| Depression                                      | 38 (27.0)                       | 14 (19.7)            |
| Anxiety                                         | 27 (19.1)                       | 6 (8.5)              |
| Insommia                                        | 22 (15.6)                       | 9 (12.7)             |
| Respiratory, Thoracic and Mediastinal Disorders | 52 (36.9)                       | 24 (33.8)            |
| Asthma                                          | 19 (13.5)                       | 8 (11.3)             |
| Dyspnoea                                        | 15 (10.6)                       | 4 (5.6)              |
| Iinmune Systen Disorders                        | 46 (32.6)                       | 24 (33.8)            |
| Drug hypersensitivity                           | 16 (11.3)                       | 6 (8.5)              |
| Seasonal allergy                                | 7 (5.0%)                        | 8 (11.3%)            |
| EndocrineDisorders                              | 35 (24.8)                       | 15 (21.1)            |
| Hypothyroidism                                  | 26 (18.4)                       | 9 (12.7)             |
| Social Circumstances                            | 26 (18.4)                       | 15 (21.1)            |
| Menopause                                       | 18 (12.8)                       | 10 (14.1)            |

Note: Medical history is classified by SOC and PT using MedDRA version 25.0.

## Prior and concomitant medications

All patients in the 25 mg Avapritinib Group and the Placebo Group were treated with at least 2 current or prior BSC medications as per study inclusion criteria. The majority of patients in the Part 2 safety population received concomitant BSC medication/therapy (99.3% in the 25 mg Avapritinib Group and 100.0% in the Placebo Group). The most commonly used BSC medications were antihistamines for systemic use such as H1 antihistamines (97.2% in the 25 mg Avapritinib Group and 100.0% in the Placebo Group) and drugs such as H2 antihistamines and proton pump inhibitors (73.8% in the 25 mg Avapritinib Group and 78.9% in the Placebo Group).

Patients also received concomitant medication/therapy other than BSC (97.9% in the 25 mg Avapritinib Group and 100.0% in the Placebo Group). The most common concomitant medication/therapies other than BSC used were viral vaccine (43.3% in the 25 mg Avapritinib Group and 43.7% in the Placebo Group) and other analgesics and antipyretics (36.2% in the 25 mg Avapritinib Group and 35.2% in the Placebo Group). Antidepressants and anxiolytic medications were also used often (19.1% and 16.3% in the 25 mg Avapritinib Group and 21.1% and 22.5% in the Placebo Groups, respectively). The use of opioids was similar between the 2 groups: 22.0% in the 25 mg Avapritinib Group and 22.5% in the Placebo Group).

<div style=\"page-break-after: always\"></div>

Table 40. Prior Mastocytosis therapy - Part 2 Baseline (Safety population)

<!-- image -->

|                                             | Placebo (N=71)   | Avapritinib 25 mg (N=141)   |
|---------------------------------------------|------------------|-----------------------------|
| Overall                                     | n (%)            | n (8)                       |
| Therapy, n(名)                               |                  |                             |
| Interferon alpha                            | 8 (11.3)         | 6.4)                        |
| Midostaurin                                 | 2 2.8)           | 8 5.7)                      |
| Cladribine (2CdA)                           | 2 2.8)           | 7 5.0)                      |
| Imatinib                                    | 1 1.4)           | 7 5.0)                      |
| Hydroxyurea                                 | 0                | 5 3.5)                      |
| Dasatinib                                   | 1.4)             | 3 2.1)                      |
| Other                                       | 2 2.8)           | 2 1.4)                      |
| PUVA                                        | 10 14.1)         | 2 1.4)                      |
| Brentuximab vedotin                         | 0                | 1 0.7)                      |
| Other TKI therapy                           | 0                | 0.7)                        |
| Radiation therapy                           | 0                | 0.7)                        |
| Masitinib                                   | 1.4)             | 0                           |
| Nilotinib                                   | 1.4)             | 0                           |
| Indication, n(名)                            |                  |                             |
| Cutaneous Mastocytosis                      | 3(4.2)           | 4 (2.8)                     |
| ISM                                         | 16 (22.5)        | 26 (18.4)                   |
| SSM                                         | 0                | 1 (0.7)                     |
| Prior lines of therapy                      |                  |                             |
| 1                                           | 13 (18.3)        | 27 (19.1)                   |
| 2                                           | 4 5.6)           | 8 5.7)                      |
| 3                                           | 2 2.8)           | 3 2.1)                      |
| 4                                           | 0                | 2 1.4)                      |
| 5                                           | 0                | 1 0.7)                      |
| 6                                           | 0                | 1 0.7)                      |
| 7                                           | 0                | 1 0.7)                      |
| NA                                          | 10 (14.1)        | 4 2.8)                      |
| n                                           | 18               | 30                          |
| Mean (StdDev)                               | 185.13 (271.142) | 108.04 (129.310)            |
| Median                                      | 52.14            | 52.21                       |
|                                             | 0.1, 791.1       | 0.1, 523.6                  |
| Best response to prior mastocytosis therapy |                  |                             |
| Improvement                                 | 10 (14.1)        | 11 7.8)                     |
| Worsening                                   | 2 2.8)           | 1 0.7)                      |
| Lack of response                            | 4 5.6)           | 12 8.5)                     |
| Other                                       | 2 2.8)           | 6 4.3)                      |

## Part 3 of study BLU 285-2203 - Long-term study

Demographic characteristics

<div style=\"page-break-after: always\"></div>

Table 41. Demographics and Baseline Characteristics Intent-to-Treat Population, Part 3 (Part 3 Baseline)

|                    | Placebo ->25mg (N=75) n/N (e)   | Avapritinib 25 -> 25 mg (N=143) n/N (e)   | PooledPlacebo/ Avapritinib 25 -> 25 mg (N=218) n/N (e)   | Avapritinib 50 -> 25 mg (N=8) n/N (e)   | Avapritinib 100->25mg (N=9) n/N ()   | Overall (N=235) n/N (e)   |
|--------------------|---------------------------------|-------------------------------------------|----------------------------------------------------------|-----------------------------------------|--------------------------------------|---------------------------|
| Age (Years) [1]    |                                 |                                           |                                                          |                                         |                                      |                           |
| n                  | 75                              | 143                                       | 218                                                      | 8                                       | 6                                    | 235                       |
| Mean (StdDev)      | 51.8 (12.58)                    | 48.7(11.65)                               | 49.8 (12.04)                                             | 48.3 (6.88)                             | 46.6 (14.97)                         | 49.6 (12.00)              |
| Median             | 53.0                            | 50.0                                      | 51.0                                                     | 50.5                                    | 45.0                                 | 51.0                      |
| Min, Max           | 26,79                           | 18, 75                                    | 18, 79                                                   | 36,57                                   | 21,72                                | 18,79                     |
| Age Group, n/N (e) |                                 |                                           |                                                          |                                         |                                      |                           |
| <65 Years          | 64/75 ( 85.3)                   | 133/143 ( 93.0)                           | 197/218 ( 90.4)                                          | 8/8 (100.0)                             | 8/9[88.9)                            | 213/235(90.6)             |
| >= 65 Years        | 11/75 ( 14.7)                   | 10/143 (7.0)                              | 21/218 (9.6)                                             | 0                                       | 1/9 ( 11.1)                          | 22/235(9.4)               |
| <65 Years          | 64/75 (85.3)                    | 133/143 (93.0)                            | 197/218 (90.4)                                           | 8/8 (100.0)                             | 8/9 [86.9)                           | 213/235 （90.6)            |
| 65 - 74 Years      | 9/75 [12.0)                     | 6.3)                                      | 18/218 8.3)                                              |                                         | 1/9 ( 11.1)                          | 19/235 8.1)               |
| 75 - 84 Years      | 2/75 2.71                       | 9/143 1/143 0.71                          | 3/218 1.4)                                               | 0                                       | 0                                    | 3/235 1.3)                |
| >= 85 Years        | 0                               | 0                                         | 0                                                        | 0 0                                     | 0                                    | 0                         |
| Sex, n/N ()        |                                 |                                           |                                                          |                                         |                                      |                           |
| Male               | 19/75 (25.3)                    | 40/143 28.0)                              | 59/218 (27.1)                                            | 3/8 ( 37.5)                             | 2/9 ( 22.2)                          | 64/235 ( 27.2)            |
| Female             | 56/75 ( 74.7)                   | 103/143 (72.0)                            | 159/218 ( 72.9)                                          | 5/8 ( 62.5)                             | 7/9 ( 77.8)                          | 171/235 ( 72.8)           |

Abbreviations: ddPCR= digital-droplet polymerase

[l] Age at the time of informed consent.

chain reaction, SM = Systemic Mastocytosis, ECoG= Eastern Cooperative Oncology Group.

[2]Baseline Body Mass Index （BMI) is calculated as weight (kg)/ (height (m)]^2.

Cross References: Listing 16.2.4.1.1, 16.2.4.1.2, 16.2.4.1.3

Program: ../BLU-285/2203\\_Blinded/CSR/Final/Programs/prod/tables/t-dm-itt-b.5as

## Baseline disease characteristics

Prior to starting Part 3, patients who were in the Placebo Group during Part 1 or Part 2 had higher symptom burden as assessed by the ISM-SAF than the patients who were in the avapritinib groups in Part 1 or Part 2.

At the Part 3 baseline, the mean (SD) TSS was 33.14 (20.061) for the 25 mg to 25 mg Avapritinib Group and 43.51 (19.761) for the Placebo to 25 mg Avapritinnib Group.

At Part 3 baseline, patients who were in the Placebo Group during Part 1 or Part 2 also had higher mast cell burden than the patients who were in the avapritinib groups as assessed by serum tryptase and KIT D816V MAF levels.

Date:10:35/15AUG2022

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 42. Analysis Populations (Part 2) in Study BLU-285-2203

| Analysis Population        | 25 mg Avapritinib n (%)a   | Placebo n (%)a   |
|----------------------------|----------------------------|------------------|
| Intent-to-treat population | 141 (100.0)                | 71 (100.0)       |
| Safety population          | 141 (100.0)                | 71 (100.0)       |
| Per-protocol population    | 123 (87.2)                 | 67 (94.4)        |

a Percentages were based on the number of patients in the intent-to-treat population.

Table 43. Analysis Populations (Part 3) in Study BLU-285-2203

| AnalysisPopulation         | Placeboto 25 mg n (%)   | Avapritinib 25mgto25mg n (%)   | Avapritinib 25mg n (%)   | Avapritinib 50mgto25mg n (%)   | Avapritinib 100mgto25mg n (%)   | All n (%)   |
|----------------------------|-------------------------|--------------------------------|--------------------------|--------------------------------|---------------------------------|-------------|
| Intent-to-Treat Population | 75 (100.0)              | 143 (100.0)                    | 218 (100.0)              | 8 (100.0)                      | 9 (100.0)                       | 235 (100.0) |
| SafetyPopulation           | 75 (100.0)              | 143 (100.0)                    | 218 (100.0)              | 8 (100.0)                      | 9 (100.0)                       | 235 (100.0) |
| Per-ProtocolPopulation     | 71 (94.7)               | 125 (87.4)                     | 196 (89.9)               | 7 (87.5)                       | 8 (88.9)                        | 211 (89.8)  |

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2, and does not include the patients who received 50 mg or 100 mg  avapritinib in Part 1.

Table 44. Analysis Populations (Parts 1, 2, and 3 [All Avapritinib Treated])

| Analysis Population        | Placebo to 25mg n (%)   | Avapritinib 25 mg to 25 mg/NA n (%)   | Avapritinib 25 mg n (%)   | Avapritinib 50 mgto 25 mg/NA n (%)   | Avapritinib 100mgto 25 mg/NA n (%)   | All n (%)   |
|----------------------------|-------------------------|---------------------------------------|---------------------------|--------------------------------------|--------------------------------------|-------------|
| Intent-to-Treat Population | 75 (100.0)              | 151 (100.0)                           | 226 (100.0)               | 10 (100.0)                           | 10 (100.0)                           | 246 (100.0) |
| SafetyPopulation           | 75 (100.0)              | 151 (100.0)                           | 226 (100.0)               | 10 (100.0)                           | 10 (100.0)                           | 246 (100.0) |
| Per-Protocol Population    | 71 (94.7)               | 132 (87.4)                            | 203 (89.8)                | 9 (90.0)                             | 8 (80.0)                             | 220 (89.4)  |

Abbreviation: NA = not applicable.

Note: Percentages were based on the number of patients in the Intent-to-Treat Population.

Note: NA denotes the patients who did not rollover to Part 3.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

## Outcomes and estimation

The analysis of efficacy for avapritinib was based primarily on Part 2 results of the comparison between placebo and the RP2D of 25 mg avapritinib.

The Part 1 analyses are based on a data cut-off date of 27 December 2019 and the Part 2 and 3 analyses are based on the data cut-off date of 23 June 2022. During the procedure, updated data of Part 3 were provided based on a data cut-off date of 07 April 2023.

## Part 1 of study BLU 285-2203

At C4D1 (12 weeks of treatment), the mean (SD) reduction in TSS of the ISM-SAF was greater in all Avapritinib Groups compared with the Placebo Group: -12.54 (13.234) for the 25 mg group, -12.32

<div style=\"page-break-after: always\"></div>

(14.194) for the 50 mg group, -21.35 (18.769) for the 100 mg group, and -3.36 (7.998) for the Placebo Group.

The 100 mg dose was associated with the greatest reduction in TSS at C4D1. However, additional analyses showed that the TSS reduction plateaued after C4D1. The 25 mg and 50 mg dose groups achieved a similar mean reduction in TSS to the 100 mg cohort by C7D1.

Table 45. Mean Change in TSS of the ISM-SAF from Baseline to C4D1 and C7D1 (Part 1 ITT Population)

<!-- image -->

| Parameter                                   | Placebo N=9                                 | 25 mg QD N=10           | 50 mg QD N=10           | 100 mg QD N=10           |
|---------------------------------------------|---------------------------------------------|-------------------------|-------------------------|--------------------------|
| Baseline                                    |                                             |                         |                         |                          |
| Mean (SD)                                   | 53.78 (19.458)                              | 53.21 (16.924)          | 56.32 (18.334)          | 49.79 (24.423)           |
| Median (Min, Max)                           | 51.00 (29.3, 99.9)                          | 56.08 (26.8, 72.7)      | 54.71 (27.5, 90.1)      | 51.75 (19.3, 88.1)       |
| C4D1                                        |                                             |                         |                         |                          |
| Mean (SD)                                   | 50.42 (15.360)                              | 40.66 (17.529)          | 48.54 (18.673)          | 31.81 (16.791)           |
| Median (Min, Max)                           | 50.71 (33.1, 80.7)                          | 44.00 (5.3, 66.1)       | 51.61 (23.1, 72.7)      | 28.14 (12.8, 63.6)       |
| C7D1 (data on file)                         |                                             |                         |                         |                          |
| Mean (SD)                                   | 50.542 (14.293)                             | 33.546 (19.076)         | 37.718 (18.773)         | 34.326 (20.414)          |
| Median (Min, Max)                           | 47.462 (31.214, 76.786)                     | 31.586 (2.786, 62.929)  | 39.000 (11.000, 70.214) | 37.750 (13.077, 67.643)  |
| Changefrombaselineat C4Dl                   |                                             |                         |                         |                          |
| Mean (SD)                                   | -3.36 (7.998)                               | -12.54 (13.234)         | -12.32 (14.194)         | 21.35 (18.769)           |
| Median (Min, Max)                           | -0.42 (-19.1, 4.6)                          | -12.49 (34.9, 6.1)      | -4.59 (-34.8, -0.2)     | -15.90 (54.8, 3.1)       |
| Difference (95% C1) with Placebo            |                                             | -9.2 (-19.93, 1.56)     | 0'6- (-20.68, 2.77)     | -18.0 (-32.99,-2.99)     |
| Change from baseline at C7Dl (data on file) | Change from baseline at C7Dl (data on file) |                         |                         |                          |
| Mean (SD)                                   | -3.241 (8.960)                              | -19.659 (20.193)        | --19.433 (19.031)       | --18.833 (16.575)        |
| Median (Min, Max)                           | -1.846 (23.071,6.500)                       | -17.934 (-59.614,6.250) | -12.100 (-57.310,1.385) | -16.545 (-48.527, 7.214) |

Abbreviations: CXDX = Cycle X Day X; CI = confidence interval, ITT = Intent-to-treat; ISM-SAF = Indolent Systemic MastocytosisSymptom Assessment Form; Max = maximum; Min = minimum; QD = once daily; SD = standard deviation; TSS = Total symptom score. Note: Baseline score is defined as the 14-day average of TSS from Day -14 to Day -1. C4D1 TSS is defined as the 14-day average of TSS from Day 71 to Day 84. If a patient is missing more than 7 days of score between Day -14 to Day -1, the baseline TSS is considered missing for the patient. If a patient is missing more than 7 days of TSS between Day 71 to Day 84, the C4D1 TSS is considered missing for the patient.

Patients in all Avapritinib Groups showed significant reductions in the key objective measures of disease compared to placebo at C4D1, with additional reductions at C7D1 in avapritinib-treated patients.

<div style=\"page-break-after: always\"></div>

Table 46. Change in Objective Measures of Mast Cell Burden from Baseline to C4D1 (Part 1 ITT Population)

| Mast cell burden                                                                  | Placebo N=9     | 25 mg QD N=10     | 50 mg QD N=10     | 100 mg QD N=10    |
|-----------------------------------------------------------------------------------|-----------------|-------------------|-------------------|-------------------|
| Mean Percentage (SD) change in seruim tryptase from baseline to C4D1              | -3.28 (14.043)  | -55.58 (24.827)   | -76.25 (8.877)    | -71.82 (28.803)   |
| Mean Percentage (SD) chamge in bone mairow mast cellsfrom baseline to C4D1        | 8.3 (45.90)     | -24.5 (82.88)     | -53.3 (24.21)     | -68.3 (22.99)     |
| Mean Percentage (SD) change in blood KIT D816V allelefractionfrombaseline to C4D1 | 2.069 (13.3289) | -46.388 (19.7829) | -30.943 (46.6143) | -73.764 (10.8258) |

Abbreviations: CXDX = Cycle X Day X, ITT = Intent-to-treat; QD = once daily, SD = standard deviation Note: Baseline score refers to the last assessment value prior to C1D1 dosing.

Based on the results from Part 1 of the study 25 mg avapritinib was chosen as the RP2D for Part 2 and Part 3. The 100 mg dose was associated with the fastest symptom reduction, with a rapid reduction in TSS to C4D1; however, the TSS reduction plateaued after C4D1. The 25 mg and 50 mg dose groups achieved a similar mean reduction in TSS to the 100 mg cohort by C7D1.

## Part 2 of study BLU 285-2203

## Primary efficacy endpoint Mean change in ISM-SAF TSS, from baseline to C7D1

At Part 2 Baseline, the mean (SD) ISM-SAF TSS was 50.17 (19.145) points for the 25 mg Avapritinib Group and 52.43 (19.823) for the Placebo Group.

During treatment, there was reduction in the ISM-SAF TSS for both groups: In the Placebo Group, there was a reduction in the ISM-SAF TSS until C3D1, consistent with an early placebo effect, followed by a plateau of the ISM-SAF TSS through C7D1 (24 weeks).

At C7D1, the LS mean (SE) change from baseline in the ISM-SAF TSS was -15.58 (1.536) points for the 25 mg Avapritinib Group and -9.15 (2.013) for the Placebo Group.

The difference (95% CI) between the groups was -6.43 (-10.90, -1.96) points. This difference was statistically significant (1-sided p-value = 0.003). As pre-specified, with a 1-sided p-value &lt; 0.025, avapritinib is considered superior in reducing SM symptoms as compared to placebo.

<div style=\"page-break-after: always\"></div>

Table 47. Mean Change in TSS of ISM-SAF from Baseline to C7D1 (Part 2 ITT Population)

| Parameter                    | Avapritinib 25 mg N=141   | Placebo N=71   |
|------------------------------|---------------------------|----------------|
| Baseline                     | Baseline                  | Baseline       |
| n                            | 139                       | 71             |
| Mean (SD)                    | 50.17 (19.145)            | 52.43 (19.823) |
| Median                       | 47.86                     | 47.79          |
| Min, Max                     | 12.1, 102.7               | 18.0, 104.4    |
| C7D1                         | C7D1                      | C7D1           |
|                              | 130                       | 65             |
| Mean (SD)                    | 33.48 (20.056)            | 42.32 (21.027) |
| Median                       | 31.39                     | 38.21          |
| Min, Max                     | 0.9,103.5                 | 5.5, 86.1      |
| CFB                          | CFB                       | CFB            |
| n                            | 128                       | 65             |
| LS Mean (SE) a               | -15.58 (1.536)            | -9.15 (2.013)  |
| 95% CIa                      | -18.61,-12.55             | -13.12,-5.18   |
| Difference (95% CI) in CFB a | -6.43 (-10.90, -1.96)     |                |
| p-value b                    | 0.003                     |                |

Abbreviations: ANCOVA = analysis of covariance; CFB = change from baseline; CI = confidence interval; CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intentto- treat; LS Mean = least squares mean; Max = maximum; Min = minimum; SD = standard deviation; SE = standard error; TSS = Total symptom score. a Change from baseline summary and difference of mean change from baseline between 25 mg avapritinib and placebo are from LS mean estimation of the ANCOVA model that controlling for randomization stratification factor (tryptase) and baseline ISM status (moderate vs severe).

b One-sided p-value from ANCOVA model controlling for randomization stratification factor (tryptase) and baseline ISM status (moderate vs severe).

Figure 33. Change from Baseline in ISM-SAF TSS (Part 2 ITT Population)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intentto treat; LS Mean = Least Squares Mean; SE = Standard Error; TSS = Total symptom score.

<div style=\"page-break-after: always\"></div>

Note: For the 3 patients who received high-dose steroids (defined as prednisone &gt; 20 mg/day or equivalent in the 7 days before C7D1 or greater than 14 consecutive days), the TSS score at C7D1 are set to missing for primary efficacy analysis but are included in the figures of change over time.

Figure 34. LS Mean Plot of TSS of the ISM-SAF from Part 2 Baseline to Part 2 Cycle 7 Day 1

<!-- image -->

Abbreviations: ISM-SAF = Indolent Systemic Mastocytosis Symptom Assessment Form; TSS = total symptom score

## Sensitivity analyses

- o Mean change from baseline in ISM-SAF TSS at C7D1 using Markov chain Monte Carlo (MCMC) imputation

A sensitivity analysis with MCMC simulation to impute the missing baseline or C7D1 values was performed in the ITT population. The sensitivity analysis was consistent with the primary analysis. At C7D1, the LS mean (SE) change from baseline in the ISM-SAF TSS was -15.33 (1.544) points for the 25 mg Avapritinib Group and -9.64 (2.023) for the Placebo Group. The difference (95% CI) between the groups was -5.69 (-10.16, -1.23) points. This difference was statistically significant (1-sided p-value = 0.006).

- o Mean change from baseline in ISM-SAF TSS at C7D1 in the PP Population

A sensitivity analysis for the primary analysis was performed in the PP population. The PP population included 123 patients in the 25 mg Avapritinib Group and 67 patients in the Placebo Group.

The sensitivity analysis was consistent with the primary analysis. Over time, there was reduction in the ISM-SAF TSS for both groups. At C7D1, the LS mean (SE) change from baseline in the ISM-SAF TSS was -16.80 (1.722) points for the 25 mg Avapritinib Group and -9.27 (2.198) for the Placebo Group. The difference (95% CI) between the groups was -7.53 (-12.36, -2.70) points. This difference was statistically significant (1-sided p-value = 0.001). The MCMC sensitivity analysis for the mean change in the ISM-SAF TSS in the PP population was consistent with the overall sensitivity analysis in the PP population and the primary analysis.

- o Cumulative density function plots

CDF plots of ISM-SAF TSS at C4D1 and C7D1 in Part 2 for the ITT were produced. The x-axis of the CDF plot presents TSS change from baseline and the y-axis presents the cumulative proportion of patients with the TSS change from baseline equal or smaller than the value specified in the x-axis. For any given

<div style=\"page-break-after: always\"></div>

value of CFB (x-axis), the proportion of patients who had a CFB equal or smaller than that value was consistently greater in the 25 mg Avapritinib Group compared with the Placebo Group at C4D1 which improved at C7D1.

## Key secondary efficacy endpoints

## · Proportion of patients with ≥ 50% and ≥ 30% reduction in ISM -SAF TSS in patients from baseline to C7D1

The proportion of patients with ≥ 50% and ≥ 30% reduction in the ISM -SAF TSS from baseline to C7D1 were evaluated as key secondary endpoints.

Over time, there was a greater increase in the percentage of patients with ≥ 50% and ≥ 30% reduction in the ISM-SAF TSS for the 25 mg Avapritinib Groups compared to the placebo group.

At C7D1, 24.8% of patients in the 25 mg Avapritinib Group (95% CI: 17.9, 32.8) vs 9.9% of patients in the Placebo Group (95% CI: 4.1, 19.3) achieved ≥ 50% reduction in the ISM -SAF TSS.

At C7D1, 45.4% of patients in the 25 mg Avapritinib Group (95% CI: 37.0, 54.0) vs 29.6% of patients in the Placebo Group (95% CI:19.3, 41.6) achieved ≥ 30% reduction in the ISM -SAF TSS.

The odds ratio (95% CI) calculated to compare the 25 mg Avapritinib Group with the Placebo Group was 3.10 (1.24, 8.64) for the ≥ 50% reduction endpoint and 2.07 (1.08, 3.99) for the ≥ 30% reduction endpoint.

Both odds ratios were statistically significant (1-sided pvalue = 0.005 for ≥ 50% TSS reduction and 0.009 for ≥ 30% TSS reduction).

Table 48. Proportion of Patients with ≥ 50% and ≥ 30% Reduction in ISM -SAF TSS at C7D1 (Part 2 ITT Population)

|                                      | Avapritinib 25 mg N=141 n/N (%) (95% CIs)   | Placebo N=71 n/N (%) (95% CIs)   | Odds Ratio (95% CIs)   |   P-Value |
|--------------------------------------|---------------------------------------------|----------------------------------|------------------------|-----------|
| Patients with >50%reduction in TSS c | 35/141 (24.8) (17.9, 32.8)                  | 7/71 (9.9) (4.1, 19.3)           | 3.10 (1.24, 8.64)      |     0.005 |
| Patients with >30%reduction in TSS c | 64/141 (45.4) (37.0, 54.0)                  | 21/71 (29.6) (19.3, 41.6)        | 2.07 (1.08, 3.99)      |     0.009 |

Abbreviations: CI = confidence interval; CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intent-to treat, TSS = Total symptom score.

a Odds Ratio is to compare 25 mg Avapritinib with Placebo for each subgroup.

b One-sided p-value is from Cochran-Mantel-Haenszel test with controlling for randomization stratification factor (Serum tryptase &lt; 20 ng/mL vs ≥ 20 ng/mL) and baseline ISM status (moderate vs severe).

c Patients with high-dose steroid use within 7 days before C7D1, or greater than 14 consecutive days at any point from C1D1 to C7D1 were counted in the denominator but not numerator

<div style=\"page-break-after: always\"></div>

Figure 35. Percent of Patients with ≥ 50% Reduction in the ISM -SAF TSS Over Time from Baseline to Part 2 C7D1 (ITT Population, Patients with Baseline TSS Score)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intent-to treat; TSS = Total Symptom Score.

Figure 36. Percent of Patients with ≥ 30% Reduction in the ISM -SAF TSS Over Time from Baseline to Part 2 C7D1 (ITT Population, Patients with Baseline TSS Score)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intent-to treat; TSS = Total Symptom Score.

## · Proportion of Patients with ≥ 50% reduction in objective measures of mast cell burden

The proportion of patients who achieved ≥ 50% reduction in objective measures of mast cell burden from baseline to C7D1 were evaluated as key secondary endpoints. These measures included serum tryptase, KIT D816V MAF, and bone marrow mast cells.

<div style=\"page-break-after: always\"></div>

Table 149. Proportion of Patients with a ≥50% Reduction in Objective Measures of Mast Cell Burden from Baseline to C7D1 (Part 2 ITT Population)

| Parameter                                                                                                                                | 25 mg Avapritinib N=141 n/N (%) (95% CI)   | Placebo N=71 n/N (%) (95% CI)   | Odds ratio (95% CIs) a   | p-Value b   |
|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------|--------------------------|-------------|
| Proportion of patients with ≥ 50% reductions in serum tryptase                                                                           | 76/141 (53.9) (45.3, 62.3)                 | 0/71 (0.0) (0.0, 5.1)           | NE (30.59, NE)           | <0.0001     |
| Proportion of patients with ≥ 50% reduction in KIT D816V MAF or undetectable (< 0.02%) for patients with detectable mutation at baseline | 80/118 (67.8) (58.6, 76.1)                 | 4/63 (6.3) (1.8, 15.5)          | 39.34 (10.93, 140.56)    | <0.0001     |
| Proportion of patients with ≥ 50% reduction in bone marrow mast cells or no aggregates for patients with aggregates at baseline          | 56/106 (52.8) (42.9, 62.6)                 | 13/57 (22.8) (12.7, 35.8)       | 4.74 (2.06, 11.45)       | <0.0001     |

Abbreviations: C7D1 = Cycle 7 Day 1; CI = confidence interval; EOS = end-of-study; ISM = indolent systemic mastocytosis; ITT = intent-to-treat; KIT = V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; MAF = mutant allele fraction; NE = not evaluable. a Odds ratio is to compare 25 mg avapritinib with placebo for each subgroup. b One-sided p-value is from Cochran-MantelHaenszel test with controlling for randomization stratification factor (serum tryptase &lt; 20 ng/mL vs. ≥ 20 ng/mL) and baselin e ISM status (moderate vs. severe). Note: Patients who reached C7D1 or EOS prior to C7D1 with missing baseline or C7D1 assessment were counted in the denominator.

The odds ratios between avapritinib and placebo were statistically significant for all 3 endpoints.

Detailed results on the objective measures of mast cell burden are given below.

## Serum tryptase

At C7D1, 53.9% of patients in the 25 mg Avapritinib Group (95% CI: 45.3, 62.3) vs. 0.0% of patients in the Placebo Group (95% CI: 0.0, 5.1) achieved ≥ 50% reduction in serum tryptase.

Of note, 58 of 107 (54.2%) patients in the 25 mg Avapritinib Group with baseline serum tryptase ≥ 20 ng/mL achieving a level of &lt; 20 ng/mL (below the SM diagnosis criterion) at C7D1, with half of these patients (29/58) achieving a level of &lt; 11.4 ng/mL (ULN), compared with 1 of the 50 (2.0%) patients in the Placebo Group with baseline serum tryptase ≥ 20 ng/Ml achieving a level of &lt; 20 ng/mL at C7D1.

## KIT D816V MAF

At C7D1, 67.8% of patients in the 25 mg Avapritinib Group (95% CI: 58.6, 76.1) vs. 6.3% of patients in the Placebo Group (95% CI: 1.8, 15.5) achieved either ≥ 50% reduction in KIT D816V MAF or became undetectable (&lt; 0.02% LLD). This analysis was limited to patients with detectable mutations at baseline (LLD 0.02%). Of note, among 109 patients in the 25 mg Avapritinib Group with detectable KIT D816V MAF at baseline, 12 (11.0%) had undetectable KIT D816V MAF at C7D1; in the Placebo Group, among 54 patients with detectable KIT D816V MAF at baseline, 3 (5.6%) had undetectable KIT D816V MAF at C7D1.

Additionally, 14/40 (35.0%) patients in the 25 mg Avapritinib Group with KIT D816V MAF ≥ 1% at baseline reduced to KIT D816V MAF &lt; 1% at C7D1; in the Placebo Group, this was 0/22 patients.

## Bone marrow mast cells

<div style=\"page-break-after: always\"></div>

At C7D1, 52.8% of patients in the 25 mg Avapritinib Group (95% CI: 42.9, 62.6) vs. 22.8% of patients in the Placebo Group (95% CI: 12.7, 35.8) achieved ≥ 50% reduction in bone marrow mast cells or no mast cell aggregates. This analysis was limited to patients with mast cell aggregates at baseline.

Of note, in the 25 mg Avapritinib Group, 33/91 (36.3%) patients with bone marrow aggregates at baseline did not have bone marrow aggregates present at C7D1.

In the Placebo Group, 6/50 (12.0%) patients with bone marrow aggregates at baseline did not have bone marrow aggregates present at C7D1.

## Additional secondary efficacy endpoints

## · Change from Baseline to C7D1 objective measures of mast cell burden

At C7D1, the mean (SD) change from baseline in serum tryptase was -26.02 (35.662) for the 25 mg Avapritinib Group and 9.65 (41.924) for the Placebo Group.

At C7D1, the mean (SD) change from baseline in KIT D816V MAF was -1.178 (2.6978) for the 25 mg Avapritinib Group and 0.139 (0.9700) for the Placebo Group.

At C7D1, the mean (SD) change from baseline in bone marrow mast cells was -3.3 (10.99) for the 25 mg Avapritinib Group and -2.0 (7.32) for the Placebo Group in the ITT population.

## · Change in BSC usage for SM symptoms

At baseline, 140 (99.3%) patients in the 25 mg Avapritinib Group and 71 (100.0%) patients in the Placebo Group were taking BSC. The most commonly used BSC medications were antihistamines for systemic use (97.2% in the 25 mg avapritinib group and 100.0% in the Placebo Group) and drugs for peptic ulcer and GERD (73.8% in the 25 mg Avapritinib Group and 78.9% in the Placebo Group). By C7D1, 30 (21.3%) patients in the 25 mg Avapritinib Group and 9 (12.7%) patients in the Placebo Group had a reduction in the dose and/or frequency of BSC medications used. Four (2.8%) patients in the 25 mg Avapritinib Group had complete discontinuation of their BSC medications. None of the patients in the Placebo Group had complete discontinuations of their BSC medications. A total of 11 (7.8%) patients in the Avapritinib Group and 8 (11.3%) patients in the Placebo Group had increases in the dose and/or frequency of BSC medications used.

## · Change in lead (most severe) domain and lead (most severe) symptom

The 'lead' (most severe) domain (GI, skin, and neurocognitive domains) and symptom of the ISM-SAF were identified on a per patient basis using the domain/symptom with the highest score for that patient.

At baseline, the most common lead (most severe) domain in both treatment groups was the skin domain reported in 46/71 (64.8%) patients in the Placebo Group and 76/139 (54.7%) patients in the 25 mg Avapritinib Group and the most common lead (most severe) symptom in both treatment groups was fatigue, reported in 59/139 (42.4%) patients in the 25 mg Avapritinib Group and 28/71 (39.4%) patients in the Placebo Group followed by spots reported in 31/139 (22.3%) patients in the 25 mg Avapritinib Group and 20/71 (28.2%) patients in the Placebo Group.

Both, the most severe domain and the most severe symptom showed a statistically significant improvement in patients with ISM treated with avapritinib compared to patients treated with placebo; see table below.

<div style=\"page-break-after: always\"></div>

Table 50. Change from Baseline in Lead (Most Severe) Domain/Symptom Scores of the ISMSAF at C7D1 (Part 2 ITT Population)

|                                          | 25 mg Avapritinib N=131   | 25 mg Avapritinib N=131   | Placebo N=66     | Placebo N=66             | Difference (95% CI) p-value   |
|------------------------------------------|---------------------------|---------------------------|------------------|--------------------------|-------------------------------|
|                                          | Mean (SD) Change          | Mean (SD) Percent Change  | Mean (SD) Change | Mean (SD) Percent Change |                               |
| Lead (most severe) domain of the ISM-SAF | -6.52 (6.218)             | -35.73 (32.454)           | -3.36 (4.490)    | -19.12 (26.486)          | -3.16 (-4.69, -1.63) <0.0001  |
| Lead (most severe) Symptom of theISM-SAF | -2.22 (2.302)             | -28.97 (28.962)           | -1.42 (1.875)    | -19.78 (25.318)          | -0.80 (-1.45, -0.16) 0.015    |

Abbreviations: CI = confidence interval; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form;

SD = standard deviation. a A 2-sample t-test and the difference between treatment and placebo groups with corresponding 95% CIs for mean changes from baseline to C7D1.

Note: The 'lead domain' refers to the domain with highest score at baseline in each patient. If patient has a tie with multiple lead domains, the average change from baseline for each domain is used for the summary. The 'lead symptom' score refers to the individual symptom with highest score (individual symptoms were scored from 0-10) at baseline in each patient. If patient has a tie with multiple lead (most severe) symptoms, the average of change from baseline is used for the summary.

## · Analysis of individual domains

The GI, skin, and neurocognitive domain scores of the ISM-SAF reduced from baseline over time for both treatment groups. Among these domains, the difference between the 25 mg avapritinib group and placebo group was greatest for the skin domain scores.

At C7D1, the mean (SD) change from baseline in the GI domain score for the 25 mg Avapritinib Group was -3.74 (4.868) and -3.14 (4.664) for the Placebo Group. The difference (95% CI) between the groups was -0.60 (-2.03, 0.83) with a 2-sample t-test p-value of 0.410.

At C7D1, the mean (SD) change from baseline in the skin domain score for the 25 mg Avapritinib Group was -5.87 (6.485) and -2.64 (4.105) for the Placebo Group. The difference (95% CI) between the groups was -3.23 (-4.73, -1.73) with a 2-sample t-test p-value of &lt; 0.0001.

At C7D1, the mean (SD) change from baseline in the neurocognitive domain score for the 25 mg Avapritinib Group was -4.03 (5.223) and -2.81 (4.285) for the Placebo Group. The difference (95% CI) between the groups was -1.22 (-2.69, 0.25) with a 2-sample t-test p-value of 0.102.

## · Analysis of individual symptoms

By C7D1, there were reductions in the mean individual symptom scores of the ISM-SAF for all symptom domains for both treatment groups. The reductions were greater for the 25 mg Avapritinib Group compared to the Placebo Group across all the individual symptoms.

For the individual symptom scores of the ISM-SAF, statistically significant differences in the mean change from baseline between the 25 mg Avapritinib Group and Placebo Group were seen at C7D1 in the following individual symptoms: spots severity, itching severity, and flushing severity.

<div style=\"page-break-after: always\"></div>

Table 51. Change from Baseline in Individual Symptom Scores of the ISM-SAF at C7D1 (Part 2 ITT Population)

| Individual Score of the ISM-SAF   | 25 mg Avapritinib N=131   | 25 mg Avapritinib N=131   | Placebo N=66     | Placebo N=66             | Difference (95% CI) p-value a   |
|-----------------------------------|---------------------------|---------------------------|------------------|--------------------------|---------------------------------|
| Individual Score of the ISM-SAF   | Mean (SD) Change          | Mean (SD) Percent Change  | Mean (SD) Change | Mean (SD) Percent Change |                                 |
| Bone pain severity                | -1.35 (2.020)             | -20.57 (57.851)           | -0.82 (1.828)    | -14.73 (36.686)          | -0.53 (-1.11, 0.05) 0.076       |
| Abdominal pain severity           | -1.54 (1.820)             | -38.18 (71.684)           | -1.20 (1.921)    | -14.59 (104.765)         | -0.33 (-0.88, 0.22) 0.236       |
| Nausea severity                   | -1.09 (1.990)             | -26.35 (119.754)          | -1.05 (1.895)    | -14.92 (112.515)         | -0.05 (-0.63, 0.54) 0.873       |
| Spots severity                    | -1.86 (2.238)             | -33.11 (46.119)           | -0.63 (1.482)    | -7.05 (41.915)           | -1.23 (-1.76, -0.70) < 0.0001   |
| Itching severity                  | -2.21 (2.704)             | -32.85 (69.982)           | -1.06 (1.953)    | -11.98 (40.633)          | -1.16 (-1.82, -0.49) <0.001     |
| Flushing severity                 | -1.80 (2.539)             | -30.19 (50.937)           | -0.96 (1.862)    | -14.80 (41.648)          | -0.84 (-1.47,-0.21) 0.009       |
| Fatigue severity                  | -1.72 (2.230)             | -16.97 (92.475)           | -1.11 (1.880)    | -15.86 (29.589)          | -0.60 (-1.23, 0.03) 0.061       |
| Dizziness severity                | -1.29 (2.123)             | -21.89 (113.088)          | -0.93 (2.019)    | -25.37 (62.566)          | -0.36 (-0.98, 0.26) 0.258       |
| Brain fog severity                | -1.40 (1.994)             | -21.06 (105.229)          | -0.98 (1.694)    | -18.85 (37.978)          | -0.42 (-0.98, 0.15) 0.146       |
| Headache severity                 | -1.34 (1.950)             | -29.85 (68.575)           | -0.89 (1.605)    | -7.21 (77.156)           | -0.45 (-0.99, 0.10) 0.110       |
| Diarrhea count                    | -0.55 (1.095)             | -31.08 (83.779)           | -0.44 (1.088)    | -18.12 (73.348)          | -0.11 (-0.44, 0.21) 0.503       |
| Diarrhea severity                 | -1.11 (1.890)             | -32.04 (78.509)           | -0.89 (1.882)    | -21.73 (82.133)          | -0.22 (-0.78, 0.34) 0.445       |

Abbreviations: CI = confidence interval; CXDX = Cycle X Day X; ISM-SAF = Indolent Systemic

Mastocytosis-Symptom Assessment Form; ITT = Intent-to-treat; SD = standard deviation.

a A 2-sample t-test and the difference between treatment and placebo group with corresponding 95% CI for mean changes from baseline to C7D1.

Note: Baseline score is defined as the 14-day average of individual symptom scores from C1D-14 to C1D-1. C7D1 score is defined as the 14-day average of individual symptom scores prior to C7D1 visit. If a patient is missing more than 7 days of score between C1D-14 and C1D-1, the baseline score is considered as missing for the patient. If a patient misses more than 7 days of the score from the 14 days period for calculating C7D1 score, then the C7D1 score is considered as missing.

## · Quality of life measures

For all QoL measures (MC-QoL, PGIS, SF-12, PGIC, and EQ-5D-5L), a greater improvement was observed at Part 2 C7D1 in the 25 mg Avapritinib Group than the Placebo Group.

<div style=\"page-break-after: always\"></div>

Figure 37. Percent Change from Baseline at C7D1 in PRO and QoL Measures (Part 2 ITT Population)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; EQ = EuroQuol; ITT = Intent-to-treat; MC-QoL = Mastocytosis Quality of Life Questionnaire; MCS = Mental Component Score; PCS = Physical Component Score; PGIS = Patient's Global Impression of Symptom Severity; PRO = Patient-Reported Outcome; QoL = Quality of Life; SF-12 = Twelve-item Short Form Health Survey; VAS = visual analogue scale.

## Exploratory efficacy endpoints

## · Change in anaphylaxis based on epinephrine use

At baseline, 7 (5.0%) patients in the 25 mg Avapritinib Group and none in the Placebo Group had anaphylaxis that required epinephrine treatment. Postbaseline, 2 (1.4%) patients in the 25 mg Avapritinib Group and 3 (4.2%) patients in the Placebo Group had anaphylaxis that required epinephrine treatment.

## · Change in bone density

A total of 78 patients in the 25 mg Avapritinib Group and 33 patients in the Placebo Group had bone density scans at baseline. At C7D1, 50 patients in the 25 mg Avapritinib Group and 23 patients in the Placebo Group had bone density scans. No trends were observed in the Z-scores.

## Part 3 of study BLU 285-2203

In Part 3 of the study, all patients received 25 mg avapritinib.

Long-term efficacy was assessed in the overall population (Part 1/2/3) using the avapritinib baseline (the last observation prior to the first dose of avapritinib in any part).

## · Reduction in ISM-SAF TSS over time

Over time there was a greater reduction in the ISM-SAF TSS in the 25 mg Avapritinib Group as compared to the Placebo Group. An initial reduction in the ISM-SAF TSS was noted for both groups, consistent with regression to the means and placebo effect. In the Placebo Group, there was a reduction in the ISM-SAF TSS until Part 2 C3D1, consistent with an early placebo effect, followed by a plateau of the ISM-SAF TSS through Part 2 C7D1. After rollover to Part 3, for patients who rolled over from 25 mg avapritinib in Part

<div style=\"page-break-after: always\"></div>

2, there was further reduction in the ISM-SAF TSS up to Part 3 C2D1 at which point the mean change in ISM-SAF TSS leveled off and remained stable through Part 3 C7D1. For patients who rolled over from placebo in Part 2 to 25 mg avapritinib in Part 3, the ISM-SAF TSS decreased through Part 3 C5D1 and stabilized through Part 3 C7D1.

Figure 38. LS Mean Plot of Change in TSS of the ISM-SAF from Baseline to Part 3 C7D1

<!-- image -->

Abbreviations: CXDX = Cycle X Day X, ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; LS Mean = Least Squares Mean; SE = Standard Error; TSS = Total symptom score.

The overall Part 1/2/3 analyses, which analyzed efficacy using the avapritinib baseline for each group, showed a greater reduction in the ISM-SAF TSS in patients who had been in the 25 mg Avapritinib Group since Part 1 or Part 2 compared to patients who rolled over to 25 mg avapritinib in Part 3 from placebo in Part 1 or 2 at all time points. At C7D1 (using the avapritinib baseline), the mean (SD) change from baseline in the ISM-SAF TSS was -16.89 (16.744) points for the group of patients who rolled over from 25 mg avapritinib in Part 1 or 2 to 25 mg avapritinib in Part 3 and -10.19 (13.948) for the patients who rolled over from placebo in Part 1 or 2 to 25 mg avapritinib in Part 3. These data show that with longer exposure there are further reductions in the ISM-SAF TSS. Indeed, for patients who had reached C13D1, additional small reductions in ISM-SAF TSS were seen. The mean (SD) change in ISMSAF TSS was -21.22 (-19.018) for patients who rolled over from 25 mg avapritinib and -12.31 (-11.653) for patients who rolled over from placebo.

Over time, for patients who rolled over from 25 mg avapritinib in Part 2 to 25 mg avapritinib in Part 3, the proportion of patients with ≥ 50% and ≥ 30% reduction in the ISM -SAF TSS further increased until Part 3 C3D1 (≥ 50%) and C5D1 (≥ 30%) and then stab ilized. For patients who rolled over from placebo in Part 2 to 25 mg avapritinib in Part 3, the proportion of patients with ≥ 50% and ≥ 30% reduction in the ISM-SAF TSS increased through Part 3 C7D1. By Part 3 C7D1, a similar proportion of patients from bo th treatment groups had reached ≥ 50% and ≥ 30% reductions in TSS.

<div style=\"page-break-after: always\"></div>

Figure 39. Percent of Patients with ≥ 50% Reduction of TSS of the ISM -SAF Over Time from Baseline to Part 3 C7D1 (ITT Population, Patients with Baseline TSS Score)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X, ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form, ITT = Intent-to-Treat; TSS = Total symptom score. Note: Denominator is calculated as patients with baseline TSS score and non-missing TSS score at the time point.

Figure 40. Percent of Patients with ≥ 30% Reduction of TSS of the ISM -SAF Over Time from Baseline to Part 3 C7D1 (ITT Population, Patients with Baseline TSS Score)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X, ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form,

ITT = Intent-to-Treat. Note: Denominator is calculated as patients with baseline TSS score and non-missing TSS score at the time point.

<div style=\"page-break-after: always\"></div>

At C7D1 (using the avapritinib baseline), among the patients who rolled over from placebo in Part 1 or Part 2 to 25 mg avapritinib in Part 3 7/37 (18.9%) of patients had ≥ 50% reduction in the ISM -SAF TSS which was similar to that reported in the 25 mg Avapritinib Group in Part 2.

Among patients who rolled over from 25 mg avapritinib in Part 1 or Part 2 to 25 mg avapritinib in Part 3, 39/151 (25.8%) had ≥ 50% reduction in the ISM -SAF TSS.

At C7D1 (using the avapritinib baseline), among the patients who rolled over from placebo in Part 1 or Part 2 to 25 mg avapritinib in Part 3, 11/37 (29.7%) of patients had ≥ 30% reduction in the ISM -SAF TSS. Among patients who rolled over from 25 mg avapritinib in Part 1 or Part 2 to 25 mg avapritinib in Part 3, 71/151 (47.0%) had ≥ 30% reduction in the ISM -SAF TSS.

## · Reduction in objective measures of mast cell burden over time

The reduction in the ISM-SAF TSS score over time in patients who rolled over from placebo in Part 1 or Part 2 to 25 mg avapritinib in Part 3 was supported by reductions over time in the objective measures of mast cell burden (tryptase, D816V MAF, percent bone marrow mast cells).

Over time, a greater proportion of patients in the 25 mg Avapritinib Group had ≥ 50% reduction in serum tryptase as compared to the Placebo Group. None of the patients in the Placebo Group had ≥ 50% reduction in serum tryptase in Part 2. After rollover to Part 3, among the patients who rolled over from placebo in Part 2 to 25 mg avapritinib in Part 3, the proportion of patients who had ≥ 50% reduction in serum tryptase increased sharply at Part 3 C2D1 reaching a plateau by Part 3 C4D1 that was maintained through Part 3 C7D1. A similar trend was observed for KIT D816V MAF, with a slower increase in the proportion of patients who reached a 50% reduction which appeared to increase with time through C7D1.

Figure 141. Percent of Patients with ≥ 50% Reduction of Tryptase Over Time from Baseline to Part 3 C7D1 (ITT Population, Patients with Baseline Tryptase)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; ITT = Intent-to-Treat. Note: Denominator is calculated as patients with baseline tryptase and non-missing assessment at the time point.

<div style=\"page-break-after: always\"></div>

Figure 42. Percent of Patients with ≥ 50% Reduction or Undetected KIT D816V Over Time from Baseline to Part 3 C7D1 (ITT Population, Patients with Detectable Mutation at Baseline)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; ITT = Intent-to-Treat. Note: Denominator is calculated as patients with detectable mutation at baseline and non-missing assessment at the time point.

At C7D1 (using the avapritinib baseline), 13/37 (35.1%) patients in the placebo to 25 mg group and 81/151 (53.6%) patients in the 25 mg to 25 mg Avapritinib Group had ≥ 50% reduction in serum tryptase.

At C7D1 (using the avapritinib baseline), 13/30 (43.3%) patients in the placebo to 25 mg group and 85/127 (66.9%) patients in the 25 mg to 25 mg Avapritinib Group had ≥ 50% reduction in (or undetected) KIT D816V MAF.

At C7D1 (using the avapritinib baseline), 1/30 (3.3%) patients in the placebo to 25 mg group and 55/116 (47.4%) patients in the 25 mg to 25 mg Avapritinib Group had ≥ 50% reduction in (or no aggregates) bone marrow mast cells.

## · PRO and QoL measures over time

Improvements in QoL measures were observed over time in the patients who rolled over from placebo or 25 mg avapritinib in Part 1 or Part 2 to 25 mg avapritinib in Part 3.

At C7D1 (using the avapritinib baseline), patients treated with 25 mg avapritinib had improvements in all PRO and QoL measures and these improvements had deepened by 48 weeks (C13D1) of avapritinib treatment.

At baseline, patients in both groups reported MC-QoL total scores in the high moderate severity range, on average. In Part 2, for the Placebo group the mean total score remained in the moderate severity range, while for the Avapritinib group there was a steady reduction in the mean total score over time, with C7D1 scores reaching the mild disease severity range. After crossover to active treatment in Part 3, mean total scores for the Placebo group reached the mild disease severity range by C4D1.

<div style=\"page-break-after: always\"></div>

Table 52. Mean and Percent Change from Baseline in QoL Measures Over Time (Part 1/2/3 ITT Population)

<!-- image -->

|                               | Avapritinib 25 mg to 25 mg 24 weeks (C7D1)   | Avapritinib 25 mg to 25 mg 24 weeks (C7D1)   | Avapritinib 25 mg to 25 mga 48 weeks (C13D1)   | Avapritinib 25 mg to 25 mga 48 weeks (C13D1)   |
|-------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|
| QoL Endpoint                  | Mean (SD) Change                             | Mean (SD) Percent Change                     | Mean (SD) Change                               | Mean (SD) Percent Change                       |
| n (MC-QoL)                    | 130                                          | 130                                          | 56                                             | 56                                             |
| MC-QoL Range: 0-100           | -19.56 (17.895)                              | -34.84 (30.626)                              | -23.15 (20.046)                                | -39.24 (36.456)                                |
| n (PGIS)                      | 130                                          |                                              | 55                                             |                                                |
| PGIS Range: 0-4               | -0.8 (1.06)                                  | NA                                           | 0.9 (1.18)                                     | NA                                             |
| n (PGIC)                      | 136                                          |                                              | 58                                             |                                                |
| PGIC Score at C7D1 Range: 1-7 | 4.3 (1.72)                                   | NA                                           | 4.8 (1.59)                                     | NA                                             |
| n (SF-12)                     | 129                                          | 129                                          | 55                                             | 55                                             |
| SF-12-physical component      | 5.48 (8.346)                                 | 19.50 (30.389)                               | 7.18 (8.891)                                   | 27.01 (36.043)                                 |
| SF-12-mental component        | 4.00 (9.255)                                 | 12.72 (26.666)                               | 3.50 (10.190)                                  | 11.73 (27.466)                                 |
| n (EQ-5D-5L VAS)              | 130                                          | 130                                          | 56                                             | 56                                             |
| EQ-5D-5L (VAS) Range: 0-100   | 6.8 (18.67)                                  | 19.3 (48.47)                                 | 8.4 (19.99)                                    | 30.5 (60.70)                                   |

Abbreviations: CXDX = Cycle X Day X; EQ-5D-5L = EuroQol-5 Dimensions-5 Levels; ITT = Intent-to-treat; MCQoL = Mastocytosis Quality of Life Questionnaire; PGIC = Patients' Global Impression of Change; PGIS = Patient Global Impression of Symptom Severity; SD = standard deviation; SF-12 = Twelve-item Short Form Health Survey; QoL = quality of life; VAS = visual analogue scale.

aThis group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

<div style=\"page-break-after: always\"></div>

Figure 43. MC-QoL Total Score Mean, ITT Patients Part 2 and Part 3

<!-- image -->

Placebo m-ean

Avapritinilo 25 mg mean

Abbreviations: CXDX = Cycle X Day X; ITT = Intent-to-treat; MC-QoL = Mastocytosis Quality of Life Questionnaire. Reference: Pulfer et al, 2021

Updated efficacy data (data cutoff date 07 April 2023)

Table 53. Long Term Efficacy (Part 1/2/3) for Avapritinib 25 mg to Avapritinib mg

|                                                         | All 25 mg Avapritiniba N=226   | All 25 mg Avapritiniba N=226   | Avapritinib25mgto25mg N=151   | Avapritinib25mgto25mg N=151   |
|---------------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|
| Efficacyparameter                                       | 24weeks (C7D1)                 | 48weeks (C13D1)                | 24weeks (C7D1)                | 48weeks (C13D1)               |
| Mean change in TSS                                      | n=213 -14.91 (16.355)          | n=184 -17.80 (19.595)          | n=141 -16.89 (16.744)         | n=128 -20.42 (19.004)         |
| % of patients achieving ≥50%reductioninTSS (95% CI)     | n=226 24.3 (18.9, 30.5)        | n=207 33.3 (27.0, 40.2)        | n=151 25.8 (19.1, 33.6)       | n=151 37.1 (29.4, 45.3)       |
| % of patients achieving ≥ 30% reduction in TSS (95% CI) | n=226 43.8 (37.2, 50.5)        | n=207 45.4 (38.5, 52.5)        | n=151 47.0 (38.9, 55.3)       | n=151 50.3 (42.1, 58.6)       |

<div style=\"page-break-after: always\"></div>

| %of patientswith a≥50% reductioninserumtryptase (95% CI)                                   | n=226 50.0 (43.3, 56.7)   | n=207 43.0 (36.2, 50.0)   | n=151 53.6 (45.4, 61.8)   | N=151 42.4 (34.4, 50.7)   |
|--------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| % of patients with a ≥ 50% reductioninperipheral bloodKITD816V MAFor undetectable (95%CI)s | n=191 62.3 (55.0, 69.2)   | 1n=174 51.1 (43.5, 58.8)  | n=127 66.9 (58.0, 75.0)   | n=127 50.4 (41.4, 59.4)   |

Abbreviations: C7D1 = Cycle 7 Day 1; CI = confidence interval; ISM = indolent systemic mastocytosis; ISM-SAF =Indolent Systemic Mastocytosis-Symptom Assessment Form;ITT=intent-to-treat; MAF =mutant allelefraction; TSS =total symptom score(s).

a All 25 mg avapritinib population includes both patients who received avapritinib 25 mg in parts 1 or 2 as well as patients,the24and48weektimepointsaremeasuredfromthetimewhenthepatientstartedavapritinibinpart 3. Avapritinib 25 mg to 25 mg population excludes patients who received placebo in part 2, and only includes patientswhoreceivedavapritinib25mgduringpart1orpart 2ofthestudy.

Source:Updated data tables data cutoff07April2023Table 14.2.1.2.1c,Table 14.2.1.3.1.1c,Table 14.2.1.3.2.1c, Table 14.2.1.3.4.1c,Table 14.2.1.3.5.1c,Table 14.2.3.3.1c,Table 14.2.4.3.1c,Table 99.2.3.4.1c,and Table 99.2.4.4.1c

<div style=\"page-break-after: always\"></div>

## Table 54. Mean Change and Percent Change from Baseline in QoL Measures Over Time (Part 1/2/3 ITT Population)

<!-- image -->

|                             | All 25 mg Avapritinib*N=226   | All 25 mg Avapritinib*N=226   | All 25 mg Avapritinib*N=226   | All 25 mg Avapritinib*N=226   | Avapritinib 25 mg to 25 mgb N =15l   | Avapritinib 25 mg to 25 mgb N =15l   | Avapritinib 25 mg to 25 mgb N =15l   | Avapritinib 25 mg to 25 mgb N =15l   |
|-----------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| QoL                         | 24 weeks (C7D1)               | 24 weeks (C7D1)               | 48 weeks (C13D1)              | 48 weeks (C13D1)              | 24 weeks (C7D1)                      | 24 weeks (C7D1)                      | 48 weeks (C13D1)                     | 48 weeks (C13D1)                     |
| endpoint                    | Mean (SD) change              | Mean (SD) percent change      | Mean (SD) change              | Mean (SD) percent change      | Mean (SD) change                     | Mean (SD) percent change             | Mean (SD) change                     | Mean (SD) percent change             |
| n (MC- QoL)                 | 189                           | 189                           | 159                           | 159                           | 132                                  | 132                                  | 117                                  | 117                                  |
| MC-QoL Range. 0-100         | -16.64 (18.390)               | -29.84 (33.749)               | -18.74 (20.031)               | -31.85 (37.743)               | -19.31 (17.910)                      | -34.35 (30.709)                      | -22.65 (20.116)                      | -38.85 (35.475)                      |
| n (PGIS)                    | 190                           | NA                            | 159                           | NA                            | 133                                  | NA                                   | 120                                  | NA                                   |
| PGIS Range: 0-4             | -0.7 (1.00)                   | NA                            | -0.9 (1.04)                   | NA                            | -0.8 (1.05)                          | NA                                   | -1.0 (1.08)                          | NA                                   |
| n (PGIC)                    | 194                           | NA                            | 162                           | NA                            | 138                                  | NA                                   | 120                                  | NA                                   |
| PGIC Range: 1-7             | 4 (1.72)                      | NA                            | 4.8 (1.75)                    | NA                            | 4..3 (1.72)                          | NA                                   | 4.7 (1.78)                           | NA                                   |
| n (SF-12)                   | 187                           | 187                           | 156                           | 156                           | 131                                  | 131                                  | 116                                  | 116                                  |
| SF-12 physical component    | 4.75 (7.952)                  | 16.75 (28.423)                | 5.23 (8.662)                  | 20.26 (33.758)                | 5.39 (8.343)                         | 19.24 (30.333)                       | 6.57 (8.683)                         | 24.86 (33.910)                       |
| SF-12 mental component      | 3.72 (9.262)                  | 11.79 (26.301)                | 3.48 (9.474)                  | 11.89 (29.602)                | 4.04 (9.192)                         | 12.78 (26.472)                       | 4.43 (9.788)                         | 14.79 (31.615)                       |
| n (EQ-5D- 5L VAS)           | 190                           | 190                           | 160                           | 160                           | 133                                  | 133                                  | 118                                  | 118                                  |
| EQ-5D-5L (VAS) Range: 0-100 | 6.7 (17.53)                   | 20.3 (52.83)                  | 8.0 (16.69)                   | 22.3 (45.05)                  | 6.4 (18.68)                          | 18.5 (48.23)                         | 8.8 (18.23)                          | 25.3 (50.25)                         |

Abbreviations: CXDX = Cycle X Day X; EQ-5D-5L = EuroQol 5-Dimension 5-Level Questiomnaires; ITT = intentto-treat; MC-QoL = Mastocytosis-Quality of Life Questionnaire; NA = not applicable; PGIC = Patients Global Impression of Change; PGIS = Patients Global Impression of Symptom Severity; QoL = quality of life; SD = standard deviation; SF-12 = 12-Item Short Form Health Survey; VAS = visual analog scale. * All 25 mg avapritinib population includes both patients who received avapritinib 25 mg in parts 1 or 2 as well as patients who received placebo in part 2 but then went on to receive 25 mg avapritinib in part 3. For the placebo patients, the 24 and 48 week time points are measured from the time when the patient started avapritinib in part 3. Avapritinib 25 mg to 25 mg population excludes patients who received placebo in part 2, and only includes patients who received avapritinmib 25 mg during part 1 or part 2 of the study.

Note: A decrease in the MC-QoL and PGIS scores indicate improvement, and an increase in the PGIC, SF-12 and EQ-5D-5L scores indicate improvement.

## Ancillary analyses

Subgroup analysis

Primary endpoint

<div style=\"page-break-after: always\"></div>

Analysis of the primary endpoint was performed for the subgroups of age (&lt; 65 years, ≥ 65 years), gender (male, female), region (North America, Europe), country, baseline ISM status (moderate, severe), baseline serum tryptase level (&lt; 20 ng/mL, ≥ 20 ng/mL) , ECOG PS (0 or 1, 2+), and prior TKI therapy (yes, no).

|                                 | Placebo                         | Placebo                         | Avapritinib                     | Avapritinib                     | Difference                      |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | n LS Mean SE                    | n LS Mean SE                    | n LS Mean SE                    | n LS Mean SE                    | (95% CI)                        |
| Overall                         | 65 -9.15                        | 2.013                           | 128 -15.58                      | 1.536                           | -6.43 (-10.90, -1.96)           |
| Age Group (Years)               | Age Group (Years)               | Age Group (Years)               |                                 |                                 |                                 |
| 65                              | 55 -10.07                       | 2.191                           | 119 -15.14                      | 1.5$3                           | -5.07 (-9.92, -0.21)            |
| $9 =<                           | 10 -5.63                        | 96°9                            | 9 -25.24                        | 8.755                           | -19.62 (-33.50, -5.73)          |
| Gender                          | Gender                          | Gender                          |                                 |                                 |                                 |
| Male                            | 17 -12.17                       | 3.446                           | 21-6                            |                                 | -0.17 (-$.03, 7.68)             |
| Female                          | 48 -8.21                        | 2.488                           | 89 -17.13                       | 1.989                           | -8.92 (-14.38, -3.46)           |
| Region                          | Region                          | Region                          | Region                          | Region                          |                                 |
| North America                   | 30-12.00                        |                                 | 53 -18.58                       | 2.413                           | -6.58 (-13.33, 0.16)            |
| Europe                          | 35 -7.19                        | 2.597                           | 75 -13.66                       | 1.970                           | -6.47 (-12.43, -0.52)           |
| Country                         | Country                         | Country                         | Country                         | Country                         | Country                         |
| CAN                             | 4 NA                            | NA                              | 8 NA                            | NA                              | NA (NA, NA)                     |
| DEU                             | 14 -9.43                        | 3.602                           | 16 -13.96                       |                                 | -4.53 (-14.17, 5.11)            |
| ESP                             | 3 NA                            | NA                              | 14 N.                           | NA                              | NA (NA, NA)                     |
| FRA                             | 6 -4.34                         |                                 | 9 -16.49                        | 3.554                           | -12.16 (-24.18, -0.13)          |
| GBR                             | t NA                            | NA                              | 1I NA                           | NA                              | NA (NA, NA)                     |
| NLD                             | 3 NA                            | NA                              | 8 VN                            | NA                              | NA (NA. NA)                     |
| NOR                             | NA                              | NA                              | NA                              | VN                              | NA (NA. NA)                     |
| USA                             | 26-12.79                        | 3.276                           | 45 -18.95                       | 2.685                           | -6.16 (-13.55, 1.24)            |
| Baseline ISM Status             | Baseline ISM Status             | Baseline ISM Status             | Baseline ISM Status             | Baseline ISM Status             | Baseline ISM Status             |
| Moderate                        | 23-4.98                         | 2.218                           | 49 -9.15                        | 1.558                           | -4.17 (-9.09, 0.75)             |
| Severe                          | 42 -13.95 2.849                 |                                 | 79 -21.75                       | 2.284                           | -7.80 (-14.34, -1.27)           |
| Baseline Serum Tryptase (ng/mL) | Baseline Serum Tryptase (ng/mL) | Baseline Serum Tryptase (ng/mL) | Baseline Serum Tryptase (ng/mL) | Baseline Serum Tryptase (ng/mL) | Baseline Serum Tryptase (ng/mL) |
| ≤20                             | 14 -14.60                       | 4.797                           | 27 -13.01                       |                                 | 1.58 (-10.14, 13.30)            |
| >= 20                           | 51 -7.55                        | 1.995                           | 101 -16.18                      | 1.437                           | -8.63 (-13.41, -3.85)           |
| ECOG Status                     | ECOG Status                     | ECOG Status                     | ECOG Status                     | ECOG Status                     | ECOG Status                     |
| [ I0 0                          | 62 -9.27                        | 2.018                           | 118 -15.97                      | 1.552                           | -6.70 (-11.24, -2.17)           |
| 2+                              | 3 NA                            | NA                              | 10 NA                           | NA                              | NA (NA. NA)                     |
| Prior TKI tberapy               | Prior TKI tberapy               | Prior TKI tberapy               | Prior TKI tberapy               | Prior TKI tberapy               | Prior TKI tberapy               |
| Yes                             | 4 NA                            | NA                              | 9 NA                            | NA                              | NA (NA, NA)                     |
| No                              | 9'8-19                          | 907                             | 119 -14.67                      | 1.571                           | -6.04 (-10.63, -1.45)           |

Figure 44. Forest Plot of mean change from baseline in ISM-SAF TSS at C7D1 (Part 2 IIT Population)

<!-- image -->

Abbreviations: CXDX = Cycle X Day X; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = Intent-to treat; LS Mean = Least Squares Mean; NA = Not applicable; SE = Standard Error; TKI = tyrosine kinase inhibitor; TSS = Total symptom score.

## Secondary endpoints

<div style=\"page-break-after: always\"></div>

Figure 45. Forest Plot of Patients with ≥ 50% Reduction in ISM -SAF TSS at C7D1 (Part 2 ITT Population)

<!-- image -->

Abbreviations: C7D1 = Cycle 7 Day 1; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; ISM = Indolent Systemic Mastocytosis; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = intent-to-treat; NE = not estimated; TKI = tyrosine kinase inhibitor; TSS = total symptom score. Note: An odds ratio of &gt; 1 indicates that treatment with avapritinib is favored.

Figure 46. Forest Plot of Patients with ≥ 30% Reduction in ISM -SAF TSS at C7D1 (Part 2 ITT Population)

<!-- image -->

Abbreviations: C7D1 = Cycle 7 Day 1; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; ISM = Indolent Systemic

Mastocytosis; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = intent-to-treat; NE = not estimated; TKI = tyrosine kinase inhibitor; TSS = total symptom score. Note: An odds ratio of &gt; 1 indicates that treatment with avapritinib is favored.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well

<div style=\"page-break-after: always\"></div>

as the benefit risk assessment (see later sections).

Table 55. Summary of efficacy for study BLU-285-2203

| Title : BLU-285-2203 study: a 3-part, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective KIT mutation-targeted tyrosine kinase inhibitor, in indolent and smouldering systemic mastocytosis with symptoms inadequately controlled with standard therapy   | Title : BLU-285-2203 study: a 3-part, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective KIT mutation-targeted tyrosine kinase inhibitor, in indolent and smouldering systemic mastocytosis with symptoms inadequately controlled with standard therapy       | Title : BLU-285-2203 study: a 3-part, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective KIT mutation-targeted tyrosine kinase inhibitor, in indolent and smouldering systemic mastocytosis with symptoms inadequately controlled with standard therapy       | Title : BLU-285-2203 study: a 3-part, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective KIT mutation-targeted tyrosine kinase inhibitor, in indolent and smouldering systemic mastocytosis with symptoms inadequately controlled with standard therapy       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                        | BLU-285-2203 EudraCT number: 2018-000588-99 PIONEER                                                                                                                                                                                                                                                                                         | BLU-285-2203 EudraCT number: 2018-000588-99 PIONEER                                                                                                                                                                                                                                                                                         | BLU-285-2203 EudraCT number: 2018-000588-99 PIONEER                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                                                                                                  | Study BLU-285-2203 is a 3-part, Phase 2, randomized, double-blind, placebo- controlled study comparing the efficacy and safety of avapritinib in combination with best supportive care (BSC) to placebo in combination with BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms were not adequately controlled by BSC. | Study BLU-285-2203 is a 3-part, Phase 2, randomized, double-blind, placebo- controlled study comparing the efficacy and safety of avapritinib in combination with best supportive care (BSC) to placebo in combination with BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms were not adequately controlled by BSC. | Study BLU-285-2203 is a 3-part, Phase 2, randomized, double-blind, placebo- controlled study comparing the efficacy and safety of avapritinib in combination with best supportive care (BSC) to placebo in combination with BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms were not adequately controlled by BSC. |
|                                                                                                                                                                                                                                                                                                                                         | Duration of Main phase (Part 2):                                                                                                                                                                                                                                                                                                            | Duration of Main phase (Part 2):                                                                                                                                                                                                                                                                                                            | Date first patient enrolled in Part 2 of the study: 24 September 2020 Data cut-off for analyses: 23 June 2022                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                         | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                   | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                   | Not applicable                                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                         | Duration of Extension phase (Part 3):                                                                                                                                                                                                                                                                                                       | Duration of Extension phase (Part 3):                                                                                                                                                                                                                                                                                                       | Ongoing, patients will continue to receive avapritinib 25 mg QD in Part 3 of study BLU- 285-2203 for up to 5 years, in 28-day cycles, inclusive of Part 1 and Part 2 of study BLU- 285-2203.                                                                                                                                                |
| Hypothesis                                                                                                                                                                                                                                                                                                                              | Superiority To evaluate efficacy and safety of avapritinib in patients with ISM with symptoms inadequately controlled with standard therapy. The primary analyses were performed for the ITT population and presented by treatment arm.                                                                                                     | Superiority To evaluate efficacy and safety of avapritinib in patients with ISM with symptoms inadequately controlled with standard therapy. The primary analyses were performed for the ITT population and presented by treatment arm.                                                                                                     | Superiority To evaluate efficacy and safety of avapritinib in patients with ISM with symptoms inadequately controlled with standard therapy. The primary analyses were performed for the ITT population and presented by treatment arm.                                                                                                     |
| Treatments groups                                                                                                                                                                                                                                                                                                                       | Avapritinib 25 mg + BSC                                                                                                                                                                                                                                                                                                                     | Avapritinib 25 mg + BSC                                                                                                                                                                                                                                                                                                                     | Oral dose of avapritinib 25 mg QD + BSC n = 141                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                         | Placebo + BSC                                                                                                                                                                                                                                                                                                                               | Placebo + BSC                                                                                                                                                                                                                                                                                                                               | Oral dose of placebo QD + BSC n = 71                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                               | Primary endpoint:                                                                                                                                                                                                                                                                                                                           | Mean change in ISM-SAF TSS from Baseline to                                                                                                                                                                                                                                                                                                 | Mean change in ISM-SAF TSS from Baseline to C7D1.                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                         | Mean change in ISM-SAF TSS (ISM-Symptom Assessment Form Total Symptom Score)                                                                                                                                                                                                                                                                | C7D1                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | Key secondary endpoints: Reduction in mast cell burden   | ≥50% reduction in serum tryptase from Baseline to C7D1                                 | ≥50% reduction in serum tryptase from Baseline to C7D1                                 | Proportion of patients with a ≥50% reduction in serum tryptase from Baseline to C7D1.                                                                                                        | Proportion of patients with a ≥50% reduction in serum tryptase from Baseline to C7D1.                                                                                                        |
|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Key secondary endpoints: Reduction in mast cell burden   | (%) ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 | (%) ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 | Proportion of patients with a ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 or undetectable (<0.02%) for patients with detectable mutation at Baseline. | Proportion of patients with a ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 or undetectable (<0.02%) for patients with detectable mutation at Baseline. |
|                                                 | Key secondary endpoints: Reduction in mast cell burden   | ≥50% reduction in bone marrow mast cells from Baseline to C7D1 (%)                     | ≥50% reduction in bone marrow mast cells from Baseline to C7D1 (%)                     | Proportion of patients with a ≥50% reduction in bone marrow mast cells from Baseline to C7D1 or no aggregates for patients with aggregates at Baseline.                                      | Proportion of patients with a ≥50% reduction in bone marrow mast cells from Baseline to C7D1 or no aggregates for patients with aggregates at Baseline.                                      |
|                                                 | Key secondary endpoints: Reduction in ISM-SAF TSS        | ≥50% reduction in ISM-SAF TSS from Baseline to C7D1 (%)                                | ≥50% reduction in ISM-SAF TSS from Baseline to C7D1 (%)                                | Proportion of patients with ≥50% reduction in ISM-SAF TSS from Baseline to C7D1.                                                                                                             | Proportion of patients with ≥50% reduction in ISM-SAF TSS from Baseline to C7D1.                                                                                                             |
|                                                 | Key secondary endpoints: Reduction in ISM-SAF TSS        | ≥30% reduction in ISM-SAF TSS from Baseline to C7D1 (%)                                | ≥30% reduction in ISM-SAF TSS from Baseline to C7D1 (%)                                | Proportion of patients with ≥30% reduction in ISM-SAF TSS from Baseline to C7D1.                                                                                                             | Proportion of patients with ≥30% reduction in ISM-SAF TSS from Baseline to C7D1.                                                                                                             |
| Database lock                                   | Data cut-off for analyses was 23 June 2022.              | Data cut-off for analyses was 23 June 2022.                                            | Data cut-off for analyses was 23 June 2022.                                            | Data cut-off for analyses was 23 June 2022.                                                                                                                                                  | Data cut-off for analyses was 23 June 2022.                                                                                                                                                  |
| Results and Analysis Analysis description       | Results and Analysis Analysis description                | Results and Analysis Analysis description                                              | Results and Analysis Analysis description                                              | Results and Analysis Analysis description                                                                                                                                                    | Results and Analysis Analysis description                                                                                                                                                    |
| Analysis population and time point description  | Primary analysis: Mean change in ISM-SAF TSS             | Primary analysis: Mean change in ISM-SAF TSS                                           | Primary analysis: Mean change in ISM-SAF TSS                                           | Primary analysis: Mean change in ISM-SAF TSS                                                                                                                                                 | which includes all received the study medication ITT population. All patients avapritinib dose/placebo they                                                                                  |
| Descriptive statistics and estimate variability | were randomly assigned received, if different.           | were randomly assigned received, if different.                                         | Avapritinib 25 mg + BSC                                                                | Avapritinib 25 mg + BSC                                                                                                                                                                      | Placebo + BSC                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Number of patients                                       | Number of patients                                                                     | 141                                                                                    | 141                                                                                                                                                                                          | 71                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Mean change in TSS from baseline to C7D1 (95% confidence | Mean change in TSS from baseline to C7D1 (95% confidence                               | -15.58                                                                                 | -15.58                                                                                                                                                                                       | -9.15                                                                                                                                                                                        |
| Effect estimate per comparison                  |                                                          |                                                                                        | (-18.61, -12.55) Comparison groups                                                     | (-18.61, -12.55) Comparison groups                                                                                                                                                           | (-13.12, -5.18) Avapritinib 25 mg + BSC versus placebo + BSC                                                                                                                                 |
| Effect estimate per comparison                  |                                                          |                                                                                        | Difference between groups                                                              | Difference between groups                                                                                                                                                                    | -6.43                                                                                                                                                                                        |
| Effect estimate per comparison                  | Mean change in TSS from Baseline to C7D1                 | Mean change in TSS from Baseline to C7D1                                               | 95% confidence interval                                                                | 95% confidence interval                                                                                                                                                                      | -10.90, -1.96                                                                                                                                                                                |
| Effect estimate per comparison                  |                                                          |                                                                                        | p-value                                                                                | p-value                                                                                                                                                                                      | 0.003                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Key secondary analyses: Reduction in mast cell burden                                                            | Key secondary analyses: Reduction in mast cell burden   | Key secondary analyses: Reduction in mast cell burden     |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------|
| Analysis population and time point description  | Same as for the primary analysis, ITT population.                                                                | Same as for the primary analysis, ITT population.       | Same as for the primary analysis, ITT population.         |
| Descriptive statistics and estimate variability | Treatment group                                                                                                  | Avapritinib 25 mg + BSC                                 | Placebo + BSC                                             |
| Descriptive statistics and estimate variability | Number of patients                                                                                               | 141                                                     | 71                                                        |
| Descriptive statistics and estimate variability | ≥50% reduction in serum tryptase from Baseline to C7D1 (%) (95% confidence interval)                             | 53.9 (45.3, 62.3)                                       | 0.0 (0.0, 5.1)                                            |
| Effect estimate per comparison                  | ≥50% reduction in serum tryptase from Baseline to C7D1 (%)                                                       | Comparison groups                                       | Avapritinib 25 mg + BSC versus placebo + BSC              |
| Effect estimate per comparison                  | ≥50% reduction in serum tryptase from Baseline to C7D1 (%)                                                       | Odds ratio                                              | NE                                                        |
| Effect estimate per comparison                  | ≥50% reduction in serum tryptase from Baseline to C7D1 (%)                                                       | 95% confidence interval                                 | 30.59, NE                                                 |
| Effect estimate per comparison                  | ≥50% reduction in serum tryptase from Baseline to C7D1 (%)                                                       | p-value                                                 | <0.0001                                                   |
| Descriptive statistics and estimate variability | Treatment group                                                                                                  | Avapritinib 25 mg + BSC                                 | Placebo + BSC                                             |
| Descriptive statistics and estimate variability | Number of patients                                                                                               | 118                                                     | 63                                                        |
| Descriptive statistics and estimate variability | ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 (%) (95% confidence interval) | 67.8                                                    | 6.3                                                       |
| Effect estimate per comparison                  |                                                                                                                  | Comparison groups                                       | Avapritinib 25 mg + BSC versus placebo + BSC              |
| Effect estimate per comparison                  | ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 (%)                           | Odds ratio                                              | 39.34                                                     |
| Effect estimate per comparison                  | ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 (%)                           | 95% confidence interval                                 | 10.93, 140.56                                             |
| Effect estimate per comparison                  | ≥50% reduction in peripheral blood KIT D816V allele fraction from Baseline to C7D1 (%)                           | p-value                                                 | <0.0001                                                   |
| Descriptive statistics and estimate variability | Treatment group                                                                                                  | Avapritinib 25 mg + BSC                                 | Placebo + BSC                                             |
| Descriptive statistics and estimate variability | Number of patients                                                                                               | 106                                                     | 57                                                        |
| Descriptive statistics and estimate variability | ≥50% reduction in bone marrow mast cells from Baseline to C7D1 (%) (95% confidence interval)                     | 52.8                                                    | 22.8                                                      |
| Effect estimate per comparison                  |                                                                                                                  | (42.9, 62.6) Comparison groups                          | (12.7, 35.8) Avapritinib 25 mg + BSC versus placebo + BSC |
| Effect estimate per comparison                  |                                                                                                                  | Odds ratio                                              | 4.74                                                      |

<div style=\"page-break-after: always\"></div>

|                                                 | ≥50% reduction in bone marrow mast cells from Baseline to C7D1 (%)                | 95% confidence interval                           | 2.06, 11.45                                               |
|-------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------|
|                                                 |                                                                                   | p-value                                           | <0.0001                                                   |
| Analysis description                            | Key secondary analyses: reduction in ISM-SAF TSS                                  | Key secondary analyses: reduction in ISM-SAF TSS  | Key secondary analyses: reduction in ISM-SAF TSS          |
| Analysis population and time point description  | Same as for the primary analysis, ITT population.                                 | Same as for the primary analysis, ITT population. | Same as for the primary analysis, ITT population.         |
| Descriptive statistics and estimate variability | Treatment group                                                                   | Avapritinib 25 mg + BSC                           | Placebo + BSC                                             |
| Descriptive statistics and estimate variability | Number of patients                                                                | 141                                               | 71                                                        |
| Descriptive statistics and estimate variability | ≥50% reduction in ISM-SAF TSS from Baseline to C7D1 (%) (95% confidence interval) | 24.8 (17.9, 32.8)                                 | 9.9 (4.1, 19.3)                                           |
| Effect estimate per comparison                  | ≥50% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | Comparison groups                                 | Avapritinib 25 mg + BSC versus placebo + BSC              |
| Effect estimate per comparison                  | ≥50% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | Odds ratio                                        | 3.10                                                      |
| Effect estimate per comparison                  | ≥50% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | 95% confidence interval                           | 1.24, 8.64                                                |
| Effect estimate per comparison                  | ≥50% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | p-value                                           | 0.005                                                     |
| Descriptive statistics and estimate variability | Treatment group                                                                   | Avapritinib 25 mg + BSC                           | Placebo + BSC                                             |
| Descriptive statistics and estimate variability | Number of patients                                                                | 141                                               | 71                                                        |
| Descriptive statistics and estimate variability | ≥30% reduction in ISM-SAF TSS from Baseline to C7D1 (%) (95% confidence interval) | 45.4                                              | 29.6                                                      |
| Effect estimate per comparison                  | ≥30% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | (37.0, 54.0) Comparison groups                    | (19.3, 41.6) Avapritinib 25 mg + BSC versus placebo + BSC |
| Effect estimate per comparison                  | ≥30% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | Odds ratio                                        | 2.07                                                      |
| Effect estimate per comparison                  | ≥30% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | 95% confidence interval                           | 1.08, 3.99                                                |
| Effect estimate per comparison                  | ≥30% reduction in ISM - SAF TSS from Baseline to C7D1 (%)                         | p-value                                           | 0.009                                                     |

## Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 20/246                                            | 4/246                                             | 0                                               |
| Non-Controlled trials | Not applicable                                    | Not applicable                                    | Not applicable                                  |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This variation application is primarily supported by the results from part 2 of the pivotal study BLU-2852203 (PIONEER), a 3-part, randomized, double-blinded, placebo-controlled, phase 2 study to evaluate the efficacy and safety of avapritinib (BLU-285) in patients with ISM with symptoms inadequately controlled with standard therapy.

Initially, patients with both ISM and smouldering systemic mastocytosis (SSM) were planned to be included in study BLU-285-2203. However, no SSM patients were finally enrolled (in Part 2). This was justified by the MAH on the following grounds: that SSM patients have higher disease burden and are at higher risk of progression to advanced systemic mastocytosis (AdvSM). The study protocol for part 2 was updated in this regard with amendment 4, and only ISM patients were included. This approach was considered acceptable.

Forty-two sites in 13 countries enrolled patients and entered data for this study, including 19 sites in North America, 20 sites in Europe, and 3 sites in the United Kingdom. The European population is considered well represented with 119 (n=212; 56%) patients from European countries included in part 2 of study BLU-285-2203.

The focus for efficacy analyses in the current procedure is on patients with ISM treated with avapritinib at a dose of 25 mg QD. The proposal for a lower dose than the one recommended for the already approved indication in the AdvSM scenario seems reasonable in the context of a 'non-aggressive/non-advanced\" disease with the aim of downgrading toxicity and taking into consideration the (expected) long-term treatment. The RP2D was established based on Part 1 of the BLU 285-2203 study (see below).

Overall, the proposed design of the study is considered adequate. The study is placebo-controlled. This is endorsed as there are no drugs specifically approved in the EU for patients with ISM, and current treatment of the disease is based on supportive care to control symptoms. A period of 24 weeks for the double-blinded placebo comparison can be accepted. Nevertheless, the interpretation of long-term efficacy data, which are considered of particular relevance in this indolent scenario, is hampered by the absence of a control arm in part 3 of the study. Further, the overall sample size of study BLU-285-2203 is limited, although this can be acknowledged taking into account the rarity of this disease.

The primary endpoint for efficacy assessment in Part 2 of the study is defined as the mean change from baseline to cycle 7 day 1 (C7D1; week 24) in the total symptom score (TSS) using the Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF). The proposal to use a continuous variable for the primary efficacy assessment of symptom reduction is considered adequate.

The ISM-SAF has been (recently) developed as a patient-reported outcome (PRO) questionnaire. It assesses the severity of eleven items (bone pain, abdominal pain, nausea, spots on the skin, itching, flushing, fatigue, dizziness, brain fog, headache and diarrhoea) which are graded on an 11-point numerical scale [from 0=no (sign/symptom) to 10=worst imaginable (sign/symptom)] using a 24-hour recall period. An additional item asks responders to record diarrhoea frequency during the prior 24 hours. The ISM-SAF can be scored at an item level or combined to create the above mentioned 'Total Symptom Score' (TSS) which is the sum of the 11 severity items ranged from 0 to 110. A 'Gastrointestinal

<div style=\"page-break-after: always\"></div>

Symptom Score', a 'Skin Symptom Score' and a 'Neurocognitive Symptom Score' can also be derived from data reported, which are scored from 0 to 30 (each of them). These scores can be calculated on a daily or a bi-weekly basis.

The development and content validity as well as the psychometric properties of this PRO were discussed during regulatory interactions at EU level (EMEA/H/SA/3738/2/2018/SME/III; EMEA/H/SA/3738/2/FU/1/2020/PA/SME/II). At that time, the questionnaire was overall regarded as an acceptable tool to quantitate efficacy in ISM.

The proposed inclusion and exclusion criteria are overall considered reflective of a patient population with ISM that  fail  to  achieve  control  under  symptomatic  therapies  and  have  remaining  moderate  to  severe symptomatology. An ISMSAF TSS ≥28 was the pre -specified symptom severity threshold for the inclusion of patients in the study. This threshold was selected based on an observational study in 103 US patients diagnosed with ISM or SSM. Based on the findings of both received operating characteristics (ROC) and contingency analyses, using the Patient Global Impression of Symptom Severity (PGIS) as an anchor, a biweekly ISM-SAF TSS cut-off value of between 21 and 28 was defined to identify patients with at least moderate symptoms. The upper value of 28 was selected by the MAH as a more conservative estimate. A similar  approach  was  used  to  identify  patients  with  severe  symptoms  for  whom  a  cutoff  of  ≥42  was selected. The proposed thresholds for inclusion in the study are considered basically acceptable.

The original protocol for study BLU-285-2203 (dated 15 February 2018) was amended 10 times: 5 were global and 5 were country-specific amendments. The study methodology presented for assessment is in accordance with the latest global protocol amendment 9 (dated 07 June 2022).

In the original protocol, the proposed primary endpoint was mean percent reduction in ISM-SAF TSS from baseline to week 12 (C4D1), which was then modified to mean change in ISM-SAF TSS from baseline to week 12 based on the feedback received from the FDA (amendment 1). In amendment 4 (15 June 2020), the primary endpoint was changed to the proportion of avapritinib-treated patients with ISM achieving ≥30% reduction in TSS from baseline to C7D1 (apparently, this change was agreed by the FDA). Later on, with amendment 9 (07 June 2022) the primary endpoint was changed, again, to mean change in ISM-SAF TSS from baseline to C7D1, compared to placebo (as discussed with the FDA).

In addition, the sample size was increased in Part 2 (and consequently in Part 3) as a result of amendment 4 and increased from 72 to 204 patients.

Even if the finally agreed/selected primary endpoint as well as the sample size can be considered overall adequate from a regulatory perspective, changes have been implemented during an ongoing study and therefore the MAH was requested to provide a detailed description on how these major changes should be expected to have not affected the integrity and the internal validity of the study. Overall, the protocol amendment 4 was made before the start of Part 2 of the study and therefore there was no impact on the integrity of the study. Regarding protocol amendment 9 the change in the primary endpoint was made prior to the last patient last visit for Part 2 (21 Jun 2022) while the study was blinded and therefore with no impact on the integrity of the study.

Regarding major protocol deviations (reported in more than 2% of patients in part 2 of the study), there was a higher rate in the avapritinib arm compared with the placebo arm (29.9% vs. 9.9%). None are thought to impact the integrity of the data.

In 2018, the MAH sought advice (EMEA/H/SA/3738/2/2018/SME/III) to ask about the appropriateness of the LOCF method to account for missing data. This method was strongly discouraged. The MAH followed the EMA advice and, in the final protocol, the approach was changed to the exclusion of patients with missing values at baseline or C7D1 TSS from the analysis. As sensitivity analysis, Markov chain Monte Carlo (MCMC) simulations to impute missing values at baseline or C7D1 was proposed. From a regulatory point of view, this is still not the preferred option to assess the agreed primary endpoint since the exclusion of

<div style=\"page-break-after: always\"></div>

potential informative data from the primary efficacy analysis, i.e. intercurrent events (ICEs), might hamper the results and, consequently, their interpretation impacting the extrapolation of (the magnitude of) the treatment effect reported in the targeted population. Generally, the treatment policy estimand (where the value of the endpoint is used regardless of the occurrence of ICEs) is the strongly preferred strategy for the handling of these events. However, it is acknowledged that in some instances, the collection of these intercurrent events is not possible. For this reason, the MAH was requested to conduct additional analyses to better contextualise these results. Results of these analyses were consistent with the primary analysis.

## Part 1 - Dose response study

The main objective was to identify the optimal dose of avapritinib (RP2D) in patients with ISM.

Baseline height and weight were similar across treatment groups. At baseline, all patients had significant sign and symptom burden as assessed by the ISM-SAF with a mean (SD) TSS of 53.3 (19.34). Baseline mean (SD) serum tryptase was 83.78 (100.530) ng/mL and 89.7% patients had bone marrow mast cell aggregates. KIT D816V mutation was detected in peripheral blood in 79.5% of patients at baseline with a mean (SD) allele fraction of 4.274 (8.4802).

At C4D1, the mean (SD) reduction in TSS of the ISM-SAF was greater in all avapritinib groups compared with the placebo group: -12.54 (13.234) for the 25 mg group, -12.32 (14.194) for the 50 mg group, 21.35 (18.769) for the 100 mg group, and -3.36 (7.998) for the placebo group.

The 100 mg dose was associated with the greatest reduction in TSS at C4D1. However, additional analyses showed that the TSS reduction plateaued after C4D1. The 25 mg and 50 mg dose groups achieved a similar mean reduction in TSS to the 100 mg cohort by C7D1.

Based on the above reported results from Part 1 of the study, 25 mg avapritinib was chosen as the RP2D for Part 2 and Part 3. The 25 mg cohort had a better safety profile in terms of Grade 3 AEs, required no dose modifications and no discontinuations of the study drug, with acceptable and comparable efficacy results and was expected by the MAH to allow long-term treatment.

As stated above, the proposed dose, which is lower than that recommended for the already approved indication in the advanced disease setting (i.e. AdvSM), is considered reasonable in a 'non-aggressive\" scenario where downgrading toxicity is of importance.

## Efficacy data and additional analyses

In Part 2, both the ITT and Safety Populations included 141 patients in the 25 mg avapritinib group and 71 patients in the placebo group. The primary efficacy assessment was based on results reported in the ITT population.

Regarding baseline characteristics, the ITT population included more females than males (70.9% vs. 29.1% in the avapritinib arm and 76.1% vs. 23.9% in the placebo arm, for female and male patients, respectively). Literature is available suggesting a female predominance (Kanamori et al, 2015), which is consistent with the patient population enrolled in the study. Most patients in both groups were &lt; 65 years (93.6% in the 25 mg avapritinib group and 84.5% in the placebo group), not Hispanic or Latino (70.2% in the 25 mg avapritinib group and 81.7% in the placebo group), and White (77.3% patients in the 25 mg avapritinib group and 85.9% patients in the placebo group), and other baseline characteristics (mean height [cm], weight [kg], and body mass index [kg/m2]) were similar in both groups. Of note, the proportion of female and white patients was higher in the placebo group.

The mean ISM-SAF TSS at baseline (SD) was comparable for the placebo and the avapritinib arms, i.e. 50.17 (19.145) points for the 25 mg avapritinib group and 52.43 (19.823) for the placebo group. Of note, while all patients seem to fulfil the eligibility criteria (eligibility TSS is defined as the 14-day average of

<div style=\"page-break-after: always\"></div>

TSS starting from the date that investigator deemed BSC medications are optimized and stabilised), there were some patients (14 in the avapritinib arm and 4 in the placebo arm) with a TSS &lt; 28 at baseline. Indeed, the minimum ISM-SAF TSS value at baseline was 12.1 in the avapritinib arm and 18 in the placebo arm. The percentage of patients with severe symptoms of ISM (i.e. defined as an ISM-SAF TSS ≥42) was balanced between the 25 mg avapritinib group (61.7%) and the placebo group (63.4%).

Overall, the 94.3% rate of KIT D816V positivity was consistent with the anticipated ~95% rate of KIT D816V positivity noted in the ISM literature (Garcia-Montero et al, 2006; Jara-Acevedo et al, 2015; Ungerstedt et al, 2022) .

The majority of patients who received avapritinib (99.3%) or placebo (100%) received concomitant best supportive care at baseline (median of 3 therapies in the avapritinib group and 4 in the placebo group). The most common therapies in patients treated with avapritinib were H1 antihistamines (97.2%), H2 antihistamines (66%), leukotriene inhibitors (34.8%) and cromolyn sodium (30.5%).

Although cyto-reductive treatment is mainly indicated in advanced mastocytosis, several patients in the current study received treatment with midostaurin, imatinib, dasatinib, etc. In total, there were 19 patients who had received prior therapy with TKIs before enrolment in the study (14 in the avapritinib arm and 4 in the placebo arm). However, according to the MAH limited information is available on the reasons for the previous treatment received but efficacy results for these patients have been provided and appear consistent with those of the overall population.

The analysis of efficacy for avapritinib was based primarily on the results from the comparison between placebo and the RP2D of 25 mg avapritinib in Part 2 of study BLU 285-2203. During treatment, there was reduction in the ISM-SAF TSS for both groups. In the placebo group, a reduction in the ISM-SAF TSS was observed until C3D1 followed by a plateau of the ISM-SAF TSS through C7D1.

At C7D1, the LS mean (SE) change from baseline in the ISM-SAF TSS was -15.58 (1.536) points for the 25 mg avapritinib group and -9.15 (2.013) for the placebo group. Change from baseline to C7D1 in ISMSAF TSS showed a difference of -6.43 (95% IC: -10.90, -1.96) between treatment arms. This difference was statistically significant (p&lt;0.003). It is noticeable that the regression to the mean observed in the placebo group is numerically larger than the estimated improvement seen with the addition of avapritinib.

Results from the analysis of the primary endpoint in relevant subgroups were overall consistent with only two subgroups (male and patients with serum tryptase &lt;20 ng/mL) apparently deriving less benefit from the experimental treatment (based on point estimates of mean change). These two subgroups are of small sample size and therefore results should be interpreted with caution.

The results for the (key) secondary efficacy endpoints showed also statistically significant results. The proportion of patients with ≥ 50% and ≥ 30% reduction in ISM -SAF TSS from baseline to C7D1 was of 24.8% vs. 9.9% and 45.4% vs 29.6% for the avapritinib and placebo groups, respectively. Also, the proportion of patients with ≥ 50% reduction in objective measures of mast cell burden (serum tryptase, KIT D816V MAF and bone marrow mast cells) showed results in favour of avapritinib treatment with all 3 endpoints reported as statistically significant.

The clinically important difference (CID) between groups for the TSS (reported using the recently developed PRO ISM-SAF), derived using distribution-based methods, may range from 6 to 10. This is based on pooled data from Part 1 and 2 of study BLU 285-2203, considered by the MAH as confirmation of the CID range previously observed for Part 1 (i.e. from 7 to 10). However, the MAH was requested to further clarify/discuss the approach followed to inform this CID, including the fact that basically the same data were used for threshold determination as well as for final inference which constitute a limitation. Moreover, considering the data submitted from the mentioned analyses, a CID of 10 would appear a more conservative threshold. The CID range was generated using two independent distribution-based methods,

<div style=\"page-break-after: always\"></div>

based on a pooled analysis of Part 1 and Part 2 data at C7D1. The methods used to determine the range of values for a CID were pre-specified in the psychometric analysis SAP and the CID analysis was performed by an independent organisation using blinded data, which is reassuring. The MAH was requested to perform an anchor-based method. However, anchor-based methods were only used to establish thresholds of meaningful within patient change (responder analysis). In this regard, based on the anchor-based method a CID range for the ISM-SAF TSS was considered as clinically relevant. Thus, at a group level, patients receiving avapritinib experienced a change in TSS that can be considered of clinical relevance in contrast to those patients receiving placebo.

Nevertheless, to assess whether between-group differences in ISM-SAF TSS values at C7D1 were clinically meaningful only distribution-based analyses were used. In addition to the above, similar concerns were identified in relation to the suitable threshold for the responder criterion in the primary endpoint, i.e. in terms of interpretation of the clinical relevance of reported statistically significant changes in within-patient score changes in the ISM-SAF TSS. Even if the argumentation that a 30% reduction in the TSS reflects a meaningful within-patient change (MWPC) can be followed, as it aligns with the treatment response criteria of ≥30% proposed by both European and American network/consortium, the relative change strongly depends not only on the absolute improvement but also on the baseline value of the included patients. Indeed, all patients included (albeit a few exceptions) had a baseline TSS above 28, according to the inclusion criteria, with a mean ISM-SAF TSS at baseline around 50. Thus, the MAH was requested to provide the number of patients that achieved a TSS &lt;28 as well as the proportion of patients with ≥30% reduction in ISM -SAF TSS from baseline to C7D1 that achieved a TSS&lt;28. The proportion of patients with TSS&lt;28 at C7D1 (week 24) was higher in the avapritinib arm compared with the placebo arm in the overall population (41.1% avapritinib vs 23.9% placebo) as well as in patients with moderate (60.5% vs 36.4%) and severe (26.4% vs 11.1%) symptoms. Moreover, the proportion of patients who achieved ≥3 0% reduction in TSS and a TSS&lt;28 was also higher in the avapritinib arm (44/141 [31%] avapritinib vs 11/71 [15.5%] placebo). These results are supportive of the primary endpoint and its clinical relevance.

The reported reduction in the dose and/or frequency of BSC medications used by C7D1 was higher in patients treated with avapritinib than in those receiving placebo, i.e. 30 (21.3%) and 9 (12.7%), respectively. Even though these observed trends to decreases of background therapy compared to placebo may not seem very compelling a further analysis of the primary endpoint with BSC as covariate and the results were consistent with the primary analysis.

Results have also been separately reported for the different 'symptom domain clusters' (GI, skin and neurocognitive) showing that the greatest effect apply to the skin symptoms. Indeed, a statistically significant difference was observed in the reduction of the mean skin domain scores between treatment arms (-5.87 and -2.64, for the avapritinib and placebo arms respectively; difference between the groups of -3.23). In contrast, the mean difference from baseline in the score for the GI and neurocognitive domains (-0.60 and -1.22, respectively) were lower and not statistically significant. Data from the analysis of individual symptoms are difficult to interpret but statistically significant differences in the mean change from baseline between the experimental and the placebo group at C7D1 were only seen in the spots severity, itching severity, and flushing severity domains/symptoms. Avapritinib is acknowledged to have beneficial effects across all ISM symptoms, since decreases in systemic measures of mast cell burden have been observed as well as improvements in all symptoms scores and domains, including improvement in most severe symptoms. Patients treated with avapritinib, to a greater or lesser extent, have shown a (higher) decrease in all individual symptoms and symptoms domains compared with placebo, although the highest effect is clearly observed in skin symptoms. Minor differences were observed in the GI domain but it was in fact the one with lower baseline scores. Besides, as pointed out by the MAH, results in other secondary endpoints of measure of mast cell burden also showed a beneficial effect with avapritinib.

<div style=\"page-break-after: always\"></div>

The change in quality of life measures based on different scales/questionnaires (i.e. MC-QoL, PGIS, PGIC, SF-12 and EQ-5D-5L) was assessed as a secondary endpoint in part 2 of study BLU 285-2203. Results seem compatible with an improvement in QoL in avapritinib treated patients.

Anaphylaxis is a common manifestation of disease in ISM. These episodes can be life threatening and are feared by patients who need to carry epinephrine auto-injectors at all times. The inclusion of an (exploratory) endpoint to compare the number of anaphylactic episodes, based on epinephrine use, is therefore welcome. At baseline, 7 (5.0%) patients in the avapritinib group and none in the placebo group had anaphylaxis that required epinephrine treatment. Post baseline, 2 (1.4%) and 3 (4.2%) patients in the avapritinib and placebo group, respectively, had anaphylaxis that required epinephrine treatment. The small sample size and the short duration of part 2 of the study limits the interpretation of this analysis.

## Part 3 - Long-term study

Of the 202 patients that completed Part 2 of the study: 1 patient in the 25 mg avapritinib group completed Part 2 but did not roll over to Part 3. Thus, 201 patients completed Part 2 and rolled over to Part 3. Additionally, 34 patients from part 1 rolled over to part 3. In total, 235 patients rolled over to Part 3 from Part 1 and Part 2 of the study. At the time of the initial data cut-off (23 June 2022), 14 patients have discontinued from Part 3 of the study and 221 patients are ongoing.

At the time of the data cut-off (23 June 2022), mean (SD) treatment duration was almost twice as long in the Part 1/2/3 All 25 mg avapritinib group (10.41 months [7.167]) compared with patients in the 25 mg avapritinib group of Part 2.

As expected, patients who were in the placebo group during Part 1 or Part 2 had higher mast cell burden than the patients who were in the avapritinib groups as assessed by serum tryptase and KIT D816V MAF levels at baseline (before starting part 3).

The results from the long-term open-label Part 3 of the study and in the overall population (Part 1/2/3) submitted seemingly show that the efficacy of avapritinib is maintained beyond C7D1, though interpretation of these data is hampered by the open label nature of this part of the study. Of note, the observed improvement in the ISM-SAF TSS and objective measures of mast cell burden, in patients previously treated with avapritinib who rolled over to avapritinib in part 3, are considered supportive.

Updated efficacy data based on a data cut-off (DCO) date of 07 April 2023 were submitted during the procedure. At the time of this DCO, of the 234 patient who rollover to Part 3, 24 had discontinued study and 211 were ongoing. Results at 48 weeks show an improvement in mean change of TSS and in the proportion of patients achieving ≥ 50% and ≥ 30% reduction in TSS compared with the assessment at 24 weeks. Regarding objective markers of mast cell burden, a decrease in the proportion of patients with a ≥ 50% reduction in serum tryptase and the proportion of patients with a ≥ 50% reduction in KIT D816V MAF was observed. No updated data on bone marrow mast cells have been provided since bone marrow biopsy was optional at week 48 and few patients have results. QoL was overall maintained at 48 weeks. The number of patients with a decrease in the use of BSC medications was higher at week 48 than at week 24 (47 [31.1%] patients vs. 38 [25.2%] patients, respectively). However, no additional patients discontinued BSC medications (4 patients).

Overall, the efficacy of avapritinib appears to be maintained with a longer follow-up although a decrease in the proportion of patients with response in mast cell burden is observed. Since Part 3 is intended to continue for up to 5 years, a commitment to submit results of Part 3 of the study annually was required. The MAH has committed to submit an annual report of study BLU-285-2203 starting in August 2024 and continuing annually until completion of the study as a Post Authorisation Measure (REC).

Of note, with protocol amendment 7 the possibility to increase the dose from 25 mg QD to 50 mg QD in Part 3 of the study was included. Nevertheless, no patient in Part 3 had escalated to 50 mg at the time at

<div style=\"page-break-after: always\"></div>

the initial data cut-off date (i.e. 23 June 2022).  Up to the new data cut-off (07 April 2023) 10 patients had dose escalated to 50 mg. Among patients who dose escalated, TSS improved in the majority of patients (in 2 patients TSS was stable or even increased and for 1 patient no information is provided). Trypsase and KITD816V VAF decreased in all patients in which it was assessed (8 and 5, respectively).

## 2.4.4. Conclusions on the clinical efficacy

Efficacy data show a statistically significant reduction in the mean change from baseline to C7D1 (week 24) in the total symptom score (TSS) using the Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF). The (key) secondary efficacy endpoints also show statistically significant results. The efficacy of avapritinib appears to be maintained in the long term although the interpretation of the data is hampered by the absence of a control arm in Part 3 of the study.

The following measures are considered necessary to address issues related to efficacy:

- Since the study BLU-285-2203 is intended to continue for up to 5 years, the MAH has committed to submit an annual report until completion of the study following recommendation from the CHMP.

## 2.5. Clinical safety

## Introduction

The safety database to support the proposed extension of indication consists of a single, phase II, placebocontrolled study in patients with ISM (study BLU-285-2203). Study BLU-285-2203 is a 3-part, Phase 2, randomized,  double-blind,  placebo-controlled  study  comparing  the  safety  and  efficacy  of  avapritinib  in combination with BSC to placebo in combination with BSC in patients with ISM whose symptoms were not adequately controlled by BSC.

Safety  data  focuses  on  ISM  patients  treated  with  avapritinib  25 mg  QD  or  placebo  in  Part 2  of Study BLU-285-2203. In addition, overall safety data, assessed across all 3 study parts, including patients who received any dose of avapritinib in any part of the study are included.

The data cut-off date for the submission was 23/06/2022. As part of the responses to the CHMP's D120 LOQ, the MAH submitted a safety update (new data cut-off date 07/04/2023) for part 3 of study BLU-285-2203.

Table 56. Overview of the Phase 2 Study BLU-285-2203 Included in the Clinical Summary of Safety

|                  | Part 1                                                                                                       | Part 2                                                                                                                                                                                                                                                                 | Part 3                                                                              |
|------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Status           | Completed                                                                                                    | Completed                                                                                                                                                                                                                                                              | Ongoing (most recent data cutoff of 07 April 2023)                                  |
| Study Design     | Multicenter, randomized, double-blind, placebo-controlled                                                    | Multicenter, randomized, double-blind, placebo-controlled                                                                                                                                                                                                              | Multicenter, open-label, long-term extension                                        |
| Study Objectives | Primary: To determine the RP2D of avapritinib in patients with ISM for use in Part 2 and Part 3 of the study | Primary: To determine mean change in ISM SAF TSS from baseline to C7D1, compared to placebo Key secondary: • To determine the proportion of avapritinib-treated patients with ISM with a ≥ 50% reduction in serum tryptase from baseline to C7D1, compared to placebo. | Primary: To assess the long-term safety and efficacy of avapritinib in ISM patients |

<div style=\"page-break-after: always\"></div>

|                                                             | Part 1                                                                                                             | Part 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Part 3                                                                                                                     |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
|                                                             | Patients with                                                                                                      | • To determine the proportion of avapritinib-treated patients with ISM with a ≥ 50% reduction in peripheral blood KIT D816V allele fraction from baseline to C7D1 or undetectable (< 0.02%) for patients with detectable mutation at baseline, compared to placebo. • To determine the proportion of avapritinib-treated patients with ISM achieving ≥ 50% reduction in ISM-SAF TSS from baseline to C7D1, compared to placebo. • To determine the proportion of avapritinib-treated patients with ISM achieving ≥ 30% reduction in ISM-SAF TSS from baseline to C7D1, compared to placebo. • To determine the proportion of avapritinib-treated patients with a ≥ 50% reduction in bone marrow mast cells from baseline to C7D1 or no aggregates for patients with aggregates at baseline, compared to placebo. |                                                                                                                            |
| Study Population                                            | ISM                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                            |
| Study Drug Doses and Regimens                               | Avapritinib: 25, 50, or 100 mg PO QD Placebo PO QD                                                                 | Avapritinib: 25 mg PO QD (RP2D) Placebo PO QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Avapritinib: 25 mg PO at the same dosing frequency as the last cycle in Part 1 or Part 2                                   |
| Treatment Duration                                          | At least 12 weeks                                                                                                  | 24 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Up to 5 years (including duration of Parts 1 and 2)                                                                        |
| Number of Countries (Sites) with Centers Enrolling Patients | 13 (42)                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                            |
| Number of Patients                                          | Planned: 40 Dosed: 39 Discontinued treatment: 5 Rollover to Part 3: 34                                             | Planned: 204 Dosed: 212 (25 mg Avapritinib: 141; Placebo: 71) Discontinued treatment: 10 (25 mg Avapritinib: 5; Placebo: 5) Rollover to Part 3: 201; 1 patient did not roll over                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Planned: 244 Dosed: 235 Discontinued treatment: 24                                                                         |
| Demographics                                                | 39 patients 9 M/30 F Age: 21-75 years (median: 51 years) White: 92.3%; Asian: 0%; Black: 2.6%; Other/Unknown: 5.1% | 25 mg Avapritinib: 141 patients; 41 M/100 F; median (range) age: 50.0 (18-77) years; White: 77.3%; Asian: 0.7%; Black: 0%; Other/Unknown: 21.9% Placebo: 71 patients; 17 M/54 F; median (range) age:54.0 (26- 79) years; White: 85.9%; Asian: 0%; Black: 0%; Other/Unknown: 14.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 235 patients 64 M/171 F Age: 18-79 years (median: 51.0 years) White: 81.7%; Asian: 0.4%; Black: 0.4%; Other/Unknown: 17.4% |

Abbreviations: C7D1 = Cycle 7 Day 1; F = female; ISM = indolent systemic mastocytosis; ISM-SAF = indolent systemic mastocytosis-symptom  assessment  form;  KIT = V-kit  Hardy-Zuckerman  4  feline  sarcoma  viral  oncogene  homolog; M = male; PO = per os (by mouth); QD = once daily; RP2D = recommended Phase 2 dose; TSS = total symptom score.

<div style=\"page-break-after: always\"></div>

Safety data have been presented separately for Part 2 (placebo-controlled) of study BLU-285-2203 and the overall safety database (all ISM patients included in the study).

## Patient exposure

The  safety population  included 246  patients  who  have  received  at  least  1  dose  of  avapritinib ('All Avapritinib' Group):

- Part 1 (completed) : Identified the recommended phase 2 dose (RP2D), it included 39 patients (placebo: 9; avapritinib 25mg: 10; avapritinib 50mg: 10; avapritinib 100mg: 10), with a median treatment duration  of 15 to 20 weeks.
- Part 2 (completed) : ISM patients were randomly assigned to the avapritinib 25mg QD in combination with BSC (141 patients) or to placebo in combination with BSC (71 patients), with a treatment duration of 24 weeks.
- Part 3 (on-going) : an open label extension cohort in which patients that participated in Part 1 or 2 could join and receive the avapritinib intended dose (25mg QD) with an overall treatment duration of up to 5 years (including Parts 1 and 2). A total of 235 patients have enrolled, including 34 patients from Part 1 and 201 patients who rolled over from Part 2.

A total of 226 patients who only received the 25 mg dose comprise the 'All 25 mg Avapritinib' Group. Of them, 151 patients had received 25 mg avapritinib in Part 1 or Part 2 (and Part 3 if they rolled over), and 75 patients  had  received  placebo  in  Part 1  or  Part 2  and  25 mg  avapritinib  in  Part 3.  Additionally, 10 patients each had received avapritinib 50 mg and 100 mg in Part 1 prior to rollover to 25 mg in Part 3.

Table 57. Summary of Analysis Populations (Part 2 and Part 1/2/3)

| Analysis Population                             | Safety Population, n (%)   |
|-------------------------------------------------|----------------------------|
| Part 2                                          |                            |
| Placebo N = 71                                  | 71 (100.0)                 |
| 25 mg Avapritinib N = 141                       | 141 (100.0)                |
| Overall Data - Part 1/2/3 (Avapritinib Treated) |                            |
| Placebo to 25 mg N = 75                         | 75 (100.0)                 |
| Avapritinib 25 mg to 25 mg/NA N = 151           | 151 (100.0)                |
| All 25 mg Avapritinib N = 226                   | 226 (100.0)                |
| Avapritinib 50 mg to 25 mg/NA N = 10            | 10 (100.0)                 |
| Avapritinib 100 mg to 25 mg/NA N = 10           | 10 (100.0)                 |
| All Avapritinib N = 246                         | 246 (100.0)                |

Abbreviations: NA = not applicable (patients who did not roll over to Part 3). Percentages were based on the number of patients in the Intent-to-Treat Population.

- Disposition

In Part 2 of the study, 5 patients in the 25 mg Avapritinib Group discontinued from the study due to: withdrawal of consent (n=2), AE (n=1), SM clinical progression (n=1), and investigator's decision (n=1). In  the  Placebo  Group,  5  patients  discontinued  due  to:  withdrawal  of  consent  (n=3)  and  other  reasons (n=2).

<div style=\"page-break-after: always\"></div>

A total of 136 patients (96.5%) treated with 25 mg avapritinib and 66 patients (93.0%) treated with placebo completed Part 2 of the study. Of these, 1 patient in the 25 mg Avapritinib Group completed Part 2 but did not roll over to Part 3.

Overall, 235 patients rolled over to Part 3 from Part 1 and Part 2 of the study. At the time of the data cutoff for the updated data (07 April 2023), 24 patients have discontinued from Part 3 of the study and 211 patients are ongoing (Figure 47).

Figure 47. Disposition of Patients in Part 1/2/3 (07 April 2023)

<!-- image -->

Abbreviations: AE = adverse event, SM = systemic mastocytosis.

- Study Drug Exposure

## Part 2 of study BLU 285 2203:

A total of 141 patients were randomized and exposed to 25 mg avapritinib and 71 patients were randomized and exposed to placebo (see table below).

Table 58. Treatment Exposure (Part 2 Safety Population)

| Parameter                        | 25 mg Avapritinib N = 141        | Placebo N = 71                   |
|----------------------------------|----------------------------------|----------------------------------|
| Number of doses administered     | Number of doses administered     | Number of doses administered     |
| n                                | 141                              | 71                               |
| Mean (SD)                        | 163.6 (24.30)                    | 162.4 (26.71)                    |
| Median (min, max)                | 169.0 (20, 195)                  | 168.0 (25, 196)                  |
| Duration of treatment (months) a | Duration of treatment (months) a | Duration of treatment (months) a |
| n                                | 141                              | 71                               |
| Mean (SD)                        | 5.46 (0.726)                     | 5.43 (0.806)                     |
| Median (min, max)                | 5.55 (0.7, 6.5)                  | 5.55 (0.8, 6.4)                  |
| Relative dose intensity b        | Relative dose intensity b        | Relative dose intensity b        |
| n                                | 141                              | NA                               |
| Mean (SD)                        | 99.7 (1.99)                      | NA                               |

<div style=\"page-break-after: always\"></div>

| Parameter         | 25 mg Avapritinib N = 141   | Placebo N = 71   |
|-------------------|-----------------------------|------------------|
| Median (min, max) | 100.0 (83, 101)             | NA               |

Abbreviations: max = maximum; min = minimum; NA = not applicable; SD = standard deviation.   a Duration of Treatment is defined as (treatment end date-treatment start date + 1)/30.4375.  b  Relative Dose Intensity: dose intensity/planned dose intensity. Planned dose intensity is based on initial assigned daily dose. Note: One month is considered to be 30.4375 days.

## Overall Avapritinib Population

The overall data are based on all 246 patients (All Avapritinib Group) who were treated with at least 1 dose of avapritinib in any part of the study (Table 59).

Table 59. Treatment Exposure (Part 1/2/3 [Avapritinib Treated] Safety Population)

|                                         | 23 June 2022 Data Cutoff Date           | 23 June 2022 Data Cutoff Date           | 07 April 2023 Data Cutoff Date          | 07 April 2023 Data Cutoff Date          |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Parameter                               | All 25 mg Avapritinib a N = 226         | All Avapritinib N = 246                 | All 25 mg Avapritinib a N = 226         | All Avapritinib N = 246                 |
| Number of doses administered            | Number of doses administered            | Number of doses administered            | Number of doses administered            | Number of doses administered            |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 311.4 (216.31)                          | 353.1 (269.02)                          | 565.4 (250.41)                          | 600.8 (297.23)                          |
| Median (min, max)                       | 269.5 (11, 1113)                        | 288.0 (4, 1113)                         | 542.0 (20, 1398)                        | 555.5 (4, 1389)                         |
| Duration of treatment (Months) c        | Duration of treatment (Months) c        | Duration of treatment (Months) c        | Duration of treatment (Months) c        | Duration of treatment (Months) c        |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 10.41 (7.167)                           | 11.84 (8.997)                           | 18.91 (8.140)                           | 20.12 (9.770)                           |
| Median (min, max)                       | 8.87 (0.5, 36.7)                        | 9.74 (0.2, 36.7)                        | 18.00 (0.7, 46.1)                       | 18.33 (0.2, 46.1)                       |
| < 6 months, n (%)                       | 53 (23.5)                               | 55 (22.4)                               | 11 (4.9)                                | 13 (5.3)                                |
| ≥ 6 months, n (%)                       | 173 (76.5)                              | 191 (77.6)                              | 215 (95.1)                              | 233 (94.7)                              |
| ≤ 12 months, n (%)                      | 155 (68.6)                              | 158 (64.2)                              | 40 (17.7)                               | 43 (17.5)                               |
| > 12 months, n (%)                      | 71 (31.4)                               | 88 (35.8)                               | 186 (82.3)                              | 203 (82.5)                              |
| Cumulative dose (total dose taken) (mg) | Cumulative dose (total dose taken) (mg) | Cumulative dose (total dose taken) (mg) | Cumulative dose (total dose taken) (mg) | Cumulative dose (total dose taken) (mg) |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 7786.4 (5407.69)                        | 9788.5 (9556.05)                        | 14220.2 (6409.23)                       | 16082.6 (10139.62)                      |
| Median (min, max)                       | 6750.0 (263, 27825)                     | 7300.0 (263, 56900)                     | 13650.0 (500, 42025)                    | 13962.5 (400, 64000)                    |
| Average daily dose (mg)                 | Average daily dose (mg)                 | Average daily dose (mg)                 | Average daily dose (mg)                 | Average daily dose (mg)                 |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 25.0 (0.02)                             | 26.6 (7.57)                             | 25.1 (0.63)                             | 26.6 (7.30)                             |
| Median (min, max)                       | 25.0 (25, 25)                           | 25.0 (25, 100)                          | 25.0 (25, 30)                           | 25.0 (25, 100)                          |
| Dose intensity (mg/day)                 | Dose intensity (mg/day)                 | Dose intensity (mg/day)                 | Dose intensity (mg/day)                 | Dose intensity (mg/day)                 |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 24.6 (1.59)                             | 25.9 (6.49)                             | 24.6 (1.97)                             | 25.8 (6.25)                             |
| Median (min, max)                       | 25.0 (12, 25)                           | 25.0 (12, 88)                           | 25.0 (12, 30)                           | 25.0 (12, 88)                           |
| Relative dose intensity c               | Relative dose intensity c               | Relative dose intensity c               | Relative dose intensity c               | Relative dose intensity c               |
| n                                       | 226                                     | 246                                     | 226                                     | 246                                     |
| Mean (SD)                               | 99.7 (1.83)                             | 99.5 (2.54)                             | 100.2 (2.69)                            | 100.0 (3.17)                            |
| Median (min, max)                       | 100.0 (75, 100)                         | 100.0 (75, 101)                         | 100.0 (91, 122)                         | 100.0 (84, 122)                         |

Abbreviations: max = maximum; min = minimum; NA = not applicable; SD = standard deviation.

a   This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

<div style=\"page-break-after: always\"></div>

- b Duration of Treatment is defined as (treatment end date-treatment start date + 1)/30.4375.

c   Relative Dose Intensity: dose intensity/planned dose intensity. Planned dose intensity is based on initial assigned daily dose.

Note: One month is considered to be 30.4375 days.

- Demographics and other characteristics of the study population (Safety population)

Demographics and Baseline disease characteristics

## Part 2 of study BLU 285 2203:

Table 60. Demographic Characteristics (Part 2 Safety Population)

| Category                                                                                     | 25 mg Avapritinib N = 141                                                                    | Placebo N = 71                                                                               |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Age (years) a                                                                                |                                                                                              |                                                                                              |
| Mean (SD)                                                                                    | 48.7 (11.70)                                                                                 | 52.2 (12.52)                                                                                 |
| Median (min, max)                                                                            | 50.0 (18, 77)                                                                                | 54.0 (26, 79)                                                                                |
| Age group, n (%)                                                                             |                                                                                              |                                                                                              |
| < 65 years                                                                                   | 132 (93.6)                                                                                   | 60 (84.5)                                                                                    |
| ≥ 65 years                                                                                   | 9 (6.4)                                                                                      | 11 (15.5)                                                                                    |
| Sex, n (%)                                                                                   |                                                                                              |                                                                                              |
| Female                                                                                       | 100 (70.9)                                                                                   | 54 (76.1)                                                                                    |
| Male                                                                                         | 41 (29.1)                                                                                    | 17 (23.9)                                                                                    |
| Ethnicity, n (%)                                                                             |                                                                                              |                                                                                              |
| Hispanic or Latino                                                                           | 6 (4.3)                                                                                      | 1 (1.4)                                                                                      |
| Not Hispanic or Latino                                                                       | 99 (70.2)                                                                                    | 58 (81.7)                                                                                    |
| Not reported                                                                                 | 22 (15.6)                                                                                    | 10 (14.1)                                                                                    |
| Unknown                                                                                      | 14 (9.9)                                                                                     | 2 (2.8)                                                                                      |
| Race, n (%)                                                                                  |                                                                                              |                                                                                              |
| Asian                                                                                        | 1 (0.7)                                                                                      | 0                                                                                            |
| White                                                                                        | 109 (77.3)                                                                                   | 61 (85.9)                                                                                    |
| Unknown                                                                                      | 27 (19.1)                                                                                    | 8 (11.3)                                                                                     |
| Other                                                                                        | 4 (2.8)                                                                                      | 2 (2.8)                                                                                      |
| Height (cm)                                                                                  |                                                                                              |                                                                                              |
| n                                                                                            | 137                                                                                          | 70                                                                                           |
| Mean (SD)                                                                                    | 169.05 (9.726)                                                                               | 166.55 (9.073)                                                                               |
| Median (min, max)                                                                            | 167.00 (152.4, 194.0)                                                                        | 165.00 (150.2, 195.0)                                                                        |
| Weight (kg)                                                                                  |                                                                                              |                                                                                              |
| n                                                                                            | 141                                                                                          | 71                                                                                           |
| Mean (SD)                                                                                    | 81.12 (17.915)                                                                               | 82.19 (17.796)                                                                               |
| Median (min, max)                                                                            | 80.20 (45.0, 126.4)                                                                          | 80.70 (44.4, 134.8)                                                                          |
| BMI (kg/m 2 ) b                                                                              |                                                                                              |                                                                                              |
| n                                                                                            | 137                                                                                          | 70                                                                                           |
| Mean (SD)                                                                                    | 28.31 (5.400)                                                                                | 29.46 (5.276)                                                                                |
| Median (min, max)                                                                            | 27.84 (17.6, 42.0)                                                                           | 28.99 (19.7, 43.7)                                                                           |
| Baseline ISM-SAF TSS c (Range:                                                               | 0-110)                                                                                       |                                                                                              |
| n                                                                                            | 139                                                                                          | 71                                                                                           |
| Mean (SD)                                                                                    | 50.17 (19.145)                                                                               | 52.43 (19.823)                                                                               |
| Median (min, max)                                                                            | 47.86 (12.1, 102.7)                                                                          | 47.79 (18.0, 104.4)                                                                          |
| Baseline ISM severity based on ISM-SAF TSS, n (%) d                                          | Baseline ISM severity based on ISM-SAF TSS, n (%) d                                          |                                                                                              |
| ≥ 42 (Severe)                                                                                | 87 (61.7)                                                                                    | 45 (63.4)                                                                                    |
| < 42 (Moderate)                                                                              | 52 (36.9)                                                                                    | 26 (36.6)                                                                                    |
| Baseline Serum Tryptase (ng/mL)                                                              | Baseline Serum Tryptase (ng/mL)                                                              |                                                                                              |
| n                                                                                            | 141                                                                                          | 71                                                                                           |
| Mean (SD)                                                                                    | 57.57 (54.371)                                                                               | 67.57 (74.248)                                                                               |
| Median (min, max)                                                                            | 38.40 (3.6, 256.0)                                                                           | 43.70 (5.7, 501.6)                                                                           |
| Baseline Percent Bone Marrow Mast Cells (Central Pathology                                   | Baseline Percent Bone Marrow Mast Cells (Central Pathology                                   | Review) e                                                                                    |
| n                                                                                            | 141                                                                                          | 71                                                                                           |
| Mean (SD)                                                                                    | 11.03 (11.087)                                                                               | 12.23 (12.611)                                                                               |
| Median (min, max)                                                                            | 7.00 (1.0, 50.0)                                                                             | 7.00 (1.0, 70.0)                                                                             |
| Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central |

<div style=\"page-break-after: always\"></div>

| Category                                                       | 25 mg Avapritinib N = 141                                      | Placebo N = 71                                                 |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| n                                                              | 141                                                            | 71                                                             |
| Mean (SD)                                                      | 2.570 (6.1287)                                                 | 3.570 (7.5691)                                                 |
| Median (min, max)                                              | 0.390 (0.00, 41.29)                                            | 0.260 (0.00, 36.74)                                            |
| Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)     | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)     | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)     |
| n                                                              | 107                                                            | 60                                                             |
| Mean (SD)                                                      | 561.2 (399.65)                                                 | 637.6 (488.71)                                                 |
| Median (min, max)                                              | 459.0 (89, 2870)                                               | 617.5 (83, 2609)                                               |
| Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional) | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional) | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional) |
| n                                                              | 106                                                            | 60                                                             |
| Mean (SD)                                                      | 152.2 (76.28)                                                  | 165.9 (166.00)                                                 |
| Median (min, max)                                              | 131.5 (35, 659)                                                | 129.0 (59, 1337)                                               |

Abbreviations: BMI = body mass index; ddPCR = digital-droplet polymerase chain reaction; ISM = indolent systemic mastocytosis; ISM-SAF = indolent systemic mastocytosis-symptom assessment form; KIT = V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; MAF = minor allele frequency; max = maximum; min = minimum; SD = standard deviation; TSS = total symptom score.

a Age at the time of informed consent.  e  BMI was calculated as weight (kg)/(height (m))^2.  c Baseline TSS score is defined as the 14-day average of TSS from C1D-14 to C1D-1. If a patient is missing more than 7 days of score between C1D-14 and C1D-1, the baseline score is considered as missing for the patient.  d Baseline refers to the last assessment value prior to C1D1 dosing in Part 2 of the study.

## Overall Avapritinib Population

## Table 61. Demographic Characteristics (Part 1/2/3 [Avapritinib Treated] Safety Population)

| Category                              | All 25 mg Avapritinib a N = 226   | All Avapritinib N = 246   |
|---------------------------------------|-----------------------------------|---------------------------|
| Age (years), n b                      |                                   |                           |
| Mean (SD)                             | 49.8 (12.28)                      | 49.7 (12.23)              |
| Median (min, max)                     | 51.0 (18, 79)                     | 51.0 (18, 79)             |
| Age group, n (%)                      |                                   |                           |
| < 65 years                            | 203 (89.8)                        | 222 (90.2)                |
| ≥ 65 years                            | 23 (10.2)                         | 24 (9.8)                  |
| Sex, n (%)                            |                                   |                           |
| Female                                | 166 (73.5)                        | 179 (72.8)                |
| Male                                  | 60 (26.5)                         | 67 (27.2)                 |
| Ethnicity, n (%)                      |                                   |                           |
| Hispanic or Latino                    | 7 (3.1)                           | 8 (3.3)                   |
| Not Hispanic or Latino                | 170 (75.2)                        | 189 (76.8)                |
| Not reported                          | 32 (14.2)                         | 32 (13.0)                 |
| Unknown                               | 17 (7.5)                          | 17 (6.9)                  |
| Race, n (%)                           |                                   |                           |
| Asian                                 | 1 (0.4)                           | 1 (0.4)                   |
| White                                 | 185 (81.9)                        | 202 (82.1)                |
| Unknown                               | 35 (15.5)                         | 37 (15.0)                 |
| Other                                 | 5 (2.2)                           | 5 (2.0)                   |
| Height (cm)                           |                                   |                           |
| n                                     | 221                               | 241                       |
| Mean (SD)                             | 168.25 (9.495)                    | 168.30 (9.626)            |
| Median (min, max)                     | 165.60 (150.2, 195.0)             | 165.90 (142.2, 195.6)     |
| Weight (kg)                           |                                   |                           |
| n                                     | 226                               | 246                       |
| Mean (SD)                             | 81.31 (18.634)                    | 81.29 (18.375)            |
| Median (min, max)                     | 80.10 (44.1, 148.9)               | 80.60 (44.1, 148.9)       |
| BMI (kg/m 2 ) c                       |                                   |                           |
| n                                     | 221                               | 241                       |
| Mean (SD)                             | 28.61 (5.644)                     | 28.58 (5.499)             |
| Median (min, max)                     | 28.10 (17.6, 51.4)                | 28.18 (17.6, 51.4)        |
| Baseline ISM-SAF TSS d (Range: 0-110) |                                   |                           |
| n                                     | 224                               | 244                       |
| Mean (SD)                             | 48.08 (19.465)                    | 48.48 (19.621)            |

<div style=\"page-break-after: always\"></div>

| Category                                                                                            | All 25 mg Avapritinib a N = 226                                                                     | All Avapritinib N = 246                                                                             |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Median (min, max)                                                                                   | 45.04 (5.2, 102.7)                                                                                  | 45.62 (5.2, 102.7)                                                                                  |
| Baseline ISM severity based on ISM-SAF TSS, n (%) d                                                 | Baseline ISM severity based on ISM-SAF TSS, n (%) d                                                 | Baseline ISM severity based on ISM-SAF TSS, n (%) d                                                 |
| ≥ 42 (Severe)                                                                                       | 131 (58.0)                                                                                          | 145 (58.9)                                                                                          |
| < 42 (Moderate)                                                                                     | 93 (41.2)                                                                                           | 99 (40.2)                                                                                           |
| Baseline Serum Tryptase (ng/mL)                                                                     | Baseline Serum Tryptase (ng/mL)                                                                     | Baseline Serum Tryptase (ng/mL)                                                                     |
| n                                                                                                   | 226                                                                                                 | 246                                                                                                 |
| Mean (SD)                                                                                           | 63.38 (70.265)                                                                                      | 67.0 (77.548)                                                                                       |
| Median (min, max)                                                                                   | 39.20 (3.6, 590.4)                                                                                  | 40.25 (3.6, 590.4)                                                                                  |
| Baseline Bone Marrow Mast Cells (Central Pathology Review) e                                        | Baseline Bone Marrow Mast Cells (Central Pathology Review) e                                        | Baseline Bone Marrow Mast Cells (Central Pathology Review) e                                        |
| n                                                                                                   | 226                                                                                                 | 246                                                                                                 |
| Mean (SD)                                                                                           | 11.14 (11.229)                                                                                      | 11.58 (11.761)                                                                                      |
| Median (min, max)                                                                                   | 7.00 (1.0, 60.0)                                                                                    | 7.00 (1.0, 60.0)                                                                                    |
| Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) | Baseline KIT D816V Mutation Allele Burden as Measured by MAF using ddPCR from Blood (Central Assay) |
| n                                                                                                   | 226                                                                                                 | 246                                                                                                 |
| Mean (SD)                                                                                           | 3.097 (6.9739)                                                                                      | 3.154 (7.0658)                                                                                      |
| Median (min, max)                                                                                   | 0.385 (0.00, 41.29)                                                                                 | 0.350 (0.00, 41.29)                                                                                 |
| Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)                                          | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)                                          | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Lesional)                                          |
| n                                                                                                   | 180                                                                                                 | 197                                                                                                 |
| Mean (SD)                                                                                           | 568.3 (439.20)                                                                                      | 579.7 (509.79)                                                                                      |
| Median (min, max)                                                                                   | 451.5 (83, 2870)                                                                                    | 446.0 (53, 4300)                                                                                    |
| Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional)                                      | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional)                                      | Mast Cell (counts/mm 2 ) in Skin by Central Lab (Non-lesional)                                      |
| n                                                                                                   | 179                                                                                                 | 196                                                                                                 |
| Mean (SD)                                                                                           | 166.4 (112.11)                                                                                      | 160.5 (109.98)                                                                                      |
| Median (min, max)                                                                                   | 133.0 (35, 837)                                                                                     | 130.0 (10,837)                                                                                      |

Abbreviations: BMI = body mass index; ddPCR = digital-droplet polymerase chain reaction; ISM = indolent systemic mastocytosis; ISM-SAF = indolent systemic mastocytosis-symptom assessment form; KIT = V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; MAF = minor allele frequency; max = maximum; min = minimum; SD = standard deviation; TSS = total symptom score.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.  b  Age at the time of informed consent.  c  BMI was calculated as weight (kg)/(height (m))^2.  d  Baseline TSS score is defined as the 14-day average of TSS from C1D-14 to C1D-1. If a patient is missing more than 7 days of score between C1D-14 and C1D-1, the baseline score is considered as missing for the patient.  e  Baseline refers to the last assessment value prior to C1D1 dosing in the study. Note: Baseline is defined as the day the first avapritinib dose was received. For the 25 mg avapritinib and all groups, this would be either Part 1 C1D1, Part 2 C1D1, or Part 3 C1D1.

Medical history and concomitant medication

## Part 2 of study BLU 285 2203:

Table 62. Ongoing Medical History in ≥ 10% of Patients Overall (Part 2 Safety Population)

| System Organ Class Preferred Term               | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|-------------------------------------------------|-----------------------------------|------------------------|
| Patients with ongoing medical history           | 141 (100.0)                       | 71 (100.0)             |
| Gastrointestinal Disorders                      | 114 (80.9)                        | 55 (77.5)              |
| Diarrhoea                                       | 85 (60.3)                         | 35 (49.3)              |
| Abdominal pain                                  | 45 (31.9)                         | 21 (29.6)              |
| Nausea                                          | 39 (27.7)                         | 19 (26.8)              |
| Gastrooesophageal reflux disease                | 38 (27.0)                         | 10 (14.1)              |
| Abdominal distension                            | 14 (9.9)                          | 8 (11.3)               |
| Constipation                                    | 13 (9.2)                          | 10 (14.1)              |
| Musculoskeletal and Connective Tissue Disorders | 112 (79.4)                        | 58 (81.7)              |
| Bone pain                                       | 53 (37.6)                         | 28 (39.4)              |
| Arthralgia                                      | 33 (23.4)                         | 7 (9.9)                |
| Osteopenia                                      | 32 (22.7)                         | 9 (12.7)               |
| Osteoporosis                                    | 27 (19.1)                         | 22 (31.0)              |
| Myalgia                                         | 19 (13.5)                         | 9 (12.7)               |
| Back pain                                       | 18 (12.8)                         | 2 (2.8)                |
| Skin and Subcutaneous Tissue Disorders          | 110 (78.0)                        | 52 (73.2)              |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|------------------------------------------------------|-----------------------------------|------------------------|
| Pruritus                                             | 61 (43.3)                         | 31 (43.7)              |
| Urticaria pigmentosa                                 | 50 (35.5)                         | 26 (36.6)              |
| Urticaria                                            | 17 (12.1)                         | 8 (11.3)               |
| Rash maculo-papular                                  | 11 (7.8)                          | 11 (15.5)              |
| General Disorders and Administration Site Conditions | 96 (68.1)                         | 39 (54.9)              |
| Fatigue                                              | 67 (47.5)                         | 30 (42.3)              |
| Feeling abnormal                                     | 37 (26.2)                         | 9 (12.7)               |
| Asthenia                                             | 16 (11.3)                         | 4 (5.6)                |
| Nervous System Disorders                             | 95 (67.4)                         | 44 (62.0)              |
| Headache                                             | 52 (36.9)                         | 26 (36.6)              |
| Dizziness                                            | 29 (20.6)                         | 13 (18.3)              |
| Migraine                                             | 22 (15.6)                         | 9 (12.7)               |
| Memory impairment                                    | 20 (14.2)                         | 8 (11.3)               |
| Disturbance in attention                             | 19 (13.5)                         | 6 (8.5)                |
| Vascular Disorders                                   | 85 (60.3)                         | 48 (67.6)              |
| Flushing                                             | 62 (44.0)                         | 35 (49.3)              |
| Hypertension                                         | 37 (26.2)                         | 15 (21.1)              |
| Metabolism and Nutrition Disorders                   | 76 (53.9)                         | 35 (49.3)              |
| Obesity                                              | 39 (27.7)                         | 20 (28.2)              |
| Psychiatric Disorders                                | 69 (48.9)                         | 30 (42.3)              |
| Depression                                           | 38 (27.0)                         | 14 (19.7)              |
| Anxiety                                              | 27 (19.1)                         | 6 (8.5)                |
| Insomnia                                             | 22 (15.6)                         | 9 (12.7)               |
| Respiratory, Thoracic and Mediastinal Disorders      | 52 (36.9)                         | 24 (33.8)              |
| Asthma                                               | 19 (13.5)                         | 8 (11.3)               |
| Dyspnoea                                             | 15 (10.6)                         | 4 (5.6)                |
| Immune System Disorders                              | 46 (32.6)                         | 24 (33.8)              |
| Drug hypersensitivity                                | 16 (11.3)                         | 6 (8.5)                |
| Endocrine Disorders                                  | 35 (24.8)                         | 15 (21.1)              |
| Hypothyroidism                                       | 26 (18.4)                         | 9 (12.7)               |
| Social Circumstances                                 | 26 (18.4)                         | 15 (21.1)              |
| Menopause                                            | 18 (12.8)                         | 10 (14.1)              |

Abbreviation: MedDRA = Medical Dictionary for Regulatory Activities. Note: Medical history is classified by system organ class and preferred term using MedDRA version 25.0.

## Overall Avapritinib Population

Table 63. Ongoing Medical History in ≥ 10% of Patients Overall (Part 1/2/3 [Avapritinib Treated] Safety Population)

| System Organ Class Preferred Term               | All 25 mg Avapritinib N = 226 n (%)   | All Avapritinib N = 246 n (%)   |
|-------------------------------------------------|---------------------------------------|---------------------------------|
| Patients with ongoing medical history           | 226 (100.0)                           | 246 (100.0)                     |
| Gastrointestinal Disorders                      | 183 (81.0)                            | 199 (80.9)                      |
| Diarrhoea                                       | 129 (57.1)                            | 139 (56.5)                      |
| Abdominal pain                                  | 66 (29.2)                             | 73 (29.7)                       |
| Nausea                                          | 64 (28.3)                             | 69 (28.0)                       |
| Gastrooesophageal reflux disease                | 52 (23.0)                             | 59 (24.0)                       |
| Constipation                                    | 24 (10.6)                             | 26 (10.6)                       |
| Musculoskeletal and Connective Tissue Disorders | 180 (79.6)                            | 197 (80.1)                      |
| Bone pain                                       | 85 (37.6)                             | 96 (39.0)                       |
| Osteoporosis                                    | 53 (23.5)                             | 56 (22.8)                       |
| Osteopenia                                      | 44 (19.5)                             | 50 (20.3)                       |
| Arthralgia                                      | 43 (19.0)                             | 48 (19.5)                       |
| Myalgia                                         | 28 (12.4)                             | 28 (11.4)                       |
| Skin and Subcutaneous Tissue Disorders          | 173 (76.5)                            | 189 (76.8)                      |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | All 25 mg Avapritinib N = 226 n (%)   | All Avapritinib N = 246 n (%)   |
|------------------------------------------------------|---------------------------------------|---------------------------------|
| Pruritus                                             | 99 (43.8)                             | 107 (43.5)                      |
| Urticaria pigmentosa                                 | 80 (35.4)                             | 90 (36.6)                       |
| Urticaria                                            | 25 (11.1)                             | 26 (10.6)                       |
| Nervous System Disorders                             | 147 (65.0)                            | 164 (66.7)                      |
| Headache                                             | 79 (35.0)                             | 92 (37.4)                       |
| Dizziness                                            | 44 (19.5)                             | 46 (18.7)                       |
| Migraine                                             | 34 (15.0)                             | 35 (14.2)                       |
| Memory impairment                                    | 29 (12.8)                             | 34 (13.8)                       |
| Disturbance in attention                             | 26 (11.5)                             | 28 (11.4)                       |
| General Disorders and Administration Site Conditions | 145 (64.2)                            | 155 (63.0)                      |
| Fatigue                                              | 103 (45.6)                            | 111 (45.1)                      |
| Feeling abnormal                                     | 48 (21.2)                             | 52 (21.1)                       |
| Vascular Disorders                                   | 136 (60.2)                            | 147 (59.8)                      |
| Flushing                                             | 98 (43.4)                             | 107 (43.5)                      |
| Hypertension                                         | 53 (23.5)                             | 58 (23.6)                       |
| Metabolism and Nutrition Disorders                   | 119 (52.7)                            | 126 (51.2)                      |
| Obesity                                              | 63 (27.9)                             | 64 (26.0)                       |
| Psychiatric Disorders                                | 106 (46.9)                            | 118 (48.0)                      |
| Depression                                           | 57 (25.2)                             | 60 (24.4)                       |
| Anxiety                                              | 37 (16.4)                             | 43 (17.5)                       |
| Insomnia                                             | 34 (15.0)                             | 43 (17.5)                       |
| Respiratory, Thoracic and Mediastinal Disorders      | 83 (36.7)                             | 94 (38.2)                       |
| Asthma                                               | 27 (11.9)                             | 33 (13.4)                       |
| Immune System Disorders                              | 72 (31.9)                             | 81 (32.9)                       |
| Drug hypersensitivity                                | 23 (10.2)                             | 25 (10.2)                       |
| Social Circumstances                                 | 47 (20.8)                             | 54 (22.0)                       |
| Menopause                                            | 31 (13.7)                             | 33 (13.4)                       |
| Endocrine Disorders                                  | 51 (22.6)                             | 52 (21.1)                       |
| Hypothyroidism                                       | 35 (15.5)                             | 36 (14.6)                       |

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities.  a  This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1. Note: Medical history is classified by system organ class and preferred term using MedDRA version 25.0.

## Concomitant Medications

## Part 2 of study BLU 285 2203:

The majority of patients who had prior treatment with cytoreductive therapies such as tyrosine kinase inhibitors for mastocytosis had 1 prior line of therapy: 19.1% patients in the 25 mg Avapritinib Group and 18.3% patients in the Placebo Group. A few patients in both groups had 2 to 3 prior lines of mastocytosis therapy. The most commonly reported concomitant BSC medication/therapies included medications such as proton pump inhibitors and H2 blockers, antihistamines for systemic use, leukotriene inhibitors and antiIgE antibodies, intestinal anti-inflammatory agents such as oral cromolyn, and corticosteroids for systemic use. Most commonly reported concomitant BSC medication/therapies included drugs for peptic ulcer and gastrooesophageal reflux disease (12.1% and 12.7%), antihistamines for systemic use (10.6% and 9.9%), intestinal anti-inflammatory agents (10.6% and 7.0%), corticosteroids for systemic use (9.9% and 2.8%), and other systemic drugs for obstructive airway diseases (6.4% and 4.2%).

The majority of patients in the Part 2 safety population received concomitant medication/therapy other than BSC (97.9% in the 25 mg Avapritinib Group and 100% in the Placebo Group). The use of concomitant medications by WHO drug classification ATC class 3 was similar between the treatment groups. The most common concomitant medication/therapies used were viral vaccine (43.3% in the 25 mg Avapritinib Group and 43.7% in the Placebo Group), other analgesics and antipyretics (36.2% in the 25 mg Avapritinib Group

<div style=\"page-break-after: always\"></div>

and 35.2% in the Placebo Group). Antidepressants and anxiolytic medications were also used often (19.1% and 16.3% in the 25 mg Avapritinib Group and 21.1% and 22.5% in the Placebo Group, respectively). The use of opioids was similar between the 2 groups: 22.0% in the 25 mg Avapritinib Group and 22.5% in the Placebo Group.

## Overall Avapritinib Population

Prior mastocytosis therapy, concomitant BSC medication, and use of concomitant medication other than BSC for the Overall Avapritinib Population (Part 1/2/3) which included patients who rolled over to Part 3 from Parts 1 and 2 were consistent with the use of these medications/therapies in Part 2.

## Adverse events

## Overall Adverse Events

## Part 2 of study BLU 285 2203

Table 64. Summary of Adverse Events (Part 2 Safety Population)

| Patients with at Least One Event                              | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|---------------------------------------------------------------|-----------------------------------|------------------------|
| Any AE                                                        | 128 (90.8)                        | 66 (93.0)              |
| AE related to study drug                                      | 77 (54.6)                         | 32 (45.1)              |
| SAE                                                           | 7 (5.0)                           | 8 (11.3)               |
| SAE related to study drug                                     | 0                                 | 0                      |
| Grade 1 AE                                                    | 48 (34.0)                         | 15 (21.1)              |
| Grade 1 AE related to study drug                              | 56 (39.7)                         | 20 (28.2)              |
| Grade 2 AE                                                    | 50 (35.5)                         | 36 (50.7)              |
| Grade 2 AE related to study drug                              | 18 (12.8)                         | 10 (14.1)              |
| Grade ≥ 3 AE                                                  | 30 (21.3)                         | 15 (21.1)              |
| Grade ≥ 3 AE related to study drug                            | 3 (2.1)                           | 2 (2.8)                |
| AE leading to interruption of study drug                      | 12 (8.5)                          | 9 (12.7)               |
| Related AE leading to interruption of study drug              | 5 (3.5)                           | 4 (5.6)                |
| AE leading to dose reduction of study drug                    | 2 (1.4)                           | 1 (1.4)                |
| Related AE leading to dose reduction of study drug            | 1 (0.7)                           | 1 (1.4)                |
| AE leading to permanent discontinuation of study drug         | 3 (2.1)                           | 1 (1.4)                |
| Related AE leading to permanent discontinuation of study drug | 2 (1.4)                           | 1 (1.4)                |
| Death                                                         | 0                                 | 0                      |

Abbreviations: AE = adverse event; SAE = serious adverse event. Notes: All AEs are Treatment Emergent AEs. Treatment Emergent AE was defined as any AE that occurred between the Part 2 Day 1 through a day prior to Part 3 Day 1, or through 30 days after the last dose if patient did not rollover to Part 3. Each patient is counted only once and with the highest severity grade. Relationship to study drug is as per the Investigator assessment.

## Overall Avapritinib Population

Table 65. Summary of Adverse Events (Part 1/2/3 [Avapritinib Treated] Safety Population)

|                                  | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|----------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Patients with at least one event | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with at least 1 AE      | 202 (89.4)                          | 221 (89.8)                      | 223 (98.7)                          | 242 (98.4)                       |
| AE related to study drug         | 130 (57.5)                          | 147 (59.8)                      | 151 (66.8)                          | 168 (68.3)                       |
| SAE                              | 24 (10.6)                           | 30 (12.2)                       | 31 (13.7)                           | 38 (15.4)                        |
| SAE related to study drug        | 1 (0.4)                             | 2 (0.8)                         | 2 (0.9)                             | 3 (1.2)                          |
| Grade 1 AE                       | 58 (25.7)                           | 58 (23.6)                       | 38 (16.8)                           | 38 (15.4)                        |
| Grade 1 AE related to study drug | 82 (36.3)                           | 87 (35.4)                       | 92 (40.7)                           | 97 (39.4)                        |

<div style=\"page-break-after: always\"></div>

|                                                               | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|---------------------------------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Patients with at least one event                              | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Grade 2 AE                                                    | 86 (38.1)                           | 91 (37.0)                       | 99 (43.8)                           | 102 (41.5)                       |
| Grade 2 AE related to study drug                              | 42 (18.6)                           | 49 (19.9)                       | 48 (21.2)                           | 55 (22.4)                        |
| Grade ≥ 3 AE                                                  | 58 (25.7)                           | 72 (29.3)                       | 86 (38.1)                           | 102 (41.5)                       |
| Grade ≥ 3 AE related to study drug                            | 6 (2.7)                             | 11 (4.5)                        | 11 (4.9)                            | 16 (6.5)                         |
| AE leading to interruption of study drug                      | 26 (11.5)                           | 37 (15.0)                       | 38 (16.8)                           | 49 (19.9)                        |
| Related AE leading to interruption of study drug              | 13 (5.8)                            | 20 (8.1)                        | 18 (8.0)                            | 25 (10.2)                        |
| AE leading to reduction of study drug                         | 7 (3.1)                             | 11 (4.5)                        | 13 (5.8)                            | 17 (6.9)                         |
| Related AE leading to reduction of study drug                 | 5 (2.2)                             | 9 (3.7)                         | 11 (4.9)                            | 15 (6.1)                         |
| AE leading to permanent discontinuation of study drug         | 7 (3.1)                             | 8 (3.3)                         | 12 (5.3)                            | 13 (5.3)                         |
| Related AE leading to permanent discontinuation of study drug | 4 (1.8)                             | 5 (2.0)                         | 6 (2.7)                             | 7 (2.8)                          |
| Death                                                         | 0                                   | 0                               | 1 (0.4)                             | 1 (0.4)                          |

Abbreviations: AE = adverse event; SAE = serious adverse event.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

Notes: All AEs are Treatment Emergent AEs. Treatment Emergent AE was defined as any AE that occurred between the Part 2 Day 1 through a day prior to Part 3 Day 1, or through 30 days after the last dose if patient did not rollover to Part 3. Each patient is counted only once and with the highest severity grade.

Relationship to study drug is as per the Investigator assessment.

## Common Adverse Events

## Part 2 of study BLU 285 2203

The most commonly reported AEs across both groups (≥ 10%) included headache, nausea, COVID-19, dizziness, and diarrhea. Of these events, COVID-19 and dizziness had a slightly higher incidence in the 25 mg Avapritinib Group compared to the Placebo Group.

Table 66. Adverse Events in ≥ 5% of Patients in Either Treatment Group by Preferred Term (Part 2 Safety Population)

| Preferred Term                       | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|--------------------------------------|-----------------------------------|------------------------|
| Patients with any AEs                | 128 (90.8)                        | 66 (93.0)              |
| Headache                             | 27 (19.1)                         | 14 (19.7)              |
| Nausea                               | 18 (12.8)                         | 12 (16.9)              |
| COVID-19                             | 17 (12.1)                         | 8 (11.3)               |
| Dizziness                            | 16 (11.3)                         | 6 (8.5)                |
| Diarrhoea                            | 15 (10.6)                         | 8 (11.3)               |
| Fatigue                              | 14 (9.9)                          | 6 (8.5)                |
| Flushing                             | 13 (9.2)                          | 3 (4.2)                |
| Oedema peripheral                    | 12 (8.5)                          | 3 (4.2)                |
| Arthralgia                           | 11 (7.8)                          | 5 (7.0)                |
| Pruritus                             | 11 (7.8)                          | 5 (7.0)                |
| Face oedema                          | 10 (7.1)                          | 1 (1.4)                |
| Blood alkaline phosphatase increased | 9 (6.4)                           | 1 (1.4)                |
| Periorbital oedema                   | 9 (6.4)                           | 2 (2.8)                |
| Abdominal pain                       | 8 (5.7)                           | 4 (5.6)                |

<div style=\"page-break-after: always\"></div>

| Preferred Term                     | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|------------------------------------|-----------------------------------|------------------------|
| Insomnia                           | 8 (5.7)                           | 2 (2.8)                |
| Alanine aminotransferase increased | 7 (5.0)                           | 2 (2.8)                |
| Alopecia                           | 6 (4.3)                           | 4 (5.6)                |
| Hypertension                       | 6 (4.3)                           | 5 (7.0)                |
| Nasopharyngitis                    | 6 (4.3)                           | 5 (7.0)                |
| Vomiting                           | 6 (4.3)                           | 4 (5.6)                |
| Urinary tract infection            | 5 (3.5)                           | 5 (7.0)                |

Abbreviations: AE = adverse event; COVID-19 = Coronavirus disease 2019; MedDRA = Medical Dictionary for Regulatory Activities. Note: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

Of all AEs reported, face oedema was the only AE that had a higher incidence in the 25 mg Avapritinib Group compared to the Placebo Group by greater than 5% (7.1% vs 1.4%; Table 67).

Table 67. Summary of Grouped Oedema Events (Part 2 Safety Population)

| Adverse Drug Reaction Term   | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|------------------------------|-----------------------------------|------------------------|
| Eye edema                    | 18 (12.8)                         | 5 (7.0)                |
| Peripheral edema             | 17 (12.1)                         | 4 (5.6)                |
| Face oedema                  | 10 (7.1)                          | 1 (1.4)                |
| General edema                | 4 (2.8)                           | 0                      |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; PT = Preferred term. Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same group. Pooled terms are as follows: Eye edema: Periorbital oedema, Eyelid oedema, Swelling of eyelid, Eye oedema, Orbital oedema, Eye swelling. General Edema: Fluid retention, Generalised oedema, Oedema. Peripheral Edema: Oedema peripheral, Peripheral swelling. Note: Face oedema is a PT and not a pooled term. Relationship to study drug is as per the Investigator assessment.

## Overall Avapritinib Population

The most commonly reported AEs (by PT) occurring in ≥ 10%  of the  226 patients in the All 25 mg Avapritinib Group were COVID-19, headache, nausea, diarrhoea, dizziness, pruritus, fatigue, and oedema peripheral, (table 68). The incidence of AEs in the All Avapritinib Group was similar to that of the All 25 mg Avapritinib Group. Data for the overall Avapritinib Group (n= 246) are similar.

Table 68. Adverse  Events  in  ≥  5%  of  Patients  by  Preferred  Term  (Part 1/2/3  [Avapritinib Treated] Safety Population)

|                                      | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|--------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                       | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with any AEs                | 202 (89.4)                          | 221 (89.8)                      | 223 (98.7)                          | 242 (98.4)                       |
| COVID-19                             | 50 (22.1)                           | 57 (23.2)                       | 92 (40.7)                           | 99 (40.2)                        |
| Headache                             | 41 (18.1)                           | 50 (20.3)                       | 50 (22.1)                           | 58 (23.6)                        |
| Nausea                               | 31 (13.7)                           | 43 (17.5)                       | 39 (17.3)                           | 50 (20.3)                        |
| Diarrhoea                            | 26 (11.5)                           | 34 (13.8)                       | 37 (16.4)                           | 45 (18.3)                        |
| Dizziness                            | 31 (13.7)                           | 39 (15.9)                       | 33 (14.6)                           | 41 (16.7)                        |
| Pruritus                             | 24 (10.6)                           | 29 (11.8)                       | 36 (15.9)                           | 41 (16.7)                        |
| Fatigue                              | 24 (10.6)                           | 29 (11.8)                       | 32 (14.2)                           | 37 (15.0)                        |
| Oedema peripheral                    | 25 (11.1)                           | 30 (12.2)                       | 32 (14.2)                           | 37 (15.0)                        |
| Arthralgia                           | 20 (8.8)                            | 25 (10.2)                       | 29 (12.8)                           | 34 (13.8)                        |
| Blood alkaline phosphatase increased | 19 (8.4)                            | 20 (8.1)                        | 23 (10.2)                           | 26 (10.6)                        |

<div style=\"page-break-after: always\"></div>

|                                    | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                     | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Flushing                           | 22 (9.7)                            | 24 (9.8)                        | 24 (10.6)                           | 26 (10.6)                        |
| Periorbital oedema                 | 17 (7.5)                            | 22 (8.9)                        | 21 (9.3)                            | 26 (10.6)                        |
| Back pain                          | 14 (6.2)                            | 19 (7.7)                        | 20 (8.8)                            | 25 (10.2)                        |
| Hypertension                       | 19 (8.4)                            | 20 (8.1)                        | 23 (10.2)                           | 25 (10.2)                        |
| Abdominal pain                     | 16 (7.1)                            | 19 (7.7)                        | 21 (9.3)                            | 24 (9.8)                         |
| Insomnia                           | 19 (8.4)                            | 21 (8.5)                        | 22 (9.7)                            | 24 (9.8)                         |
| Upper respiratory tract infection  | 10 (4.4)                            | 14 (5.7)                        | 19 (8.4)                            | 23 (9.3)                         |
| Vomiting                           | 9 (4.0)                             | 13 (5.3)                        | 19 (8.4)                            | 23 (9.3)                         |
| Weight increased                   | 14 (5.7)                            | 14 (5.7)                        | 19 (8.4)                            | 22 (8.9)                         |
| Nasopharyngitis                    | 14 (5.7)                            | 14 (5.7)                        | 20 (8.8)                            | 21 (8.5)                         |
| Urinary tract infection            | 11 (4.9)                            | 13 (5.3)                        | 17 (7.5)                            | 20 (8.1)                         |
| Constipation                       | 13 (5.8)                            | 16 (6.5)                        | 16 (7.1)                            | 19 (7.7)                         |
| Anaphylactic reaction              | 9 (4.0)                             | 15 (6.1)                        | 12 (5.3)                            | 18 (7.3)                         |
| Face oedema                        | 14 (6.2)                            | 19 (7.7)                        | 13 (5.8)                            | 18 (7.3)                         |
| Hypersensitivity                   | 6 (2.7)                             | 10 (4.1)                        | 13 (5.8)                            | 17 (6.9)                         |
| Rash                               | 11 (4.9)                            | 12 (4.9)                        | 16 (7.1)                            | 17 (6.9)                         |
| Sinusitis                          | 10 (4.4)                            | 11 (4.5)                        | 16 (7.1)                            | 17 (6.9)                         |
| Abdominal distension               | 12 (5.3)                            | 13 (5.3)                        | 15 (6.6)                            | 16 (6.5)                         |
| Pain in extremity                  | 6 (2.7)                             | 9 (3.7)                         | 13 (5.8)                            | 16 (6.5)                         |
| Alopecia                           | 12 (5.3)                            | 13 (5.3)                        | 14 (6.2)                            | 15 (6.1)                         |
| Cough                              | 10 (4.4)                            | 10 (4.1)                        | 15 (6.6)                            | 15 (6.1)                         |
| Disturbance in attention           | 9 (4.0)                             | 11 (4.5)                        | 13 (5.8)                            | 15 (6.1)                         |
| Fall                               | 6 (2.7)                             | 9 (3.7)                         | 12 (5.3)                            | 15 (6.1)                         |
| Palpitations                       | 11 (4.9)                            | 13 (5.3)                        | 13 (5.8)                            | 15 (6.1)                         |
| Dyspnoea                           | 9 (4.0)                             | 13 (5.3)                        | 10 (4.4)                            | 14 (5.7)                         |
| Peripheral swelling                | 10 (4.4)                            | 12 (4.9)                        | 12 (5.3)                            | 14 (5.7)                         |
| Alanine aminotransferase increased | 8 (3.5)                             | 11 (4.5)                        | 10 (4.4)                            | 13 (5.3)                         |
| Blood creatinine increased         | 8 (3.5)                             | 9 (3.7)                         | 12 (5.3)                            | 13 (5.3)                         |
| Bone pain                          | 9 (4.0)                             | 10 (4.1)                        | 12 (5.3)                            | 13 (5.3)                         |
| Paraesthesia                       | 7 (3.1)                             | 11 (4.5)                        | 9 (4.0)                             | 13 (5.3)                         |
| Contusion                          | 11 (4.9)                            | 11 (4.5)                        | 12 (5.3)                            | 12 (4.9)                         |

Abbreviations: AE = adverse event; COVID-19 = Coronavirus disease 2019; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

Note: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

## Adverse Events by Severity

## Part 2 of study BLU 285 2203

Most of the patients experienced Grade 1 or 2 AEs in both treatment groups.

In the 25 mg Avapritinib Group, 48 patients (34.0%) experienced Grade 1 AEs, 50 patients (35.5%) had Grade  2  AEs,  28 patients  (19.9%)  had  Grade 3  AEs,  and  2 patients  (1.4%)  had  Grade 4  AEs.  In  the Placebo Group,  15 patients  (21.1%)  experienced  Grade 1  AEs,  36 patients  (50.7%)  had  Grade 2  AEs, 15 patients (21.1%) had Grade 3 AEs, and no patients had Grade 4 AEs.

In  the  25 mg Avapritinib Group,  1 patient  experienced  a  Grade 4  event  of  acute  myeloid  leukaemia associated with a Grade 4 event of neutrophil count decreased, both were assessed as not related to study drug by the Investigator. The other Grade 4 event was hypokalaemia that occurred in a patient with a medical history of intermittent diarrhoea and was assessed as not related to study drug by the Investigator.

<div style=\"page-break-after: always\"></div>

The most commonly reported Grade 3 event was anaphylactic reaction, reported in 4 patients (2.8%); the event was assessed as not related to study drug by the Investigator in all 4 patients. Anaphylactic reaction is a common clinical manifestation of ISM. All other Grade 3 AEs were reported in 1 or 2 patients. Most Grade 3 AEs were assessed as not related by the Investigator. The only related Grade 3 AEs were blood alkaline phosphatase increased, disturbance in attention, and neutrophil count decreased, all reported in 1 patient (0.7%) each.

In the Placebo Group, the most commonly reported Grade 3 event was anaphylactic reaction in 3 patients (4.2%) and was assessed as not related to study drug in all cases. All other Grade 3 AEs were reported in 1  or  2 patients  each.  Most  of  the  Grade 3  AEs  were  assessed  as  not  related  to  study  drug  by  the Investigator. The only related Grade 3 AEs were headache, diarrhea, and anxiety, all reported in 1 patient (1.4%) each.

## Overall Avapritinib Population

Of  the  226 patients  in  the  25 mg Avapritinib  Group,  86 patients  (38.1%)  experienced  Grade ≥3  AEs. Grade ≥3 anaphylactic reaction AEs were reported in 12 patients (5.3%), in all cases they were assessed as not related to study drug by the Investigator. Grade ≥3 hypertension AEs were reported in 10 patients (4.4%). The types and incidences of AEs by severity grade in the All Avapritinib Group were similar to those in the All 25 mg Avapritinib Group and no trends or concerns were identified.

In the All 25 mg Avapritinib Group, most of the patients experienced Grade 1 or Grade 2 AEs (Table 69). An increase of ≥ 10% compared with the original submission was noted for Grade ≥ 3 AEs (25.7% vs 38.1%), however the  incidence  of  related  Grade ≥ 3  AEs  remained  similar  to  what  was  reported  in  the  original submission (2.7% vs 4.9%). One new related SAE and one not related death were reported in the update period.

Table 69. Grade ≥ 3 Adverse Events Occurring in More than One Patient by Preferred Term (Part 1/2/3 [Avapritinib Treated] Safety Population)

|                                                 | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|-------------------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                                  | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with at least one grade 3 or higher AE | 58 (25.7)                           | 72 (29.3)                       | 86 (38.1)                           | 102 (41.5)                       |
| Anaphylactic reaction                           | 9 (4.0)                             | 14 (5.7)                        | 12 (5.3)                            | 18 (7.3)                         |
| Hypertension                                    | 5 (2.2)                             | 5 (2.0)                         | 10 (4.4)                            | 10 (4.1)                         |
| Diarrhoea                                       | 2 (0.9)                             | 4 (1.6)                         | 5 (2.2)                             | 7 (2.8)                          |
| Hypersensitivity                                | 1 (0.4)                             | 3 (1.2)                         | 5 (2.2)                             | 7 (2.8)                          |
| Arthralgia                                      | 1 (0.4)                             | 4 (1.6)                         | 3 (1.3)                             | 6 (2.4)                          |
| Abdominal pain                                  | 3 (1.3)                             | 3 (1.2)                         | 4 (1.8)                             | 4 (1.6)                          |
| Headache                                        | 0                                   | 2 (0.8)                         | 2 (0.9)                             | 4 (1.6)                          |
| Neutrophil count decreased                      | 2 (0.9)                             | 2 (0.8)                         | 4 (1.8)                             | 4 (1.6)                          |
| Dizziness                                       | 2 (0.9)                             | 2 (0.8)                         | 3 (1.3)                             | 3 (1.2)                          |
| Mast cell activation syndrome                   | 2 (0.9)                             | 2 (0.8)                         | 3 (1.3)                             | 3 (1.2)                          |
| Mastocytosis                                    | 2 (0.9)                             | 2 (0.8)                         | 3 (1.3)                             | 3 (1.2)                          |
| Migraine                                        | 2 (0.9)                             | 2 (0.8)                         | 3 (1.3)                             | 3 (1.2)                          |
| Syncope                                         | 3 (1.3)                             | 3 (1.2)                         | 3 (1.3)                             | 3 (1.2)                          |
| Weight increased                                | 0                                   | 0                               | 3 (1.3)                             | 3 (1.2)                          |
| Anaphylactic shock                              | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |

<div style=\"page-break-after: always\"></div>

|                                | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|--------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                 | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Back pain                      | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Bone pain                      | 1 (0.4)                             | 1 (0.4)                         | 1 (0.4)                             | 2 (0.8)                          |
| COVID-19                       | 0                                   | 1 (0.4)                         | 1 (0.4)                             | 2 (0.8)                          |
| COVID-19 pneumonia             | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| Disturbance in attention       | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Electrocardiogram QT prolonged | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Fall                           | 0                                   | 1 (0.4)                         | 0                                   | 2 (0.8)                          |
| Flushing                       | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| Gastroenteritis                | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Gastrointestinal disorder      | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Hypokalaemia                   | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Mastocytic leukaemia           | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Nephrolithiasis                | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Pancreatitis acute             | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Pruritus                       | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| Rash maculo-papular            | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| Tooth abscess                  | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Tooth infection                | 1 (0.4)                             | 1 (0.4)                         | 1 (0.4)                             | 2 (0.8)                          |

Abbreviations: AE = adverse event; COVID-19 = Coronavirus disease 2019; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

## Adverse Events by Relationship to Study Drug

## Part 2 of study BLU 285 2203

In Part 2, the incidence of AEs assessed as related to study drug by the Investigator was higher in the 25 mg Avapritinib Group (54.6%) than in the Placebo Group (45.1%).

## Table 70. Related Adverse Events in ≥ 2% of Patients in Either Treatment Group by Preferred Term (Part 2 Safety Population)

| Preferred Term                       | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|--------------------------------------|-----------------------------------|------------------------|
| Patients with any AEs                | 77 (54.6)                         | 32 (45.1)              |
| Headache                             | 11 (7.8)                          | 7 (9.9)                |
| Nausea                               | 9 (6.4)                           | 6 (8.5)                |
| Oedema peripheral                    | 9 (6.4)                           | 1 (1.4)                |
| Periorbital oedema                   | 9 (6.4)                           | 2 (2.8)                |
| Fatigue                              | 6 (4.3)                           | 2 (2.8)                |
| Flushing                             | 6 (4.3)                           | 0                      |
| Alopecia                             | 5 (3.5)                           | 3 (4.2)                |
| Blood alkaline phosphatase increased | 5 (3.5)                           | 0                      |
| Contusion                            | 5 (3.5)                           | 0                      |
| Eyelid oedema                        | 5 (3.5)                           | 1 (1.4)                |
| Face oedema                          | 5 (3.5)                           | 0                      |

<div style=\"page-break-after: always\"></div>

| Preferred Term                        | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|---------------------------------------|-----------------------------------|------------------------|
| Aspartate aminotransferase increased  | 4 (2.8)                           | 1 (1.4)                |
| Diarrhoea                             | 4 (2.8)                           | 2 (2.8)                |
| Dizziness                             | 4 (2.8)                           | 5 (7.0)                |
| Hair colour changes                   | 4 (2.8)                           | 1 (1.4)                |
| Photosensitivity reaction             | 4 (2.8)                           | 0                      |
| Alanine aminotransferase increased    | 3 (2.1)                           | 1 (1.4)                |
| Blood lactate dehydrogenase increased | 3 (2.1)                           | 0                      |
| Dry mouth                             | 3 (2.1)                           | 1 (1.4)                |
| Muscle spasms                         | 3 (2.1)                           | 0                      |
| Disturbance in attention              | 2 (1.4)                           | 2 (2.8)                |
| Weight increased                      | 1 (0.7)                           | 2 (2.8)                |
| Eye pain                              | 0                                 | 2 (2.8)                |
| Paraesthesia                          | 0                                 | 2 (2.8)                |
| Vision blurred                        | 0                                 | 2 (2.8)                |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities. Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term. Relationship to study drug is as per the Investigator assessment.

## Overall Avapritinib Population

The  most  common  studydrug  related  AEs  (as  assessed  by  the  Investigator)  reported  in  ≥ 5% of  the 226 patients in the All 25 mg Avapritinib Group, were headache, oedema peripheral, nausea, and periorbital oedema (table 71).

Table 2 71. Related  Adverse  Events  in  ≥  2%  of  Patients  by  Preferred  Term  (Part 1/2/3 [Avapritinib Treated] Safety Population)

|                                      | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|--------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                       | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with any AEs                | 130 (57.5)                          | 147 (59.8)                      | 151 (66.8)                          | 168 (68.3)                       |
| Oedema peripheral                    | 18 (8.0)                            | 23 (9.3)                        | 23 (10.2)                           | 28 (11.4)                        |
| Nausea                               | 17 (7.5)                            | 28 (11.4)                       | 17 (7.5)                            | 27 (11.0)                        |
| Headache                             | 18 (8.0)                            | 24 (9.8)                        | 20 (8.8)                            | 25 (10.2)                        |
| Periorbital oedema                   | 16 (7.1)                            | 21 (8.5)                        | 18 (8.0)                            | 23 (9.3)                         |
| Face oedema                          | 8 (3.5)                             | 13 (5.3)                        | 8 (3.5)                             | 13 (5.3)                         |
| Fatigue                              | 10 (4.4)                            | 12 (4.9)                        | 11 (4.9)                            | 13 (5.3)                         |
| Diarrhoea                            | 7 (3.1)                             | 9 (3.7)                         | 10 (4.4)                            | 12 (4.9)                         |
| Dizziness                            | 10 (4.4)                            | 13 (5.3)                        | 9 (4.0)                             | 12 (4.9)                         |
| Alopecia                             | 10 (4.4)                            | 10 (4.1)                        | 11 (4.9)                            | 11 (4.5)                         |
| Hair colour changes                  | 7 (3.1)                             | 10 (4.1)                        | 7 (3.1)                             | 11 (4.5)                         |
| Blood alkaline phosphatase increased | 7 (3.1)                             | 8 (3.3)                         | 8 (3.5)                             | 9 (3.7)                          |
| Weight increased                     | 5 (2.2)                             | 5 (2.0)                         | 9 (4.0)                             | 9 (3.7)                          |
| Eyelid oedema                        | 6 (2.7)                             | 6 (2.4)                         | 8 (3.5)                             | 8 (3.3)                          |
| Aspartate aminotransferase increased | 4 (1.8)                             | 5 (2.0)                         | 6 (2.7)                             | 7 (2.8)                          |
| Blood creatinine increased           | 4 (1.8)                             | 4 (1.6)                         | 7 (3.1)                             | 7 (2.8)                          |
| Contusion                            | 7 (3.1)                             | 7 (2.8)                         | 7 (3.1)                             | 7 (2.8)                          |
| Disturbance in attention             | 4 (1.8)                             | 5 (2.0)                         | 6 (2.7)                             | 7 (2.8)                          |
| Flushing                             | 7 (3.1)                             | 7 (2.8)                         | 7 (3.1)                             | 7 (2.8)                          |

<div style=\"page-break-after: always\"></div>

|                                    | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                     | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Alanine aminotransferase increased | 3 (1.3)                             | 4 (1.6)                         | 5 (2.2)                             | 6 (2.4)                          |
| Hypophosphataemia                  | 1 (0.4)                             | 1 (0.4)                         | 4 (1.8)                             | 6 (2.4)                          |
| Muscle spasms                      | 4 (1.8)                             | 5 (2.0)                         | 5 (2.2)                             | 6 (2.4)                          |
| Palpitations                       | 5 (2.2)                             | 6 (2.4)                         | 5 (2.2)                             | 6 (2.4)                          |
| Photosensitivity reaction          | 4 (1.8)                             | 4 (1.6)                         | 6 (2.7)                             | 6 (2.4)                          |
| Decreased appetite                 | 3 (1.3)                             | 5 (2.0)                         | 3 (1.3)                             | 5 (2.0)                          |
| Hypertension                       | 2 (0.9)                             | 3 (1.2)                         | 4 (1.8)                             | 5 (2.0)                          |
| Lacrimation increased              | 3 (1.3)                             | 3 (1.2)                         | 4 (1.8)                             | 5 (2.0)                          |
| Vomiting                           | 1 (0.4)                             | 3 (1.2)                         | 3 (1.3)                             | 5 (2.0)                          |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

Relationship to study drug is as per the Investigator assessment.

Data for the overall Avapritinib Group (n= 246) were consistent.

## Analysis of Adverse Events by Organ System or Syndrome

## Part 2 of study BLU 285 2203

In the 25 mg Avapritinib Group, the SOC in which most patients experienced AEs was Nervous System Disorders  (54 patients  [38.3%]),  followed  by  Gastrointestinal  Disorders  (52  patients  [36.9%]).  In  the Placebo  Group,  these  were  also  the  most  common  SOCs  (24  patients  [33.8%]  and  27  [38.0%], respectively). This likely reflects the burden of the underlying disease.

The SOC in which most patients experienced SAEs was Infections and Infestations (2 patients [1.4%]) in the 25 mg Avapritinib Group, and Infections and Infestations (3 patients [4.2%]) and Immune System Disorders (2 patients [2.8%]) in the Placebo Group. In other SOCs, only 1 patient each experienced an SAE. None of the SAEs were assessed as related to study drug by the Investigator.

The SOC in which patients had dose reductions were Gastrointestinal Disorders, General Disorders and Administration Site Conditions, and Nervous System Disorders in the 25 mg Avapritinib Group and Nervous System Disorders in the Placebo Group. All were reported in 1 patient each and the event in the Nervous System Disorders SOC (memory impairment) was assessed as related to study drug by the Investigator in both patients in the 25 mg Avapritinib Group and the Placebo Group.

The SOC in which most patients in the 25 mg Avapritinib Group had AEs leading to permanent study drug discontinuation was Nervous System Disorders (2 patients [1.4%]). The events were assessed as related to study drug by the Investigator in both patients. In other SOCs, AEs leading to study drug discontinuation were assessed as not related to study drug by the Investigator and were reported by 1 patient each. In the Placebo Group, 1 patient (1.4%) experienced AEs leading to discontinuation in 3 SOCs (Gastrointestinal Disorders, General Disorders and Administration Site Conditions, and Nervous System Disorders), that were all assessed as related to study drug by the Investigator.

## Table 72. Adverse Events in ≥ 10% of Patients in Either Treatment Group by SOCs (Part 2 Safety Population)

<div style=\"page-break-after: always\"></div>

| System Organ Class                                   | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|------------------------------------------------------|-----------------------------------|------------------------|
| Patients with any AE                                 | 128 (90.8)                        | 66 (93.0)              |
| Nervous System Disorders                             | 54 (38.3)                         | 24 (33.8)              |
| Gastrointestinal Disorders                           | 52 (36.9)                         | 27 (38.0)              |
| General Disorders and Administration Site Conditions | 51 (36.2)                         | 15 (21.1)              |
| Infections and Infestations                          | 49 (34.8)                         | 22 (31.0)              |
| Skin and Subcutaneous Tissue Disorders               | 43 (30.5)                         | 21 (29.6)              |
| Investigations                                       | 33 (23.4)                         | 14 (19.7)              |
| Musculoskeletal and Connective Tissue Disorders      | 32 (22.7)                         | 19 (26.8)              |
| Eye Disorders                                        | 28 (19.9)                         | 10 (14.1)              |
| Vascular Disorders                                   | 28 (19.9)                         | 9 (12.7)               |
| Psychiatric Disorders                                | 19 (13.5)                         | 5 (7.0)                |
| Respiratory, Thoracic, and Mediastinal Disorders     | 18 (12.8)                         | 8 (11.3)               |
| Metabolism and Nutrition Disorders                   | 16 (11.3)                         | 5 (7.0)                |
| Injury, Poisoning, and Procedural Complications      | 14 (9.9)                          | 10 (14.1)              |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; SOC = system organ class. Note: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same SOC.

The most common SOCs (in ≥ 10% of patients) with AEs that were assessed as related to study drug by the Investigator were the following:

In the 25 mg Avapritinib Group:

- Nervous  System  Disorders  (23 patients  [16.3%]);  mainly  headache  (11 patients  [7.8%])  and dizziness (4 patients [2.8%]), all others in 1 or 2 patients each.
- General  Disorders  and  Administration  Site  Conditions  (21 patients  [14.9%]);  mainly  oedema peripheral (9 patients [6.4%]), fatigue (6 patients [4.3%]), and face oedema (5 patients [3.5%]), all others in 1 or 2 patients each. The majority of these events were Grade 1 and there were no SAEs.
- Eye  Disorders  (19 patients  [13.5%]);  mainly  periorbital  oedema  (9 patients  [6.4%]  and  eyelid oedema (5 patients [3.5%], all others in 1 or 2 patients each.
- Skin  and  Subcutaneous  Tissue  Disorders  (19 patients  [13.5%]);  mainly  alopecia  (5 patients [3.5%]), hair colour change (4 patients [2.8%]), and photosensitivity reaction (4 patients [2.8%]), all others in 1 or 2 patients each.
- Gastrointestinal  Disorders  (18 patients  [12.8%]);  mainly  nausea (9 patients [6.4%]), diarrhoea (4 patients [2.8%]), and dry mouth (3 patients [2.1%]), all others in 1 patient each.
- Investigations  (16 patients  [11.3%]);  mainly  blood  alkaline  phosphatase  increased  (5 patients [3.5%]),  aspartate  aminotransferase  increased  (4 patients  [2.8%]),  alanine  aminotransferase increased (3 patients [2.1%]), and blood lactate dehydrogenase increased (3 patients [2.1%]), all others in 1 or 2 patients each. The majority of these events were Grade 1 or 2 and there were no SAEs.

In the Placebo Group:

- Nervous System Disorders (15 patients [21.1%]); mainly headache (7 patients [9.9%]), and dizziness (5 patients [7.0%]), all others in 1 or 2 patients each.
- Eye Disorders (9 patients [12.7%]); mainly periorbital oedema, eye pain, and vision blurred (2 patients [2.8%] each), all others in 1 patient each.

<div style=\"page-break-after: always\"></div>

- Gastrointestinal Disorders (8 patients [11.3%]); mainly nausea (6 patients [8.5%]), all others in 1 or 2 patients each.
- Skin and Subcutaneous Tissue Disorders (8 patients [11.3%]); mainly alopecia (3 patients [4.2%]), all others in 1 patient each.

In the 25 mg Avapritinib Group, 3 patients (2.1%) experienced Grade 3 AEs assessed as related to study drug by the Investigator. These were in the SOCs Investigations (blood alkaline phosphatase increased and neutrophil count decrease) and Nervous System Disorders (disturbance in attention). In the Placebo Group, 2 patients (2.8%) experienced a total of 3 Grade 3 AEs assessed as related by the Investigator. These were in the SOCs Gastrointestinal Disorders (diarrhoea), Nervous System Disorders (headache), and Psychiatric Disorders (anxiety). All other AEs assessed as related to study drug by the Investigator were Grade 1 or 2.

## Overall Avapritinib Population

In the All 25 mg Avapritinib Group, the SOC in which most patients experienced AEs was Infections and Infestations (155 patients [68.6%]), followed by Gastrointestinal Disorders ( 117 patients [51.8]). These were similar with the observations in the All Avapritinib Group. Overall, no clinically meaningful differences were observed as compared to Part 2 of the study.

Table 73. Adverse Events with ≥ 5%Incidence Rate by SOCs (Part 1/2/3 [Avapritinib Treated] Safety Population, 07 April 2023)

| System Organ Class/ Preferred Term                   | All 25 mg Avapritinib N = 226 n (%)   | All 25 mg Avapritinib N = 226 n (%)   | All Avapritinib N = 246 n (%)   | All Avapritinib N = 246 n (%)   |
|------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------|---------------------------------|
|                                                      | All Grades                            | Grade ≥3                              | All Grades                      | Grade ≥3                        |
| Patients with at least one AE                        | 223 (98.7)                            | 86 (38.1)                             | 242 (98.4)                      | 102 (41.5)                      |
| Blood and lymphatic system disorders                 | 35 (15.5)                             | 9 (4.0)                               | 40 (16.3)                       | 9 (3.7)                         |
| Cardiac disorders                                    | 31 (13.7)                             | 3 (1.3)                               | 34 (13.8)                       | 3 (1.2)                         |
| Palpitations                                         | 13 (5.8)                              | 0                                     | 15 (6.1)                        | 0                               |
| Congenital, familial and genetic disorders           | 5 (2.2)                               | 1 (0.4)                               | 5 (2.0)                         | 1 (0.4)                         |
| Ear and labyrinth disorders                          | 21 (9.3)                              | 0                                     | 22 (8.9)                        | 0                               |
| Endocrine disorders                                  | 6 (2.7)                               | 0                                     | 8 (3.3)                         | 0                               |
| Eye disorders                                        | 70 (31.0)                             | 0                                     | 77 (31.3)                       | 0                               |
| Periorbital oedema                                   | 21 (9.3)                              | 0                                     | 26 (10.6)                       | 0                               |
| Gastrointestinal disorders                           | 117 (51.8)                            | 18 (8.0)                              | 132 (53.7)                      | 20 (8.1)                        |
| Nausea                                               | 39 (17.3)                             | 0                                     | 50 (20.3)                       | 0                               |
| Diarrhoea                                            | 37 (16.4)                             | 5 (2.2)                               | 45 (18.3)                       | 7 (2.8)                         |
| Abdominal pain                                       | 21 (9.3)                              | 4 (1.8)                               | 24 (9.8)                        | 4 (1.6)                         |
| Vomiting                                             | 19 (8.4)                              | 0                                     | 23 (9.3)                        | 0                               |
| Constipation                                         | 16 (7.1)                              | 0                                     | 19 (7.7)                        | 0                               |
| Abdominal distension                                 | 15 (6.6)                              | 1 (0.4)                               | 16 (6.5)                        | 1 (0.4)                         |
| General disorders and administration site conditions | 102 (45.1)                            | 6 (2.7)                               | 114 (46.3)                      | 7 (2.8)                         |
| Fatigue                                              | 32 (14.2)                             | 0                                     | 37 (15.0)                       | 1 (0.4)                         |
| Oedema peripheral                                    | 32 (14.2)                             | 1 (0.4)                               | 37 (15.0)                       | 1 (0.4)                         |
| Face oedema                                          | 13 (5.8)                              | 0                                     | 18 (7.3)                        | 0                               |
| Peripheral swelling                                  | 12 (5.3)                              | 0                                     | 14 (5.7)                        | 0                               |

<div style=\"page-break-after: always\"></div>

| System Organ Class/ Preferred Term                                  | All 25 mg Avapritinib N = 226 n (%)   | All 25 mg Avapritinib N = 226 n (%)   | All Avapritinib N = 246 n (%)   | All Avapritinib N = 246 n (%)   |
|---------------------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------|---------------------------------|
|                                                                     | All Grades                            | Grade ≥3                              | All Grades                      | Grade ≥3                        |
| Hepatobiliary disorders                                             | 11 (4.9)                              | 0                                     | 12 (4.9)                        | 0                               |
| Immune system disorders                                             | 25 (11.1)                             | 16 (7.1)                              | 32 (13.0)                       | 23 (9.3)                        |
| Anaphylactic reaction                                               | 12 (5.3)                              | 12 (5.3)                              | 18 (7.3)                        | 18 (7.3)                        |
| Hypersensitivity                                                    | 13 (5.8)                              | 5 (2.2)                               | 17 (6.9)                        | 7 (2.8)                         |
| Infections and infestations                                         | 155 (68.6)                            | 14 (6.2)                              | 170 (69.1)                      | 18 (7.3)                        |
| COVID-19                                                            | 92 (40.7)                             | 1 (0.4)                               | 99 (40.2)                       | 2 (0.8)                         |
| Upper respiratory tract infection                                   | 19 (8.4)                              | 0                                     | 23 (9.3)                        | 0                               |
| Nasopharyngitis                                                     | 20 (8.8)                              | 0                                     | 21 (8.5)                        | 0                               |
| Urinary tract infection                                             | 17 (7.5)                              | 1 (0.4)                               | 20 (8.1)                        | 1 (0.4)                         |
| Sinusitis                                                           | 16 (7.1)                              | 0                                     | 17 (6.9)                        | 0                               |
| Injury, poisoning and procedural complications                      | 49 (21.7)                             | 2 (0.9)                               | 60 (24.4)                       | 6 (2.4)                         |
| Fall                                                                | 12 (5.3)                              | 0                                     | 15 (6.1)                        | 2 (0.8)                         |
| Contusion                                                           | 12 (5.3)                              | 0                                     | 12 (4.9)                        | 0                               |
| Investigations                                                      | 88 (38.9)                             | 12 (5.3)                              | 99 (40.2)                       | 13 (5.3)                        |
| Blood alkaline phosphatase increased                                | 23 (10.2)                             | 1 (0.4)                               | 26 (10.6)                       | 1 (0.4)                         |
| Weight increased                                                    | 19 (8.4)                              | 3 (1.3)                               | 22 (8.9)                        | 3 (1.2)                         |
| Alanine aminotransferase increased                                  | 10 (4.4)                              | 1 (0.4)                               | 13 (5.3)                        | 1 (0.4)                         |
| Blood creatinine increased                                          | 12 (5.3)                              | 0                                     | 13 (5.3)                        | 0                               |
| Metabolism and nutrition disorders                                  | 43 (19.0)                             | 3 (1.3)                               | 51 (20.7)                       | 4 (1.6)                         |
| Musculoskeletal and connective tissue disorders                     | 105 (46.5)                            | 10 (4.4)                              | 115 (46.7)                      | 16 (6.5)                        |
| Arthralgia                                                          | 29 (12.8)                             | 3 (1.3)                               | 34 (13.8)                       | 6 (2.4)                         |
| Back pain                                                           | 20 (8.8)                              | 1 (0.4)                               | 25 (10.2)                       | 2 (0.8)                         |
| Pain in extremity                                                   | 13 (5.8)                              | 1 (0.4)                               | 16 (6.5)                        | 1 (0.4)                         |
| Bone pain                                                           | 12 (5.3)                              | 1 (0.4)                               | 13 (5.3)                        | 2 (0.8)                         |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 17 (7.5)                              | 3 (1.3)                               | 20 (8.1)                        | 3 (1.2)                         |
| Nervous system disorders                                            | 114 (50.4)                            | 13 (5.8)                              | 128 (52.0)                      | 17 (6.9)                        |
| Headache                                                            | 50 (22.1)                             | 2 (0.9)                               | 58 (23.6)                       | 4 (1.6)                         |
| Dizziness                                                           | 33 (14.6)                             | 3 (1.3)                               | 41 (16.7)                       | 3 (1.2)                         |
| Disturbance in attention                                            | 13 (5.8)                              | 1 (0.4)                               | 15 (6.1)                        | 2 (0.8)                         |
| Paraesthesia                                                        | 9 (4.0)                               | 0                                     | 13 (5.3)                        | 0                               |
| Psychiatric disorders                                               | 47 (20.8)                             | 1 (0.4)                               | 55 (22.4)                       | 3 (1.2)                         |
| Insomnia                                                            | 22 (9.7)                              | 0                                     | 24 (9.8)                        | 0                               |
| Renal and urinary disorders                                         | 20 (8.8)                              | 3 (1.3)                               | 27 (11.0)                       | 3 (1.2)                         |
| Reproductive system and breast disorders                            | 23 (10.2)                             | 0                                     | 24 (9.8)                        | 0                               |
| Respiratory, thoracic and mediastinal disorders                     | 45 (19.9)                             | 1 (0.4)                               | 50 (20.3)                       | 1 (0.4)                         |

<div style=\"page-break-after: always\"></div>

| System Organ Class/ Preferred Term     | All 25 mg Avapritinib N = 226 n (%)   | All 25 mg Avapritinib N = 226 n (%)   | All Avapritinib N = 246 n (%)   | All Avapritinib N = 246 n (%)   |
|----------------------------------------|---------------------------------------|---------------------------------------|---------------------------------|---------------------------------|
|                                        | All Grades                            | Grade ≥3                              | All Grades                      | Grade ≥3                        |
| Cough                                  | 15 (6.6)                              | 0                                     | 15 (6.1)                        | 0                               |
| Dyspnoea                               | 10 (4.4)                              | 0                                     | 14 (5.7)                        | 0                               |
| Skin and subcutaneous tissue disorders | 119 (52.7)                            | 4 (1.8)                               | 131 (53.3)                      | 4 (1.6)                         |
| Pruritus                               | 36 (15.9)                             | 2 (0.9)                               | 41 (16.7)                       | 2 (0.8)                         |
| Rash                                   | 16 (7.1)                              | 0                                     | 17 (6.9)                        | 0                               |
| Alopecia                               | 14 (6.2)                              | 0                                     | 15 (6.1)                        | 0                               |
| Hair colour changes                    | 7 (3.1)                               | 0                                     | 11 (4.5)                        | 0                               |
| Social circumstances                   | 3 (1.3)                               | 0                                     | 3 (1.2)                         | 0                               |
| Surgical and medical procedures        | 1 (0.4)                               | 0                                     | 1 (0.4)                         | 0                               |
| Vascular disorders                     | 64 (28.3)                             | 12 (5.3)                              | 72 (29.3)                       | 12 (4.9)                        |
| Flushing                               | 24 (10.6)                             | 10 (4.4)                              | 26 (10.6)                       | 10 (4.1)                        |
| Hypertension                           | 23 (10.2)                             | 2 (0.9)                               | 25 (10.2)                       | 2 (0.8)                         |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; NA = not applicable; SOC = system organ class.

Note: AEs are coded using MedDRA version 25.0. All AEs are treatment emergent AEs. A patient is counted only once for multiple events within the same SOC.

Note: NA denotes the patients who did not rollover to Part 3.

a  This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

## Serious adverse event/deaths/other significant events

## Deaths

One fatal SAE of multiple organ dysfunction syndrome, assessed as not related by the Investigator, was reported in the update period. The event was assessed to be due to patient's anaphylaxis.

## Serious Adverse Events

Part 2 of study BLU 285 2203

Table 74. Serious Adverse Events by Preferred Term (Part 2 Safety Population)

| Preferred Term               | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|------------------------------|-----------------------------------|------------------------|
| Patients with at least 1 SAE | 7 (5.0)                           | 8 (11.3)               |
| Abdominal pain               | 1 (0.7)                           | 0                      |
| Acute myeloid leukaemia      | 1 (0.7)                           | 0                      |
| Anaphylactic reaction        | 1 (0.7)                           | 1 (1.4)                |
| Bacteraemia                  | 1 (0.7)                           | 0                      |
| COVID-19 pneumonia           | 1 (0.7)                           | 1 (1.4)                |
| Chest pain                   | 1 (0.7)                           | 0                      |
| Pelvic haematoma             | 1 (0.7)                           | 0                      |
| Adenovirus infection         | 0                                 | 1 (1.4)                |
| Allergy to vaccine           | 0                                 | 1 (1.4)                |
| COVID-19                     | 0                                 | 1 (1.4)                |
| Foot deformity               | 0                                 | 1 (1.4)                |
| Hypertension                 | 0                                 | 1 (1.4)                |
| Mastocytosis                 | 0                                 | 1 (1.4)                |
| Mental status changes        | 0                                 | 1 (1.4)                |
| Tachycardia                  | 0                                 | 1 (1.4)                |

<div style=\"page-break-after: always\"></div>

Abbreviations: AE = adverse event; COVID-19 = Coronavirus Disease 2019; MedDRA = Medical Dictionary for Regulatory Activities; SAE = serious adverse event. Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

## Overall Avapritinib Population

The most commonly reported SAEs, anaphylactic reaction (1.8%) reported in 4 patients and mastocytosis (0.9%) reported in 3 patients, occur frequently in patients with ISM. All other events were reported in ≤2 patients each and no trends were observed (Table 75). One new SAE, Grade 3 oedema peripheral, assessed by the Investigator as related to study drug was reported in the update period ( 07 April 2023). The patient later resumed with reduced dose with no further worsening of the edema.

Table 75. Serious Adverse Events by Preferred Term (Part 1/2/3 [Avapritinib Treated] Safety Population)

|                                       | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|---------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                        | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with at least one serious AE | 24 (10.6)                           | 30 (12.2)                       | 31 (13.7)                           | 38 (15.4)                        |
| Anaphylactic reaction                 | 1 (0.4)                             | 2 (0.8)                         | 4 (1.8)                             | 5 (2.0)                          |
| Hypersensitivity                      | 1 (0.4)                             | 2 (0.8)                         | 2 (0.9)                             | 3 (1.2)                          |
| Mastocytosis                          | 2 (0.9)                             | 2 (0.8)                         | 3 (1.3)                             | 3 (1.2)                          |
| Abdominal pain                        | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| COVID-19 pneumonia                    | 2 (0.9)                             | 2 (0.8)                         | 2 (0.9)                             | 2 (0.8)                          |
| Gastrointestinal disorder             | 1 (0.4)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Headache                              | 0                                   | 1 (0.4)                         | 1 (0.4)                             | 2 (0.8)                          |
| Mast cell activation syndrome         | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Nephrolithiasis                       | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |
| Pancreatitis acute                    | 1 (0.4)                             | 1 (0.4)                         | 2 (0.9)                             | 2 (0.8)                          |

Abbreviations: AE = adverse event; COVID-19 = Coronavirus disease 2019; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

Notes: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term.

## Other Significant Adverse Events

## Adverse Events of Special Interest

The AESIs include intracranial bleeding (ICB) and cognitive effects.

## Intracranial bleeding

There were no ICB events reported in the study up to the latest cut-off date.

## Cognitive Effects

Patients  with  ISM  typically  have  a  higher  incidence  of  neurocognitive  symptoms  related  to  underlying disease (Gülen et al, 2016) compared to the general population.

## Part 2 of study BLU 285 2203:

The incidence of cognitive effect AEs was slightly lower in the 25 mg Avapritinib Group (4 patients [2.8%]) than  in  the  Placebo Group  (3 patients  [4.2%]).  The  most  commonly  reported  event  was  memory impairment, in 2 patients (1.4%) in the 25 mg Avapritinib Group and 1 patient (1.4%) in the Placebo Group. Amnesia and mood altered occurred in 1 patient (0.7%) each in the 25 mg Avapritinib Group, and mental impairment and mental status changes occurred in 1 patient (1.4%)

<div style=\"page-break-after: always\"></div>

each in the Placebo Group. Most of the AEs were Grade 1 in the 25 mg Avapritinib Group with only 1 patient experiencing a Grade 2 AE (memory impairment). In the Placebo Group, 1 patient experienced a Grade 3 event, which was reported as serious (mental status changes); all other events were reported as Grade 1 events. None of the events led to study drug discontinuation in either treatment group and 1 patient in each group experienced events leading to dose reduction (These data indicate that treatment with 25 mg avapritinib is not associated with an increased risk of cognitive effects in patients with ISM.

Table 76. Adverse Events of Cognitive Effect by Preferred Term (Part 2 Safety Population)

| Preferred Term                                  | 25 mg Avapritinib N = 141 n (%)   | Placebo N = 71 n (%)   |
|-------------------------------------------------|-----------------------------------|------------------------|
| Patients with at least 1 AE of cognitive effect | 4 (2.8)                           | 3 (4.2)                |
| Memory impairment                               | 2 (1.4)                           | 1 (1.4)                |
| Amnesia                                         | 1 (0.7)                           | 0                      |
| Mood altered                                    | 1 (0.7)                           | 0                      |
| Mental impairment                               | 0                                 | 1 (1.4)                |
| Mental status changes                           | 0                                 | 1 (1.4)                |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities. Note: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term/category.

## Overall Avapritinib Population

In the All 25 mg Avapritinib Group, a total of 15 patients (6.6%) experienced cognitive effect AEs through the update period. These were assessed as related to study drug in 7 patients (3.1%). The most commonly reported event through the update period was memory impairment in 9 patients (4.0%) and cognitive disorders in 3 patients (1.3%) through the update period and all other events were reported in 1 patient each. In the All Avapritinib Group, other than the patients already reported in the All 25 mg Avapritinib Group, there were no additional patients who experienced cognitive effects during the update period.

Table 77.  Adverse  Events  of  Cognitive  Effect  by  Preferred  Term  (Part  1/2/3  [Avapritinib Treated] Safety Population)

|                                                 | 23 June 2022 Data Cutoff Date       | 23 June 2022 Data Cutoff Date   | 07 April 2023 Data Cutoff Date      | 07 April 2023 Data Cutoff Date   |
|-------------------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|----------------------------------|
| Preferred Term                                  | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)   | All 25 mg Avapritinib N = 226 n (%) | All Avapritinib N = 246 n (%)    |
| Patients with at least 1 AE of cognitive effect | 8 (3.5)                             | 16 (6.5)                        | 15 (6.6)                            | 23 (9.3)                         |
| Memory impairment                               | 5 (3.3)                             | 7 (2.8)                         | 9 (4.0)                             | 10 (4.1)                         |
| Cognitive disorder                              | 1 (0.7)                             | 4 (1.6)                         | 3 (1.3)                             | 6 (2.4)                          |
| Agitation                                       | 1 (0.7)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Amnesia                                         | 1 (0.7)                             | 2 (0.8)                         | 1 (0.4)                             | 2 (0.8)                          |
| Confusional state                               | 0                                   | 2 (0.8)                         | 0                                   | 2 (0.8)                          |
| Delirium                                        | 0                                   | 1 (0.4)                         | 0                                   | 1 (0.4)                          |
| Disorientation                                  | 0                                   | 1 (0.4)                         | 0                                   | 1 (0.4)                          |
| Mood altered                                    | 1 (0.7)                             | 1 (0.4)                         | 1 (0.4)                             | 1 (0.4)                          |
| Psychotic disorder                              | 0                                   | 0                               | 1 (0.4)                             | 1 (0.4)                          |
| Somnolence                                      | 0                                   | 1 (0.4)                         | 0                                   | 1 (0.4)                          |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

<div style=\"page-break-after: always\"></div>

Note: AEs are coded using MedDRA version 25.0. All AEs are Treatment Emergent AEs. A patient is counted only once for multiple events within the same preferred term/category.

## Laboratory findings

## Serum Chemistry

## Part 2 of study BLU 285 2203

An initial and transient increase in ALP (mean  within the normal ranges) was  noted in the 25 mg Avapritinib Group. This was observed initially with its peak at C2D1 returning to baseline by C6D1. This transient increase in ALP was possibly due to lysis of mast cells infiltrating the bone and was not considered clinically meaningful.

Figure 48. Box Plot of Alkaline Phosphatase Laboratory Test (Part 2 Safety Population)

<!-- image -->

A summary of shifts reported in ≥ 5% patients in Part 2 is presented in Table 7 8.

Table 78. Patients  with  Shifts  in  Serum  Chemistry  Parameters  (≥ 5%  in  Any  Group)  from Baseline to Worst on-Treatment Value CTCAE Grade (Part 2 Safety Population)

| Serum Chemistry Parameters   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   |
|------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|
| Serum Chemistry Parameters   | Any Shift                           | Shift to Grade 2                    | Shift to Grade 3 or 4               | Any Shift                | Shift to Grade 2         | Shift to Grade 3 or 4    |
| Creatinine increase          | 29/141 (20.6)                       | 0                                   | 0                                   | 9/71 (12.7)              | 0                        | 0                        |
| ALP increase                 | 29/141 (20.6)                       | 2 (1.4)                             | 0                                   | 6/71 (8.5)               | 0                        | 0                        |
| AST increase                 | 18/141 (12.8)                       | 0                                   | 0                                   | 4/70 (5.7)               | 0                        | 0                        |
| Direct bilirubin increase    | 17/126 (13.5)                       | 4/126 (3.2)                         | 0                                   | 3/63 (4.8)               | 0                        | 0                        |
| ALT increase                 | 13/141 (9.2)                        | 0                                   | 1/141 (0.7)                         | 7/71 (9.9)               | 0                        | 0                        |
| Total bilirubin increase     | 12/141 (8.5)                        | 3/141 (2.1)                         | 1/141 (0.7)                         | 2/71 (2.8)               | 1/71 (1.4)               | 0                        |
| Potassium increase           | 9/141 (6.4)                         | 0                                   | 1/141 (0.7)                         | 6/71 (8.5)               | 0                        | 0                        |

<div style=\"page-break-after: always\"></div>

| Serum Chemistry Parameters   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   |
|------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|
| Serum Chemistry Parameters   | Any Shift                           | Shift to Grade 2                    | Shift Grade or 4                    | Any Shift                | Shift to Grade 2         | Shift to Grade 3 or 4    |
| Potassium decrease           | 14/141 (9.9)                        | 0                                   | 2/141 (1.4)                         | 4/71 (5.6)               | 0                        | 0                        |
| Calcium decrease             | 12/141 (8.5)                        | 1/141 (0.7)                         | 0                                   | 5/69 (7.2)               | 0                        | 0                        |
| Glucose decrease             | 7/141 (5.0)                         | 0                                   | 0                                   | 0                        | 0                        | 0                        |
| Magnesium decrease           | 7/137 (5.1)                         | 0                                   | 1/137 (0.7)                         | 2/69 (2.9)               | 0                        | 0                        |

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event. Note: Percentages are based on patients with baseline and at least one on-treatment CTCAE grade.

## Overall Avapritinib Population

Shift analyses from baseline to highest, lowest, and worst value on treatment based on the NCI CTCAE were conducted for selected chemistry parameters. A summary of shifts reported in ≥ 5% patients in the Part 1/2/3 overall analyses is presented in Table 79.

Table 79. Patients with Shifts in Serum Chemistry Parameters ( ≥ 5% in Any Group) from Baseline to Worst On-treatment Value CTCAE (Part 1/2/3 Safety Population 07 April 2023)

| Serum Chemistry Parameter   | All 25 mg Avapritinib N = 226 n/N (%)   | All 25 mg Avapritinib N = 226 n/N (%)   | All 25 mg Avapritinib N = 226 n/N (%)   | All Avapritinib N = 246 n/N (%)   | All Avapritinib N = 246 n/N (%)   | All Avapritinib N = 246 n/N (%)   |
|-----------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| s                           | Any Shift                               | Shift to Grade 2                        | Shift to Grade 3 or 4                   | Any Shift                         | Shift to Grade 2                  | Shift to Grade 3 or 4             |
| Creatinine increase         | 71/226 (31.0)                           | 1/226 (0.4)                             | 0                                       | 80/245 (32.7)                     | 1/245 (0.4)                       | 0                                 |
| ALP increase                | 60/226 (26.2)                           | 4/226 (1.8)                             | 0                                       | 70/245 (28.6)                     | 6/245 (2.0)                       | 1/245 (0.4)                       |
| AST increase                | 50/226 (22.1)                           | 1/226 (0.4)                             | 0                                       | 59/245 (24.1)                     | 2/245 (0.8)                       | 1/245 (0.4)                       |
| Direct bilirubin increase   | 45/203 (22.2)                           | 15/203 (7.4)                            | 1/203 (0.5)                             | 49/221 (22.2)                     | 15/221 (6.8)                      | 1/221 (0.5)                       |
| ALT increase                | 44/226 (19.5)                           | 3/226 (1.3)                             | 1/226 (0.4)                             | 51/245 (20.8)                     | 3/245 (1.2)                       | 1/245 (0.4)                       |
| Total bilirubin increase    | 30/226 (13.3)                           | 9/226 (4.0)                             | 1/226 (0.4)                             | 32/245 (13.1)                     | 10/245 (4.1)                      | 1/245 (0.4)                       |
| Potassium increase          | 21/226 (9.3)                            | 2/226 (0.9)                             | 1/226 (0.4)                             | 23/245 (9.4)                      | 2/245 (0.8)                       | 1/245 (0.4)                       |
| Sodium increase             | 19/226 (8.4)                            | 2/226 (0.9)                             | 0                                       | 21/245 (8.6)                      | 2/245 (0.8)                       | 0                                 |
| Calcium increase            | 18/226 (8.0)                            | 0                                       | 0                                       | 20/245 (8.2)                      | 0                                 | 0                                 |
| Potassium decrease          | 39/226 (17.3)                           | 0                                       | 3/225 (1.3)                             | 44/245 (18.0)                     | 0                                 | 3/245 (1.2)                       |
| Calcium decrease            | 33/226 (14.6)                           | 2/226 (0.9)                             | 2/226 (0.9)                             | 38/245 (15.5)                     | 2/245 (0.8)                       | 2/245 (0.8)                       |

<div style=\"page-break-after: always\"></div>

| Glucose decrease   | 29/226 (12.8)   | 4/226 (1.8)   | 0           | 33/245 (13.5)   | 4/245 (1.6)   | 0           |
|--------------------|-----------------|---------------|-------------|-----------------|---------------|-------------|
| Magnesium decrease | 16/222 (7.2)    | 1/222 (0.5)   | 1/222 (0.5) | 18/241 (7.5)    | 1/241 (0.4)   | 1/241 (0.4) |
| Sodium decrease    | 16/226 (7.1)    | 2/226 (0.9)   | 0           | 18/245 (7.3)    | 2/245 (0.8)   | 0           |

Abbreviations: ALP = alkaline phosphatase;  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

b This column also includes patients from the 50 mg to 25 mg and 100 mg to 25 mg Avapritinib Groups.

Note: Percentages are based on patients with baseline and at least 1 on-treatment CTCAE grade.

## Liver Function Tests

There were no patients that met the criteria for potential Hy's law defined as post-baseline total bilirubin elevation to ≥ 2x upper limit of normal (ULN) occurring on or within 30 days after a post -baseline ALT or AST elevation to ≥ 3x ULN and concurrent ALP is &lt; 2x ULN.

A limited number of patients had bilirubin elevation ≥ 2x ULN. These were generally not associated with ALT/AST increase and ALP values were within normal ranges, which doesn't suggest a clinically meaningful cholestasis. All patients had confounding factors including Gilbert's syndrome, ongoing medical history of increase in bilirubin levels, cholelithiasis or dyslipidemia. Relevant AEs were reported in 3 patients, all assessed as not related to study drug, and resolved while receiving continued treatment with avapritinib.

## Haematology

## Part 2 of study BLU 285 2203

Shift analyses from baseline to highest, lowest, and worst value on treatment based on the NCI CTCAE were conducted for hematology parameters. A summary of shifts reported in ≥ 5% patients is presented in Table 80.

Table 80. Patients with Shifts in Hematology Parameters from Baseline to Worst on-Treatment CTCAE Grade (Part 2 Safety Population)

| Hematology Parameters   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | 25 mg Avapritinib N = 141 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   | Placebo N = 71 n/N (%)   |
|-------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|
|                         | Any Shift                           | Shift to Grade 2                    | Shift to Grade 3 or 4               | Any Shift                | Shift to Grade 2         | Shift to Grade 3 or 4    |
| Hemoglobin decrease     | 21/141 (14.9)                       | 2/141 (1.4)                         | 0                                   | 9/71 (12.7)              | 1/71 (1.4%)              | 0                        |
| Leukocytes decrease     | 22/141 (15.6)                       | 2/141 (1.4)                         | 1/141 (0.7)                         | 4/71 (5.6)               | 1/71 (1.4)               | 1/71 (1.4)               |
| Lymphocytes decrease    | 6/140 (4.3)                         | 2/140 (1.4)                         | 0                                   | 3/71 (4.2)               | 0                        | 0                        |
| Neutrophils decrease    | 11/141 (7.8)                        | 3/141 (2.1)                         | 2/141 (1.4)                         | 7/71 (9.9)               | 3/71 (4.2)               | 0                        |
| Platelets decrease      | 5/141 (3.5)                         | 0                                   | 0                                   | 2/71 (2.8)               | 0                        | 0                        |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Event. Note: Percentages are based on patients with baseline and at least one on-treatment CTCAE grade.

## Overall Avapritinib Population

<div style=\"page-break-after: always\"></div>

Shift analyses from baseline to highest, lowest, and worst value on treatment based on the NCI CTCAE were conducted for hematology parameters. A summary of shifts from baseline reported in ≥ 5% patients in the Part 1/2/3 overall analyses through the update period is presented in Table 81.

Table 81. Patients with Shifts in Hematology Parameters from Baseline to Worst on-Treatment Value CTCAE Grade (Part 1/2/3 Safety Population)

| Hematology Parameters   | All 25 mg Avapritinib N = 226 n/N (%)   | All 25 mg Avapritinib N = 226 n/N (%)   | All 25 mg Avapritinib N = 226 n/N (%)   | All Avapritinib N = 246 n/N (%)   | All Avapritinib N = 246 n/N (%)   | All Avapritinib N = 246 n/N (%)   |
|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                         | Any Shift                               | Shift to Grade 2                        | Shift to Grade 3 or 4                   | Any Shift                         | Shift to Grade 2                  | Shift to Grade 3 or 4             |
| Hemoglobin decrease     | 52/226 (23.0)                           | 6/226 (2.7)                             | 0                                       | 61/245 (24.9)                     | 9/245 (3.7)                       | 0                                 |
| Leukocytes decrease     | 56/226 (24.8)                           | 10/226 (4.4)                            | 1/226 (0.4)                             | 59/245 (24.1)                     | 10/245 (4.1)                      | 1/245 (0.4)                       |
| Lymphocytes decrease    | 31/226 (13.7)                           | 12/226 (5.3)                            | 3/226 (1.3)                             | 34/245 (13.9)                     | 14/245 (5.7)                      | 3/245 (1.2)                       |
| Neutrophils decrease    | 43/226 (19.0)                           | 16/226 (7.1)                            | 5/226 (2.2)                             | 46/245 (18.8)                     | 4/245 (1.6)                       | 5/245 (2.0)                       |
| Platelets decrease      | 14/226 (6.2)                            | 0                                       | 0                                       | 16/245 (6.5)                      | 0                                 | 0                                 |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Event.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1

b This column also includes patients from the 50 mg to 25 mg and 100 mg to 25 mg Avapritinib Groups.

Note: Percentages are based on patients with baseline and at least 1 on-treatment CTCAE grade.

## Coagulation

## Part 2 of study BLU 285 2203

AEs associated with coagulation were activated partial thromboplastin time prolonged and blood fibrinogen decreased in 1 (0.7%) patient each in the 25 mg Avapritinib Group; both AEs were nonserious. The AE of activated  partial  thromboplastin  time  prolonged  was  assessed  as  not  related  to  avapritinib  by  the Investigator and the AE of blood fibrinogen decreased was assessed as related to avapritinib.

## Overall Avapritinib Population

Apart from the AEs associated with coagulation reported in Part 2, a Grade 1 non-serious AE of activated partial thromboplastin time prolonged was reported in one patient in the All 25 mg Avapritinib Group. The event  was  assessed  as  related  to  study  drug  by  the  investigator.  No  additional  AEs  associated  with coagulation were reported in the All Avapritinib Group.

With the most recent data cut-off, there were no clinically meaningful changes from baseline over time observed in coagulation parameters of activated partial thromboplastin time, fibrinogen, and prothrombin international normalized ratio, and prothrombin time across groups through the update period.

## Vital sign measurements

## Part 2 of study BLU 285 2203

<div style=\"page-break-after: always\"></div>

There were few clinically significant abnormalities reported as AEs associated with vital signs parameters, and they were similar between the two treatment groups. In the 25 mg Avapritinib Group the following AEs were  reported,  hypertension  in  6  (4.3%)  patients,  weight  increased  in  4  (2.8%)  patients,  and  weight decreased,  hypotension,  and  orthostatic  hypotension  in  1 (0.7%)  patient  each.  In  the  Placebo Group, hypertension  was  reported  in  5 (7.0%)  patients,  weight  increased  in  3  (4.2%)  patients,  and  weight decreased in 1 (1.4%) patient. All AEs associated with vital signs parameters were nonserious for the patients in the 25 mg Avapritinib Group, and 1 patient reported an SAE of hypertension (unrelated) in the Placebo Group. The AEs of hypertension and weight increased in 1 patient each were assessed as related to  avapritinib  by  the  Investigator;  and  the  AEs  of  weight  increased  in  2  patients  and  hypertension  in 1 patient were assessed as related in the Placebo Group.

## Overall Avapritinib Population (initial submission)

AEs associated with vital signs parameters were hypertension in 19 (8.4%) patients, weight increased in 11  (4.9%)  patients,  weight  decreased  in  4  (1.8%)  patients,  hypotension  in  2  (0.9%)  patients,  and orthostatic hypotension, blood pressure increased, and prehypertension in 1 (0.4%) patient each in the All 25 mg Avapritinib  Group.  All  AEs  associated  with  vital  signs  parameters  were  nonserious  in  the All 25 mg Avapritinib Group. The AEs of weight increased in 5 patients, hypertension in 2 patients, and blood pressure increased, and weight decreased in 1 patient each were assessed as related to avapritinib by the Investigator.

## Cardiovascular effects

## Part 2 of study BLU 285 2203

One patient each in the 25 mg Avapritinib Group had QTcF &gt; 480 msec and &gt; 500 msec compared to no patients in the Placebo Group. Overall, 10 patients (7.1%) in the 25 mg Avapritinib Group and 5 patients (7.9%)  in  the  Placebo Group  had  a  QTcF  increase  of  &gt; 30 msec  from  baseline.  An  increased  QTcF &gt; 60 msec from baseline was reported in 3 (2.1%) patients in the 25 mg Avapritinib Group and none in the Placebo Group. It should be noted that a QTcF &gt; 480 msec was an exclusion criterion for the study (as of Amendment 2). All patients with &gt; 60 msec increase from baseline were female. QTcF was &gt; 500 msec in 1 of the patients and was not associated with any relevant AEs. In the remaining 2 patients, QTcF didn't increase beyond 470 msec which is considered to be within the upper normal range in female patients and therefore considered not clinically meaningful.

AEs associated with ECG findings were electrocardiogram QT prolonged in 2 patients and electrocardiogram T wave inversion in 1 patient in the 25 mg Avapritinib Group; electrocardiogram QT prolonged in 1 patient in the Placebo Group. All AEs were nonserious. The AEs of electrocardiogram QT prolonged were of severity Grade 3 (unrelated) and Grade 1 (related), and electrocardiogram T wave inversion was Grade 1 (related), all reported in 1 patient each in the 25 mg Avapritinib Group. The AE of electrocardiogram QT prolonged was Grade 2, and not related to study drug by the Investigator.

A search of the AE dataset was performed using the PTs from the SMQ Torsade de pointes/QT Prolongation. The search revealed 3 patients (2.1%) in the 25 mg Avapritinib Group and 1 patient (1.4%) in the Placebo Group  who  experienced  events  within  the  SMQ.  The  reported  events  included  electrocardiogram  QT prolonged (2 patients in the 25 mg Avapritinib Group and 1 patient in the Placebo Group) and syncope (2 patients in the 25 mg Avapritinib Group). None of the events were serious. One patient with a medical history of intermittent dizziness experienced a Grade 3 syncope assessed as not related to study drug. The event  was  not  associated  with  QT  prolongation  at  the  time  of  the  occurrence.  The  patient  continued treatment  with  no  new  episodes  reported.  Syncope,  Grade  1  in  severity,  was  not  associated  with  QT prolongation in the other patient either. It is important to note that patients with ISM frequently suffer from mast cell mediator related symptoms that include syncope. Patients with QT prolongation reported as AEs are described above.

<div style=\"page-break-after: always\"></div>

## Overall Avapritinib Population (initial submission)

Overall, 2 patients in the All 25 mg Avapritinib Group had QTcF &gt; 480 msec and 1 patient had &gt; 500 msec (described in Part 2). In  the All  25 mg Avapritinib Group, 24  patients (10.6%) had a QTcF increase of &gt; 30 msec from baseline. An increased QTcF &gt; 60 msec from baseline was reported in 6 patients (2.7%) in this group.

AEs associated with ECG findings were limited and included electrocardiogram QT prolonged in 4 patients, and electrocardiogram QRS complex prolonged and electrocardiogram T wave inversion in 1 patient each in the All 25 mg Avapritinib Group. Except for 1 AE of Grade 3, nonserious, electrocardiogram QT prolonged (unrelated),  all  other  AEs  were  nonserious,  Grade 1,  and  assessed  as  related  to  avapritinib  by  the Investigator.

The search using SMQ Torsade de pointes/QT Prolongation revealed 8 patients overall who experienced events in Part 1/2/3. In addition to the 6 patients described above in Part 2 results, 5 patients experienced events in the All Avapritinib Group. 3 of them occurred while on Part 3. Of these, 2 patients had received Placebo prior to 25 mg Avapritinib in Part 3: 1 experienced a Grade 1 loss of consciousness assessed as not related by the Investigator with no ECG abnormalities findings, the other patient experienced a Grade 1 QT prolonged event described above; one patient experienced a Grade 3 syncope assessed as not related by the Investigator and had no QT prolongation findings in the ECG results. None of the events were serious and all resolved with continued treatment. 2 out of 5 patients experienced events within the SMQ during Part 1: one patient experienced a Grade 3 syncope while receiving 25 mg avapritinib, which resolved with continued treatment, was assessed as not related to study drug by the Investigator and patient had QTcF within the normal ranges at the time of reported event; the remaining patient experienced a Grade 1 QT prolonged AE while receiving 100 mg avapritinib, assessed as not related to study drug by the Investigator. None of the events were serious.

## ECOG Performance Status

## Part 2 of study BLU 285 2203

Most patients (&gt; 90%) had a baseline ECOG performance status of 0 or 1 in both treatment groups; and 10 (7.1%) patients in the 25 mg Avapritinib Group and 4 (5.6%) patients in the Placebo Group had a baseline ECOG performance status of 2. There were no shifts to ECOG performance status of 4 and only 1 shift to an ECOG performance status of 3 in the 25 mg Avapritinib Group during Part 2 of the study.

## Overall Avapritinib Population (initial submission)

Overall, most patients (&gt; 90%) had a baseline ECOG performance status of 0 or 1, 17 (7.5%) patients had 2 in the All 25 mg Avapritinib Group. Shifts to an ECOG performance status of 3 or higher were uncommon. Most patients maintained their baseline score, with some patients shifting to a score of 0 or 1.

## Brain Imaging Assessment (initial submission)

Brain imaging was performed at screening and patients with baseline abnormalities indicative of risk for intracranial haemorrhage, or prior, recent, or current intracranial haemorrhage, were excluded from the study. One patient in the 25 mg Avapritinib Group had abnormal brain imaging findings at Part 1 C5D1, that was assessed as related to sinusitis.

## Safety in special populations

## Intrinsic and Extrinsic Factors

Subgroup analyses of AEs were performed for intrinsic factors of age (&lt; 65 years, ≥ 65 years), sex (female, male), baseline ISM status (moderate, severe), baseline serum tryptase (&lt; 20 ng/mL, ≥ 20 ng/mL), and

<div style=\"page-break-after: always\"></div>

extrinsic factors of region (North America, Europe), number of baseline BSC therapies (&lt; 4, ≥ 4), prior cytoreductive therapy (yes, no), and baseline opioid use (yes, no).

## Part 2 of study BLU 285 2203

Treatment with avapritinib 25 mg was not associated with an increase in the probability of having an AE in the subgroups of age, sex, baseline serum tryptase, baseline cytoreductive therapy and baseline opioids, as compared with placebo (odds ratio &lt; 1.0) (Figure 49). A higher probability of experiencing AEs occurred with avapritinib treatment for patients with severe baseline ISM status, number of baseline BSC ≥ 4, and in  the  North  America  region  (odds  ratio  &gt;  1);  however,  none  of  these  comparisons  were  statistically significant. Because the odds ratio for the North America region only just exceeded 1 (odds ratio 1.04), and no relevant trends were seen compared with Europe, this analysis is not considered further.

The majority of the patients were female (76.9%), &lt; 65 years of age (87.2%), White (92.3%), and not Hispanic  and  Latino  (89.7%),  therefore  analyses  of  AEs  by  subgroups  based  on  these  factors  are  not informative.  The  main  differences  observed  between  25  mg  avapritinib  and  placebo  in  the  subgroup analyses of baseline ISM status and number of baseline BSC therapies are summarized below.

Figure 49. Forest Plot of Adverse Events (Part 2 Safety Population)

<!-- image -->

Abbreviations: BSC = best supportive care; CI = confidence interval; ISM = indolent systemic mastocytosis; N = total number of subjects in the subgroup; n = number of subjects with events. Note: Odds ratio and p-value obtained using logistic regression with placebo as the reference category. - represents odds ratios and p-values that were not estimable due to quasi-complete separation. An odds ratio of &gt; 1 indicates that treatment with avapritinib is favored.

## Baseline ISM Status

Compared with placebo, an increase in the probability of having an AE with 25 mg avapritinib was observed in patients with severe ISM (odds ratio = 1.32). In patients with severe ISM, this difference in favor of placebo was accounted for mainly by higher incidences of AEs with 25 mg avapritinib in the SOCs of:

Nervous System Disorders (placebo 35.6%, 25 mg avapritinib 41.4%, not on account of any specific types of AEs)

<div style=\"page-break-after: always\"></div>

Gastrointestinal  Disorders  (placebo  31.1%,  25 mg  avapritinib  40.2%,  mostly  on  account  of diarrhoea and constipation)

Eye Disorders (placebo 15.6%, 25 mg avapritinib 24.1%, mostly on account of periorbital oedema and eyelid oedema)

Investigations (placebo 20.0%, 25 mg avapritinib 27.6%, mostly on account of liver transaminases)

Metabolism and Nutrition Disorders (placebo 6.7%, 25 mg avapritinib 17.2%, mostly on account of hypokalaemia, decreased appetite, iron deficiency, fluid retention, and hypophosphataemia)

Psychiatric Disorders (placebo 4.4%, 25 mg avapritinib 13.8%, mostly on account of anxiety and insomnia)

Conversely, in the following SOCs, higher incidences of AEs occurred with 25 mg avapritinib in patients with moderate ISM, but not in patients with severe ISM:

Infections and Infestations (placebo 15.4%, 25 mg avapritinib 34.6%, mostly on account of COVID19, sinusitis, and upper respiratory tract infection)

## Number of Baseline BSC Therapies

Compared with placebo, an increase in the probability of having an AE with 25 mg avapritinib was observed in patients with ≥ 4 BSC medications at baseline (odds ratio = 1.29). In patients with ≥ 4 BSC at baseline, this  difference  in  favor  of  placebo  was  accounted  for  mainly  by  higher  incidences  of  AEs  with  25 mg avapritinib in the SOCs of:

Nervous  System  Disorders  (placebo  33.3%,  25 mg  avapritinib  43.5%,  mostly  on  account  of dizziness and disturbance in attention)

Skin  and  Subcutaneous  Tissue  Disorders  (placebo  27.8%,  25 mg  avapritinib  34.8%,  mostly  on account of pruritus)

Eye Disorders (placebo 16.7%, 25 mg avapritinib 24.6%, mostly on account of periorbital oedema, eyelid edema, and lacrimation increased)

Psychiatric Disorders (placebo 5.6%, 25 mg avapritinib 15.9%, mostly on account of anxiety and insomnia)

Reproductive System and Breast Disorders (placebo 0%, 25 mg avapritinib 7.2%, not on account of any specific types of AEs)

Conversely, in the following SOCs, higher incidences of AEs occurred with 25 mg avapritinib in patients with &lt; 4 BSC at baseline, but not in patients with ≥ 4 BSC at baseline:

Investigations  (placebo  20.0%,  25 mg  avapritinib  25.0%,  mostly  on  account  of  aspartate aminotransferase increased)

Metabolism and Nutrition Disorders (placebo 5.7%, 25 mg avapritinib 11.1%, not on account of any specific types of AEs)

Renal and Urinary Disorders (placebo 0%, 25 mg avapritinib 5.6%, not on account of any specific types of AEs)

## Related Adverse Events (Investigator Assessment)

Subgroup  analyses  of  study  drug-related  AEs,  as  assessed  by  the  Investigator  generally  indicated  an increase in the probability of having a related AE with avapritinib 25 mg, compared with placebo, in all

<div style=\"page-break-after: always\"></div>

subgroup  categories,  with  the  highest  probability  being  for  the  age  group  ≥ 65 years  old  (Table  21); however the number of patients in this category is small and hence the analysis is not informative.

Figure 2 50. Forest Plot of Related Adverse Events (Part 2 Safety Population)

<!-- image -->

Abbreviations:  AE = adverse  event;  BSC = best  supportive  care;  CI = confidence  interval;  ISM = indolent  systemic mastocytosis; N = total number of subjects in the subgroup; n = number of subjects with events. Notes: Odds ratio and p-value obtained using logistic regression with placebo as the reference category.

- represents odds ratios and p-values that were not estimable due to quasi-complete separation. An odds ratio of &gt; 1 indicates that treatment with avapritinib is favored. Relationship of AE to treatment was defined as AE that is considered to be related to the study drug by the Investigator according to the predefined criteria.

## Overall Avapritinib Population

The subgroup analyses for the overall population (Part 1/2/3) of Study BLU-285-2203 did not reveal any new concerns pertaining to any of the subgroup categories with longer exposure to 25 mg avapritinib beyond Part 2 of the study. Among the subgroups of baseline ISM status and number of baseline BSC medications used (as summarized for Part 2 in Section 5.1.1.1), none of the SOCs and PTs with a higher incidence in the 25 mg Avapritinib Group than in the Placebo Group in Part 2 showed any relevant change in incidence in the overall population.

## Age

As part of the responses to CHMP's D120 LOQ, additional safety data in elderly patients was provided.

Part 2: The number of patients in the 65-74 years of age subgroup is limited (8 and 9 patients in the 25 mg Avapritinib Group and the Placebo Group respectively) and very few patients were in the 75-84 years of age subgroup (1 and 2 patients in the 25 mg Avapritinib Group and the Placebo Group respectively). There were no patients ≥85 years old (this column has been removed from the table 8 2).

<div style=\"page-break-after: always\"></div>

Table 82. Summary of Selected Safety Data by Age Subgroups (Part 2, Safety Population, 23 June 2022)

|                                                                                       | Avapritinib 25 mg N=141   | Avapritinib 25 mg N=141   | Avapritinib 25 mg N=141   | Placebo N=71         | Placebo N=71           | Placebo N=71          |
|---------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|----------------------|------------------------|-----------------------|
| MedDRA Terms                                                                          | Age <65 N =132 n (%)      | Age 65- 74 N = 8 n (%)    | Age 75- 84 N =1 n (%)     | Age <65 N = 60 n (%) | Age 65- 74 N = 9 n (%) | Age 75- 84 N =2 n (%) |
| Total AEs                                                                             | 120 (90.9)                | 7 (87.5)                  | 1 (100)                   | 55 (91.7)            | 9 (100)                | 2 (100)               |
| Serious AEs - Total                                                                   | 6 (4.5)                   | 0                         | 1 (100)                   | 6 (10.0)             | 2 (22.2)               | 0                     |
| - Fatal                                                                               | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| - Hospitalization New                                                                 | 6 (4.5)                   | 0                         | 0                         | 3 (5.0)              | 2 (22.2)               | 0                     |
| - Prolonged existing hospitalization                                                  | 1 (<1)                    | 0                         | 0                         | 1 (1.7)              | 0                      | 0                     |
| - Life-threatening                                                                    | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| - Disability/incapacity                                                               | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| - Other (medically significant)                                                       | 1 (<1)                    | 0                         | 1 (100)                   | 1 (1.7)              | 0                      | 0                     |
| AE leading to drop-out                                                                | 2 (1.5)                   | 0                         | 1 (100)                   | 1 (1.7)              | 0                      | 0                     |
| Psychiatric disorders                                                                 | 18 (13.6)                 | 1 (12.5)                  | 0                         | 4 (6.7)              | 1 (11.1)               | 0                     |
| Nervous system disorders                                                              | 53 (40.2)                 | 1 (12.5)                  | 0                         | 20 (33.3)            | 3 (33.3)               | 1 (50.0)              |
| Accidents and injuries                                                                | 10 (7.6)                  | 0                         | 1 (100)                   | 4 (6.7)              | 0                      | 0                     |
| Cardiac disorders                                                                     | 10 (7.6)                  | 0                         | 1 (100)                   | 5 (8.3)              | 0                      | 0                     |
| Vascular disorders                                                                    | 27 (20.5)                 | 0                         | 1 (100)                   | 8 (13.3)             | 1 (11.1)               | 0                     |
| Cerebrovascular disorders                                                             | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| Infections and infestations                                                           | 47 (35.6)                 | 2 (25.0)                  | 0                         | 18 (30.0)            | 3 (33.3)               | 1 (50.0)              |
| Anticholinergic syndrome                                                              | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| Quality of life decreased                                                             | 0                         | 0                         | 0                         | 0                    | 0                      | 0                     |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 21 (15.9)                 | 0                         | 0                         | 7 (11.7)             | 2 (22.2)               | 0                     |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities.

Overall Data (Part 1/2/3): there is a small number of patients in the 65-74 years of age subgroup (19 and 20 patients in the All 25 mg Avapritinib Group and All Avapritinib Group respectively) and very few patients were in the 75-84 years of age subgroup (4 patients in each, All 25 mg Avapritinib Group and All Avapritinib Group). There were no patients ≥ 85 years old (this column has been removed from the table 83).

<div style=\"page-break-after: always\"></div>

Table 83. Summary of Selected Safety Data by Age Subgroups (Part 1/2/3, Safety Population, 07 April 2023)

|                                                                                       | All 25 mg Avapritinib a N = 226 n (%)   | All 25 mg Avapritinib a N = 226 n (%)   | All 25 mg Avapritinib a N = 226 n (%)   | All Avapritinib N = 246 n (%)   | All Avapritinib N = 246 n (%)   | All Avapritinib N = 246 n (%)   |
|---------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|---------------------------------|---------------------------------|---------------------------------|
| MedDRA Terms                                                                          | Age <65 N = 203 n (%)                   | Age 65- 74 N = 19 n (%)                 | Age 75- 84 N = 4 n (%)                  | Age <65 N = 222 n (%)           | Age 65- 74 N = 20 n (%)         | Age 75- 84 N = 4 n (%)          |
| Total AEs                                                                             | 200 (98.5)                              | 19 (100)                                | 4 (100)                                 | 218 (98.2)                      | 20 (100)                        | 4 (100)                         |
| Serious AEs - Total                                                                   | 27 (13.3)                               | 3 (15.8)                                | 1 (25.0)                                | 33 (14.9)                       | 4 (20.0)                        | 1 (25.0)                        |
| - Fatal                                                                               | 0                                       | 1 (5.3)                                 | 0                                       | 0                               | 1 (5.0)                         | 0                               |
| - Hospitalization New                                                                 | 26 (12.8)                               | 2 (10.5)                                | 0                                       | 32 (14.4)                       | 3 (15.0)                        | 0                               |
| - Prolonged existing hospitalization                                                  | 1 (<1)                                  | 1 (5.3)                                 | 0                                       | 1 (<1)                          | 1 (5.0)                         | 0                               |
| - Life-threatening                                                                    | 1 (<1)                                  | 1 (5.3)                                 | 0                                       | 1 (<1)                          | 1 (5.0)                         | 0                               |
| - Disability/incapacity                                                               | 0                                       | 1 (5.3)                                 | 0                                       | 0                               | 1 (5.0)                         | 0                               |
| - Other (medically significant)                                                       | 1 (<1)                                  | 0                                       | 1 (25.0)                                | 1 (<1)                          | 0                               | 1 (25.0)                        |
| AE leading to drop-out                                                                | 10 (4.9)                                | 1 (5.3)                                 | 1 (25.0)                                | 11 (5.0)                        | 1 (5.0)                         | 1 (25.0)                        |
| Psychiatric disorders                                                                 | 43 (21.2)                               | 3 (15.8)                                | 1 (25.0)                                | 50 (22.5)                       | 4 (20.0)                        | 1 (25.0)                        |
| Nervous system disorders                                                              | 107 (52.7)                              | 6 (31.6)                                | 1 (25.0)                                | 120 (54.1)                      | 7 (35.0)                        | 1 (25.0)                        |
| Accidents and injuries                                                                | 21 (10.3)                               | 3 (15.8)                                | 1 (25.0)                                | 25 (11.3)                       | 3 (15.0)                        | 1 (25.0)                        |
| Cardiac disorders                                                                     | 30 (14.8)                               | 0                                       | 1 (25.0)                                | 33 (14.9)                       | 0                               | 1 (25.0)                        |
| Vascular disorders                                                                    | 57 (28.1)                               | 4 (21.1)                                | 3 (75.0)                                | 64 (28.8)                       | 5 (25.0)                        | 3 (75.0)                        |
| Cerebrovascular disorders                                                             | 1 (<1)                                  | 0                                       | 0                                       | 2 (<1)                          | 0                               | 0                               |
| Infections and infestations                                                           | 140 (69.0)                              | 12 (63.2)                               | 3 (75.0)                                | 154 (69.4)                      | 13 (65.0)                       | 3 (75.0)                        |
| Anticholinergic syndrome                                                              | 0                                       | 0                                       | 0                                       | 0                               | 0                               | 0                               |
| Quality of life decreased                                                             | 0                                       | 0                                       | 0                                       | 0                               | 0                               | 0                               |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 52 (25.6)                               | 3 (15.8)                                | 2 ( 0.0)                                | 62 (27.9)                       | 4 (20.0)                        | 2 (50.0)                        |

Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities.

a This group includes the patients who received placebo or 25 mg avapritinib in Part 1 or Part 2 and does not include the patients who received 50 mg or 100 mg avapritinib in Part 1.

MAH provided safety data broken down by age groups (e.g. &lt; 65 years, ≥ 65 years) as part of the responses to CHMP's D120 LOQ.

The majority of the patients were &lt; 65 years of age, 203/226 and 222/246 in the All 25 mg Avapritinib Group and All Avapritinib Group respectively.

The proportion of patients ≥ 65 years old experiencing any AE in the All 25 MG Avapritinib Group was very similar to that of patients &lt; 65 years old (98.5% and 100% respectively).

<div style=\"page-break-after: always\"></div>

Compared with patients &lt; 65 years old, in the All 25 mg Avapritinib Group, a higher incidence of events in the following SOCs was observed in patients ≥ 65 years of age. These were similar in the All Avapritinib Group.

- -Eye Disorders [29.6% (60/203 patients) and 43.5% (10/23 patients)], driven by periorbital edema which is a known event to occur with avapritinib and was frequently reported in patients &lt; 65 years of age as well;
- -Skin and subcutaneous tissue disorders [51.7% (105/203 patients) and 60.9% (14/23 patients)], driven by pruritus, which was reported frequently in patients &lt; 65 years of age as well.

Compared with patients &lt; 65 years old, a higher incidence of the following events was observed in patients ≥ 65 years of age in the All 25 mg Avapritinib Group: oedema peripheral (12.3% and 30.4%), face oedema (4.4% and 17.4%), nausea (16.3% and 26.1%), arthralgia (11.8% and 21.7%) and cough (5.4% and 17.4%), however these were not considered clinically meaningful. No additional observations were noted in the All Avapritinib Group.

Overall, the number of SAEs was limited in patients ≥ 65 years and no trends were observed. Similarly, no trends were observed regarding Grade ≥3 AEs and cognitive AEs in patients ≥ 65 years old compared to patients &lt; 65 years old.

Overall, the data does not suggest that elderlies are at higher risk for developing AEs, SAEs, Grade ≥ 3 AEs or cognitive AEs when compared to younger population, however the number of patients in this category is significantly smaller.

## Exposure-Response Analysis

The exposure-response analysis of the safety endpoints from Study BLU-285-2203, in which the time to event for AEs of interest and avapritinib Cave categorized by quartiles was evaluated, revealed no clear relationships between avapritinib exposure and the very low incidences of all Grade ≥ 3 AEs, Grade ≥ 1 cognitive effect AEs, and Grade ≥ 1 weight gain. There was evidence for an association between avapritinib exposure and oedema AEs. In the 25 mg group, most of the oedema AEs were Grade 1 or 2 in severity (majority Grade 1) and none were Grade ≥ 3. None of the oedema AEs were reported as serious or led to discontinuation of avapritinib.

## Safety related to drug-drug interactions and other interactions

## Drug Interactions

Information in this section was submitted previously and is available in Module 2.7.4, Section 5.3, Original Application (GIST) and in Module 2.7.4, Section 5.3 for the AdvSM indication.

## Use in Pregnancy and Lactation

There are no data in pregnant women exposed to avapritinib, the secretion of avapritinib in human milk or its  effects  on  the  breastfed  infant,  or  on  milk  production  to  assess  the  risks.  Further  discussion  was submitted previously and is available in Module 2.7.4, Section 5.4, AdvSM indication.

## Overdose

No cases of overdose have been reported. The highest dose of avapritinib studied clinically is 600 mg PO Overdose includes any dose higher than the intended dose as per the protocol. There is limited experience with cases of overdose reported in humans. There were 7 cases of overdose (due to additional 25 mg doses administered) reported in 5 patients treated with avapritinib 25 mg QD, none of them were associated with

<div style=\"page-break-after: always\"></div>

AEs (CSR BLU-285-2203, Listing 16.2.5.1). It should be noted that higher doses of avapritinib (200 mg and 300 mg) are approved and the safety profile at these doses is well known.

There is no known antidote for avapritinib overdose. In the event of suspected overdose, avapritinib dosing should be interrupted and supportive care instituted. Based on the large volume of distribution of avapritinib and extensive protein binding, dialysis is unlikely to result in significant removal of avapritinib.

## Drug Abuse

There have been no reports of patient abuse of or dependence on avapritinib. Because avapritinib is not pharmacologically  or  structurally  related  to  drugs  known  to  have  abuse  potential,  drug  abuse  with avapritinib is unlikely.

## Withdrawal and Rebound

No  formal  studies  of  withdrawal  or  rebound  effects  associated  with  avapritinib  treatment  have  been conducted. There have been no AEs of 'drug withdrawal syndrome' (MedDRA PT) reported to date.

## Effects on Ability to Drive or Operate Machinery or Impairment of Mental Ability

No formal studies on the effects of avapritinib on the ability to drive or operate machinery have been performed.

## Supportive Data

## Clinical Pharmacology Studies in Healthy Subjects

In addition to earlier clinical studies, the clinical pharmacology of avapritinib was further characterized in the Phase 2 (BLU-285-2203) efficacy and safety study in patients with ISM (Module 2.7.2), and in the Phase 1 study (BLU-285-0107) investigating the effect of severe HI on the PK of avapritinib. Study BLU285-0107 demonstrated that severe HI was associated with a 20% increase in AUC0∞ and a 20% decrease in Cmax for total plasma avapritinib, together with a 61% increase in AUC0∞ and an 8% increase in Cmax for unbound plasma avapritinib. Further details are available in CSR BLU 285-0107.

## Compassionate Use Program

One patient with ISM has been treated in the avapritinib compassionate use program. As of the data cutoff date (23 June 2022), this patient was still ongoing, and no SAEs had been reported.

## Expanded Access Program

No patients with ISM were treated with avapritinib as part of the Expanded Access Program as of the data cutoff date of 23 June 2022.

## Discontinuation due to adverse events

- Adverse Events Leading to Study Drug Discontinuation

## Part 2 of study BLU 285 2203

Three  (3)  patients  (2.1%)  in  the  25  mg  Avapritinib  Group  experienced  AEs  leading  to  study  drug discontinuation,  including  palpitation,  non-cardiac  chest  pain,  acute  myeloid  leukaemia,  disturbance  in attention (related), dizziness (related), dyskinesia (related), dyspnoea, and hypertension. In the Placebo Group, 1 patient (1.4%) experienced AEs leading to discontinuation (diarrhoea, general physical health deterioration, and headache, all related). In the 25 mg Avapritinib Group, 1 AE of Grade 4 acute myeloid leukaemia (unrelated) leading to study drug discontinuation in 1 patient was reported as serious.

Overall Avapritinib Population (original submission)

<div style=\"page-break-after: always\"></div>

Of the 226 patients in the All 25 mg Avapritinib Group, 7 patients (3.1%) experienced AEs leading to study drug discontinuation during 25 mg avapritinib treatment. Dyspnoea was reported in 2 patients (0.9%), all others  were  reported  in  1  patient  each  (acute  myeloid  leukaemia,  disturbance  in  attention  [related], dizziness [related], dyskinesia [related], hypertension, mastocytotic leukaemia, migraine [related], noncardiac  chest  pain,  pain  in  extremity  [related],  palpitations,  peripheral  swelling,  and  weight  decreased [related]). Of these, 2 AEs that were assessed as not related to study drug by the Investigator, Grade 4 acute myeloid leukaemia and Grade 3 mastocytotic leukaemia in 1 patient each, were reported as serious in the All 25 mg Avapritinib Group. No new concerns were observed from the patients in the All Avapritinib Group regarding the AEs that led to discontinuation. In this group, there was 1 additional patient, who experienced a Grade 2 delirium (related) that led to discontinuation while on 50 mg avapritinib during Part 1 of the study.

- Adverse Events Leading to Dose Modification

Dose-modification  guidelines  for  toxicities  assessed  as  related  to  avapritinib  by  the  Investigator  were followed as per BLU-285-2203, Protocol, and included a change in dosing regimen from QD to QOD in patients who received 25 mg and reduction to a lower dose for patients who received 50 mg and 100 mg.

## Part 2 of study BLU 285 2203

Low proportion of patients experienced AEs leading to dose reduction in both treatment groups. These included 2 patients (1.4%) in the 25 mg Avapritinib Group (1 patient with diarrhoea [unrelated], nausea [unrelated], face oedema [unrelated] and 1 patient with memory impairment [related]), and 1 patient in the Placebo Group (memory impairment; related). Out of these, 1 patient each rolled over to Part 3 at QOD (avapritinib-treated patient) and QD (placebo treated patient) regimens. The remaining patient in the 25 mg Avapritinib Group, later withdrew consent and did not roll over to Part 3. None of the events leading to dose reduction were serious.

AEs leading to dose interruptions occurred in 12 patients (8.5%; related in 5 patients [3.5%]) in the 25 mg Avapritinib Group compared to 9 patients (12.7%; related in 4 patients [5.6%]) in the Placebo Group.

In  the  25 mg Avapritinib Group,  dizziness  (all  related)  was  the  only  AE  leading  to  dose  interruption  in 2 patients (1.4%), and all other AEs were reported in 1 patient each. In the Placebo Group, 3 patients (4.2%) reported headache [2 related], 2 patients (2.8%) reported vision blurred [1 related], and all other AEs leading to dose interruption were reported in 1 patient each. In the 25 mg Avapritinib Group, 2 patients had  SAEs  leading  to  dose  interruption  (Grade 3  COVID-19  pneumonia  in  1 patient  and  Grade 2  pelvic haematoma in 1 patient; both unrelated) and in the Placebo Group, 2 patients had SAEs leading to dose interruptions (COVID-19 pneumonia in 1 patient and COVID-19 in 1 patient; both Grade 3 unrelated).

## Overall Avapritinib Population (original submission)

Of the 226 patients in the All 25 mg Avapritinib Group, 7 patients (3.1%) experienced AEs leading to dose reduction (neutropenia [related], diarrhoea [unrelated], nausea [unrelated], face oedema [related], non-cardiac  chest  pain  [related],  liver  function  test  increased  [unrelated],  neutrophil  count  decreased [related], and pain in extremity [related]) reported in 1 patient each. None of these events were serious. No new concerns were observed in the All Avapritinib Group regarding AEs leading to dose reduction. There were 4 additional patients who experienced AEs leading to dose reduction, and all occurred while being on a higher dose of avapritinib in Part 1, including 1 SAE of Grade 3 gastrointestinal disorder that was assessed as related to study drug in a patient who received 50 mg avapritinib.

Of the 226 patients in the All 25 mg Avapritinib Group, 26 patients (11.5%) experienced AEs leading to dose interruption during 25 mg avapritinib treatment; of whom 13 patients (5.8%) had AEs assessed as related to study drug by the Investigator. Dizziness was reported in 3 patients (1.3%; all related), headache (all related), nausea (1 related), COVID-19 (all unrelated), COVID 19 pneumonia (all unrelated), migraine

<div style=\"page-break-after: always\"></div>

(all related), neutrophil count decreased (1 related), and non-cardiac chest pain (1 related) were reported in 2 patients (0.9%) each, all others were reported in 1 patient each. Additional to the events reported above, 3 AEs (Grade 3 pancreatitis, Grade 3 nephrolithiasis, and Grade 3 COVID 19 pneumonia in 1 patient each; all unrelated) leading to dose interruption in 1 patient each were reported as serious in the All 25 mg Avapritinib Group. No new concerns were observed in the All Avapritinib Group regarding the AEs that led to dose interruption. There were 3 additional patients with SAEs leading to dose interruption (delirium in Part 1 in a patient with 50 mg avapritinib, fall in Part 1 in a patient with 100 mg avapritinib, and arthralgia in Part 3 in a patient who had rolled over from 100 mg avapritinib).

## Post marketing experience

Avapritinib has not been yet approved in any country or region for the treatment of patients with ISM; therefore, no postmarketing data are available regarding the use of avapritinib in patients with ISM.

Since the initial marketing authorization of avapritinib for GIST and the extension to include AdvSM, postmarketing reported events are consistent with the known safety profile of avapritinib in these indications; no new risks have been identified. Cumulatively, since the International Birth Date until 08 July 2022 (Data Lock Point of the avapritinib PBRER 4), the overall estimated post-marketing exposure to avapritinib is 1223 patient-years, and this exposure is aligned with the higher doses of avapritinib given for GIST and AdvSM, 300 mg and 200 mg daily, respectively.

## Late breaking safety data

After the data cutoff date (23 June 2022 for Study BLU-285-2203) through the late breaking data cutoff date (within 30 days after the last dose of avapritinib) (23 August 2022), one SAE of hypersensitivity, assessed as unrelated by the Investigator, was received. No deaths or related SAEs, as assessed by the Investigator, have been reported since the data cutoff date through the late breaking data cutoff date.

## Adverse drug reaction as reported in the SmPC

## Indolent systemic mastocytosis

| System Organ Class / frequency category              | Adverse reactions                                    | Avapritinib (25 mg once daily) + Best Supportive Care All grades%   | Grades ≥ 3 %   |
|------------------------------------------------------|------------------------------------------------------|---------------------------------------------------------------------|----------------|
| Psychiatric disorders                                | Psychiatric disorders                                |                                                                     |                |
| Common                                               | Insomnia                                             | 5.7                                                                 | -              |
| Vascular disorders                                   | Vascular disorders                                   |                                                                     |                |
| Common                                               | Flushing                                             | 9.2                                                                 | 1.4            |
| Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               |                                                                     |                |
| Common                                               | Photosensitivity reaction                            | 2.8                                                                 | -              |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions                |                |
| Very common                                          | Peripheral oedema 1                                  | 12.1                                                                | -              |
| Common                                               | Face oedema                                          | 7.1                                                                 | -              |
| Investigations                                       | Investigations                                       | Investigations                                                      |                |
| Common                                               | Blood alkaline phosphatase increased                 | 6.4                                                                 | 0.7            |

1 Peripheral oedema (including oedema peripheral and peripheral swelling)

-: no adverse reactions reported

No intracranial haemorrhages were reported in 141 patients with ISM receiving 25 mg of avapritinib during the 24-week duration of Part 2 of the PIONEER study.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The MAH has provided safety data from a single, phase II, 3-part study in patients with ISM (study BLU285-2203). Safety data have been presented separately for the 24-week, placebo-controlled part of the study (Part 2) and the overall study population. For the present assessment, the subset of ISM patients included in Part 2 (n=141) is the most relevant patient subset to characterise safety in the intended target population,  as  it  provides  short-term  comparative  safety,  while  the  rest  of  patient  subsets  are  mainly supportive.

At the time of the most recent data cut-off (07/04/2023), parts 1 and 2 of study BLU-285-2203 had been completed, while part 3 was still ongoing (planned overall study follow-up: up to 5 years). Safety data from the avapritinib 25mg Safety Population, which include 226 patients treated with avapritinib 25mg across Part 1/2/3 of study BLU-285-2203, is the key subset for long-term data.

## Patient exposure

In Part 2 of study BLU-285-2203, which consisted of a 24-week, double-blind period, the median (SD) treatment  duration  was  limited  (5.46  months  (0.726)  for  patients  in  25 mg Avapritinib Group  and 5.43 months (0.806) for patients in the Placebo Group). Longer exposure was reported for the Overall Avapritinib Population, where the median (range) treatment duration was 25.0 (12, 25) months in the All 25 mg Avapritinib Group, with 76.5% patients received ≥ 6 months of avapritinib treatment and 31.4% patients received &gt; 12 months of avapritinib treatment.

In  general,  treatment  discontinuations  were  low  in  part  2  of  the  study,  and  similar  in  number  in  both treatment groups (5 patients each). At the time of the data cut-off, 14 additional patients had discontinued treatment in part 3 of the study (main reason AE). Likewise, the number of ISM patients who had dose modifications was also low in part 2 and the overall safety population. Overall, avapritinib 25 mg QD appears to be reasonably tolerated, and toxicities seem manageable with dose modifications.

Regarding the population included, although some small differences are observed between both treatment groups on part 2 (e.g., higher % of patients in the placebo group are 65 or older, have higher baseline serum tryptase median levels, higher KIT D816V mutation burden), overall it appears to be representative of the intended target population.

Regarding  the  avapritinib  25mg  Safety  Population,  as  of  the  most  recent  data  cut-off  (07/04/2023), treatment exposure also increased, had a median duration of 18.00 months (range: 0.7-46.1) for the avapritinib  25mg  treatment  group,  211  patients  were  still  ongoing  in  part  3  of  the  study  and  24  had discontinued. The most frequent reasons for study discontinuation were withdrawal of consent and AE (n=7, each). These 2 reasons account for 2/3 of all discontinuations, although the number of discontinuations is low, which is reassuring.

## Adverse events

## Common AEs

In part 2, the most commonly reported AEs across both groups (≥ 10%) were headache, nausea, COVID19, dizziness, and diarrhoea. The frequency of G≥3 AEs (overall and related) was similar in both groups.

Incidence of AEs and SAEs increased over time with the increased treatment duration, as seen in the overall avapritinib population (25mg and all-doses avapritinib populations).

## No deaths were reported in part 2 of the study.

In the placebo-controlled part of the study, SAEs were more frequently reported in the placebo group than in the avapritinib group (11.3% vs. 5.0%, respectively). No SAEs related to treatment were reported on either group in this part of the study.

<div style=\"page-break-after: always\"></div>

Related AEs were reported by 77 (54.6%) and 32 (45.1%) avapritinib and placebo patients respectively, in the  placebo-controlled  part  of  the  study.  Frequency  increased  slightly  with  the  increased  treatment duration, which is not unexpected, and could also be affected by the open-label nature of part 3.

Regarding AE Severity in part 2, similar % of patients in the avapritinib and placebo groups experienced Grade ≥3 AEs . Proportion of patients with Grade ≥3 AEs increased slightly with treatment exposure. The most common Grade ≥3 AEs reported during any pa rt of the study was anaphylactic reaction, which is also seen in ISM. Due to its potential severity and outcomes, the SmPC has been amended to adequately reflect this.

The  proportion  of  patients  with  any  AEs  leading  to  dose  modifications  or  permanent  treatment discontinuations were generally low across the different parts of the study. In the placebo-controlled part, 3 (2.1%) in avapritinib 25mg group and 1 (1.4%) in placebo group permanently discontinued treatment due  to  AEs,  while  12  and  9  patients  required  dose  interruptions  and  2  and  1  patients  required  dose adjustments. In the overall avapritinib population the discontinuations and dose modifications remained low. These findings suggest an acceptable tolerability, manageable by dose adjustments.

Regarding the avapritinib 25mg  Safety Population (data cut-off date 07/04/2023), overall, no concerning/worrisome differences in the type of AEs, their incidence, seriousness or severity emerged with treatment over a longer period of time. An increase of ≥ 10% compared with the original data was noted for Grade ≥3 AEs, however the incidence of related Grade ≥3 AEs remained low. One new related SAE and one not related death were reported in the update period.

One single death was reported in the study up to the most recent cut-off date. It occurred in part 3 of the study, in the context of a SAE of multiple organ dysfunction syndrome, and it was assessed as not related by the Investigator.

Intracranial bleeding and cognitive effects are important identified risk for avapritinib in GIST and AdvSM and have been included as important potential risks for ISM. No intracranial bleeding AEs were reported in study BLU-285-2203 up to the most recent cut-off date. (see SmPC section 4.4). Regarding cognitive effects in the All 25 mg avapritinib Group, a total of 15 patients (6.6%) experienced cognitive effect AEs. These were assessed as related to study drug in 7 patients (3.1%). The most commonly reported event was memory impairment in 9 patients (4.0%) and cognitive disorders in 3 patients (1.3%) and all other events were reported in 1 patient each. In Part 2 of the PIONEER study, cognitive effects occurred in 2.8% of patients with ISM who received 25 mg of avapritinib (see section 4.4); all cognitive effects were Grade 1 or  2.  Overall,  none  of  the  patients  who  received  avapritinib  in  Part  2  of  PIONEER  required  permanent treatment discontinuation for cognitive effects. Overall, cognitive effects were reported at lower frequencies than those previously reported for GIST and AdvSM indications, the reasons for these differences are not entirely clear since the mechanism of occurrence is not well-known and CNS involvement isn't unusual in SM. However, the non-severe (G&lt;3) nature of most of the events is reassuring.

Although oedema AEs were not predefined as AESIs, these AEs were reported in the previous GIST and AdvSM submissions and 'fluid retention (pleural effusion)' was defined as identified risks.

The  MAH  provided  data  on  these  AEs  separately  for  the  part  2  population  and  the  overall  avapritinib population. Oedema AEs were frequent in the placebo-controlled part of the study and the overall avapritinib population. Most of these AEs were considered related by the investigators and were mostly grade &lt;3 in intensity. In addition, longer treatment exposure did not appear to increase their occurrence.  Localised (peripheral, facial) oedemas in patients with ISM, have been included in the PI with a frequency category of at least common (see SmPC sections 4.4 and 4.8).

In patients with ISM, QT interval assessments by ECG should be considered, in particular in patients with concurrent factors that could prolong QT (e.g. age, pre-existing heart rhythm disorders, etc.)- see SmPC section 4.4.

<div style=\"page-break-after: always\"></div>

The number of and elderly patients (≥65 years old) included in the study is rather small (9 patients in part 2, and 23 patients treated with avapritinib 25mg in all 3 parts of the study), while no patients over the age of 85 were included. SAEs, in the 25mg avapritinib groups, AEs leading to drop-out, accident/injuries AEs and vascular disorders occurred slightly more frequently in patients age ≥ 65 than those &lt;65 years of age. Overall,  no  meaningful  differences  in  safety  were  observed  between  patients  ≥65 years  and  those &lt;65 years.

The small size of the safety database in patients with ISM (226 patients treated with avapritinib 25mg QD; 246 patients treated with any dose) is a limitation in this assessment, however prior knowledge on the safety of avapritinib in the GIST and AdvSM indications sufficiently alleviate this concern. The recommended dose of avapritinib is 25 mg once daily (QD), with the possibility to perform dose adjustment based on tolerability. This selected dose for patients with ISM, Avapritinib 25mg QD, is almost ten times lower than that  for  AdvSM,  and  more  than  ten  times  lower  than  the  GIST  dose  appears  to  have  an  acceptable tolerability,  manageable  by dose modifications. Further, annual updates from study BLU-285-2203 and submission of the final CSR will provide additional data in this context.

## 2.5.2. Conclusions on clinical safety

Avapritinib 25mg was well tolerated based on the low frequency of AEs leading to dose interruptions/reductions. The recommendations for dose adjustments appear to mitigate these toxicities over time. Overall, the safety profile appears consistent to that known in previous indications, no new safety concerns have been identified. Safety data have been reflected in the product information.

The following measures are considered necessary to address issues related to efficacy:

- The MAH will provide updated safety results of the study BLU-285-2203 annually until completion of the study. The final CSR should also be submitted when available following recommendation from the CHMP.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version 4.0 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.4 is acceptable.

The CHMP endorsed the Risk Management Plan version 4.4 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                                                                                 |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Intracranial haemorrhage (GIST and AdvSM) Cognitive effects (GIST and AdvSM) Drug-drug interactions with moderate or strong CYP3A inhibitors or inducers (all indications) |

<div style=\"page-break-after: always\"></div>

| Important potential risks   | Intracranial haemorrhage (ISM) Cognitive effects (ISM) Cardiac toxicity, including QT prolongation (all indications) Embryofoetal toxicity (all indications)   |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information         | Use in patients with severe hepatic impairment (all indications) Drug-drug interactions with CYP3A substrates (all indications)                                |

Abbreviations: AdvSM = advanced systemic mastocytosis; GIST = gastrointestinal stromal tumour; ISM = indolent systemic mastocytosis.

## Pharmacovigilance plan

No amendment to the current pharmacovigilance plan is proposed, which is accepted.

| Study/Status                                                                                                                                                                                                                                 | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Safety Concerns Addressed                                                                                                                                                                                                                                                                          | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                   | Category 2 - imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                                                                                                                                                                                                                                               | Category 2 - imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                         | Category 2 - imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| Study BLU-285-1406 'Observational study evaluating the long-term safety and efficacy of avapritinib in the first-line treatment of patients with platelet-derived growth factor alpha D842V mutated gastrointestinal stromal tumour' Ongoing | The overall objective is to collect long- term safety and efficacy data for avapritinib in first- line patients with PDGFRA D842V- mutated GIST. Primary objective: - To describe types, severity, and rates of adverse events, serious adverse events, adverse events leading to discontinuation or decreased dosing of avapritinib, adverse events of special interest, and deaths. Secondary objective: - To evaluate efficacy in terms of disease response to treatment, progression-free survival, and overall survival, as well as duration of treatment and duration of response. | - Intracranial haemorrhage - Cognitive effects - Drug-drug interactions with moderate or strong CYP3A inhibitors or inducers - Cardiac toxicity, including QT prolongation - Embryofoetal toxicity - Use in patients with severe hepatic impairment - Drug-drug interactions with CYP3A substrates | - Annual progress reports - Interim report - Final clinical study report                                                                                                                                                   | - Annually starting from August 2022 until August 2025 - February 2025 - Q1 2027                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Study/Status                                                                                              | Summary of Objectives                                                                                                  | Safety Concerns Addressed                                     | Milestones                                                    | Due Dates                                                     |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - required additional pharmacovigilance activities                                             | Category 3 - required additional pharmacovigilance activities                                                          | Category 3 - required additional pharmacovigilance activities | Category 3 - required additional pharmacovigilance activities | Category 3 - required additional pharmacovigilance activities |
| Study BLU-285- 1107 'Clinical drug- drug interaction study of avapritinib with a CYP3A substrate' Ongoing | - To investigate net effect of CYP3A inhibition and induction by avapritinib on midazolam pharmacokinetics in patients | - Drug-drug interactions with CYP3A substrates                | - Study completion - Final clinical study report              | - December 2024 - May 2025                                    |

Abbreviations: CYP3A = cytochrome P450 isozyme 3A; GIST = gastrointestinal stromal tumour; PDGFRA = plateletderived growth factor receptor alpha; Q = quarter.

## Risk minimisation measures

Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                 | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                                                        |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intracranial haemorrhage (GIST and AdvSM)      | Routine risk minimisation measures: - SmPC sections 4.2, 4.4 and 4.8 - PL sections 2 and 4 SmPC section 4.2 contains recommendation on dose interruptions, permanent discontinuation, and platelet support. SmPC section 4.4 provides guidance on MRI/CT, platelet count monitoring, and recommendation on permanent drug discontinuation. PL section 2 gives recommendation on treatment interruption. PL section 4 provides guidance on MRI/CT. Restricted prescription medicine Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond signal detection and adverse reactions reporting: - Follow-up questionnaire Additional pharmacovigilance activities: - Study BLU-285-1406 (final study report: Q1 2027) |
| Cognitive effects (GIST and AdvSM)             | Routine risk minimisation measures: - SmPC sections 4.2, 4.4, 4.7 and 4.8 - PL sections 2 and 4 SmPC section 4.2 contains recommendations on dose modifications and permanent discontinuation of therapy. Restricted prescription medicine Additional risk minimisation measures: None                                                                                                                                                                                                                                         | Routine pharmacovigilance activities beyond signal detection and adverse reactions reporting: - Follow-up questionnaire Additional pharmacovigilance activities: - Study BLU-285-1406 (final study report: Q1 2027) |
| Drug-drug interactions with moderate or strong | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Additional pharmacovigilance activities:                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                | Risk Minimisation Measures                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                          |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CYP3A inhibitors or inducers (all indications)                | - SmPC sections 4.2, 4.4, 4.5, and 5.2 - PL section 2 SmPC section 4.2 contains recommendation on concomitant use of avapritinib with moderate or strong CYP3A inhibitors. Restricted prescription medicine Additional risk minimisation measures: None                                                        | - Study BLU-285-1406 (final study report Q1 2027)                                                                                                                     |
| Intracranial haemorrhage (ISM)                                | Routine risk minimisation measures: - SmPC sections 4.2, 4.4 and 4.8 - PL section 2 SmPC section 4.4 provides guidance on MRI/CT and permanent drug discontinuation. PL section 2 gives recommendation on treatment interruption. Restricted prescription medicine Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond signal detection and adverse reactions reporting: - Follow-up questionnaire Additional pharmacovigilance activities: None |
| Cognitive effects (ISM)                                       | Routine risk minimisation measures: - SmPC sections 4.2, 4.4, 4.7 and 4.8 - PL section 2 Restricted prescription medicine Additional risk minimisation measures: None                                                                                                                                          | Routine pharmacovigilance activities beyond signal detection and adverse reactions reporting: - Follow-up questionnaire Additional pharmacovigilance activities: None |
| Cardiac toxicity, including QT prolongation (all indications) | Routine risk minimisation measures: - SmPC sections 4.4, 4.8 and 5.1 - PL sections 2 and 4 SmPC section 4.4 includes recommendation for interval assessment of QT interval. Restricted prescription medicine Additional risk minimisation measures: None                                                       | Additional pharmacovigilance activities: - Study BLU-285-1406 (final study report: Q1 2027)                                                                           |
| Embryofoetal toxicity (all indications)                       | Routine risk minimisation measures: - SmPC sections 4.6 and 5.3 - PL section 2 SmPC section 4.6 and PL section 2 includes recommendation on the use of effective contraception during therapy. Restricted prescription medicine Additional risk minimisation measures: None                                    | Additional pharmacovigilance activities: - Study BLU-285-1406 (final study report Q1 2027)                                                                            |
| Use in patients with severe hepatic                           | Routine risk minimisation measures: - SmPC sections 4.2 and 5.2                                                                                                                                                                                                                                                | Additional pharmacovigilance activities:                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                | Risk Minimisation Measures                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                    |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| impairment (all indications)                                  | - PL section 3 SmPC section 4.2 includes dosing recommendations in patients with severe hepatic impairment. Restricted prescription medicine Additional risk minimisation measures: None | - Study BLU-285-1406 (final study report Q1 2027)                                                                                               |
| Drug-drug interaction with CYP3A substrates (all indications) | Routine risk minimisation measures: - SmPC sections 4.5 and 5.2 - PL section 2 Restricted prescription medicine Additional risk minimisation measures: None                              | Additional pharmacovigilance activities: - Study BLU-285-1406 (final study report: Q1 2027) - Study BLU-285-1107 (final study report: May 2025) |

Abbreviations: AdvSM = advanced systemic mastocytosis; CT = computed tomography; CYP3A = cytochrome P450 isozyme 3A; GIST = gastrointestinal stromal tumour; ISM = indolent systemic mastocytosis; MRI = magnetic resonance imaging; PL = package leaflet; Q = quarter; QD = once daily; SmPC = summary of product characteristics

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3of the SmPC have been updated.  The Package Leaflet has been updated accordingly.

Please refer to Attachment 1, which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The Package Leaflet changes included in this Type II variation are not significant for its readability, as there are no new critical safety issues and no new key messages for the safe use of Ayvakyt. In addition, the MAH noted that the format, design, layout and writing style of the Package Leaflet remain the same as in the Package Leaflets that went through consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved indication is:

AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment (see section 5.1).

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

There are currently no approved treatments for patients with ISM to reduce their disease burden, treat the underlying driver of ISM, or which impact the ISM disease course.

Therapies currently recommended for ISM are considered palliative, administered with the intent of only improving symptoms.

## 3.1.3. Main clinical studies

This application is based on the results from the ongoing 3-part, randomized, double-blind, placebocontrolled phase-2 Study BLU-285-2203 (PIONEER) in patients with ISM with moderate or severe symptoms that failed to achieve control under symptomatic therapies.

The study was conducted in 3 parts:

- In Part 1 , the optimal dose of avapritinib (RP2D) was identified in patients with ISM.
- In Part 2 , patients with ISM were randomly assigned in 2:1 ratio to the avapritinib RP2D (25 mg QD) identified in Part 1 in combination with BSC, or to placebo in combination with BSC.
- In Part 3 , patients who complete treatment in Part 1 or Part 2 of the study can participate in a long-term extension, receiving avapritinib at the RP2D in combination with BSC.

The main efficacy data come from Part 2 of the study in which 212 patients were enrolled (141 in the avapritinib arm and 71 in the placebo arm). Overall, 235 patients (34 patients from Part 1 and 201 patients from Part 2) rolled over to Part 3 from Part 1 and Part 2 of the study.

The primary endpoint in Part 2 of the study was defined as the mean change from baseline to cycle 7 day 1 (C7D1; week 24) in the total symptom score (TSS) using the Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF) compared to placebo.

The results of Part 2 are based on a data cut-off date of 23 June 2022. Updated efficacy and safety data from Part 3 were provided during the procedure with a data cut-off date of 7 April 2023. At the time of this last DCO, Part 3 was ongoing.

## 3.2. Favourable effects

## Primary endpoint

At C7D1, the LS mean (SE) change from baseline in the ISM-SAF TSS was -15.58 (1.536) points for the 25 mg avapritinib group and -9.15 (2.013) for the placebo group. The difference (95% CI) between the groups was -6.43 (-10.90, -1.96) points. This difference was statistically significant (1-sided p-value = 0.003).

## Key secondary endpoints

The results of the key secondary endpoints at C7D1 supported the primary efficacy analysis.

- 24.8% (95% CI: 17.9, 32.8) of patients in the avapritinib group vs 9.9% (95% CI: 4.1, 19.3) of patients in the placebo group achieved ≥ 50% reduction in the ISM -SAF TSS. The odds ratio (OR) was 3.10 (95% CI: 1.24, 8.64); 1-sided p-value = 0.005.
- 45.4% (95% CI: 37.0, 54.0) of patients in the Avapritinib group vs 29.6% (95% CI: 19.3, 41.6) of patients in the placebo group achieved ≥ 30% reduction in the ISM -SAF TSS. The OR was 2.07 (95% CI: 1.08, 3.99); 1-sided p-value = 0.009.

<div style=\"page-break-after: always\"></div>

- 53.9% (95% CI: 45.3, 62.3) of patients in the avapritinib group vs 0.0% (95% CI: 0.0, 5.1) of patients in the placebo group achieved ≥50% reduction in serum tryptase. The OR was not evaluable (95% CI: 30.59, not evaluable); 1-sided p-value &lt; 0.0001.
- 67.8% (95% CI: 58.6, 76.1) of patients in the avapritinib group vs 6.3% (95% CI: 1.8, 15.5) of patients in the placebo group achieved either ≥50% reduction in KIT D816V MAF or became undetectable (&lt; 0.02%). The OR was 39.34 (95% CI: 10.93, 140.56); 1-sided p-value &lt; 0.0001.
- 52.8% (95% CI: 42.9, 62.6) of patients in the avapritinib group vs 22.8% (95% CI: 12.7, 35.8) of patients in the placebo group achieved either ≥ 50% reduction in bone marrow mast cells or no mast cell aggregates. The OR 4.74 (95% CI: 2.06, 11.45); 1-sided p-value &lt; 0.0001.

## 3.3. Uncertainties and limitations about favourable effects

While a period of 24 weeks for the double-blinded placebo comparison can be accepted, the interpretation of long-term efficacy data, which are considered of particular relevance in this indolent scenario, is hampered by the absence of a control arm in Part 3 of the study. The MAH will provide updated efficacy results of the study BLU-285-2203 annually until completion of the study. The final CSR will be submitted when available.

## 3.4. Unfavourable effects

## Placebo-controlled part of study BLU 285 2203 (Part 2)

Overall,  128 patients  (90.8%)  in  the  25 mg Avapritinib Group  and  66 patients  (93.0%)  in  the  Placebo Group  experienced  at  least  1 AE.  Of  them,  77 patients  (54.6%)  in  the  25 mg Avapritinib Group  and 32 patients (45.1%) in the Placebo Group experienced related AEs.  Grade ≥ 3 AEs were reported in 21.3% and 21.1% patients, respectively. Related Grade ≥ 3 AEs were reported in 3 patients (2.1%) in the 25 mg Avapritinib Group and 2 patients (2.8%) in the Placebo Group.

The  most  common  AEs  in  ISM  patients  (≥  10%  of  patients)  on  either  group  were headache  (19.1% avapritinib  vs.  19.7%  placebo),  nausea  (12.8%  vs.  16.9%),  COVID-19  (12.1%  vs.  11.3%),  dizziness (11.3% vs. 8.5%), and diarrhea (10.6% vs. 11.3%).

SAEs were reported in 5.0% and 11.3% patients in the 25 mg Avapritinib Group compared to the Placebo Group, respectively. No SAEs were assessed as related to study drug by the Investigator in either group.

There were no deaths in Part 2 of the study.

AEs led to interruption of study treatment in 8.5% and 12.7% of patients in the 25 mg Avapritinib Group and Placebo Group, respectively; Related AEs leading to treatment interruptions occurred in 3.5% of patients in the 25 mg Avapritinib Group and 5.6% of patients in the Placebo Group.

AEs led to dose reduction in  2  patients (1.4%) in the 25 mg Avapritinib Group (related in 1 patient [0.7%]) and 1 patient (1.4%) in the Placebo Group (related). AEs led to permanent study treatment discontinuation in 3 patients (2.1%) in the 25 mg Avapritinib Group (related in 2 patients [1.4%]) and 1 patient (1.4%) in the Placebo Group (related).

By SOC, in  the  avapritinib  25mg  group,  nervous  system  disorders  were  the  most  commonly  reported (38.3%), followed by GI disorders (36.9%), general disorders and administration site conditions (36.2%), infections and infestations (34.8%) and skin/subcutaneous tissue disorders (30.5%).  In the placebo group, GI disorders were the most commonly reported (38.0%), followed by nervous system disorders (33.8%), and infections and infestations (31.0%).

<div style=\"page-break-after: always\"></div>

Cognitive effects and intracranial bleedings were considered AESI in the study. Cognitive effects were reported by 2.8% and 4.2%, in avapritinib 25mg and placebo groups, respectively, a majority of the cases were considered treatment related.

No intracranial bleedings AESIs were reported.

## Overall avapritinib 25 mg population (data cut-off date 07 April 2023)

Of the 226 patients in the All 25 mg Avapritinib Group, 223 (98.7%) patients experienced AEs and 151 (66.8%) patients experienced AEs that were assessed as related to study drug by the Investigator. A total of 86 (38.1%) patients experienced Grade ≥ 3 AEs. Among these patients, AEs were assessed as related to study drug by the Investigator in 11 (4.9%) patients. The most common AEs in ISM patients treated with 25 mg QD (≥ 10% of patients) were COVID-19 (22.1%) headache (18.1%), nausea (13.7%), dizziness (13.7%), diarrhoea (11.5%), oedema peripheral (11.1%), fatigue and pruritus (10.6%, each).

A total of 31 (13.7%) patients had SAEs and 1 patient (0.4%) experienced an SAE that was assessed as related to the study drug by the Investigator. One single deaths was reported during part 3 of the study, in the context of a multiple organ dysfunction syndrome (SAE, non-related).

AEs led to interruption of study treatment in 38 (16.8) of patients (assessed as related in 18 (8.0%) patients). Overall, 13 (5.8%) patients experienced AEs leading to dose reduction (related in 11 (4.9%)) and 12 (5.3%) of patients had AEs leading to permanent treatment discontinuation (related in 6 (2.7%)).

By SOC , infections and infestations were the most commonly reported disorders (n=170, 69.1%), followed by GI disorders (n=132; 53.7%).

Of the 226 patients, 15 (6 .6%) experienced cognitive effects (most common: memory impairment, 9 [4%]). No intracranial bleedings AESIs were reported up to the most recent cut-off date.

## 3.5. Uncertainties and limitations about unfavourable effects

The main limitations for the characterization of the safety profile of avapritinib in the ISM indication, in particular with regards to long-term safety and less common ADRs, are related to the small size of the safety database (246 ISM patients, 226 received 25mg QD) and limited long-term follow-up, with all evidence deriving from a single on-going study. The MAH will provide updated safety results of the study BLU-285-2203 annually until completion of the study. The final CSR will be submitted when available.

Moreover, there is uncertainty regarding the potential effect on the course of the disease after avapritinib treatment discontinuation.

The  uncertainties  regarding  the  carcinogenic  potential  of  avapritinib  is  also  considered  of  concern.  To address this, a 2-year study in rats will be submitted by the MAH following the recommendation of the CHMP.

## 3.6. Effects Table

## Table 84. Effects Table for Patients with ISM in Study BLU-285-2203 (PIONEER) at C7D1(Part 2 ITT Population) - DCO 23 June 2022

| Effect                                       | Short description Unit                       | Avapritinib 25 mg + BSC (N= 141)             | Control Placebo + BSC (N=71)                 | Uncertainties / Strength of evidence References   |
|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|---------------------------------------------------|
| Favourable Effects-Part 2 study BLU-285-2203 | Favourable Effects-Part 2 study BLU-285-2203 | Favourable Effects-Part 2 study BLU-285-2203 | Favourable Effects-Part 2 study BLU-285-2203 | Favourable Effects-Part 2 study BLU-285-2203      |
| Primary endpoint                             | Primary endpoint                             | Primary endpoint                             | Primary endpoint                             | Primary endpoint                                  |

<div style=\"page-break-after: always\"></div>

| Effect                                                                                 | Short description                                                                             | Unit                    | Avapritinib 25 mg + BSC (N= 141)   | Control Placebo + BSC (N=71)   | Uncertainties / Strength of evidence                                | References              |
|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------|------------------------------------|--------------------------------|---------------------------------------------------------------------|-------------------------|
| Mean change in ISM-SAF TSS                                                             | Mean change in ISM-SAF TSS from Baseline to C7D1                                              | Mean (95% CI)           | -15.58 (-18.61, -12.55)            | -9.15 (-13.12, -5.18)          | Difference (95% CI): -6.43 (-10.90, -1.96); 1-sided P-value = 0.003 | CSR                     |
| Key secondary endpoints                                                                | Key secondary endpoints                                                                       | Key secondary endpoints | Key secondary endpoints            | Key secondary endpoints        | Key secondary endpoints                                             | Key secondary endpoints |
| %of patients achieving ≥ 50% reduction in ISM-SAF TSS                                  | %of patients achieving ≥ 50% reduction in ISM-SAF TSS at C7D1                                 | % (95% CI)              | 24.8 (17.9, 32.8)                  | 9.9 (4.1, 19.3)                | OR (95% CI): 3.10 (1.24, 8.64); 1-sided P-value = 0.005             | CSR                     |
| %of patients achieving ≥ 30% reduction in ISM-SAF TSS                                  | %of patients achieving ≥ 30% reduction in ISM-SAF TSS at C7D1                                 | % (95% CI)              | 45.4 (37.0, 54.0)                  | 29.6 (19.3, 41.6)              | OR (95% CI): 2.07 (1.08, 3.99); 1-sided P-value = 0.009             | CSR                     |
| %of patients with a ≥ 50% reduction in serum tryptase                                  | %of patients with a ≥ 50% reduction in serum tryptase at C7D1                                 | % (95% CI)              | 53.9 (45.3, 62.3)                  | 0 (0.0, 5.1)                   | OR (95% CI): NE (30.59, NE); 1-sided P-value < 0.0001               | CSR                     |
| %of patients with a ≥ 50% reduction in peripheral blood KIT D816V MAF or undetectabl e | %of patients with a ≥ 50% reduction in peripheral blood KIT D816V MAF or undetectable at C7D1 | N % 95% IC              | N=118 67.8 (58.6, 76.1)            | N=63 6.3 (1.8, 15.5)           | OR (95% CI): 39.34 (10.93, 140.56); 1-sided P-value < 0.0001        | CSR                     |
| %of patients with a ≥ 50% reduction in bone marrow mast cells or no aggregates         | %of patients with a ≥ 50% reduction in bone marrow mast cells or no aggregates at C7D1        | N % 95% IC              | N=106 52.8 (42.9, 62.6)            | N=57 22.8 (12.7, 35.8)         | OR (95% CI): 4.74 (2.06, 11.45); 1-sided P-value < 0.0001           | CSR                     |

<div style=\"page-break-after: always\"></div>

| Effect                         | Short description                        | Unit   | Avapritinib 25 mg + BSC (N= 141)   | Control Placebo + BSC (N=71)   | Uncertainties / Strength of evidence   | References   |
|--------------------------------|------------------------------------------|--------|------------------------------------|--------------------------------|----------------------------------------|--------------|
| Part 2 *                       | AE overall                               | %      | 90.8                               | 93.0                           |                                        |              |
|                                | ≥ G3 AEs                                 |        | 21.3                               | 21.1                           |                                        |              |
|                                | SAEs                                     |        | 5.0                                | 11.3                           |                                        |              |
|                                | AEs leading to death                     |        | 0.0                                | 0.0                            |                                        |              |
|                                | AE leading to treatment discontinuati on |        | 2.1                                | 1.4                            |                                        |              |
|                                | AE leading to dose reductions            |        | 1.4                                | 1.4                            |                                        |              |
|                                | AE leading to dose interruptions         |        | 8.5                                | 12.7                           |                                        |              |
| Avapritinib 25mg QD population | AE overall                               | n (%)  | 223 (98.7)                         | N/A                            |                                        |              |
| **                             | ≥ G3 AEs                                 |        | 86 (38.1)                          |                                |                                        |              |
|                                | SAEs                                     |        | 31 (13.7)                          |                                |                                        |              |
|                                | AEs leading to death                     |        | 1 (0.4)                            |                                |                                        |              |
|                                | AE leading to treatment discontinuati on |        | 12 (5.3)                           |                                |                                        |              |
|                                | AE leading to dose reductions            |        | 13 (5.8)                           |                                |                                        |              |
|                                | AE leading to dose interruptions         |        | 38 (16.8)                          |                                |                                        |              |

Abbreviations: C7D1 = Cycle 7 Day 1; CI = confidence interval; ISM = indolent systemic mastocytosis; ISM-SAF = Indolent Systemic Mastocytosis-Symptom Assessment Form; ITT = intent-to-treat; NE = not evaluable; TSS = total symptom score(s). MAF = mutant allele fraction.

Notes: * Data cut-off date 23 June 2022; ** Data cut-off date 07 April 2023.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The efficacy and safety of avapritinib in the indication for the treatment of ISM is based on a 3-part, placebo-controlled, Phase 2 study (BLU-285- 2203). In part 2 of the study a statistically significant reduction in the mean change from baseline to week 24 (C7D1) in the TSS using the ISM-SAF has been reported. The results for the (key) secondary efficacy endpoints also show statistically significant results in favour of the avapritinib arm.

<div style=\"page-break-after: always\"></div>

The positive results observed in the primary endpoint are supported by a clear benefit of avapritinib over placebo in the secondary endpoints, including a decrease in systemic measures of mast cell burden, which is reasuring. Besides, while the effect of avapritinib was higher in skin symptoms, a decrease in all individual symptoms is observed to a greater or lesser extent. Thus, the effect of avapritinib in patients with ISM can be considered of clinical relevance.

Efficacy data in the long-term showed that the efficacy appears to be maintained in the long term, but additional data would be required. The MAH will submit an annual report of study BLU-285-2203 and continuing annually until completion of the study as per the recommendation of the CHMP (REC).

Regarding safety issues, the overall safety database for avapritinib in patients with ISM is small and the long-term exposure is limited, which raises concerns regarding the characterisation of long-term safety profile and less frequent adverse events . However, prior knowledge on the GIST and AdvSM indications could alleviate to some extent the concern, and longer-term data provided during the current variation further substantiate the safety of avapritinib in the intended indication.

The overall incidence of adverse events, including serious and severe AEs is lower in ISM patients than those previously reported for the higher doses used in the GIST/AdvSM indications. Avapritinib 25mg was acceptably tolerated based on the low frequency of AEs leading to dose interruptions/reductions. The recommendations for dose adjustments appear to mitigate these toxicities over time.

It is encouraging to note a low number of adverse events, as well as no intracranial haemorrhage events in view of the reported safety profile of avapritinib. However, it is recognized that a lower dose of avapritinib has been used in the current study and ISM patients with known risk factors for ICB were excluded. In addition, it needs to be taken into account that it is expected to treat patients over an extended period of time. Overall, the safety profile appears consistent to that known in previous indications, no new safety concerns have been identified. Annual updates and the final CSR data for study (BLU-285- 2203) will complement the current knowledge.

## 3.7.2. Balance of benefits and risks

Avapritinib has shown benefit in terms of the primary and key secondary endpoints in patients with moderate to severe ISM inadequately controlled with standard symptomatic therapy.

The overall safety profile of avapritinib appears consistent with that seen in the GIST/AdvSM indications. Avapritinib 25mg QD was acceptably tolerated and toxicity was overall manageable in the proposed treatment setting.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Ayvakyt is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include for avapritinib treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.4 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Ayvakyt is not similar to Rydapt within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Ayvakyt-H-C-5208-II-0023'